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Chapter 1. Introduction, Aims and Outline
1GENERAL INTRODUCTION
Over the last several decades, the growth of health care expenditures in developed 
countries has consistently outpaced overall economic growth (Figure 1). Currently, health 
care expenditures represent 10-12% of the gross domestic product in many western 
European countries, while this proportion is nearly 18% in the United States.2
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Figure 1. Trend in Health Care Expenditure as a Percentage of Gross Domestic Product, 1980-20102
Moreover, more than 9% the total health care budget is spent on cardiovascular diseases, 
making it the second most expensive diagnosis group (Figure 2).1
The unsustainable trend of increasing health care costs threatens the fi nancial stability 
of governments and necessitates diffi  cult resource allocation decisions by policy-makers 
and physicians:
“It’s not the investments that we’ve made to rescue our economy during this crisis. 
By a wide margin, the biggest threat to our nation’s balance sheet is the skyrocketing 
cost of health care. It’s not even close.”
 Atul Gawande, 2009
To inform medical decision-making and health care policy, clinical outcomes, quality of 
life and cost data need to be evaluated together. Quality of life and health economic 
studies aim to provide such information. The main drivers of rising healthcare costs 
are the aging population and the continued development of costly new technologies,3 
including new therapies for aortic stenosis and coronary artery disease.
Part I. Introduction
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AIMS
The aim of this thesis is to study the clinical, economic and quality-of-life considerations 
for clinical decision-making and policy development in cardiovascular interventions.
More specifi cally the goals are:
1. To investigate the disease prevalence, adoption trends, quality of life, and economic 
aspects associated with therapies of aortic stenosis.
2. To explore the economic and policy aspects of alternative revascularization therapies 
for coronary artery disease.
3. To study the performance of risk prediction models in cardiovascular clinical decision-
making.
4. To appraise and improve the methodology of cardiovascular research, including 
systematic reviews, cost-eff ectiveness analyses, and observational studies.
OUTLINE
Within the preface, Chapters 2 and 3 introduce the reader to alternative therapies for 
aortic stenosis (Part I) and coronary artery disease coronary revascularization (Part II), 
respectively. The current status of clinical, economic and quality of life considerations 
for these two cardiovascular diseases is discussed. Moreover, several risk scores, the 
infl uence of results on clinical practice and policy, and the appropriateness of the revas-
cularization method are introduced.
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1Part II. Aortic Stenosis
The fi rst part of this thesis focuses on the disease prevalence, adoption trends, quality of 
life and economic aspects of therapies for severe aortic stenosis. First, the disease preva-
lence of severe aortic stenosis and the potential number of candidates for transcatheter 
aortic valve implantation (TAVI) are studied (Chapter 4). The actual adoption of TAVI in 
Europe and factors infl uencing device utilization are evaluated in Chapter 5. In Chapter 
6, quality of life after TAVI is assessed in patients that were at extreme risk for surgical 
aortic valve replacement (SAVR). Subsequently, the costs associated with SAVR and TAVI 
are studied. The costs of SAVR according to pre-operative risk categories are evaluated in 
Chapter 7. In Chapter 8 costs and resource use associated with TAVI and SAVR are com-
pared in a propensity-matched cohort of intermediate risk patients. Chapter 9 discusses 
controversies on the (cost-)eff ectiveness of TAVI. The fi nal chapter of this part reviews 
non-cardiac surgery in patients with severe aortic stenosis (Chapter 10).
Part III. Coronary Revascularization
The second part concerns economic and policy aspects of alternative revascularization 
therapies for coronary artery disease. In Chapter 11 the long-term clinical benefi ts and 
cost-eff ectiveness of coronary artery bypass grafting (CABG) and percutaneous coronary 
intervention (PCI) with drug-eluting stents (DES) are studied from a U.S. health care 
perspective. Chapter 12 aims to evaluate the lifetime cost-eff ectiveness of CABG versus 
DES-PCI from a European perspective, thereby also assessing the discriminative power 
of a new risk score that incorporates both pre-operative clinical risk factors and the 
anatomical complexity of coronary artery disease. Subsequently, Chapter 13 describes 
a prediction model for costs and length of stay after CABG. These models are applied in 
Chapter 14 to compare costs, quality and value of CABG across centers. In Chapter 15, 
the appropriate application of guidelines and evidence based medicine is discussed for 
both CABG and PCI.
Part IV. Risk Prediction in Cardiac Surgery
In this part we compare the performance of U.S. and European risk prediction models 
for cardiac surgical procedures, including CABG, SAVR, and mitral procedures (Chapter 
16). Chapter 17 concerns a comprehensive systematic review describing traditional 
and novel risk factors for death, stroke, renal failure and prolonged length of stay after 
cardiac surgery. Chapter 18 refl ects on long-term prediction models for CABG and PCI.
Part V. Methodological Appraisal of Cardiovascular Research
The last part of this thesis is an appraisal of several methodological aspects in cardiovas-
cular research. Chapter 19 and 20 critically appraise the association between CYP2C19 
loss-of-function alleles and clinical effi  cacy of clopidogrel. Chapter 21 reviews the 
Part I. Introduction
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current practice of systematic reviews and meta-analyses in the cardiovascular fi eld 
and provides recommendations for improvement. Subsequently we critically appraise 
the methodology of an observational study (Chapter 22), a cost-eff ectiveness analysis 
(Chapter 23), and a clinical trial (Chapter 24).
21
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Aortic stenosis (AS) is the most common valvular heart disease in developed countries, 
and its burden of disease is expected to increase due to population aging.1 Until recently, 
surgical aortic valve replacement (SAVR) was the only treatment option in patients with 
severe AS, with approximately 67,500 SAVRs performed each year in the US alone.2 
Consequently, also the economic burden of treating this disease is substantial.
One of the most promising advances in cardiovascular medicine in recent years has 
been the development of safe and reliable catheter-based techniques for treatment of 
valvular heart disease.3 However, the rapid development and widespread application of 
transcatheter aortic valve implantation (TAVI) for treatment of patients with calcifi c AS 
has raised important questions about the value of these technologies.4 Given the high 
cost of these therapies as well as the growing population of potential candidates, it is 
clear that therapies such as TAVI require not only clinical evaluation, but also careful 
Figure 1. Graphical Representation of Transcatheter Aortic Valve Implantation
Graphical representation of Transcatheter Aortic Valve Implantation (TAVI) for the treatment of severe Aor-
tic Stenosis. After retrograde advancing the transcatheter valve from the insertion in the femoral artery 
across the aortic arch, the valve is positioned at the level of the native aortic valve. This type of transcath-
eter valve is deployed by infl ating a balloon during a brief period of rapid ventricular pacing. Reproduced 
with permission from Smith et al.,17 Copyright Massachusetts Medical Society.
Part I. Introduction
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economic evaluation. Cost-eff ectiveness analysis is a formal approach to these issues 
that seeks to inform both medical decision-making and health care policy by comparing 
the benefi t of a new therapy with its costs.
COST-EFFECTIVENESS OF TAVI VERSUS MEDICAL THERAPY
Several studies have examined the cost-eff ectiveness of TAVI versus optimal medical 
management in inoperable patients (Table 1).5-11 The analyses represent a broad range 
of healthcare systems and incorporate diff erent modeling methodologies, willingness-
to-pay-thresholds, and discount rates. An individual patient cost-eff ectiveness analysis 
based on Cohort B of the Placement of Aortic Transcatheter Valves (PARTNER) trial 
estimated an incremental cost-eff ectiveness ratio (ICER) of $50 212 per life-year gained 
(Figure 2).9 Other studies have used Markov models (generally based on the aggregate 
PARTNER B outcomes and survival data) and reported incremental cost-eff ectiveness 
ratios ranging from £16 200 (approx. $25 000) per quality-adjusted life-year (QALY) 
Figure 2. Cost-Eff ectiveness Results of PARTNER Cohort B: TAVI versus Standard Therapy
The mean incremental cost-eff ectiveness ratio of TAVI versus standard therapy is plotted as the dark circle, 
along with 5000 bootstrap replications (cloud of circles). In this cost-eff ectiveness plane the incremental 
cost-eff ectiveness ratio is expressed in US $ per life-year gained. The two dashed lines represent two 
willingness-to-pay thresholds of $100 000 or $ 50 000 per LYG.
LE, life-expectancy; LYG, life-years gained; TAVI, transcatheter aortic valve implantation. Reprinted with 
permission from Reynolds et al.9
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gained to $61 889 per QALY.5-8, 10, 11 Despite underlying diff erences in methodology and 
healthcare systems across these studies, the relatively consistent results lead to the 
conclusion that TAVI is economically attractive compared with medical management in 
patients who are not candidates for surgery. In other words, the increased life expectancy 
and quality-adjusted life expectancy after TAVI is achieved at an incremental cost that is, 
for most countries, within the range of other accepted therapies.
In addition to the general fi nding that TAVI is reasonably cost-eff ective for inoperable 
patients with severe AS, several broad themes have emerged from these studies. The 
fi rst is that for patients who are considered inoperable, TAVI results in higher overall 
healthcare costs. In fact, even if the TAVI prosthesis were provided free of charge, overall 
healthcare expenditures would be increased.9 This fi nding refl ects the fact that inoper-
able patients with severe AS have very a relatively short life expectancy (median survival 
<2 years), which is prolonged substantially if they undergo TAVI. The second factor that 
underlies this conclusion is the fi nding that even after successful TAVI, patients who 
were otherwise inoperable continue to accrue substantial healthcare related costs (on 
the order of $30,000 per year) due to their severe comorbidity. Thus, by extending their 
lives, the net cost to the healthcare system actually increases.
The second general conclusion to be drawn from these studies is that in order for TAVI 
to be cost-eff ective in inoperable patients with AS, it must result in substantial gains in 
life expectancy (in the order of one to two years minimum) as well as improved quality of 
life.9 Sensitivity analyses based on the PARTNER trial demonstrate that if quality of life did 
not improve after TAVI (but survival did improve), the ICER for TAVI compared with medi-
cal therapy would increase to ~$80,000 per quality-adjusted life year (QALY) gained—a 
value that exceeds societal willingness to pay levels in many Western societies.12
COST-EFFECTIVENESS OF TAVI VERSUS SAVR
In Cohort A of the PARTNER trial, 699 patients at high surgical risk were randomized to 
TAVI via either a TF or TA approach or SAVR. Over a two-year follow-up period, there was 
no diff erence in survival comparing TAVI with SAVR (66.1% vs. 65.0%, p = 0.78).13 Thus, 
in contrast to the results of TAVI in inoperable patients, among high risk but operable 
AS patients, the main benefi t of the less invasive procedure is in quality of life. Indeed, 
a formal quality of life study conducted alongside PARTNER Cohort A demonstrated that 
TAVI did result in improved quality of life compared with SAVR in the short term, but 
that these benefi ts were restricted to patients who were eligible for a transfemoral TAVI 
(TF-TAVI) procedure and were limited to the fi rst six months of follow-up.14 In contrast, 
29
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among patients who were only suitable for TA access, there were no quality of life ben-
efi ts with TAVI compared with SAVR, and there were trends toward worse quality of life 
at the 1 and 6 month assessments.14 Given these fi ndings, it is not surprising that when 
these results were expressed in quality-adjusted life years for the purpose of economic 
analysis, TF-TAVI was associated with a small but signifi cant gain of 0.068 QALYs (95% 
CI, 0.017-0.1230) over the fi rst year of follow-up, whereas in the TA subset, TAVI was 
associated with a loss of 0.070 QALYs compared with SAVR (95% CI, −0.151-0.012).15 
With comparable survival and only small diff erences in quality of life, costs thus play a 
pivotal role in the cost-eff ectiveness of TAVI when compared with SAVR.
Table 2 provides an overview of the published studies that have investigated the cost-
eff ectiveness of TAVI vs. surgical aortic valve replacement (SAVR) for patients at high 
risk of mortality from SAVR.5-7, 11, 15, 16 From the US perspective, individual patient cost-
eff ectiveness analysis of Cohort A in the PARTNER trial showed that TF-TAVI route was 
an economically attractive strategy compared with SAVR with lower one-year costs and 
greater quality adjusted life expectancy (Figure 3). In contrast, transapical TAVI (TA-TAVI) 
was associated with higher costs and lower quality-adjusted life expectancy, rendering 
it both clinically and economically unfavorable relative to SAVR. Gada and colleagues 
Figure 3. Cost-Eff ectiveness Results of PARTNER Cohort A: TAVI versus SAVR
The mean incremental cost-eff ectiveness ratios for transfemoral TAVI versus SAVR are plotted as dark cir-
cles. The cloud of open circles represents each of the individual 1000 bootstrap replications based on 
the observed trial results. The dashed line represents a willingness-to-pay threshold of $50 000 per QALY 
gained. In this base-case analysis, TF-TAVI was associated with a gain of 0.068 QALYs and cost savings of 
$1 250 per patient, leading to a position of economic dominance. SAVR, surgical aortic valve replacement 
TF-TAVI, TAVI via transfemoral access; TAVI, transcatheter aortic valve implantation; QALY, quality-adjusted 
life-year. Reprinted with permission from Reynolds et al.15
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examined the cost-eff ectiveness of TA-TAVI using a disease simulation model and also 
concluded that it was economically dominated by SAVR.6
One interesting fi nding from the available literature is that even though most model-
based cost-eff ectiveness analyses have used the PARTNER A trial as the key source for 
their base case assumptions, these studies draw markedly diff erent conclusions that 
depend largely on the healthcare system in which the analysis is conducted.5-7, 11, 16 For 
example, one model that incorporated a UK perspective found TAVI to be economically 
dominant compared with SAVR for high risk patients;16 another model that considered 
a US perspective found that TF-TAVI was slightly more costly than SAVR but still cost-
eff ective by conventional standards.7 However, two studies that considered a Belgian and 
a Canadian perspective have concluded that TAVI is substantially more costly and only 
minimally more eff ective than SAVR, suggesting that TAVI is relatively unattractive from 
an economic standpoint for patients who are otherwise candidates for SAVR.
By far, the most important factor that explains these discrepant results is diff erences in 
the cost of high-risk SAVR in various healthcare settings. In countries where high-risk 
SAVR is quite costly (US, UK), it appears that the reductions in length of stay following 
TAVI result in substantial cost off sets to the healthcare system. In other settings (e.g., 
Canada, Western Europe), however, the costs of SAVR appear to be markedly lower. 
Whether these diff erences relate to true diff erences in health care costs across health 
systems or relate to diff erences in the types of patients that form the basis for the surgi-
cal cost estimates is unclear. One consistent fi nding from the available studies is that 
the cost-eff ectiveness of TAVI vs. SAVR depends on the access route. In particular, no 
study to date has demonstrated a favorable ICER for TAVI vs. SAVR among patients who 
are not suitable for transfemoral access. In general, these fi ndings relate to the observa-
tions from the PARTNER A trial that TA-TAVI did not lead to measurable improvements in 
survival, quality of life, or length of stay compared with SAVR14. Since these results were 
derived from the very earliest US experience with TA-TAVI, however, it will be important 
to revisit these analyses as operator and institutional experience increases and also to 
assess whether other access routes (e.g., subclavian, direct aortic) might provide more 
favorable economic outcomes.
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In the 1960s, the fi rst saphenous vein bypass from the ascending aorta to the anterior 
descending coronary artery was performed,1 thereby laying the foundation of coronary 
artery bypass grafting (CABG) and the treatment of coronary artery disease. CABG was 
quickly integrated in clinical practice, although the fi rst trial comparing it to medical 
therapy was only published in 1983.2 In 1977, Gruentzig performed the fi rst percutane-
ous coronary intervention (PCI) by reopening coronary lesions with a distensible balloon.3 
Both PCI and CABG have since been considered for treatment of coronary artery disease. 
Nowadays, approximately 3700 individuals per million US adults undergo coronary 
artery revascularization with PCI, while 1100 undergo CABG.4 The number of patients 
undergoing PCI remained constant between 2001 and 2008, whereas the number of 
CABGs dropped from 1700 per million US adults to 1100 in 2008.
CABG VERSUS MEDICAL THERAPY
Soon after the introduction of CABG, it quickly became apparent that it was successful in 
relieving angina pectoris.1 It was, however, more diffi  cult to prove that CABG prolonged 
life compared with medical therapy and thus randomized studies were performed in the 
1970s and 1980s. The largest three studies included approximately 800 patients each5-7 
but were underpowered to detect small risk reductions.
In a collaborative meta-analysis, patient-level data of seven trials were pooled; 83% of 
the patients had MVD and were predominantly middle-aged males.8 Only 10% of CABGs 
was performed with internal mammary grafts and 20% of the patients were treated with 
antiplatelet therapy. The meta-analysis showed that at 10 years, 41% of the medically 
managed group had undergone CABG surgery. Notably, there was a clear survival benefi t 
for CABG compared with medical therapy at 5 years (10.2% vs. 15.8% mortality), 7 years 
(15.8% vs. 21.7% mortality) and 10 years (26.4% vs. 30.5% mortality). Since survival 
was particularly improved in patients with more extensive coronary artery disease, the 
meta-analysis also confi rmed the hypothesis that the benefi ts of CABG are higher when 
the myocardium at risk is larger. Moreover, the advantages of surgery were not restricted 
to patients with left main coronary artery disease, but also applied to MVD patients. The 
current guidelines recommend CABG over optimal medical therapy (OMT) with a class I 
recommendation in the majority of patients with MVD.9, 10
Part I. Introduction
38
CABG VERSUS PCI
Over the past two decades, almost 30 randomized controlled trials have investigated 
CABG versus PCI.9, 11-13 Initially, CABG was compared with balloon angioplasty, then with 
BMS and most recently with drug-eluting stents (DES).
CABG versus Balloon Angioplasty or BMS
A meta-analysis of 23 randomized trials showed that survival at 1 and 5 years was similar 
in patients undergoing CABG or PCI (balloon angioplasty or BMS).11 More specifi cally, in 
patients with MVD, survival at 5 years was 91% after CABG and 90% after PCI. There was 
no substantial diff erence between trials using balloon angioplasty versus trials using 
BMS (Table 1).14-27
Another collaborative meta-analysis pooled data of MVD patients from six CABG versus 
balloon angioplasty trials,14-17, 19, 21 and four CABG versus BMS trials.20, 24, 26, 27 At a median 
follow-up of 5.9 years, there was no diff erence in death (CABG 8% vs. PCI 10%) and 
the composite of death and MI (CABG 15% vs. PCI 17%; Figure 1).28 There were more 
deaths and repeat revascularizations with CABG than with PCI (CABG 10% vs. PCI 25%). 
In addition, angina relief was greater with CABG (CABG 14% vs. PCI 26%).
Figure 1. Outcomes of Treatment with CABG or PCI in ten Randomized Trials
Pooled data from 10 randomized trials show overall unadjusted mortality (A) and the composite endpoint 
of death or myocardial infarction (B) after randomization to CABG or PCI. Data on the composite endpoint 
was not available from the EAST trial.21 *Number of patients available for follow-up.
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention
Reproduced with permission from Hlatky et al.28
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CABG versus DES
To reduce the high rate of restenosis and repeat revascularization, the DES was devel-
oped and introduced commercially in 2002. The coating of the stent contains a powerful 
immunosuppressive drug that should prevent restenosis and thereby the need for repeat 
revascularization. A meta-analysis showed that DES are indeed more eff ective in reduc-
ing restenosis compared with BMS.29
Table 1. Studies comparing CABG with Balloon Angioplasty/BMS in Patients with MVD
Study
Size, 
n
Age, 
y
Enrollment
Primary 
endpoint
Follow-
up, y
CABG 
using 
arterial 
grafts,%
PCI using 
stents,%
5 year 
survival,%
PCI CABG
GABI19 323 NR 1986-1991 Angina 13 37 0 93 95
EAST45 392 61 1987-1990 Death, MI 8 86 0 88 91
ERACI I92 127 58 1988-1990
Death, MI, Angina, 
Revascularization
3 77 0 NR NR
BARI16 1829 61 1988-1991 Death 10 82 0 86 89
RITA I87 1011 57 1988-1991 Death, MI 6.5 74 0 95 95
CABRI15 1054 60 1988-1992 Death 1 81 0 NR NR
Toulouse17 152 67 1989-1993 Angina 5 58 0 87 87
Balloon Overall 89 91
MASS II99 408 60 1995-2000
Death, MI, Repeat 
revascularization
5 92 68 86 84
AWESOME22 454 67 1995-2000 Death 5 76 54 79 73
ERACI II24 450 62 1996-1998
Death, MI, 
CVA, Repeat 
revascularization
5 89 100 93 88
SoS trial27 988 61 1996-1999
Repeat 
revascularization
3 93 100 NR NR
ARTS I26 1205 61 1997-1998
Death, MI, 
CVA, Repeat 
revascularization
5 93 100 92 92
Octostent18 280 60 1998-2000
Death, MI, Repeat 
revascularization
1 100 100 NR NR
Myoprotect I23 44 70 1998-2001
Death, MI, Repeat 
revascularization
1 NR 100 NR NR
BMS Overall 91 89
Adapted from Bravata et al.11
ARTS, Arterial Revascularization Therapies Study; AWESOME, Angina with Extremely Serious Operative Mor-
tality Evaluation; BARI, Bypass Angioplasty Revascularization Investigation; CABG, coronary artery bypass 
grafting; CABRI, Coronary Angioplasty versus Bypass Revascularization Investigation; EAST, Emory Angio-
plasty versus Surgery Trial; ERACI, Argentine randomized trial of percutaneous transluminal coronary an-
gioplasty versus coronary artery bypass surgery in multivessel disease; GABI, German Angioplasty Bypass 
Surgery Investigation; MASS, Medicine, Angioplasty, or Surgery Study; MVD, multivessel disease; n, number 
of participants; NR, not reported; PCI, percutaneous coronary intervention; Ref, reference; RITA, Random-
ized Intervention Treatment of Angina; SoS, Stent or Surgery; y, years.
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With the introduction of DES, a new era of comparisons between CABG and PCI started. A 
meta-analysis of nine observational, nonrandomized studies compared CABG with DES in 
24,268 patients with MVD.30 At 20 months, the incidence of the composite end point of 
death, acute MI and cerebrovascular accidents was similar between the two treatments. 
Importantly, however, there was a signifi cantly higher risk of repeat revascularization in 
the PCI group (HR: 4.06; p < 0.001).
The SYNTAX trial is the most important trial that randomized patients to CABG or PCI 
with DES.31, 32 The trial was set-up as an all-comers study and patients with three-vessel 
and/or left main disease were discussed in the heart team with the local cardiac surgeon 
and interventional cardiologist. At 5 years, the composite primary end point of death 
from any cause, stroke, MI or repeat revascularization occurred less often with CABG 
compared with PCI (CABG 26.9% vs. PCI 37.3%; p < 0.001; Figure 2). This diff erence was 
mainly driven by a higher rate repeat revascularization in PCI (CABG: 13.7% vs. 25.9%; 
p < 0.001), but also MI (CABG 3.8% vs. PCI 9.7%; p < 0.001) occurred more often with PCI 
compared with CABG. The hypothesis-generating subgroup of 1095 patients with three 
vessel disease showed a similar picture with a 5-year rate of the composite primary end 
point that was lower in CABG (CABG: 24.2% vs. PCI: 37.5%; p < 0.001).31, 33 Moreover, 
survival at 5 years was better with surgery (CABG 9.2% vs. PCI 14.6%; p = 0.006).31 The 
trial also introduced the SYNTAX score. This measure of coronary complexity showed 
signifi cant interaction with clinical outcomes; CABG was better in patients with more 
complex coronary anatomy, whereas PCI proved to be an acceptable revascularization 
in anatomically less complex disease. Also in the three-vessel cohort, the diff erence in 
the rates of the composite end point increased according to the SYNTAX score categories 
(low: PCI 33.3% vs. CABG 26.8%, p = 0.21; intermediate: PCI 37.9% vs. CABG 22.6%, 
p = 0.0008; high: PCI: 41.9% vs. CABG 24.1%, p = 0.0005). Using both the randomized 
and registry data, the conclusion was that CABG off ers a survival advantage and reduc-
tion in repeat revascularization in almost 79% of all patients with three-vessel disease.34
Two large registries used comparative eff ectiveness methodology to validate the SYNTAX 
results in real-world clinical practice. They provided supportive evidence for a survival 
benefi t with CABG.35, 36 In New York State, adverse outcomes (death, death or MI and 
repeat revascularization) with CABG and PCI with DES were compared in almost 18,000 
patients with MVD.36 At 18 months follow-up, patients who underwent surgery had lower 
rates of repeat revascularization (CABG 5.2% vs. PCI 30.6%; p < 0.001). Moreover, CABG 
was associated with greater adjusted survival (CABG 94.0% vs. PCI 92.7%; p = 0.03) 
and the end point freedom of death and MI (CABG 92.1% vs. 89.7%; p < 0.001). In the 
American College of Cardiology Foundation (ACCF) and Society of Thoracic Surgeons 
(STS) Database Collaboration on the ASCERT study, more than 180,000 patients from 
41
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the ACCF NCDR and STS Adult Cardiac Surgery databases were linked with data from the 
Centers for Medicare and Medicaid Services for the years 2004 through 2008.35 Mean 
age was 74 years and all patients had two- or three-vessel disease. At 1 year, there was 
no signifi cant diff erence in adjusted mortality between groups (CABG 6.2% vs. PCI 6.6%; 
risk ratio: 0.95; 95% CI: 0.90–1.00). At 4-year follow-up, however, there was signifi cantly 
lower mortality with surgery compared with PCI (CABG 16.4% vs. 20.8%; risk ratio: 0.79; 
95% CI: 0.76–0.82).
Figure 2. SYNTAX trial 5-year Kaplan-Meier cumulative Event Curves
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; MACCE, major adverse 
cardiac and cerebrovascular events.
Reproduced with permission from Mohr et al.31
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In summary, data from registries and the SYNTAX trial show that there is suffi  cient 
evidence to state that in the majority of patients with MVD, CABG outperforms PCI with 
regard to long-term survival, MI and repeat revascularization. This evidence is refl ected in 
the recommendations by the European and American guidelines on myocardial revascu-
larization that CABG has a class I recommendation for the majority of patients with MVD, 
whereas PCI has a class IIa/b recommendation.9, 10
A potential explanation for the survival benefi t is that diff use atherosclerosis is bypassed 
with one or two grafts to the mid-coronary vessel, providing extra sources of blood fl ow 
to the myocardium.37 This results in protection of the entire distal myocardium for cur-
rent and future proximal obstructive disease. Stents, however, aim to restore the native 
vessel without protection against new proximal disease. In addition, multiple stents are 
needed in diff use disease each with its own risks of restenosis.
The evidence from trials and registries have resulted in class Ia recommendations for 
CABG over PCI in the majority of patients with stable coronary artery disease.9, 10 By 
randomizing 2600 patients with left main, or left main-equivalent disease to CABG or 
PCI with DES, the XIENCE the EXCEL trial is expected to provide additional insights on the 
optimal revascularization strategy (ClinicalTrials.gov identifi er: NCT01471522205776).
DIABETICS
In patients with diabetes mellitus (DM), the process of atherosclerosis is accelerated 
through prothrombotic and proinfl ammatory states in combination with endothelial 
dysfunction and metabolic disorders.38 Although the benefi ts of glycemic control on 
microvascular problems of DM have been demonstrated in clinical trials, the evidence for 
benefi ts of lowering HbA1c levels on cardiovascular disease is less proven.9 Therefore, 
and because of the high prevalence of diabetes, these patients form a specifi c group of 
interest in the revascularization debate.39, 40 Indeed, a Danish cohort study showed that 
patients with DM, but without a history of coronary artery disease, had a similar 5-year 
cardiac mortality risk as non-DM patients with a history of MI.41
Revascularization versus Medical Therapy in Diabetics
There are two major trials comparing the outcomes of revascularization and medical 
therapy in diabetics.42, 43 The BARI-2D trial was a dedicated trial in which 2368 diabet-
ics were randomized between medical therapy and revascularization (PCI or CABG).42 
At 5 years, there was no diff erence in the rate of survival (revascularization 88.3% vs. 
medical therapy 87.8%; p = 0.97) and the composite of death, MI or stroke (revasculariza-
43
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tion 77.2% vs. medical therapy 75.9%; p = 0.70). A subgroup analysis of the COURAGE 
trial showed that PCI coupled with OMT did not reduce the rate of adverse events as 
compared with OMT alone.43
CABG versus PCI in Diabetics
The BARI trial provided the fi rst evidence that patients with DM had better survival after 
CABG than after PCI.16 Initially, these results were not replicated in other trials,44-46 but 
a meta-analysis with pooled data from ten randomized trials showed that 23% of the 
615 diabetics assigned to CABG and 29% of the 618 diabetics assigned to PCI died.28 In 
the patients without DM, 13% and 14% died in the CABG and PCI group, respectively 
(p = 0.014 for interaction). This interaction remained after adjustment for other patient 
characteristics (p = 0.008).
In a subgroup of 452 DM patients from the SYNTAX trial, those who underwent PCI had a 
higher risk of the composite of death, MI, stroke and repeat revascularization at 5 years 
(CABG 46.5% vs. PCI 29.0%; p < 0.001). This diff erence was driven by a signifi cant diff er-
ence in repeat revascularization (CABG 14.6% vs. PCI 35.3; p < 0.001),47 while the other 
individual outcomes were similar. Similar to the overall cohort of the trial, the diff erence 
between PCI and CABG in diabetics increased according to the SYNTAX score.
The CARDIa trial randomized 510 patients with DM and multivessel or complex single-
vessel disease to either CABG or PCI.48 At 1 year, there was no diff erence in the composite 
primary end point of death, MI and stroke (CABG 10.5% vs. PCI 13.0%; p = 0.39). However, 
the trial was underpowered and only 69% of patients underwent PCI with DES, while the 
remaining 31% received BMS.
Recently, the results of the FREEDOM trial were published.49 In this trial, 1900 patients 
with DM and MVD were randomized to undergo either PCI with DES or CABG. At 5 years, 
the primary composite outcome of death, MI and stroke occurred more frequently in the 
PCI group (CABG 18.7% vs. PCI 26.6%; p = 0.005). CABG also had signifi cantly lower rates 
of mortality (CABG 10.9% vs. PCI 16.3%; p = 0.049) and MI (CABG 6.0% vs. PCI 6.0%; 
p < 0.001); however, there were more strokes in the surgical group (CABG 5.2% vs. PCI 
2.4%; p = 0.03), mostly due to strokes that occurred within 30 days after the procedure. 
Interestingly, no interaction was observed with the SYNTAX score in the FREEDOM trial. 
Including the FREEDOM trial, there is compelling evidence from 13 trials and more than 
4000 diabetic patients that CABG results in better survival compared with PCI.13 In non-
diabetic patients, however, there seems to be no diff erence in survival between CABG 
and PCI.
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THE INFLUENCE OF TRIAL RESULTS ON CLINICAL PRACTICE
One of the main concerns of clinical trials is the potentially limited applicability of its 
results to everyday clinical practice. In general, randomized clinical trials are considered 
to provide the most unbiased and precise evidence for clinicians.50 Blinding, randomiza-
tion and other issues of internal validity receive much attention, but the external validity 
or generalizability determines what the usability of the results will be in clinical practice. 
There is a delicate balance between the need for exclusion criteria to optimize internal 
validity of effi  cacy and the need for less stringent criteria to determine an intervention’s 
eff ectiveness for clinical practice. Elderly patients and patients with common concomi-
tant medical conditions are frequently excluded,51 whereas these patients refl ect an 
important share of all patients that suff er from MVD.
In the early CABG versus PCI trials (Table 1), only 5–10% of all patients screened for par-
ticipation were randomized,14 thereby limiting the applicability of the results to everyday 
clinical practice. For instance, in the BARI trial, only 7% (1829 of 25,200) of all screened 
patients with MVD were eventually randomized.52 The trial excluded patients above 80 
years of age, which clearly limits the applicability of the results of the trial.
As noted earlier, the SYNTAX trial used an all-comer design to increase generalizability 
and determine the best treatment option in a real-world population.53, 54 All patients with 
three-vessel and/or left main disease were discussed by the heart team. Inclusion was 
based on discussions between a cardiologist and cardiac surgeon, applying the limited 
number of exclusion criteria. When both agreed that the patient was equally eligible 
for CABG or PCI, the patient was randomized. If the patient was not randomized, he/she 
was still followed in the appropriate PCI or CABG registry. In total, 4337 patients were 
screened and discussed, of which 3075 (71%) were included in the study. Of these, 1800 
patients were randomly assigned to undergo CABG (897 patients) or PCI (903 patients) 
and the remaining 1275 were followed in the registries.32, 55 These data show that the 
trial indeed refl ected a real-world population as much as possible, while also preserving 
internal validity. Therefore, the results of the SYNTAX trial are particularly well applicable 
to everyday clinical practice.
Large comparative eff ectiveness studies of registries are the only way to assess the gen-
eralizability of trial results in everyday clinical practice. There are two major comparative 
eff ectiveness studies that provide insights on revascularization in patients with MVD.35, 36 
While exclusions might limit the generalizability of randomized trials, comparative ef-
fectiveness suff er from selection bias. There are always specifi c factors why PCI or CABG 
is preferred. For instance, the patient’s frailty or expected treatment adherence can play 
45
Chapter 3. Coronary Revascularization
3
Ta
bl
e 
2.
 E
co
no
m
ic
 A
na
ly
se
s 
of
 C
A
BG
 v
er
su
s 
PC
I i
n 
M
V
D
 p
at
ie
nt
s
St
ud
y
Fo
ll
ow
-u
p,
 y
PC
I u
si
ng
 
st
en
t,
 %
En
ro
ll
m
en
t
CA
BG
 
co
st
PC
I c
os
t
∆ 
co
st
s 
(C
AB
G
-P
CI
)
IC
ER
Co
nc
lu
si
on
EA
ST
98
3
0
19
87
-1
99
0
25
,3
10
23
,7
34
1,
57
6
N
R
Ea
rly
 c
os
t b
en
efi
 t 
of
 P
CI
 is
 lo
st
EA
ST
97
8
0
19
87
-1
99
0
46
,5
48
44
,4
91
2,
05
7
N
R
Ea
rly
 c
os
t b
en
efi
 t 
of
 P
CI
 is
 lo
st
ER
AC
I I
25
1
0
19
88
-1
99
0
12
,9
38
6,
95
2
5,
98
6
N
R
Co
st
s 
hi
gh
er
 w
ith
 C
AB
G
ER
AC
I I
92
3
0
19
88
-1
99
0
13
,0
00
7,
52
4
5,
47
6
N
R
Co
st
s 
hi
gh
er
 w
ith
 C
AB
G
BA
RI
89
5
0
19
88
-1
99
1
58
,8
89
56
,2
25
2,
66
4
26
,1
17
/L
Y 
a
CA
BG
 c
os
t e
ff e
ct
iv
e 
an
d 
be
tt
er
 Q
oL
BA
RI
88
12
0
19
88
-1
99
1
12
3,
00
0
12
0,
75
0
2,
25
0
14
,3
00
/L
Y 
a
CA
BG
 c
os
t e
ff e
ct
iv
e 
an
d 
be
tt
er
 Q
oL
RI
TA
93
2
0
19
88
-1
99
1
£8
,7
39
£6
,9
16
£1
,8
23
N
R
Co
st
 h
ig
he
r w
ith
 C
AB
G
RI
TA
87
6.
5
0
19
88
-1
99
1
£9
,2
68
£8
,8
42
£4
26
N
R
Ea
rly
 c
os
t b
en
efi
 t 
of
 P
CI
 is
 lo
st
M
AS
S 
II8
6
1
68
 (B
M
S)
19
95
-2
00
0
14
,0
95
b
13
,0
99
b
99
6
N
R
Co
st
s 
w
er
e 
si
m
ila
r
M
AS
S 
II9
6
5
68
 (B
M
S)
19
95
-2
00
0
24
,6
14
b
25
,8
31
b
−1
,2
17
N
R
CA
BG
 c
os
t-
eff
 e
ct
iv
e
AW
ES
O
M
E9
5
5
54
 (B
M
S)
19
95
-2
00
0
10
0,
52
2
81
,7
90
18
,7
32
PC
I d
om
in
an
t
PC
I e
co
no
m
ic
al
ly
 d
om
in
an
t
AR
TS
 I9
4
1
10
0 
(B
M
S)
19
97
-1
99
8
13
,6
38
10
,6
65
2,
97
3
21
,0
00
/p
at
ie
nt
 w
ho
 
su
rv
iv
es
 e
ve
nt
 fr
ee
CA
BG
 c
os
t-
eff
 e
ct
iv
e
AR
TS
 I9
0
3
10
0 
(B
M
S)
19
97
-1
99
8
€1
6,
10
0
€1
4,
30
2
€1
,7
98
€1
9,
25
7/
pa
tie
nt
 w
ho
 
su
rv
iv
es
 e
ve
nt
 fr
ee
CA
BG
 is
 m
or
e 
co
st
ly
, b
ut
 a
ls
o 
m
or
e 
eff
 e
ct
iv
e.
 C
AB
G
 
se
em
s 
ec
on
om
ic
al
ly
 a
tt
ra
ct
iv
e
SY
N
TA
X8
5
1
10
0 
(D
ES
)
20
05
-2
00
7
39
,5
81
35
,9
91
3,
59
0
PC
I d
om
in
an
t
PC
I l
ar
ge
ly
 e
co
no
m
ic
al
ly
 d
om
in
an
t, 
ex
ce
pt
 fo
r h
ig
h 
co
m
pl
ex
 p
at
ie
nt
s
FR
EE
D
O
M
91
5,
 a
nd
 li
fe
tim
e 
pr
oj
ec
tio
n
10
0 
(D
ES
)
20
05
-2
01
0
11
4,
57
1
10
9,
17
9
5,
39
2
8,
13
2/
Q
AL
Y
D
es
pi
te
 h
ig
he
r i
ni
tia
l c
os
ts
, C
AB
G
 is
 h
ig
hl
y 
co
st
-
eff
 e
ct
iv
e 
in
 d
ia
be
tic
s
Co
st
s 
ar
e 
in
 U
S 
$,
 u
nl
es
s 
st
at
ed
 o
th
er
w
is
e.
 a  
in
 fa
vo
r o
f C
AB
G
. b
 re
po
rt
ed
 a
s 
an
gi
na
-f
re
e 
co
st
s.
AR
TS
, A
rt
er
ia
l R
ev
as
cu
la
ri
za
ti
on
 T
he
ra
pi
es
 S
tu
dy
; A
W
ES
O
M
E,
 A
ng
in
a 
w
it
h 
Ex
tr
em
el
y 
Se
ri
ou
s 
O
pe
ra
ti
ve
 M
or
ta
lit
y 
Ev
al
ua
ti
on
; B
AR
I, 
By
pa
ss
 A
ng
io
pl
as
ty
 R
ev
as
cu
la
ri
za
ti
on
 
In
ve
st
ig
at
io
n;
 C
AB
G
, c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
ti
ng
; E
AS
T,
 E
m
or
y 
An
gi
op
la
st
y 
ve
rs
us
 S
ur
ge
ry
 T
ri
al
; E
RA
C
I, 
Ar
ge
nt
in
e 
ra
nd
om
iz
ed
 t
ri
al
 o
f 
pe
rc
ut
an
eo
us
 t
ra
ns
lu
m
in
al
 
co
ro
na
ry
 a
ng
io
pl
as
ty
 v
er
su
s 
co
ro
na
ry
 a
rt
er
y 
by
pa
ss
 s
ur
ge
ry
 in
 m
ul
ti
ve
ss
el
 d
is
ea
se
; F
RE
ED
O
M
, F
ut
ur
e 
Re
va
sc
ul
ar
iz
at
io
n 
Ev
al
ua
ti
on
 in
 P
at
ie
nt
s 
w
it
h 
D
ia
be
te
s 
M
el
lit
us
: 
O
pt
im
al
 M
an
ag
em
en
t o
f 
M
ul
ti
ve
ss
el
 D
is
ea
se
; I
C
ER
, i
nc
re
m
en
ta
l c
os
t-
eff
 e
ct
iv
en
es
s 
ra
ti
o;
 M
AS
S,
 M
ed
ic
in
e,
 A
ng
io
pl
as
ty
, o
r 
Su
rg
er
y 
St
ud
y;
 M
V
D
, m
ul
ti
ve
ss
el
 d
is
ea
se
 ; 
N
R,
 
no
t r
ep
or
te
d;
 P
C
I, 
pe
rc
ut
an
eo
us
 c
or
on
ar
y 
in
te
rv
en
ti
on
; R
IT
A,
 R
an
do
m
iz
ed
 In
te
rv
en
ti
on
 T
re
at
m
en
t o
f A
ng
in
a;
 S
oS
, S
te
nt
 o
r S
ur
ge
ry
; S
YN
TA
X,
 S
YN
er
ge
ry
 B
et
w
ee
n 
PC
I W
it
h 
TA
XU
S 
an
d 
C
ar
di
ac
 S
ur
ge
ry
; y
, y
ea
rs
Part I. Introduction
46
a role, but there might also be factors are diffi  cult to capture and adjust in comparative 
analyses. Residual confounding is another issue in observational research, which may 
distort the validity of the results. Diff erences in age, comorbidities and the urgency of 
treatment can be controlled, but there might be factors that cannot be measured and 
adjusted. This could have had an infl uence on the survival diff erence between CABG 
and PCI in the two studies. The ASCERT study used sophisticated sensitivity analyses to 
show the potential impact and the authors acknowledge the potential impact of residual 
confounding.
The issues of external validity in randomized trials and the internal validity problems 
of comparative eff ectiveness research show that the two are complementary. The ap-
plicability of trials can be improved through less stringent exclusion criteria, whereas 
more accurate and elaborate registries will enhance the internal validity of comparative 
eff ectiveness studies.
Appropriateness of the Revascularization Method
The best treatment option in the individual patient is not always straightforward, since 
there are multiple factors that have to be taken into account and patients do not com-
pletely align with the guidelines. Therefore, the ACCF updated their appropriate use 
criteria (AUC), incorporating guidelines, trial evidence and expert opinion. The result is 
an appropriateness scale for a wide range of clinical scenarios. The selected treatment 
is deemed appropriate when the expected benefi ts exceeded the expected negative 
consequences of the treatment.56
The criteria provide a methodology to quantify the impact of trial evidence on everyday 
clinical practice. Large registries found rates of inappropriate revascularization proce-
dures in both PCI (12–14%) and CABG (1–2%).57-59 The rate of inappropriate revascu-
larizations should not be expected to be zero, due to the exceptions that have not been 
captured in the predefi ned clinical scenarios. However, the evidence of inappropriate 
PCIs is increasing and several factors are likely to play a role. First, a patient’s perceptions 
and the physician’s guidance about the risks and benefi ts of PCI or CABG are likely to 
play a role. Patients may prefer the early and rapid recovery after PCI over the long-term 
survival benefi ts of CABG.60 A second explanation is that the clinical decision pathway 
is more in favor of PCI than CABG; it is a small step to perform ad hoc stenting after 
initial diagnostic angiography. Another explanation is that some physicians believe that 
following guidelines does more harm than benefi t to patients. A recent Medscape survey 
showed that 43% of 645 interviewed physicians believe that guidelines have a negative 
impact on patient care.61
47
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There are some limitations to the AUC. First, there is only moderate concordance be-
tween a series of cardiologists and the AUC panel that developed the methodology.62 
In addition, this technical panel is relatively small (n = 17) and the number of clinical 
scenarios is limited. Despite the criticisms, the growth and increasing use of appropriate-
ness criteria provide valuable information for improving the framework and underline 
that this methodology provides an important tool of measuring how evidence from trials, 
large registries and guidelines is integrated in clinical practice.63
Risk Scores
In clinical practice, the decision to revascularize depends on the expected risks and 
benefi ts of the treatment options. Risk models are important tools in these clinical 
considerations. For patients with coronary artery disease, there are several risk models 
available, which can be divided into clinical, anatomical and combined models.
Clinical risk models use patient characteristics, comorbidities, cardiac history, ejection 
fraction and the type of procedure to predict short-term mortality after the revasculariza-
tion.64-68 The original EuroSCORE overpredicts surgical mortality in contemporary datas-
ets.69, 70 The EuroSCORE II improved calibration in patients with a predicted mortality of 
<30%.71, 72 The original EuroSCORE, however, has been shown to be a well-calibrated 
predictor of in-patient mortality in patients undergoing PCI,73 thereby forming a useful 
tool for decision-making in patients with coronary artery disease. The STS score is widely 
used in the USA for predicting operative mortality (STS-PROM), as well as eight other 
outcomes, such as risk of prolonged length of stay, stroke and renal failure.67 For patients 
undergoing PCI, the NCDR CathPCI risk score represents a contemporary and accurate 
risk prediction model with good calibration and discrimination.74
Anatomy-based scores focus on the anatomical complexity of the lesion for the predic-
tion of mortality.68, 75 The SYNTAX score takes into account anatomical characteristics of 
the lesion including bifurcations, total occlusions, thrombus, calcifi cation and small ves-
sels.68 The score is a strong predictor of death and other adverse events during long-term 
follow-up for PCI, but is of less signifi cance for CABG.76 Hypothesis-generating subgroup 
analyses from the SYNTAX trial showed that there was a stepwise increase in events, 
according to SYNTAX score categories in the PCI cohort, while there was no predictive 
value of the score for the CABG group.33
Since clinical and anatomical variables are complementary, risk models implementing a 
combination of the two are expected to improve risk prediction. Several attempts to com-
bine factors such as age, lung disease, renal function and other patient characteristics 
with the SYNTAX score have been undertaken.77-82 The results of these initial studies are 
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promising and more validation studies are expected.65 Recently, the SYNTAX score II was 
developed and subsequently validated in a large external registry.79 The score consists 
of two angiographic (SYNTAX score and presence of left main disease) and six clinical 
variables (age, creatinine clearance, left ventricular ejection fraction, peripheral vascular 
disease, gender and chronic obstructive pulmonary disease). The new score can be used 
to better guide decision-making between CABG and PCI.
HEART TEAM
Despite the attempts to incorporate additional variables in the risk scores, there will 
always be factors that are not included but still need to be considered in the decision-
making. Currently, factors that are not considered in risk scores consist of frailty, expected 
treatment adherence, hostile chest and BMI. Moreover, no single risk score can accurately 
predict outcome in the individual patient for which the treatment decision at hand has to 
be made. Therefore, risk scores should be considered a complement to clinical judgment.
These considerations should be done in a multidisciplinary heart team.58 In the SYNTAX 
trial, this approach was used to decide whether patients were eligible for both CABG and 
PCI and could, thus, be randomized. The team consists of at least a clinical cardiologist, 
interventional cardiologist and cardiac surgeon, and is currently recommended by major 
cardiac associations.9, 10 With the combination of all this expertise, the patient is more 
likely to undergo the treatment that is most benefi cial for their specifi c situation.
In order to ensure implementation of the heart team, fi nancial and clinical incentives 
should be aligned. Heart team meetings require time investment of medical specialists 
and therefore appropriate reimbursement is an important precondition. For instance, in 
the Netherlands, heart team discussions are reimbursed since payers recognize the long-
term benefi ts of the appropriate revascularization method. Healthcare systems should 
carefully evaluate whether the short-term payer is the same as the payer for long-term 
costs.
HEALTH ECONOMICS OF REVASCULARIZATION
Approximately, 33% (84 million) of all American adults have some form of cardiovas-
cular disease and of these, 15 million suff er from coronary heart disease.83 The annual 
total costs of cardiovascular disease and stroke in the USA are approximately US$313 
billion, representing 15% of the total healthcare expenditures.83 For comparison, the 
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expenditure on cancer and benign neoplasms was US$228 billion in 2008. In the future, 
a rise in expenditure on coronary heart disease is projected (2020: US$470 billion; 2025: 
US$622 billion; 2030: US$818 billion). The expenditure on ischemic heart disease is 
expected to increase from US$47 billion in 2015 to US$106 billion in 2030. Modern so-
cieties are becoming increasingly more aware of this unsustainable growth of healthcare 
expenditures.84
Therefore, cost–eff ectiveness considerations become increasingly important. Several 
trials of MVD patients have published health economic analyses in addition to clinical 
outcomes (Table 1).25, 85-98 With the exception of one study,25, 92 all initial trials showed 
that the early cost benefi t of balloon angioplasty compared with CABG was lost at long-
term follow-up. The BARI trial showed that the incremental cost–eff ectiveness ratio for 
CABG was acceptable at 5 years (US$26,117/life year gained)89 and even better at 12 
years of follow-up (US$14,300/life year gained).88 The RITA trial found higher costs with 
CABG at 2 years,93 but this diff erence disappeared at long-term follow-up.87
The economic analyses of CABG versus BMS show confl icting results. The MASS II and 
ARTS found that CABG was cost eff ective, both at short and long-term follow-up.86, 90, 94, 96 
This means that CABG was more costly, but also more eff ective in improving clinical out-
comes for patients with MVD. The AWESOME study, however, showed considerably lower 
costs (US$18,732) and better outcomes with PCI. Therefore, PCI was an economically 
dominant strategy.
The SYNTAX trial showed that PCI with DES was less costly, and more eff ective than CABG, 
leading to an economically dominant position of PCI at 1 year.85 However, in patients with 
a more complex anatomy, PCI was increasingly expensive (US$43,486/quality-adjusted 
life year). The cost–eff ectiveness analysis of the FREEDOM trial was the most elaborate 
economic analysis in diabetic patients with MVD and combined 5-year trial data with 
lifetime projections.91 The initial higher costs of CABG (∆ = US$8622), narrowed to a 
diff erence of US$3641 at 5 years, while gaining 0.03 quality-adjusted life years. Using 
lifetime projections, the incremental cost–eff ectiveness ratio of CABG versus DES was 
US$8132 per quality-adjusted life year gained. These results suggest that CABG is a more 
attractive treatment option than PCI, both clinically and economically.
Across all economic analyses, the more invasive CABG procedure and longer hospital stay 
contribute to the higher upfront costs with CABG compared with PCI. At longer follow-up, 
the higher rate of repeat revascularizations with PCI counterbalance this diff erence, lead-
ing to similar costs with CABG and PCI. Contemporary long-term clinical outcomes show 
that CABG is more eff ective. Combined with the similar long-term costs, it is expected 
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that CABG will be superior both clinically and economically. This hypothesis is to be 
tested in the upcoming 5-year cost–eff ectiveness analysis of the SYNTAX trial. Due to its 
contemporary all-comer design, its results are anticipated to give the fi nal answer on the 
cost–eff ectiveness of CABG versus PCI in patients with left-main or MVD.
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ABSTRACT
Objectives
The purpose of this study was to evaluate the prevalence of aortic stenosis (AS) in the 
elderly and to estimate the current and future number of candidates for transcatheter 
aortic valve replacement (TAVR).
Background
Severe AS is a major cause of morbidity and mortality in the elderly. A proportion of these 
patients is at high or prohibitive risk for surgical aortic valve replacement, and is now 
considered for TAVR.
Methods
A systematic search was conducted in multiple databases, and prevalence rates of pa-
tients (>75 years) were pooled. A model was based on a second systematic literature 
search of studies on decision-making in AS. Monte Carlo simulations were performed to 
estimate the number of TAVR candidates in 19 European countries and North America.
Results
Data from 7 studies (n = 9,723 subjects) were used. The pooled prevalence of all AS in the 
elderly was 12.4% (95% confi dence interval [CI]: 6.6% to 18.2%), and the prevalence 
of severe AS was 3.4% (95% CI: 1.1% to 5.7%). Among elderly patients with severe AS, 
75.6% (95% CI: 65.8% to 85.4%) were symptomatic, and 40.5% (95% CI: 35.8% to 
45.1%) of these patients were not treated surgically. Of those, 40.3% (95% CI: 33.8% 
to 46.7%) received TAVR. Of the high-risk patients, 5.2% were TAVR candidates. Projec-
tions showed that there are approximately 189,836 (95% CI: 80,281 to 347,372) TAVR 
candidates in the European countries and 102,558 (95% CI: 43,612 to 187,002) in North 
America. Annually, there are 17,712 (95% CI: 7,590 to 32,691) new TAVR candidates in 
the European countries and 9,189 (95% CI: 3,898 to 16,682) in North America.
Conclusions
With a pooled prevalence of 3.4%, the burden of disease among the elderly due to 
severe AS is substantial. Under the current indications, approximately 290,000 elderly 
patients with severe AS are TAVR candidates. Nearly 27,000 patients become eligible for 
TAVR annually.
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INTRODUCTION
Aortic stenosis (AS) is the most common valvular heart disease in developed countries, 
and its impact on public health and health care resources is expected to increase due 
to aging Western populations.1, 2 Each year, approximately 67,500 surgical aortic valve 
replacements (SAVR) are performed in the United States.3 Studies describing the preva-
lence of AS are scarce and report disparate results (3% to 23%),4, 5 and currently there is 
no systematic overview of population-based studies that have assessed the prevalence 
of AS.
The emergence of transcatheter aortic valve replacement (TAVR) has renewed interest in 
the epidemiology of AS. In particular, these data may be important to predict the number 
of TAVR candidates, service development, fi nancial planning, and physician training. In 
addition, estimates of potential TAVR candidates at intermediate and low surgical risk 
are not available. Several factors must be considered when estimating the number of 
TAVR candidates: the percentage of patients with severe AS who are symptomatic; the 
proportion of patients with symptomatic severe AS who do not undergo SAVR and could 
thus be considered TAVR candidates; and the percentage of those patients referred for 
TAVR who actually receive a transcatheter valve.
Therefore, we sought to assess the prevalence of AS in the general elderly population (age 
≥75 years) through a systematic review and meta-analysis of population-based studies. 
The second objective was to systematically estimate the number of elderly patients who 
are TAVR candidates in both the European countries and North America.
METHODS
Studies were identifi ed through a systematic search of MEDLINE and EMBASE in February 
2012. Keywords included “valvular heart disease,” “heart valve disease,” “aortic steno-
sis,” “aortic valve stenosis,” “epidemiology,” “incidence,” “prevalence,” and “survey.” 
No time restrictions were applied. Reference lists of selected studies and (systematic) 
reviews were examined, and the related article feature in PubMed was used to maximize 
relevant study identifi cation.
All titles and abstracts were screened independently by two investigators using the 
following criteria: 1) the publication was an original full-length manuscript in a peer-
reviewed journal; 2) the publication reported numbers of AS cases and sample size or 
the prevalence of AS in the general elderly population (≥75 years of age); and 3) AS 
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and AS severity was diagnosed with echocardiography.6, 7 The defi nition of AS used in 
each study was extracted, as was other relevant information including study location, 
inclusion period, and patient characteristics. After excluding manuscripts on the basis 
of title and abstract, the remaining full-text manuscripts were carefully assessed and 
were evaluated according to the criteria. If overlap between studies existed, only the 
publication with the largest population was included. Disagreement on study inclusion 
was solved by consensus.
For each included study, the prevalence rate of AS and its 95% binomial confi dence 
interval (CI) was calculated based on the numbers of subjects in the sample and the num-
ber of patients with AS. These rates were subsequently combined to produce a pooled 
prevalence rate of both AS and severe AS. Both fi xed- and random-eff ects models were 
used, and results of the appropriate model are presented as Forest plots. The fi xed-eff ects 
model was performed using the inverse variance method and the random-eff ects model 
with the DerSimonian and Laird method. Heterogeneity was assessed by the Cochran Q 
test and I2 statistics, derived from the inverse variance fi xed-eff ects model.8 All analyses 
were performed with Stata SE version 12.0 (StataCorp, College Station, Texas).
Estimation of TAVR Candidates
To estimate the number of elderly patients who could potentially be treated with 
TAVR under current indications, we performed a second literature search on clinical 
decision-making in patients with severe AS. Specifi cally, we searched for studies that 
reported: 1) the percentage of patients with severe AS who experienced symptoms; 2) 
the percentage of patients with symptomatic severe AS who did not undergo SAVR and 
could thus be considered potential TAVR candidates; and/or 3) the percentage of those 
patients referred for TAVR who actually received a transcatheter valve. As TAVR is an 
approved therapy for patients at high operative risk, we also determined the proportion 
of elderly high-risk patients (The Society of Thoracic Surgery-Predicted Risk Of Mortality 
[STS-PROM] score ≥10%) undergoing SAVR,9 and the percentage of patients who would 
be considered TAVR-eligible. In anticipation of current and potential future trials in lower 
risk groups, estimates of the proportion of intermediate- and low-risk patients were also 
derived. For all studies, the point estimate and 95% binomial CI were calculated.
These data were combined to produce a pooled percentage estimate for each individual 
search. In each case, a fi xed- or random-eff ects model was used and heterogeneity was 
assessed. To calculate national estimates of the number of patients with AS and TAVR 
candidates, we obtained population demographic data focusing on the elderly (≥75 years 
of age) for the following nations: Austria, Belgium, Czech Republic, Denmark, Finland, 
France, Germany, Greece, Italy, the Republic of Ireland, Luxembourg, Norway, Poland, 
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Portugal, Spain, Sweden, Switzerland, the Netherlands, the United Kingdom, Canada, and 
the United States.10-12 The annual number of new TAVR candidates was calculated using 
the number of people ages 75 years old in 2011 in the individual countries.
A fl owchart was built in TreeAge Pro 2011 (TreeAge Software, Williamstown, MA). The 
probabilities in the fl owchart were based on the pooled estimates from the systematic 
literature searches. Beta distributions were used and 10,000 Monte Carlo simulations 
were performed to estimate the number of elderly patients who are eligible to undergo 
TAVR, along with its 95% percentile CI.
To account for the heterogeneous nature of the studies, sensitivity analyses were per-
formed. In particular, the proportion of patients receiving TAVR after referral for TAVR 
assessment was determined using European studies alone and then by combining Euro-
pean and U.S. studies. This analysis was performed to account for the diff erent adoption 
of TAVR in the United States, where until recently TAVR was only used in the context 
of clinical trials. In a second sensitivity analysis, we varied the percentage of high-risk 
SAVR-eligible patients who undergo TAVR.
RESULTS
The systematic literature search yielded 1,523 studies. After the title and abstract were 
screened, 1,408 studies were excluded because they did not focus on the epidemiology of 
disease. After assessing full-text articles, another 109 studies were excluded because they 
were not performed in the general elderly population, AS was not assessed, or because it 
was not an original publication. After the inclusion of an additional study through cross-
referencing, our fi nal analysis consisted of 7 studies, with a total of 9,723 elderly patients 
(Fig. 1).1, 4, 5, 13-16 The characteristics of these studies are outlined in Table 1. The 7 studies 
reported the prevalence of AS in 9 study populations on 3 continents. The study periods 
ranged from 1989 to 2009. All studies had a cross-sectional character, and most were part 
of larger population-based cohort studies. In all 7 studies, echocardiography was used to 
diagnose AS, although defi nitions of AS and its severity were variable (Table 1).
The combined prevalence of AS in the elderly was reported in 6 studies and ranged from 
2.6% to 22.8% (Fig. 2A).4, 5, 13, 15, 16 The pooled prevalence was 12.4% (95% CI: 6.6% to 
18.2%) using a random-eff ects model (I2 = 98.5%; Q = 337.70, p < 0.001). The prevalence 
of severe AS in the elderly was reported separately in 5 studies and ranged from 1.2% to 
6.1% (Fig. 2B).1, 4, 5, 13, 14, 16 The pooled prevalence of severe AS was 3.4% (95% CI: 1.1% 
to 5.7%) using a random-eff ects model (I2 = 85.7%; Q = 27.99, p < 0.001).
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These estimates of the prevalence of AS in patients ≥75 years old correspond to approxi-
mately 4.9 million elderly patients with AS in the European countries and 2.7 million in 
North America. If only symptomatic severe AS is considered, this translates to 1.0 million 
elderly patients in the European countries and 540,000 in North America. In 2011, 8.5% 
of the population in the 19 European countries was ≥75 years of age, and this number is 
expected to increase to 10.7% in 2025 and 16.6% in 2050.11 In North America, similar 
increases in the population demographics of the elderly are expected (2025, 8.3%, 
and 2050, 11.8%).10, 12 These numbers correspond to approximately 1.3 million and 
2.1 million patients with symptomatic severe AS in the 19 European countries in 2025 
and 2050, respectively. In North America, there will be an estimated 0.8 million and 1.4 
million patients with symptomatic severe AS in 2025 and 2050, respectively.
Estimates of TAVR Candidates
The number of elderly patients who could potentially benefi t from TAVR was estimated 
using the model outlined in Figure 3, with inputs from the systematic search and meta-
analyses (Fig. 4). Seven studies reported the percentage of patients with severe AS who 
Figure 1. Flow Chart of Study Selection
AS, Aortic stenosis
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were symptomatic, resulting in a pooled estimate of severe symptomatic AS of 75.6% 
(95% CI: 65.8% to 85.4%) (Fig. 4A, Supplementary Table 1). Of these patients with 
symptomatic severe AS, 40.5% (95% CI: 35.8% to 45.1%) did not undergo SAVR and 
thus could be considered candidates for TAVR (Fig. 4B, Supplementary Table 2). Nine 
studies reported the percentage of patients referred for TAVR who actually received a 
transcatheter valve (Supplementary Table 3). Three of these studies were performed in 
Figure 2. Forest Plots on the Prevalence of AS
2A.  Mild, moderate and severe AS in the elderly, using a random-eff ect model. I2=97.1%; Q=140.25, 
p<0.001.
2B. Severe AS in the elderly, using a random-eff ect model. I2=85.7%, Q=27.99, p<0.001.
AS, Aortic stenosis.
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Europe, and 6 in the United States. The pooled percentage including both European and 
U.S. studies was 28.7% (95% CI: 22.8% to 34.6%) (Figs. 4C and 4D, respectively). The 
European pooled percentage was 40.3% (95% CI: 33.8% to 46.7%), whereas the U.S. 
pooled percentage was 24.4% (95% CI: 18.9% to 29.8%). In total, 12.3% of patients 
with symptomatic severe AS at prohibitive surgical risk are TAVR candidates.
To assess the proportion of elderly SAVR patients who was deemed to be at high surgical 
risk, we used a study that reported on all elderly SAVR patients in the United States 
between 1999 and 2007.17 Among elderly patients undergoing isolated SAVR, 5.2% 
(95% CI: 4.9% to 5.4%) were at high risk (STS-PROM ≥10%), 15.8% (95% CI: 15.4% 
to 16.2%) at intermediate risk (STS-PROM 5% to 10%), and 79.1% (95% CI: 78.6% to 
79.5%) at low risk (STS-PROM <5%). A recent study showed that in a group of operable 
patients with a EuroSCORE (European System for Cardiac Operative Risk Evaluation) ≥15, 
approximately 80% were treated with TAVR.18
In 2011, there were 39,316,978 people ≥75 years of age in the European countries and 
21,182,683 in North America.10-12 Combining these fi gures with the Monte Carlo simula-
tions in the model (Fig. 3), we estimated that a total of 292,000 high- or prohibitive-risk 
elderly patients with symptomatic severe AS are candidates for TAVR. Specifi cally, there 
Figure 4. Forrest Plots of the Diff erent Steps in the Estimation Model
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are 189,836 (95% CI: 80,281 to 347,372) TAVR candidates in the European countries and 
102,558 (95% CI: 43,612 to 187,002) in North America. Annually there are 17,712 (95% 
CI: 7,590 to 32,691) new TAVR candidates in the European countries and 9,189 (95% CI: 
3,898 to 16,682) in North America. The total and annual number of TAVR candidates in 
the individual countries is presented in Figures 5 and 6, respectively.
The intermediate surgical risk group comprises approximately 145,000 elderly patients 
with symptomatic severe AS. Specifi cally, there are 94,730 (95% CI: 40,574 to 171,896) 
patients at intermediate risk in the European countries and 50,733 (95% CI: 22,148 to 
90,451) in North America. The low surgical risk group includes approximately 730,000 
patients with symptomatic severe AS. Specifi cally, there are 477,314 (95% CI: 206,798 to 
862,958) patients at low-risk in the European countries and 255,727 (95% CI: 108,549 
to 460,026) in North America.
Sensitivity Analyses
In the pre-specifi ed sensitivity analysis that varied the proportion of patients receiving 
TAVR after referral for TAVR assessment according to study location (28.7%, 95% CI: 
Figure 5. Total of TAVR Candidates in the Diff erent Countries under the Current Treatment Indications
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22.8% to 34.6% in Europe and the United States combined), we estimated that ap-
proximately 220,000 patients are TAVR candidates. Of these, 142,658 (95% CI: 61,065 
to 263,795) candidates lived in the European countries and 76,962 (95% CI: 32,805 to 
140,673) in North America.
In the sensitivity analysis varying the percentage of high-risk operable patients who 
would undergo TAVR, the total number of TAVR candidates was 277,570 (95% CI: 119,406 
to 512,707) assuming that 50% would undergo TAVR whereas there were 302,865 (95% 
CI: 129,433 to 550,562) candidates if all the high-risk patients would undergo TAVR. 
Finally, we estimated that the total number of patients with symptomatic severe AS in 
the intermediate-risk category was 145,936 (95% CI: 62,802 to 263,340), and 733,861 
(95% CI: 310,623 to 1,302,586) in the low-risk category.
Figure 6. Annual Number of TAVR Candidates in the Diff erent Countries under the Current Treatment 
Indications
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DISCUSSION
The current study found that the prevalence of AS in the elderly (≥75 years of age) is 
12.4%, and severe AS is present in 3.4%. Among elderly patients with severe AS, 75.6% 
are symptomatic, and 40.5% of these patients are not treated surgically. From those, 
40.3% are potentially treated with TAVR. In total, 12.3% of the prohibitive risk group 
are TAVR candidates. Among patients undergoing SAVR for severe symptomatic AS, 5.2% 
are high risk and 80% of those are potential TAVR candidates. Based on these data, we 
estimated that there are currently approximately 190,000 and 100,000 TAVR candidates 
in the European countries and North America, respectively. Each year, approximately 
18,000 new TAVR candidates emerge in the European countries and 9,000 in North 
America.
The Prevalence of AS
Our estimates of the prevalence demonstrate that the overall burden of disease due 
to AS in the general elderly population is substantial. Population demographics clearly 
show that Western populations are aging, thereby further increasing the impact of AS. No 
eff ective medical therapy is available for patients with AS, and if not treated by interven-
tion, the estimated 5-year survival of severe AS is only 15% to 50%.7 These data suggest 
that the treatment of AS in the elderly will have an increasing impact on public health 
and health care resource consumption in the future.
Based on echocardiographic diagnosis, we found that severe AS occurs in 12.4% of the 
general elderly (≥75 years of age) population. Previous autopsy series and a study based 
on aortic valve diagnoses in Medicare claims have reported AS prevalence estimates of 
9.2% and 16%, respectively.19, 20 Our pooled prevalence of AS (12.4%) is lower than 
the estimates from Medicare claims, but covered a lower age group and did not include 
diagnoses of aortic regurgitation. The methodological diff erences between studies are 
likely to account for the variability in AS estimates.
We explored heterogeneity by assessing the individual study characteristics, but the 
limited number of studies prevented separate analyses. The heterogeneity is refl ective 
of diff erent diagnostic defi nitions for AS, dissimilar recruitment methods, and varying 
study periods (Table 1). Study participation was only 50% to 60% in 2 studies, making 
their results vulnerable for selection bias.5, 15 In 1 study, AS was diagnosed using clini-
cally indicated echocardiography.1 That might have caused a lower prevalence rate of AS. 
Moreover, improvements of echocardiographic techniques and interobserver variability 
might have had an infl uence on the prevalence rates and heterogeneity.
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The Number TAVR Candidates
Nearly 40.5% of all patients with symptomatic severe AS did not undergo SAVR (Fig. 4B). 
Possible explanations for the lower than expected rates of SAVR include excessive opera-
tive risk, advanced age, comorbidities, and patient preference.21, 22 TAVR is a safe, eff ec-
tive, and less invasive treatment strategy for a highly selected proportion of the patients 
who do not undergo SAVR,23 represented by the 40.3% of patients who underwent TAVR 
(Fig. 4C). The treatment decisions refl ect heart team discussions, in which (interventional) 
cardiologists and cardiac surgeons combine risk models with additional factors such as 
frailty, porcelain aorta, and vessel tortuosity.24
The estimated large number of TAVR candidates has clinical, economic, and social impli-
cations. If the index admission costs (US $72,000) of the PARTNER (Placement of Aortic 
Transcatheter Valves) trial are applied,25 treating all TAVR candidates would represent 
a budget impact of $13.7 billion in the European countries and $7.2 in North America. 
At a price of $30,000, the total device turnover would be approximately $8.7 billion. 
Although TAVR is cost eff ective in the United States for patients at high and prohibitive 
risk,25, 26 data from other countries show that, for intermediate-risk patients, the costs 
of TAVR at 1 year are considerably higher than the costs of SAVR.27 Importantly, cost is 
not the only factor that determines the adoption of novel technologies such as TAVR.28 
Reimbursement strategies, physician training, and health care culture may be related to 
the dissemination of this costly technology.
Despite budgetary concerns, current clinical trials are evaluating TAVR for patients at 
intermediate surgical risk (NCT01314313 and NCT01586910).9, 29 If TAVR proves to be 
noninferior to SAVR in this population, we estimate that a further 145,000 patients 
would become TAVR eligible. Indeed, there is some evidence that suggests that TAVR is 
already being performed in these intermediate-risk patients.18, 30 Thus, our estimates of 
the impact of positive outcomes in the ongoing trials are likely to be conservative. In the 
future, TAVR may even compete with SAVR in patients at low surgical risk,30, 31 a group 
that comprises 730,000 severe AS patients in the European countries and North America 
combined.
TAVR learning curve analyses show increasing profi ciency with evidence of plateau after 
the fi rst 30 cases.32 In addition, governmental bodies mandate that each TAVR center 
performs at least 20 to 50 TAVR procedures per year.33-35 These requirements, combined 
with the fi gures from this study, are useful to estimate the number of TAVR centers and 
physicians who need to be trained in TAVR in the individual countries. For example, the 
526 (95% CI: 224 to 965) new TAVR candidates per year in the Netherlands justify ap-
proximately 10 certifi ed centers, assuming that each center performs 50 cases annually. 
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Similarly, the 8,205 (95% CI: 3,470 to 15,139) new TAVR candidates per year in the 
United States suggest a requirement of approximately 165 certifi ed TAVR centers.
The divergent standards of medical evidence required to introduce new therapies in Eu-
rope and the United States are likely to account for the diff erence in TAVR dissemination 
between the continents.36 Although the Edwards Sapien valve (Edwards Lifesciences, Inc., 
Irvine, CA) and Medtronic CoreValve (Medtronic, Inc., Minneapolis, MN) both received the 
Conformité Européenne (CE) mark in 2007, the U.S. Food and Drug Administration used 
trial data to approve the Edwards Sapien valve for patients at prohibitive and high surgi-
cal risk only in November 2011 and October 2012, respectively. Consequently, TAVR has 
been performed with greater frequency and for a wider range of indications in Europe 
than in the United States. The studies on decision-making in patients with AS refl ect the 
commercial use of TAVR in Europe, whereas the U.S. studies display decision-making in 
a time when TAVR use was restricted to clinical trials. These diff erences in practice are 
likely to disappear after the commercialization of TAVR in the United States and were 
taken into account in our sensitivity analyses.
Study Limitations
Although we systematically searched the literature, relatively few reports on the 
prevalence of AS in the general population were identifi ed. Additional population-based 
studies that use a unifi ed echocardiographic defi nition of AS are warranted. The current 
study, however, refl ects all of the currently available evidence on the prevalence of AS.
The estimation of TAVR candidates is as accurate as the currently available inputs and 
assumptions from the literature. However, we used sensitivity analyses to assess the 
infl uence of uncertain parameters. In addition, we included measures of uncertainty in 
each step of the model to calculate confi dence intervals, representing the likelihood of 
the fi nal estimates.
Conclusions
This systematic review and meta-analysis of population-based studies found that the 
prevalence of AS and severe AS among the elderly is 12.4%, and 3.4%, respectively. 
The overall burden of disease due to severe AS in the general elderly population is sub-
stantial. Our model showed that under the current indications approximately 290,000 
elderly patients at high or prohibitive surgical risk could potentially be treated with 
TAVR in Europe and North America, and that each year there are approximately 27,000 
new TAVR candidates. These estimates have considerable clinical, economic, and social 
implications.
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ABSTRACT
Objectives
We sought to examine the adoption of transcatheter aortic valve replacement (TAVR) in 
Western Europe and investigate factors that may infl uence the heterogeneous use of 
this therapy.
Background
Since commercialization in 2007, the number of TAVR procedures has grown exponen-
tially.
Methods
The adoption of TAVR was investigated in 11 European countries: Germany, France, Italy, 
United Kingdom, Spain, Netherlands, Switzerland, Belgium, Portugal, Denmark, and Ire-
land. Data were collected from two sources: (1) lead physicians submitted nation-specifi c 
registry data; (2) an implantation-based TAVR-market tracker. Economic indices such as 
healthcare expenditure per capita, sources of healthcare funding, and reimbursement 
strategies were correlated to TAVR utilization. Furthermore, we assessed the extent to 
which TAVR has penetrated its potential patient population.
Results
Between 2007 and 2011, 34,317 patients underwent TAVR. Considerable variation in 
TAVR utilization existed across nations. In 2011, the number of TAVR implants per mil-
lion ranged from 6.1 in Portugal to 88.7 in Germany (mean±standard deviation:33±25). 
The annual number of TAVR implants performed per center across nations also varied 
widely (range:10-89). The weighted average TAVR penetration rate was low: 17.9%. 
Signifi cant correlation was found between TAVR use and healthcare spending per capita 
(r = 0.80,p = 0.005). TAVR-specifi c reimbursement systems were associated with higher 
TAVR use than restricted systems (698±232 vs. 213±112 implants/million ≥75 years, 
p = 0.002).
Conclusions
Our fi ndings indicate that TAVR is underutilized in high and prohibitive surgical risk 
patients with severe aortic stenosis. National economic indices and reimbursement 
strategies are closely linked with TAVR use and help explain the inequitable adoption of 
this therapy.
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INTRODUCTION
Transcatheter aortic valve replacement (TAVR) gained Conformité Européenne (CE)-mark 
approval in 2007, and in subsequent years the number of patients undergoing TAVR in 
Europe has increased exponentially. Despite the encouraging results from randomized 
controlled trials and registries,1-4 there is anecdotal evidence that the utilization of TAVR 
varies markedly across European nations.
Disparate adoption of medical technology is pervasive and results in inequitable patient 
access.5 Adoption kinetics of a novel medical technology such as TAVR and the factors 
infl uencing these variables have not been previously described. Regional diff erences 
in TAVR adoption are likely to have emerged due to variations in social, regulatory, eco-
nomic, and political circumstances, as well as disease prevalence and longevity. This 
information may be of interest to patients, healthcare professionals, regulatory authori-
ties, the medical device industry and healthcare payers. In addition, these data may have 
implications for healthcare resource allocation, service development planning, assessing 
equitable patient access, and physician training.
We sought to address this information gap by examining the trends in both the number 
of TAVR implants and centers across 11 European countries since CE-mark approval. In 
addition, we investigated factors that may infl uence the heterogeneous adoption of this 
novel technology across nations.
METHODS
Data Sourcing
We investigated TAVR utilization in 11 European countries: Germany, France, Italy, the 
United Kingdom (UK) including Northern Ireland, Spain, the Netherlands, Switzerland, 
Belgium, Portugal, Denmark and the Republic of Ireland. Data were collected from two 
distinct sources. Firstly, we identifi ed data from published national registries and large 
databases in countries where reimbursement is linked to registry inclusion.3,4,6-8 Lead 
physicians from each nation submitted data from national registries regarding the annual 
number of patients treated with TAVR and the annual number of implanting centers from 
2007 to 2011. Lead physicians take responsibility for the integrity of the data (Supple-
mentary Table 1).
Secondly, we present data from BIBA MedTech (London, United Kingdom), a cardiovas-
cular market analysis group tracking TAVR utilization since mid-2009. These data were 
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gathered through specifi cally designed questionnaires and pre-arranged telephone 
interviews with an extensive research panel comprising interventional cardiologists, 
cardiac surgeons and administrators from a large number of TAVR centers throughout Eu-
rope. National implant estimates were extrapolated using an algorithm that incorporated 
the following variables: device pricing; national guidelines; national reimbursement poli-
cies; portfolio; spread; and trend. This fi nal dataset was cross-referenced with published 
registries.
Nation-specifi c data were combined with European Union derived year-end population 
estimates to calculate:9 (1) the annual and cumulative number of TAVR performed in 
each nation; (2) the annual number of TAVR implants per million of population and TAVR 
implants per million of population age ≥75 years; (3) the annual and cumulative number 
of TAVR centers in each nation; (4) the number of TAVR centers per million of population; 
and (5) the mean number of TAVR implants per center for each nation.
TAVR Penetration
The penetration rate of a therapy is a descriptor of the use of that therapy among eligible 
patients. Thus, TAVR penetration in each nation was determined as a measure of actual 
TAVR use relative to potential use. The numerator for calculating penetration was the 
number of living TAVR recipients at year-end in each country. This was calculated as 
the sum of patients receiving TAVR in that calendar year and the number of living TAVR 
recipients from previous years. Annual mortality rates at 1, 2, 3 and 4 years following 
TAVR were assumed to be 24%, 33%, 49%, 57%, respectively.10 The denominator was 
an estimate of the prevalence of patients with symptomatic severe aortic stenosis at 
high or excessive surgical risk that could potentially be treated with TAVR.11 Briefl y, the 
proportion of elderly inhabitants of each country ≥75 years of age with severe aortic 
stenosis (3.4%) was determined by a random-eff ects meta-analysis. Among these pa-
tients, 75.6% were estimated to be symptomatic, 40.5% were deemed to be inoperable 
due to excessive surgical risk, and among the patients that received surgical aortic valve 
replacement, 5.2% were determined to be at high operative risk (Society of Thoracic 
Surgeons risk of mortality ≥10%). Finally, 40.3% of inoperable patients and 80.0% of 
the high-risk patients were deemed to be potential TAVR candidates.
Economic Indices
National economic indices and healthcare parameters for 2011 were obtained from Euro-
pean Union and Organisation for Economic Co-operation and Development databases.12 
In order to establish economic factors associated with TAVR utilization, we correlated the 
number of TAVR implants per million (≥75 years) to the volume indexed gross domestic 
product (GDP) per capita in purchasing power standards (PPS). GDP per capita in PPS 
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is obtained by converting GDP per capita to a fi ctive currency using purchasing power 
parities (PPP) that eliminates diff erences in currency and price levels between countries, 
thereby allowing meaningful volume comparisons of GDP. In addition, we correlated the 
number of TAVR implants per million (≥75 years) with the percentage of GDP spent on 
healthcare and the PPP-adjusted total healthcare expenditure per capita (United States 
dollars). In Europe, healthcare is funded either by taxation or by social insurance institu-
tions, which are largely outside the commercial marketplace. We classifi ed healthcare 
fi nancing in each country according to the principal source of funding and compared 
TAVR utilization between these systems.
TAVR Reimbursement
Medical device reimbursement in Europe is inconsistent as healthcare regulators with 
diverse policies dictate the method of reimbursement.13 We divided existing 2011 TAVR-
reimbursement into two categories and compared TAVR use between these schemes: 
(1) “TAVR-specifi c” systems where TAVR is completely reimbursed via a therapy-specifi c 
national diagnosis related group (DRG) tariff ; and (2) “constrained” systems where TAVR 
reimbursement is only partially funded by an existing national DRG tariff  or where the 
cost is borne by a local healthcare trust or hospital budget.
Statistics
Continuous variables are presented as mean ± standard deviation or median with inter-
quartile range according to distribution. Normally distributed variables were compared 
with the Student’s t-test and non-normally distributed variables compared with the Wil-
coxon rank-sum test. Categorical variables are presented as numbers and percentages. 
Bland-Altman plots were used to graphically compare the two sources of TAVR implant 
data. Correlation between economic indices and TAVR implants per million (≥75 years) 
was assessed using Pearson’s or Spearman’s correlation according to distribution. A 
probability value <0.05 was considered to indicate statistical signifi cance. Analyses were 
performed using SPSS version 17.0 (SPSS Inc., Chicago, Illinois).
RESULTS
Data Sourcing
With the exception of one small center (<30 TAVR implants per annum) in both the Neth-
erlands and Belgium, complete data were available from the 11 study nations. Herein, 
we report the results from the national databases which include TAVR implant data since 
CE-mark approval in 2007. The BIBA MedTech dataset includes data from 2009 to 2011 
and is presented as Appendix.
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Implantation Rates
Between January 2007 and December 2011, a total of 34,317 patients underwent TAVR in 
the 11 study nations (Figure 1A). Almost half of all implants were performed in Germany 
(45.9%), with Italy (14.9%) and France (12.9%) the next most frequent implanters (Table 
1). Ireland accounted for the smallest proportion of implants (0.4%). In 2011, the high-
est annual increase in procedural volume was observed in France (61%) and Germany 
(49%), while Ireland (−15%) and Portugal (−3%) were the only nations to experience a 
decline. The annual number of implants increased 33-fold from 455 in 2007 to 14,946 
Figure 1. TAVR Adoption in Europe
(A) Cumulative TAVR implants in 11 Western European nations between 2007 and 2011; and (B) TAVR im-
plants per annum and percentage annual increase (solid line).
TAVR = transcatheter aortic valve replacement.
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in 2011 (Figure 1B). Although the annual procedural volume growth rate has decreased 
from 429% in 2008 to 40% in 2011, it remained positive.
We observed a wide variation in the number of TAVR implants per million of population 
(Figure 2 A, B). Germany (88.7) and Portugal (6.1) accounted for the highest and lowest 
number of TAVR implants per million of population in 2011, respectively. Among the 11 
study nations, the mean number of TAVR implants per million was 32.9±24.9 while the 
mean number of TAVR implants per million ≥75 years was 398±283.
Implanting Centers
The number of centers performing TAVR increased approximately 9-fold from 37 in 
2007 to 342 in 2011 (Figure 3A). In 2011, Germany (90) and Italy (87) had the high-
est number of TAVR centers whereas Portugal, Denmark and Ireland (3) had the lowest 
(Table 2). Belgium had the highest number of TAVR centers per million of population 
(2.1) and Portugal (0.3) the lowest (Figure 3B). On average, there were 0.9±0.6 TAVR 
centers per million of population. These numbers led to an average of 41±28 TAVR 
implants per center in 2011, with estimates in individual countries ranging from 10 in 
Ireland to 89 in Germany (Figure 3C). On account of the high number of TAVR centers 
per million of population, Belgium had the second lowest number of TAVR implants per 
center (13).
Table 1. TAVR Implants in Each Nation
TAVR implants per annum (% increase) Cumulative
TAVR
Cumulative
TAVR (%)2007 2008 2009 2010 2011
Germany 157 921 (487) 2,566 (179) 4,859 (89) 7,252 (49) 15,755 45.9
France 58 82 (41) 320 (290) 1,523 (376) 2,447 (61) 4,430 12.9
Italy 71 450 (534) 1,138 (153) 1,581 (39) 1,879 (19) 5,119 14.9
United Kingdom 66 295 (347) 561 (90) 778 (39) 1,037 (33) 2,737 8.0
Spain 12 151 (1,158) 426 (182) 655 (54) 770 (18) 2,014 5.9
Netherlands* 40 123 (208) 226 (84) 329 (46) 438 (33) 1,156 3.4
Switzerland 18 127 (606) 277 (118) 382 (38) 501 (31) 1,305 3.8
Belgium* 10 100 (900) 163 (63) 257 (58) 289 (12) 819 2.4
Portugal 4 13 (225) 52 (300) 67 (29) 65 (−3) 201 0.6
Denmark 9 81 (800) 126 (56) 190 (51) 239 (26) 645 1.9
Ireland 0 12 61 (408) 34 (−44) 29 (−15) 136 0.4
Total
(% increase)
445 2,355 (429) 5,916 (151) 10,655 (81) 14,946 (40) 34,317 100
Data are actual numbers and percentages. * Excludes one low-implant volume center (<30 TAVR implants 
per annum) in both the Netherlands and in Belgium. TAVR, transcatheter aortic valve replacement.
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TAVR Penetration
In 2011, we estimate that there were 28,400 living TAVR recipients and 158,371 po-
tential TAVR candidates in the 11 study nations (Table 3). Thus, the calculated weighted 
average TAVR penetration rate in 2011 was 17.9%. The estimated collective and nation-
specifi c TAVR penetration rates are presented in Figure 4 (A, B). Germany (36.2%) and 
Figure 2. TAVR Implants per Million in the Study Nations
TAVR implant dynamics in the study nations between 2007 and 2011: (A) TAVR implants per million of 
population; and (B) TAVR implants per million ≥75 years old. Broken line represents mean. Abbreviation 
as in Figure 1.
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Figure 3. TAVR Centers in Europe
(A) Cumulative TAVR centers in 11 Western European nations from 2007 to 2011; (B) TAVR centers per 
million of population in 2011; and (C) mean number of TAVR implants per center in each nation in 2011. 
Broken line represents mean. Abbreviation as in Figure 1.
Part II. Aortic Stenosis
102
Switzerland (34.5%) had the highest TAVR penetration rates; Portugal (3.4%) and Spain 
(8.4%) had the lowest penetration rates.
Economic Indices
We assessed the association between several economic indices and TAVR use (Table 4). 
The volume indexed GDP per capita, which is considered to be a reliable indicator of a 
country’s standard of living, was not associated with TAVR use (r = 0.53, p = 0.10: Figure 
5A). In contrast, a signifi cant linear correlation was found between the number of TAVR 
implants per million (≥75 years) and healthcare spending as a percentage of GDP (r = 0.68, 
p = 0.025: Figure 5B), and healthcare spending per capita (r = 0.80, p = 0.005: Figure 5C). 
We also found an association between the principal source of healthcare funding and the 
number of TAVR implants per million (Figure 5D). Although not statistically signifi cant, 
there was a trend towards increased TAVR use in those nations where healthcare was 
funded principally by social insurance (Germany, France, the Netherlands, Switzerland, 
and Belgium) than those principally funded by taxation (Italy, UK, Spain, Portugal, Den-
mark, Ireland) (571±290 versus 252±192 implants per million ≥75 years, p = 0.056).
TAVR Reimbursement
TAVR reimbursement strategies across the study nations were heterogeneous (Table 4, 
Figure 6). TAVR-specifi c national DRG-based reimbursement occurs in Germany, France, 
Switzerland, and Denmark. Constrained reimbursement systems were noted for the UK, 
Table 2. Implant Centers
Cumulative TAVR centers
TAVR 
centers, 
2011 (%)
TAVR 
centers per 
million, 
2011
TAVR 
implants 
per center, 
2011
2007 2008 2009 2010 2011
Germany 6 36 61 80 90 26.3 1.1 81
France 6 12 16 33 33 9.6 0.5 74
Italy 8 21 50 75 87 25.4 1.4 22
United Kingdom 6 19 26 31 33 9.6 0.5 31
Spain 2 10 20 39 48 14.0 1.0 16
Netherlands 3 6 7 7 7 2.0 0.4 63
Switzerland 1 7 8 11 12 3.5 1.5 42
Belgium 2 7 13 20 23 6.7 2.1 13
Portugal 1 2 3 3 3 0.9 0.3 22
Denmark 2 3 3 3 3 0.9 0.5 80
Ireland 0 1 3 3 3 0.9 0.7 10
Total 37 124 210 305 342 100 0.9±0.6 41±28
Data are actual number or mean ± SD. Abbreviation as in Table 1.
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Spain, the Netherlands, Belgium, Portugal and Ireland where the cost of TAVR is borne by 
a local healthcare trust (UK) or by the hospital budget. Reimbursement systems evolved 
over the course of the study. For example, a TAVR-specifi c DRG was introduced in Ger-
many in January 2008 as opposed to France where it was introduced in December 2009.
We investigated the association between reimbursement system and both TAVR utiliza-
tion (implants per million ≥75 years) and the number of TAVR implants per center. Italy 
was excluded from the analysis as reimbursement strategies varied across provinces. 
Figure 4. TAVR Penetration in Europe
(A) Estimated TAVR penetration among the 11 study nations from 2007 to 2011; and (B) TAVR penetration 
in each nation in 2011. Broken line represents weighted average. Abbreviation as in Figure 1.
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TAVR-specifi c reimbursement systems were associated with a 3.3-fold higher number 
of TAVR implants per million (≥75 years) than constrained systems (698±232 versus 
213±112, p = 0.002: Figure 5E). Furthermore, TAVR-specifi c reimbursement systems 
Figure 5. Factors Infl uencing TAVR Adoption in Europe
(A) Correlation between TAVR implants per million (≥75 years) and (A) volume indexed gross domestic 
product (GDP), (B) healthcare expenditure (% of GDP), and (C) annual healthcare spend per capita (US dol-
lars). Number of TAVR implants per million (≥75 years) according to (D) the principle source of healthcare 
funding (social insurance or taxation), and (E) the system of reimbursement (TAVR-specifi c or constrained). 
(F) The average number of TAVR implants per center in 2011 and the system of reimbursement. DRG, diag-
nosis related group; PPS, purchasing power standards; other abbreviation as in Figure 1.
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were associated with 2.5 times more TAVR implants per center than constrained systems 
(69±18 vs. 26±20 implants per center (p = 0.008, Figure 5F).
Comparison Between Registry and BIBA Datasets
The correlation between national registry and BIBA MedTech datasets for TAVR implant 
numbers is presented by a Bland-Altman plot (Supplementary Figure 1). There was sat-
isfactory agreement between the two sources of information and both provided similar 
results and conclusions (Supplementary Tables 2-5, Figures 2-6).
DISCUSSION
This study describes the adoption of TAVR in 11 Western European nations since the 
2007 CE mark approval of the Edwards Sapien (Edwards Lifesciences Inc., Irvine, CA, 
USA) and Medtronic CoreValve (Medtronic Inc., Minneapolis, MN, USA) systems. The main 
fi ndings are: (1) more than 34,000 patients received TAVR between 2007 and 2011; (2) 
there is substantial variation in the adoption of TAVR across nations; (3) there is disparity 
Table 4. Economic Indices and Reimbursement Schemes
Volume 
indexed GDP 
per capita 
(PPP)
Healthcare 
spend (% of 
GDP)
Healthcare 
spend per 
capita (2010, 
US$, PPP)
Principle 
source of 
healthcare 
funding
TAVR reimbursement
Germany 120 11.6 4,338
Social 
insurance
National TAVR DRG
France 107 11.6 3,974 Taxation National TAVR DRG
Italy 101 9.3 2,964 Taxation Region dependent
United Kingdom 108 9.6 3,433 Taxation Cost borne by local trust
Spain 99 9.6 3,056 Taxation Cost borne by hospital
Netherlands 131 12.0 5,056
Social 
insurance
Cost borne by hospital
Switzerland 151 11.5 5,270
Social 
insurance
National TAVR DRG
Belgium 118 10.5 3,969
Social 
insurance
Cost borne by hospital
Portugal 77 10.7 2,728 Taxation
National SAVR DRG. 
Remainder of cost borne by 
hospital
Denmark 125 11.1 4,464 Taxation National TAVR DRG
Ireland 127 9.2 3,718 Taxation Cost borne by hospital
Values are actual numbers. GDP, gross domestic product; US$, United States dollars; PPP, purchasing power 
parity; DRG, diagnosis related group; SAVR, surgical aortic valve replacement.
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in the annual number of TAVR implants per center across nations (mean: 41±28); (4) TAVR 
remains greatly underutilized with an estimated weighted penetration rate of 17.9%; 
and (5) economic and reimbursement indices may help explain the variability in TAVR 
adoption across nations.
We found considerable variation in TAVR utilization across nations. Germany had more 
than two times the implant rate of all other nations except Switzerland, and 14 times 
the implant rate of Ireland and Portugal. Regional variation in the adoption of medical 
technology is not unique to TAVR. In Europe, disparate use of drug-eluting stents (DES) 
and implantable cardioverter defi brillators (ICD) has previously been described.5,14,15 The 
identifi cation of inequitable access to medical technologies is important as it generates 
discussion and initiatives to address inequalities and the corresponding impact on pa-
tient outcomes through payer and physician led programs (E.g. Stent for Life Initiative).16
Figure 6. Reimbursement Systems and TAVR Penetration across Europe
Map of the 11 study nations depicting estimated TAVR penetration rate and the 2011 TAVR-reimbursement 
systems. DRG, diagnosis-related group; SAVR, surgical aortic valve replacement; other abbreviation as in 
Figure 1.
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Explanations for the divergence in TAVR adoption among countries are numerous and 
varied. The economic challenge of providing progressive care for an ageing population 
has mandated that the utilization of new medical device technologies be not only deter-
mined by the expectation of improved clinical outcomes, but also by cost-eff ectiveness. 
It is axiomatic therefore, that the magnitude of healthcare resources infl uences the 
adoption of new medical device technology. Consistent with our fi ndings that healthcare 
expenditure correlated with TAVR utilization, the use of ICDs in Europe has also been 
associated with national economic performance.5,14 Not surprisingly, the lowest TAVR 
implantation rates were found in Spain, Portugal and Ireland who are currently expe-
riencing substantial economic hardship. In these nations, the medical device industry 
could provide additional support to develop and maintain TAVR programs. As was the 
case with DES and ICDs, the introduction of competitive TAVR systems should decrease 
procedural costs and consequently increase TAVR adoption.
Procedural reimbursement and healthcare funding are critical factors in determining the 
adoption of new medical device technology. Previously, these factors have been shown 
to infl uence the use of ICDs and coronary stents. In the current study, TAVR utilization 
and the number of TAVR implants per center were found to be higher in the presence 
of nationwide TAVR-specifi c reimbursement schemes than restrictive reimbursement 
schemes. The impact of restrictive reimbursement systems was evident in the UK, Spain, 
the Netherlands, Belgium, Portugal, and Ireland. We also observed a trend towards in-
creased TAVR use in nations where social insurance rather than taxation was the principle 
source of healthcare funding (p = 0.056).
Our estimates of TAVR penetration suggest that TAVR remains underutilized in Western 
Europe. While the TAVR penetration rate in 2011 was >30% in Germany and Switzer-
land, the weighted average penetration among the 11 nations studied was 17.9%, 
and penetration rates were <15% in two thirds of the countries. The adoption of new 
technology can be a slow process. It requires a threshold of robust clinical evidence, 
device iteration, physician training, clinical and fi nancial planning. Moreover, the cultural 
change required to embrace new therapies often evolves gradually. Given the therapeu-
tic benefi t associated with TAVR in inoperable patients (number needed to treat = 5) (1), 
the demonstrable cost-eff ectiveness in both excessive and high-risk cohorts,17-19 and the 
less invasive nature of TAVR procedures, the protracted uptake of TAVR technology may 
have negative consequences for patients, physicians, and administrators. Although TAVR 
penetration is not necessarily a surrogate for quality of medical care, it may suggest the 
need for enhanced patient access to novel and potentially life-saving therapies. Indeed, 
it is interesting to speculate that in nations with higher TAVR penetration rates, a move 
towards treating patients at less extreme surgical risk may be emerging.20
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The impressive clinical trial outcomes with TAVR are attributable, in part, to the partici-
pation of experienced physicians and institutions. These outcomes are not necessarily 
reproducible in lower-volume settings.21-23 For these reasons, volume-based guidelines 
for catheter-based and surgical procedures exist.24,25 The recommended centralization 
of TAVR procedures in high-volume tertiary referral centers aims to ensure adequate op-
erator and center volume for these complex procedures.26-28 National health technology 
assessments and position papers have suggested that each center perform a minimum of 
24 TAVR procedures per annum.27,29,30 We observed centers with low procedural volume 
and therefore non-adherence to these criteria in several nations. In particular, centers 
in Ireland, Belgium and Spain performed on average less than 20 implants in 2011. 
Two distinct observations explain the low procedural volume: (1) low number of TAVR 
implants per million (Ireland); and (2) an excessive number of TAVR centers (Belgium and 
Spain). The reasons for the variation in the number of TAVR centers per million and center 
volume across nations are unclear. National political and fi nancial concerns, healthcare 
policy, population density and profi le, reimbursement strategy, and cultural factors may 
be important in determining the number of centers in each nation.
The way complex medical technology is disseminated has been revolutionized by TAVR. 
Clinical site selection, mandatory physician and team training, and detailed algorithms 
outlining patient selection have become the standard of care. Nevertheless, the variation 
in the adoption of TAVR in Western Europe is clear. Physicians, medical societies, the 
medical device industry, and other stakeholders have a responsibility to ensure the ap-
propriate use and sensible dispersion of this innovative technology.
Limitations
Several limitations are of note. Firstly, although every attempt was made to ensure the 
validity of the implant data, both data sources should be considered to be estimates. 
Registry data may underestimate the true scale of TAVR use as some cases or small 
implant centers may not have been included. Secondly, the estimates of TAVR use are 
likely to have included patients treated for off -label indications, such as patients at lower 
surgical risk, which may have aff ected the estimates of TAVR penetration.
Conclusions
Despite the rapid adoption of TAVR across Europe, our fi ndings indicate that a sizeable 
treatment gap remains for high/prohibitive surgical risk patients with severe aortic ste-
nosis. National economic indices and reimbursement strategies are closely linked with 
TAVR use and may explain the inequitable adoption of TAVR across nations.
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Supplementary Table 1. Sources of National Registry Data
Country Physician Institution
Germany Ruediger Lange German Heart Center, Munich
France Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy
Italy Francesco Maisano San Raff aele Hospital, Milan
United Kingdom Neil Moat Royal Brompton Hospital and on behalf of NICOR, London
Northern Ireland Ganesh Manoharan The Heart Centre, Royal Victoria Hospital, Belfast 
Spain Eulogio Garcia Hospital Clínico San Carlos, Madrid
Netherlands Peter de Jaegere Erasmus University Medical Center, Rotterdam
Switzerland Peter Wenaweser Bern University Hospital, Bern
Belgium Johan Bosmans University of Antwerp, Wilrijk
Portugal Rui C Teles Hospital de Santa Cruz, Lisbon
Denmark Lars Søndergaard Rigshospitalet, Copenhagen
Ireland Darren Mylotte University Hospital, Galway
Supplementary Table 2. TAVR Implants in Each Nation (BIBA Medical)
TAVR implants per annum (% increase)
Cumulative TAVR Cumulative TAVR (%)
2009 2010 2011
Germany 1,693 6,282 (271) 7,916 (26) 15,891 45.4
France 416 1,579 (280) 2,328 (47) 4,323 12.3
Italy 573 1,602 (180) 2,175 (36) 4,350 12.4
United Kingdom 376 1,068 (184) 1,244 (16) 2,688 7.7
Spain 344 952 (177) 1,082 (14) 2,378 6.8
Netherlands 294 809 (175) 793 (−2) 1,896 5.4
Switzerland 228 602 (164) 618 (3) 1,448 4.1
Belgium 147 437 (197) 552 (26) 1,136 3.2
Portugal 40 84 (110) 74 (−12) 198 0.6
Denmark 125 214 (71) 339 (58) 678 1.9
Ireland N/A 19 22 41 0.1
Total (% increase) 4236 13,648 (222.2) 17,143 (25.6) 35,027 100
Data represents as actual number and percentage growth.
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Supplementary Table 3. TAVR Centers (BIBA Medical)
TAVR centers
TAVR centers (%)
TAVR centers per 
million, 2011
TAVR implants 
per center, 20112010 2011
Germany 59 69 25.5 0.8 115
France 34 34 12.5 0.5 68
Italy 44 53 19.6 0.9 41
United Kingdom 24 32 11.8 0.5 39
Spain 27 29 10.7 0.6 37
Netherlands 14 14 5.2 0.8 57
Switzerland 10 10 3.7 1.3 62
Belgium 6 20 7.4 1.8 28
Portugal 2 3 1.1 0.3 25
Denmark 3 4 1.5 0.7 85
Ireland 3 3 1.1 0.7 7
Total 226 271 100 Mean±SD 0.8±0.4 Mean±SD 51±30
Data represents actual number or mean ± SD.
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Bland-Altman: TAVR Implant Data: 2010 
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Bland-Altman: TAVR Implant Data: 2011 
0 2000 4000 6000 8000
-1000
-800
-600
-400
-200
0
200
400
600
800
1000
1200
1400
Average TAVR per annum by twomethods
95% limits of agreement
Mean difference (208)
D
iff
er
en
ce
 T
A
V
R
 p
er
 a
nn
um
 (B
IB
A
-R
eg
ist
ry
) 
A
B
Supplementary Figure 1. Comparison of Registry and BIBA MedTech Datasets
Bland-Altman plots comparing national TAVR implants per annum between the registry and BIBA medical 
data sources. In each plot, the solid line represents the mean diff erence, and the dashed line represents 
two standard deviations. TAVR = transcatheter aortic valve replacement.
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TAVR Implants per Annum in 11 European Nations
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Supplementary Figure 2. TAVR Adoption in Europe (BIBA Medical)
(A) Cumulative TAVR implants in 11 Western European nations between 2009 and 2011; and (B) TAVR 
implants per annum and percentage annual increase (solid line). TAVR = transcatheter aortic valve replace-
ment.
Part II. Aortic Stenosis
120
TAVR Implants per Million 2009-2011
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Supplementary Figure 3. TAVR Implants per Million Population in the Study Nations (BIBA Medical)
TAVR implant dynamics in the study nations between 2009 and 2011: (A) TAVR implants per million of 
population; and (B) TAVR implants per million ≥75 years old. Broken line represents mean. Abbreviation as 
in Supplementary Figure 2.
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TAVR Centers per Million: 2011
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Mean Number of TAVR Implants per Center: 2011
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Supplementary Figure 4. TAVR Centers in Europe (BIBA Medical)
(A) Cumulative TAVR centers in 11 Western European nations in 2010 and 2011; (B) TAVR centers per 
million of population in 2011; and (C) mean number of TAVR implants per center in each nation in 2011. 
Broken line represents mean. Abbreviation as in Supplementary Figure 2.
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TAVR Penetration in 11 European Nations: 2009-2011
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Supplementary Figure 5. TAVR Penetration in Europe (BIBA Medical)
(A) Estimated TAVR penetration among the 11 study nations from 2009 to 2011; and (B) TAVR penetration 
in each nation in 2011. Broken line represents weighted average. Abbreviation as in Supplementary Figure 
2.
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Supplementary Figure 6. Factors Infl uencing TAVR Adoption in Europe (BIBA Medical)
Legend. (A) Correlation between TAVR implants per million (≥75 years) and (A) volume indexed gross do-
mestic product (GDP), (B) healthcare expenditure (% of GDP), and (C) annual healthcare spend per capita 
(US dollars). Number of TAVR implants per million (≥75 years) according to (D) the principle source of 
healthcare funding (social insurance or taxation), and (E) the system of reimbursement (TAVR-specifi c or 
constrained). (F) The average number of TAVR implants per center in 2011 and the system of reimburse-
ment. PPS = purchasing power standards. DRG = diagnosis-related group.  Other abbreviation as in Supple-
mentary Figure 2.
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Health Status after Transcatheter 
Aortic Valve Replacement in 
Patients at Extreme Surgical Risk: 
Results from the CoreValve U.S. Trial
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Stoler R, Burton T, Kleiman N, Reardon MJ, Adams DH, Popma JJ, Cohen DJ.
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ABSTRACT
Background and Objectives
For many patients considering TAVR, improvement in quality of life may be of even 
greater importance than prolonged survival.
The aim of this study was to characterize health status outcomes after transcatheter 
aortic valve replacement (TAVR) with a self-expanding bioprosthesis among patients at 
extreme surgical risk and to identify pre-procedural patient characteristics associated 
with a poor outcome.
Methods
Patients with severe, symptomatic aortic stenosis who were considered to be at prohibi-
tive risk for surgical aortic valve replacement were enrolled in the single-arm CoreValve 
U.S. Extreme Risk Study. Health status was assessed at baseline and at 1, 6, and 12 
months after TAVR using the Kansas City Cardiomyopathy Questionnaire (KCCQ), the 
Short-Form-12 (SF-12), and the EuroQOL-5D. The overall summary scale of the KCCQ 
(range 0-100; higher scores = better health) was the primary health status outcome. A 
poor outcome after TAVR was defi ned as either death, a KCCQ-overall summary score 
(KCCQ-OS) <45 or a decline in KCCQ-OS of 10 points at 6-month follow-up.
Results
A total of 471 patients underwent TAVR via the transfemoral approach, of whom 436 
(93%) completed the baseline health status survey. All health status measures demon-
strated considerable impairment at baseline. After TAVR, there was substantial improve-
ment in both disease-specifi c and generic health status measures, with an increase in the 
KCCQ-OS of 23.9 points (95% confi dence interval [CI] 20.3-27.5) at 1 month, 27.4 points 
(95% CI 24.2-30.6) at 6 months, 27.4 points (95% CI 24.1-30.8) at 12 months, along with 
substantial increases in SF-12 scores and EQ-5D utilities as well (all p < 0.003 compared 
with baseline). Nonetheless, 39% of patients had a poor outcome after TAVR. Baseline 
factors independently associated with poor outcome included wheelchair dependency, 
lower mean aortic valve gradient, prior CABG, oxygen dependency, very high predicted 
mortality with surgical AVR, and low serum albumin.
Conclusions
Among patients with severe aortic stenosis, TAVR with a self-expanding bioprosthesis 
resulted in substantial improvements in both disease-specifi c and generic health-related 
quality of life, but there remained a large minority of patients who died or had very poor 
quality of life despite TAVR. Predictive models based on a combination of clinical factors 
as well as disability and frailty may provide insight into the optimal patient population 
for which TAVR is benefi cial.
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INTRODUCTION
Aortic stenosis is the most common form of valvular heart disease in the elderly and is as-
sociated with high morbidity and mortality once cardiac symptoms develop1. In patients 
who are at extreme risk for serious complications during or after surgery, transcatheter 
aortic valve replacement (TAVR) has been shown to result in substantial reductions in 
mortality and improvement in quality of life compared with standard therapy2, 3. Despite 
these health benefi ts, extreme risk patients who undergo TAVR have high rates of both 
short- and long-term mortality, with mortality rates of 30% and 43% at 1 and 2 years, 
respectively2, 4. Moreover, given the advanced age and multiple comorbid conditions that 
are invariably present in the extreme risk population, improvements in quality of life may 
be of even greater importance than improved survival.
The CoreValve transcatheter heart valve (Medtronic, Inc., Minneapolis, MN) is a self-
expanding bioprosthesis that is widely used outside the U.S. In a recently completed 
trial, the CoreValve was shown to be safe and eff ective for patients with symptomatic 
severe aortic stenosis at extreme risk for surgical valve replacement5, but the quality of 
life benefi ts of this device are unknown. To address this gap in knowledge, we sought 
to characterize health status outcomes among patients at extreme surgical risk who 
were enrolled in the CoreValve U.S. Pivotal Trial. Our secondary objective was to identify 
pre-procedural patient characteristics (including comorbidities, surgical risk scores, and 
measures of frailty and disability) associated with a poor outcome after self-expanding 
TAVR.
METHODS
Study Design and Patient Population
The design and results of the CoreValve U.S. Extreme Risk Pivotal Trial have been reported 
previously5. Briefl y, the trial enrolled patients with severe aortic stenosis and New York 
Heart Association class II, III or IV heart failure symptoms. Patients were classifi ed as 
extreme risk if the 30-day risk of mortality or irreversible morbidity was estimated to be 
≥50% by 2 cardiac surgeons and 1 interventional cardiologist5. In the screening process, 
each patient was reviewed in detail by a national screening committee that included at 
least 2 cardiac surgeons and 1 interventional cardiologist, each of whom had to agree 
that the patient met eligibility, risk, and imaging criteria for the trial. After confi rmation 
by the trial oversight committee, patients underwent TAVR via an iliofemoral approach, 
using the Medtronic self-expanding CoreValve system (Medtronic, Inc., Minneapolis, MN). 
Part II. Aortic Stenosis
128
The study was approved by the institutional review board at each site, and all patients 
provided written informed consent prior to participation.
Health Status Assessment
Disease-specifi c and generic health status were assessed at baseline, and at 1, 6 and 
12 months after enrollment using written questionnaires. Questionnaires were adminis-
tered either during in-person visits to the study sites or by mail. Disease-specifi c health 
status was assessed with the Kansas City Cardiomyopathy Questionnaire (KCCQ), a 23-
item self-administered questionnaire that assesses specifi c health domains pertaining to 
heart failure: symptoms, physical limitation, social limitation, self-effi  cacy, and quality of 
life6. The individual domains can be combined into an overall summary score (KCCQ-OS), 
which was the pre-specifi ed primary endpoint for this study. Values for all KCCQ domains 
and the summary score range from 0 to 100, with higher scores indicating less symptom 
burden and better quality of life. Prior studies have shown that the KCCQ-OS generally 
correlates with New York Heart Association functional class as follows: Class I: KCCQ-OS 
75 to 100; Class II: 60 to 74; Class III: 45 to 59; Class IV: 0 to 447, 8. Changes in the KCCQ-
OS of 5, 10, and 20 points correspond to small, moderate or large clinical improvements, 
respectively7. The KCCQ has been shown to be a reliable, responsive and valid measure 
of symptoms, functional status and quality of life among a variety of patients with heart 
failure symptoms, including those with severe, symptomatic aortic stenosis8.
Generic health status was evaluated with the Medical Outcomes Study Short-Form 12 
(SF-12) questionnaire9 and the EuroQOL (EQ-5D)10. Derived from the Short-Form 36, the 
SF-12 provides mental and physical summary scores that are scaled to overall US norms 
of 50 with standard deviations of 10. Higher scores indicate better quality of life, and 
the minimum clinically important diff erence for the SF-12 summary scores is 2 to 2.5 
points11. The EQ-5D is a generic health status measure consisting of 5 domains (mobil-
ity, self-care, usual activities, pain/discomfort, and anxiety/depression), which can be 
converted to utilities using an algorithm developed for the U.S. population12. Utilities are 
preference-weighted health status assessments with scores that range from 0 to 1, with 1 
representing perfect health and 0 corresponding to the worst imaginable health state13.
Statistical Analysis
At each follow-up time-point, scores for each of the disease-specifi c and generic health 
status scores were compared with baseline values using paired t-tests. At each time-
point, the baseline value comparator consisted of only those patients that had a quality 
of life assessment performed at that time-point, thereby addressing survivor bias caused 
by attrition of sicker patients over time.
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To provide additional insight into the changes in health status over time, we also per-
formed several categorical analyses. First, among the survivors at each time-point, we 
calculated the proportion of patients who had a moderate (≥10 points) or large (≥20 
points) improvement in the KCCQ-OS compared with baseline. Second, we calculated the 
proportion of enrolled patients at each time-point with favorable and excellent outcomes, 
defi ned as being both alive and having a moderate or large improvement, respectively, in 
the KCCQ-OS compared with baseline. For these latter metrics, death was considered to 
be the same as failure to improve by the specifi ed amount. The 95% confi dence interval 
for proportion was based on the binomial distribution.
Finally, we calculated the proportion of patients with a poor outcome at 6 months after 
TAVR. For this analysis, a poor outcome was defi ned as any of the following at 6 months 
after TAVR: (1) death; (2) KCCQ-OS <45; or (3) decrease of ≥10 points on the KCCQ-OS 
from baseline14. We then used multivariable logistic regression to identify pre-procedural 
factors associated with poor 6-month outcome. Candidate variables for this analysis are 
listed in Supplementary Table 1. We used stepwise selection to identify variables associ-
ated with poor outcome at a signifi cance level of p ≤ 0.10, and then refi t the model with 
the identifi ed variables. The baseline score on the KCCQ-OS was forced into the model.
Subjects not enrolled (N=18) 
ITT Population 
N=634  
Screening Comittee Approved 
N=737 
Subjects Enrolled 
N=719 
Roll-in subjects (N=63) 
23 mm subjects (N=22) 
Non-Iliofemoral Access (N=147) 
ITT Iliofemoral Population 
N=487 
Exited before procedure (N=11) 
No Iliofemoral Access (N=5) 
As treated Population 
N=471 
Missing baseline QOL data (N=35) 
As treated Population with QOL 
N=436 
Figure 1. Patient Flow Chart
Consort diagram showing patient fl ow for the CoreValve U.S. Pivotal trial. The black box indicates the pri-
mary analytic population for this quality of life study.
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Table 1. Baseline Characteristics of the CoreValve Extreme Risk Cohort
“As Treated” Population
n=436
Socio-demographic characteristics
Age, y 84.0 ± 8.5
Male 49.1% (214/436)
White Race 95.6% (417/436)
Body Mass Index, kg/m2 28.6 ± 7.0
Clinical characteristics
STS Risk Score 10.4 ± 5.6
STS: <5 12.6% (55/436)
STS: 5 - <10 42.7% (186/436)
STS: 10 - <15 26.1% (114/436)
STS: ≥15 18.6% (81/436)
Logistic EuroSCORE 22.8 ± 17.7
NYHA Class
II 8.3% (36/434)
III 65.0% (282/434)
IV 26.7% (116/434)
Prior MI 31.7% (138/436)
Prior CABG 40.6% (177/436)
Prior Stroke 13.8% (60/436)
Home Oxygen 29.8% (130/436)
Chronic Kidney Disease 13.2% (57/431)
Mean Aortic Valve Gradient, mmHg 47.6 ± 14.8
Frailty and Disability Measures
Albumin <3.3 g/dl 17.6% (75/427)
Wheelchair Bound 15.8% (69/436)
6-Minute Walk Distance, meters 167.5 ± 117
5-Meter Gait Speed > 6 seconds 84.5% (262/310)
Low Grip Strength* 65.7% (286/435)
Charlson Comorbidity Index
Mild (1-2) 8.7% (38/436)
Moderate (3-4) 32.8% (143/436)
Severe (5) 58.5% (255/436)
Quality-of-Life Measures
KCCQ overall summary 37.9 ± 22.2
75-100, % 7.1% (31/436)
60-74, % 9.6% (42/436)
45-59, % 18.8% (82/436)
0-45, % 64.4% (281/436)
131
Chapter 6. Quality of Life after TAVR
6
All statistical analyses were performed using SAS software, version 9.2 (SAS Institute, 
Inc., Cary, NC). A 2-sided p-value <0.05 was considered statistically signifi cant with no 
correction for multiple comparisons.
RESULTS
Patient Population
Between February 2011 and August 2012, 737 patients with severe symptomatic aortic 
stenosis at extreme surgical risk from 41 U.S. sites were approved by the trial screening 
committee for inclusion in the CoreValve U.S. Extreme Risk Study. Of these, 18 were not 
enrolled (due to withdrawal by the patient or treating physician), 85 were roll-in patients 
or were treated in a separate registry with the 23 mm CoreValve, and 147 were planned 
for non-iliofemoral access, leaving 487 patients in the intention-to-treat population. 
Sixteen patients subsequently did not undergo iliofemoral TAVR, and an additional 35 
did not have baseline health status data. With the exception of being somewhat younger, 
patients with missing baseline health status assessments were generally similar to those 
patients with complete baseline data (Supplementary Table 2). As such, the analytic 
population for our study included 436 patients who underwent iliofemoral TAVR and 
had baseline health status assessment (Figure 1).
The baseline characteristics of these patients are summarized in Table 1. The mean age 
was 84 years, and 49% were male. The mean aortic valve gradient was 48 mmHg, and 
92% were classifi ed as NYHA Class III-IV. The patients had a high burden of chronic medi-
cal conditions, including 30% who were on home oxygen and 16% who were wheel-
Table 1. Baseline Characteristics of the CoreValve Extreme Risk Cohort (continued)
“As Treated” Population
n=436
KCCQ symptoms 48.1 ± 24.2
KCCQ physical limitation 35.3 ± 24.9
KCCQ social limitation 30.5 ± 28.4
KCCQ quality-of-life 36.3 ± 24.5
SF-12 physical summary score 28.5 ± 8.3
SF-12 mental summary score 45.8 ± 12.3
EQ-5D 0.65 ± 0.24
EQ-5D, European Quality of Life Group instrument-5 dimensions; KCCQ, Kansas City Cardiomyopathy 
Questionnaire; NYHA, New York Heart Association; MI, myocardial infarction; SF-12, Short Form-12 General 
Health Survey; STS, Society of Thoracic Surgeons; QOL, quality-of-life.* defi ned according to the thresholds 
proposed by Luna-Heredia et al.24
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Table 2. Mean Follow-up Scores and Changes in Disease-Specifi c and Generic Health Status Mea-
sures Compared with Baseline
Scale/Time Point Mean (±SD) Value Mean ∆ vs. Baseline 95% CI p-value
KCCQ summary
1 month 62.0 ± 25.8 23.9 (20.3, 27.5) <0.001
6 months 67.6 ± 24.2 27.4 (24.2, 30.6) <0.001
12 months 68.5 ± 23.6 27.4 (24.1, 30.8) <0.001
KCCQ total symptoms
1 month 69.0 ± 23.8 22.1 (18.6, 25.7) <0.001
6 months 73.6 ± 23.1 23.0 (19.8, 26.2) <0.001
12 months 74.2 ± 21.4 22.8 (19.5, 26.1) <0.001
KCCQ physical limitations
1 month 53.2 ± 30.7 16.5 (12.0, 21.0) <0.001
6 months 57.5 ± 28.7 19.4 (15.5, 23.3) <0.001
12 months 53.7 ± 28.6 14.1 (9.9, 18.2) <0.001
KCCQ social limitation
1 month 58.5 ± 33.7 24.8 (19.6, 29.9) <0.001
6 months 63.8 ± 31.2 27.2 (22.4, 32.1) <0.001
12 months 64.7 ± 31.0 29.1 (23.8, 34.4) <0.001
KCCQ quality of life
1 month 64.7 ± 28.1 28.9 (24.7, 33.0) <0.001
6 months 72.0 ± 26.7 33.7 (30.0, 37.4) <0.001
12 months 74.8 ± 25.0 36.3 (32.5, 40.1) <0.001
SF-12 physical
1 month 35.0 ± 10.2 5.8 (4.4, 7.2) <0.001
6 months 33.6 ± 11.3 5.0 (3.5, 6.4) <0.001
12 months 34.1 ± 10.6 5.1 (3.7, 6.5) <0.001
SF-12 mental
1 month 49.7 ± 12.3 3.9 (1.9, 5.8) <0.001
6 months 51.4 ± 11.1 4.5 (2.7, 6.3) <0.001
12 months 51.7 ± 11.8 5.1 (3.3, 7.0) <0.001
EQ-5D utility
1 month 0.726 ± 0.238 0.084 (0.047, 0.121) <0.001
6 months 0.757 ± 0.202 0.092 (0.065, 0.120) <0.001
12 months 0.727 ± 0.208 0.058 (0.027, 0.090) 0.003
CI indicates confi dence interval; EQ-5D KCCQ, Kansas City Cardiomyopathy Questionnaire; and SF-12, 
Short-Form-12 General Health Survey. *p-value derived from paired t-tests comparing follow-up score 
and baseline.
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chair bound. Both disease-specifi c and generic health status measures demonstrated 
substantial impairment at baseline. The mean KCCQ-OS score was 37.9 ± 22.2 (roughly 
comparable to New York Heart Association Class IV); the mean SF-12 physical summary 
score was 28.5 ± 8.3 (~2 SD below the standard for the general U.S. population); the mean 
SF-12 mental summary score was 45.8 ± 12.3; and the mean baseline EQ-5D score was 
0.65 ± 0.24.
Figure 2. Disease-specifi c Health Status after TAVR
Changes in disease-specifi c health status according to the KCCQ overall summary scale (panel A) and sub-
scales (panels B-E) at 1, 6, and 12 months after TAVR. Baseline values indicated by the dashed line corre-
spond to the evaluable patient population at each time point. Mean values and p-values are derived from 
paired t-tests comparing each patient with his or her own baseline value. TAVR, transcatheter aortic valve 
replacement.
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Follow-up Health Status
Follow-up health status data were available for 58% of surviving patients at 1 month, 
74% at 6 months, and 77% at 12 months after TAVR. Mean scores and the mean changes 
from baseline at each follow-up time-point are summarized in Table 2 and Figure 2. 
On average, KCCQ-OS scores increased by 23.9 points at 1 month and 27.4 points at 6 
and 12 months after TAVR compared with baseline (p < 0.001 for all comparisons). The 
individual KCCQ subscales showed similar patterns (Table 2, Figure 2). The SF-12 physical 
and mental summary scores improved by ~5 points at 6 and 12 months compared with 
baseline, and EQ-5D utility values also increased substantially at all time-points as well 
(p < 0.003 for all comparisons; Table 2, Figure 3).
Categorical Analyses
The rates of moderate and large improvements in KCCQ-OS and favorable and excellent 
outcomes at each time-point are shown in Table 3. Among responders to the surveys, the 
proportion of patients with large KCCQ-OS improvements was 58% at 1 month and 59% 
at 12 months after TAVR. The proportion of treated patients with an excellent outcome 
Table 3. Proportion of Patients with Clinically Important Improvement in the KCCQ Summary 
Score
Population and Level of Benefi t Proportion (95% CI) [n/N]
Among responders to the survey
Moderate improvement (≥10-point increase from baseline)
1 month 70.0% (63.9, 75.6) [175/250]
6 months 71.1% (65.3, 76.4) [192/270]
12 months 71.3% (65.3, 76.7) [181/254]
Large improvement (≥20-point increase from baseline)
1 month 58.0% (51.6, 64.2) [145/250]
6 months 61.1% (55.0, 67.0) [165/270]
12 months 59.1% (52.7, 65.1) [150/254]
Among all treated patients*
Favorable outcome (alive with ≥10-point increase from baseline)*
1 month 62.3% (56.3, 68.0) [175/281]
6 months 54.9% (49.5, 60.1) [192/350]
12 months 49.5% (44.2, 54.7) [181/366]
Excellent outcome (alive with ≥20-point increase from baseline)*
1 month 51.6% (45.6, 57.6) [145/281]
6 months 47.1% (41.8, 52.5) [165/350]
12 months 41.0% (35.9, 46.2) [150/366]
*Denominator includes patients who died but excludes patients who voluntarily withdrew from the study 
before the time point.
KCCQ, Kansas City Cardiomyopathy Questionnaire.
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(i.e., alive with a large improvement in KCCQ-OS) was 52% at 1 month and 41% at 12 
months after TAVR.
Factors Associated with Poor Outcome
The proportion of patients with a poor outcome was 39% at 6 months (22% death, 
16% very poor quality of life, and 1.4% quality of life decline). Pre-procedural factors 
that were independently associated with a poor outcome are shown in Table 4. Patients 
who were wheelchair-bound were 2.6 times more likely to have a poor outcome after 
TAVR, compared with patients who were able to ambulate (95% CI, 1.3-5.2). In addition, 
having a lower aortic valve gradient, previous CABG, and requiring home oxygen were 
strongly associated with a poor outcome. The association between the STS risk score 
(i.e., the predicted risk of operative mortality with surgical AVR) and a poor outcome of 
TAVR was only signifi cant for an STS mortality risk >15%. When patients were compared 
according to whether they met VARC criteria for procedural success15, those patients who 
achieved procedural success had greater improvements in health status (mainly at the 
Figure 3. Generic Health Status after TAVR
Changes in generic health status according to the SF-12 and EQ-5D at 1, 6, and 12 months after TAVR. 
Baseline values indicated by the dashed line correspond to the evaluable patient population at each time 
point. Mean values and p-values are derived from paired t-tests comparing each patient with his or her own 
baseline value. TAVR, transcatheter aortic valve replacement.
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1 month time point) and were more likely to experience favorable or excellent outcomes 
at all timepoints (Supplementary Tables 3 and 4). After adjusting for those pre-procedure 
factors summarized in Table 4, procedural success was inversely associated with a poor 
outcome after TAVR (adjusted odds ratio 0.40, p < 0.001).
DISCUSSION
The CoreValve U.S. Extreme Risk Study has demonstrated that TAVR using a self-expanding 
bioprosthesis is safe and eff ective in patients with symptomatic severe aortic stenosis at 
prohibitive risk for surgical replacement5. In this pre-specifi ed quality of life sub-study, 
we found that among patients at prohibitive risk of surgical complications, treatment 
with the CoreValve device via a transfemoral approach leads to substantial improvement 
in disease-specifi c and general health status. These benefi ts were evident by 1 month 
after TAVR and were followed by modest additional improvement through 12 months. 
In addition, we identifi ed several factors, including comorbid conditions, disability/
frailty, and valve physiology, that were independently associated with poor outcomes 
after TAVR—a fi nding which, if replicated in future studies, may help to inform clinical 
decision-making in patients considering TAVR.
We observed substantial improvements in both disease-specifi c and generic health 
status measures after TAVR. Among surviving patients, the mean improvements in the 
KCCQ-OS scale were >20 points at all follow-up time-points; in previous studies, a 
5-point change in this scale has been found to be clinically meaningful and also cor-
Table 4. Predictors of Poor Outcome*
Predictor OR (95% CI) p-value
Baseline KCCQ overall score 1.0 (1.0, 1.0) 0.488
Prior CABG 1.9 (1.2, 3.3) 0.011
Mean aortic valve gradient (per 10 mmHg)** 0.8 (0.7, 0.9) 0.007
STS Score*** 0.052
STS 10-15 1.1 (0.6, 2.2)
STS ≥15 2.0 (1.1, 3.7)
Home oxygen 1.7 (1.0, 3.0) 0.044
Albumin <3.3 g/dl 1.8 (0.9, 3.5) 0.073
Wheelchair Bound 2.6 (1.3, 5.2) 0.006
* Poor outcome defi ned as 1) Death within 6 months; 2) KCCQ-OS < 45; or 3) KCCQ-OS decrease more than 
10 points vs. baseline.
** Resting gradient
*** Reference category is STS mortality risk score <10
Model C-statistic = 0.72
137
Chapter 6. Quality of Life after TAVR
6
relates with important diff erences in survival and health care costs16, 17. Furthermore, we 
observed increases in SF-12 physical and mental component scores of ~5 points. This 
increment represents twice the minimum clinically important diff erence for an individual 
patient11 and is roughly comparable to reversing 10 years of normal decline in health in 
the general population18.
Previous studies have also reported substantial improvements in health status after surgi-
cal AVR19, 20 and TAVR3, 21-23. However, most of these studies have only examined changes 
in generic health status. To date, only one other multicenter trial, the Placement of AoRTic 
TraNscathetER Valve (PARTNER) trial, has rigorously evaluated disease-specifi c health 
status after TAVR3, 23. In PARTNER Cohort B, which included patients who were considered 
surgically inoperable (i.e. similar to the CoreValve Extreme Risk U.S, trial), TAVR resulted 
in substantial improvement in both disease-specifi c and generic health status. Although 
cross-trial extrapolation should be considered purely exploratory, the health status out-
comes observed in the CoreValve Extreme Risk and PARTNER B trials were roughly com-
parable with respect to both disease-specifi c and generic health status measures through 
the fi rst year of follow-up (Supplementary Table 5). The current study thus confi rms that 
the health status benefi ts of TAVR are not restricted solely to balloon-expandable trans-
catheter valves but also apply to the CoreValve self-expanding transcatheter valve.
Although many patients have excellent outcomes after TAVR, we also found that nearly 
40% of patients did not experience meaningful improvements in survival or functional 
status at 6 months after TAVR. We identifi ed pre-operative factors that are associated 
with poor outcomes, which included measures of disability and frailty (e.g., wheelchair 
dependency, low serum albumin), comorbidity (prior CABG, extremely high predicted 
surgical mortality, oxygen dependency) and valve physiology (mean aortic valve gradi-
ent). Compared with prior work investigating predictors of poor outcome after TAVR in 
the PARTNER population (both inoperable and high risk patients) we found some similar 
predictors (e.g. poor functional status, oxygen dependence, low aortic valve gradient) 
and some novel predictors (e.g. low albumin, prior bypass surgery) in the CoreValve 
population14. Further work is needed to establish a model that can be applied across all 
TAVR patients, regardless of valve type and surgical risk, such that patients at high-risk 
for poor outcomes may be identifi ed prospectively. In the future, this information could 
be invaluable to both patients and physicians, to help them decide whether or not to 
undergo TAVR and also to set realistic expectations for recovery.
Our study has several potential limitations. First and foremost, the CoreValve U.S. Extreme 
Risk Study was a single-arm trial, and as such, there was no control arm to which the 
results of TAVR could be compared. Originally, the study design intended to randomize 
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patients CoreValve implantation vs. medical therapy. However, after publication of the 
results from Cohort B of the PARTNER trial2, the investigators and the FDA felt that it 
was no longer ethical to randomize these patients to standard therapy. Consequently, 
we were limited to comparing health status after TAVR with each patient’s individual 
baseline. Of note, the control arm of the PARTNER B trial, which enrolled a similar patient 
population, demonstrated modest short-term improvements in health status (most likely 
attributable to the high rate of balloon aortic valvuloplasty) that were not sustained at 
1-year3. Second, the proportion of patients with missing quality of life data increased 
modestly over time due to both mortality and non-response among surviving patients. 
To address this issue, we also reported categorical outcome variables that included all 
treated patients (as opposed to responding patients; i.e., excellent outcome), thereby 
treating patients with missing data (including death) as ‘treatment failures’. If sicker 
patients were less likely to respond, we may have overestimated the extent of clinical 
benefi t. Third, our study was restricted to the iliofemoral cohort of the CoreValve ex-
treme risk trial and included only 12 months of follow-up. Thus, the durability of the 
observed health status improvements, as well as the health status improvement after 
non-iliofemoral procedures remain unknown.
Conclusions
In patients with severe symptomatic aortic stenosis who are at extreme risk of surgical 
complications, TAVR using the CoreValve self-expanding aortic bioprosthesis via a trans-
femoral approach resulted in large improvements in both disease-specifi c and generic 
health status measures in the majority of surviving patients. Nonetheless, similar to prior 
studies with a balloon expandable transcatheter valve, there remains a substantial mi-
nority of patients who do not derive a meaningful survival or quality of life benefi t from 
TAVR. A combination of pre-procedural clinical, frailty, disability. and physiologic factors 
may provide further insight into identifying patients at high-risk for poor outcomes.
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Supplementary Table 1. Variables considered for the Multivariable Logistic Regression Model
Baseline KCCQ-OS Score
Age
Male
COPD (None/Mild/Moderate/Severe)
Severe vs. None
Moderate vs. None
Mild vs. None
Diabetes
Prior stroke
Renal failure
Prior CABG
Prior Myocardial Infarction
Peripheral Vascular Disease
Moderate/Severe mitral regurgitation
Left Ventricular Ejection Fraction
Mean aortic valve gradient
Logistic EuroSCORE
STS Risk Score (<10, 10-15, ≥15)
STS ≥15 vs. STS <10
STS 10-15 vs. STS <10
Home Oxygen
Charlson Comorbidity Score
score 5 or more vs. score 1/2
score 3/4 vs. score 1/2
Albumin <3.3
5-meter Gait Speed >6 seconds
6-minute Walk Test
Grip Strength < Threshold
Katz ’Activities of Daily Living >0
Mini-Mental Status Exam <25
Wheelchair Bound
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Supplementary Table 2. Comparison of Baseline Characteristics among Patients with or without Base-
line Health Status Data
Patients with baseline 
health status data
(n=436)
Patients without 
baseline health status 
data (n=35)
p-value
Socio-demographic characteristics
Age 84.0 ± 8.5 80.3 ± 8.8 0.014
Male 49.1% (214/436) 48.6% (17/35) 0.954
White 95.6% (417/436) 91.4% (32/35) 0.219
BMI 28.6 ± 7.0 29.5 ± 8.2 0.454
Clinical characteristics
STS Risk Score 10.4 ± 5.6 8.7 ± 4.6 0.088
STS Risk Score Category 0.624
STS: <5 12.6% (55/436) 20.0% (7/35)
STS: 5 - <10 42.7% (186/436) 42.9% (15/35)
STS: 10 - <15 26.1% (114/436) 22.9% (8/35)
STS: >=15 18.6% (81/436) 14.3% (5/35)
Logistic EuroSCORE 22.8 ± 17.7 20.5 ± 12.5 0.452
NYHA Class 0.391
II 8.3% (36/434) 14.7% (5/34)
III 65.0% (282/434) 61.8% (21/34)
IV 26.7% (116/434) 23.5% (8/34)
Prior MI 31.7% (138/436) 25.7% (9/35) 0.466
Prior CABG 40.6% (177/436) 40.0% (14/35) 0.945
Previous Stroke 13.8% (60/436) 11.4% (4/35) 1.000
Home oxygen 29.8% (130/436) 37.1% (13/35) 0.364
Chronic kidney disease 13.2% (57/431) 5.7% (2/35) 0.290
Mean aortic valve gradient 47.6 ± 14.8 45.0 ± 14.0 0.324
Frailty and disability measures
Albumin<3.3g/dL 17.6% (75/427) 16.7% (5/30) 0.900
Wheelchair bound 15.8% (69/436) 28.6% (10/35) 0.052
6 minute walk test 167.5 ± 117.0 218.2 ± 152.7 0.164
5 meter gait speed>6 secs 84.5% (262/310) 75.0% (9/12) 0.413
Grip strength < threshold* 65.7% (286/435) 85.7% (30/35) 0.015
Charlson comorbidity score 0.928
Mild (score 1,2) 8.7% (38/436) 5.7% (2/35)
Moderate (score 3,4) 32.8% (143/436) 34.3% (12/35)
Severe (score 5) 58.5% (255/436) 60.0% (21/35)
NYHA, New York Heart Association; MI, myocardial infarction; STS, Society of Thoracic Surgeons; * defi ned 
according to the thresholds proposed by Luna-Heredia et al.24
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Supplementary Table 4. Proportion of Patients with Clinically Important Improvement in the KCCQ 
Overall Summary Score According to Procedural Success
Population and
Level of Benefi t
Patients with procedural success
Patients without procedural 
success p-value**
Proportion (95% CI) [n/N] Proportion (95% CI) [n/N]
Among responders to the survey
Moderate improvement (≥10-point increase from baseline)
1 month 73.1% (67.0%, 79.1%) (152/208) 55.3% (39.5%, 71.1%) (21/38) 0.027
6 months 70.7% (64.7%, 76.7%) (157/222) 75.0% (62.2%, 87.8%) (33/44) 0.566
12 months 72.7% (66.7%, 78.8%) (152/209) 65.9% (51.3%, 80.4%) (27/41) 0.372
Large improvement (≥20-point increase from baseline)
1 month 61.5% (54.9%, 68.2%) (128/208) 44.7% (28.9%, 60.5%) (17/38) 0.053
6 months 60.8% (54.4%, 67.2%) (135/222) 63.6% (49.4%, 77.9%) (28/44) 0.725
12 months 59.3% (52.7%, 66.0%) (124/209) 58.5% (43.5%, 73.6%) (24/41) 0.925
Among all treated patients*
Favorable outcome (alive with ≥10-point increase from baseline)*
1 month 72.0% (66.0%, 78.1%) (152/211) 34.4% (22.5%, 46.3%) (21/61) < 0.001
6 months 60.6% (54.7%, 66.6%) (157/259) 42.3% (31.3%, 53.3%) (33/78) 0.004
12 months 56.5% (50.6%, 62.4%) (152/269) 33.3% (23.1%, 43.6%) (27/81) < 0.001
Excellent outcome (alive with ≥20-point increase from baseline)*
1 month 60.7% (54.1%, 67.3%) (128/211) 27.9% (16.6%, 39.1%) (17/61) < 0.001
6 months 52.1% (46.0%, 58.2%) (135/259) 35.9% (25.3%, 46.5%) (28/78) 0.012
12 months 46.1% (40.1%, 52.1%) (124/269) 29.6% (19.7%, 39.6%) (24/81) 0.009
*Denominator includes patients who died but excludes patients who voluntarily withdrew from the study 
before the time point.
KCCQ, Kansas City Cardiomyopathy Questionnaire. **P comparing proportions of good outcomes in suc-
cessful vs. unsuccessful procedures.
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Supplementary Table 5. Comparison of 12-month Health Status Outcomes between the CoreValve Ex-
treme Risk and PARTNER B Trials
Scale CoreValve Extreme Risk PARTNER B
12 month ∆ vs. Baseline
 KCCQ summary 27.4 31.8
 KCCQ total symptoms 22.8 26.2
 KCCQ physical limitations 14.1 16.8
 KCCQ quality of life 36.3 41.2
 SF-12 physical 5.1 6.6
 SF-12 mental 5.1 7.0
Favorable outcome (alive with ≥10-point increase from baseline)*
 12 months 49.5% 47.5%
Excellent outcome (alive with ≥20-point increase from baseline)*
 12 months 41.0% 38.0%
* Denominator includes patients who died but excludes patients who voluntarily withdrew from the study 
before the time point.
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ABSTRACT
Introduction
The introduction of transcatheter aortic valve replacement (TAVR) has led to more rig-
orous evaluation of surgical aortic valve replacement (SAVR) as a benchmark for TAVR. 
However, limited real-life cost data of SAVR are available. Therefore, the purpose or our 
study was to assess actual costs and resource utilization of SAVR in patients at diff erent 
operating risk.
Methods
Study data were drawn from a multi-institutional statewide database comprised of all 
cardiac surgical procedures in the Commonwealth of Virginia. The current study included 
2,530 elective, primary, isolated SAVRs performed from 2003 to 2012. Clinical data were 
matched with universal billing data. Cost-to-charge ratios were applied, and price indices 
were used to convert all costs to 2012 U.S. dollars. Patients were stratifi ed into low, 
intermediate and high risk categories according to STS-PROM score: 0-4%, 4-8% and 
>8%, respectively. Clinical outcomes, resource use, and costs were compared between 
categories.
Results
Mean total costs for the overall cohort were $37,559 ± 27,557. There was an increase 
in mean total costs from the low (n = 2,002) to intermediate (n = 415) to high (n = 113) 
risk category ($35,021 ± 22,642 versus $46,101 ± 42,460 versus $51,145 ± 31,655; 
p < 0.001). With increasing risk, there were higher rates of post-operative mortality (low 
1.2% versus intermediate 2.7% versus high 6.2%, p < 0.001) and stroke (1.0% versus 
2.4% versus 2.7%; p = 0.37). The proportion of patients with any post-operative compli-
cation was higher with increasing risk (34% versus 48% versus 53%; p < 0.001). Length 
of stay increased from 6.8 days in the low risk category to 10.2 and 11.3 days in the 
intermediate and high risk category, respectively (p < 0.001).
Conclusions
Higher STS-PROM was signifi cantly associated with higher costs, post-operative mortal-
ity, complications, and length of stay. The SAVR cost data in the intermediate and high 
risk category provide a basis for the analysis of TAVR cost-eff ectiveness.
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INTRODUCTION
The standard treatment for patients with symptomatic severe aortic stenosis (AS) is 
surgical aortic valve replacement (SAVR). Approximately 67,500 SAVR procedures are 
performed annually in the United States.1, 2 As the population is aging, the prevalence of 
AS and consequently the utilization of SAVR are expected to increase.
Transcatheter aortic valve replacement (TAVR) is a less-invasive treatment in patients at 
high or prohibitive surgical risk.3, 4 In the recent randomized PARTNER trial, TAVR was as-
sociated with similar clinical outcomes and a small quality-of-life gain as compared with 
SAVR in high risk patients.5-7 Therefore and due to the fact that health care expenditure 
outpace the growth of the economy, costs have become a crucial factor in the decision-
making in patients with AS at high risk.8 However, little is known about the costs of SAVR 
in everyday practice.
We therefore sought to assess the costs and resource use of SAVR stratifi ed on the 
Society of Thoracic Surgery Predicted Risk of Mortality (STS-PROM), thereby providing a 
benchmark for the cost of TAVR in current and future everyday practice.
METHODS
Study Population
The clinical records of patients undergoing cardiac surgery were prospectively collected 
in the Virginia Cardiac Surgery Quality Initiative (VCSQI) database. For this project, all 
elective isolated SAVRs between January 2003 and June 2012 were selected. Patients 
with infective endocarditis or previous valve surgery were excluded, leading to 2,562 
eligible patients. After exclusion of 32 patients with data errors, 2,530 patients remained 
for analysis.
VCSQI is a voluntary consortium of 17 hospitals and 13 cardiac surgical centers provid-
ing cardiac surgery in the Commonwealth of Virginia.9 Approximately 99% of all cardiac 
surgical procedures were captured in the database. VCSQI members contributed their 
data to The Society of Thoracic Surgeons (STS) Adult Cardiac Database. Each of VCSQI’s 
hospital members agreed in advance to share data for secondary statistical analysis. 
Patient data are de-identifi ed and aggregated for research purposes only. Business As-
sociates Agreements are in place between VCSQI, its 17 member hospitals, and database 
vendor (Armus Corporation, San Mateo CA). Database retrievals and analyses conducted 
by VCSQI primarily for secondary analyses are not normally reviewed by hospital In-
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stitutional Review Boards (IRBs). However, individual member hospitals are invited to 
circulate study prospectuses to their IRBs for review and exemption prior to launching 
specifi c quality improvement initiatives.
Clinical Data
Clinical data included all the data routinely collected in the STS database and post-
operative outcomes included death, stroke, renal failure, atrial fi brillation, deep sternal 
wound infection, permanent stroke, prolonged ventilation and reoperations, all defi ned 
according to the STS database defi nitions.10 Each institution was responsible for coding 
and submitting its data to VCSQI’s repository and agreed on the data defi nitions, data 
collection and timely submission.
Cost Data
The process of combining clinical and fi nancial data in the VCSQI database has been de-
scribed elsewhere.11 Briefl y, STS patient records were matched with universal billing (UB) 
discharge records, which are used by institutional health care providers throughout the 
U.S. The UB-04 form replaced its predecessor UB-92 in 2007 and represents the patient’s 
fi nal hospital bill. Charges for all of the ICD-9 (International Classifi cation of Diseases, 
9th revision) revenue codes were grouped into 20 logical cost categories (see list in the 
Appendix). Subsequently, cost-to-charge ratios from each participating institution were 
applied to the costs in these 20 categories. The total costs estimate was the sum of all 
the 20 categories. The medical care service component of the U.S. consumer price index 
was used to convert all costs to U.S. dollars for the year 2012.12
Statistical Analysis
Patients were subdivided into low (STS-PROM<4), intermediate (STS-PROM 4-8) and 
high (STS-PROM>8) risk categories. The three categories were analyzed for diff erences 
in baseline characteristics, clinical outcomes, resource use and costs. Variables were 
tested for normality using the Kolmogorov-Smirnov test; normally distributed variables 
were compared between risk categories using one-way analysis-of-variance and for 
non-parametric distributions, the Kruskal-Wallis test was used. Pairwise post-hoc com-
parisons were done with Bonferroni correction, using t-tests for parametric distributions 
and Mann-Whitney U-tests for non-parametric distributions. Categorical variables were 
compared by the Pearson chi-square test. Cost and length of stay data are reported as 
both mean and median values and were compared using t-tests, which are appropriate 
given our focus on comparing mean costs between risk categories.13 All analyses were 
performed using Excel 2010 (Microsoft, Redmond, Wash) and SPSS for Windows (version 
20.0.0; SPSS, Chicago, Ill).
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RESULTS
Patient Characteristics
Patient characteristics of the overall cohort and diff erent risk categories are presented in 
Table 1. The low risk category consisted of 2,002 (79%) patients, the intermediate risk 
category of 415 (16%) patients and the high risk category of 113 (5%) patients. There 
was a signifi cant diff erence in the mean STS-PROM score according to risk category: 1.8 ± 
0.9, 5.4 ± 1.1 and 12.6 ± 4.3 in the low, intermediate, and high risk category, respectively. 
The cohort existed of elderly patients (67.4 ± 12.7 years), with signifi cantly younger 
patients in the low risk category (64.6 ± 12.2 years) compared to the intermediate (77.7 ± 
7.8 years) and high risk category (79.5 ± 7.3 years; p < 0.001). As expected, comorbidities 
were more prevalent in the higher risk categories.
Table 1. Patient Characteristics
Overall 
Cohort
(n=2,530)
Low risk
(n=2,002)
Intermediate 
risk
(n=415)
High risk
(n=113)
p-value
Age, years 67.4 ± 12.7 64.6 ± 12.2 77.7 ± 7.8 79.5 ± 7.3 <0.001a
Female, n (%) 1054 (41.7) 788 (39.4) 212 (51.1) 54 (47.8) <0.001b
STS-PROM, % 2.9 ± 2.8 (2.1) 1.8 ± 0.9 (1.7) 5.4 ± 1.1 (5.2) 12.6 ± 4.3 (11.1) <0.001a
Body Mass Index, kg/m2 29.5 ± 6.7 30.0 ± 6.7 27.9 ± 6.5 27.4 ± 6.3 <0.001b
Creatinine, mg/dl 1.13 ± 0.85 1.03 ± 0.60 1.30 ± 1.13 2.26 ± 1.91 <0.001a
Caucasian 2206 (87.2) 1747 (88.8) 359 (88.6) 100 (89.3) 0.98
Ejection Fraction <30% 67 (2.6) 41 (2.0) 14 (3.4) 12 (10.6) <0.001c
History of smoking 314 (12.4) 272 (13.6) 33 (8.0) 9 (8.0) 0.03d
Chronic Lung Disease 460 (18.2) 287 (14.3) 120 (28.9) 53 (46.9) <0.001a
Hypertension 1823 (72.1) 1355 (67.7) 366 (88.2) 102 (90.3) <0.001b
Diabetes 657 (26.0) 423 (21.1) 175 (42.2) 59 (52.2) <0.001b
History renal failure 42 (3.1) 9 (0.8) 11 (6.4) 22 (27.5) <0.001a
History of MI ≤7 days 153 (6.0) 65 (3.2) 60 (14.5) 28 (24.8) <0.001a
NYHA class (III, IV) 754 (45.4) 483 (40.8) 194 (52.7) 77 (73.3) <0.001b
Peripheral artery disease 204 (8.1) 82 (4.1) 73 (17.6) 49 (43.4) <0.001a
Prior stroke 115 (8.9) 59 (2.9) 39 (13.8) 17 (23.3) <0.001a
Cerebral vascular disease 310 (12.3) 178 (8.9) 91 (21.9) 41 (36.3) <0.001a
Prior Cardiovascular Surgery 280 (11.1) 107 (5.3) 114 (27.5) 59 (52.2) <0.001a
Values are mean ± standard deviation (median) or n (%). asignifi cant diff erence between all risk categories. 
bsignifi cant diff erence between low and intermediate/high risk categories. csignifi cant diff erence between 
low/intermediate and high risk categories. dsignifi cant diff erence between low and intermediate risk cat-
egory.
MI, myocardial infarction; STS-PROM, Society of Thoracic Surgery Predicted Risk Of Mortality.
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Clinical Outcomes
Clinical outcomes are presented in Table 2. From low to intermediate to high risk, there 
were stepwise increases in post-operative mortality (low 1.2% versus intermediate 
2.7% versus high 6.2%), stroke (low 1.0% versus intermediate 2.4% versus high 2.7%), 
and renal failure (low 2.7% versus intermediate 7.2% versus high 10.6%; Figure 1). In 
general, the proportion of patients with any post-operative complication was higher with 
increasing risk (33.8% versus 47.7% versus 53.1%; p < 0.001).
Table 2. Clinical Outcomes
Overall Cohort
(n=2,530)
Low risk
(n=2,002)
Intermediate 
risk
(n=415)
High risk
(n=113)
p-value
30-day mortality 42 (1.7) 24 (1.2) 11 (2.7) 7 (6.2) <0.001d
Post-operative complications 935 (37.0) 677 (33.8) 198 (47.7) 60 (53.1) <0.001b
Permanent stroke 34 (1.3) 21 (1.0) 10 (2.4) 3 (2.7) 0.37
Renal failure 97 (3.8) 55 (2.7) 30 (7.2) 12 (10.6) 0.001b
 Requiring dialysis 36 (1.4) 16 (0.8) 13 (3.1) 7 (6.2) 0.03d 
Atrial fi brillation 574 (22.6) 435 (21.7) 110 (26.5) 28 (46.7) 0.01d
Pneumonia 59 (2.3) 36 (1.8) 18 (4.3) 4 (3.5) 0.15
Prolonged ventilation time (>24h) 207 (8.2) 117 (5.8) 67 (16.1) 23 (20.4) <0.001b
Deep sternal wound infection 7 (0.3) 6 (0.3) 1 (0.2) 0 (0.0) 0.68
Reoperation for bleeding 84 (3.3) 62 (3.1) 18 (4.3) 4 (3.5) 0.81
Reoperation other cardiac reason 38 (1.5) 33 (1.6) 5 (1.2) 0 (0.0) 0.09
Reoperation non-cardiac reasons 48 (1.9) 26 (1.3) 16 (3.9) 6 (5.3) 0.01b
Values are mean ± standard deviation (median) or n (%). a signifi cant diff erence between all risk categories. 
b signifi cant diff erence between low and intermediate/high risk categories. c signifi cant diff erence between 
low/intermediate and high risk categories. d signifi cant diff erence between low and high risk category.
Figure 1. 30-day Clinical Outcomes
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Resource Use and Costs
Resource use and costs are summarized in Table 3 and Figure 2. The hospital stay was 
6.8 ± 5.1 days in the low risk category, 10.2 ± 10.2 days in the intermediate risk category, 
and 11.3 ± 7.4 days in the high risk category. This was refl ected in the stepwise increase 
of hospital stay costs from low to intermediate to high risk (low $8,724 ± 8,968 versus 
intermediate $14,067 ± 19,276 versus high $15,962 ± 14,019; p < 0.001). There was 
no signifi cant diff erence in readmission rates (p = 0.44). More expenses were incurred 
for the diagnostics of intermediate and high risk patients as compared with low risk 
patients (low $2,669 ± 2,439 versus intermediate $3,857 ± 4,406 versus high $4,532 ± 
3,724; p < 0.001). The overall costs of the intervention were remarkably similar between 
the diff erent risk categories (p = 0.28). There were higher costs of blood products in the 
higher risk categories (low $601 ± 1,114 versus intermediate $1,172 ± 1,982 versus high 
$1,305 ± 1,570; p < 0.001).
Interestingly the operating room costs were lower in the high risk category (low $7,516 ± 
4,173 versus intermediate $7,426 ± 4,482 versus high: $6,291 ± 4,410; p = 0.01). There 
were higher costs of general supportive care according to risk category (low $3,127 ± 
4,636 versus intermediate $5,692 ± 11,301 versus high $6,196 ± 7,488; p < 0.001). The 
higher rate of renal failure in the higher risk categories are reproduced in the higher costs 
of dialysis with increasing risk (low $34 ± 608 versus intermediate $300 ± 2,931 versus 
high $769 ± 2,132).
The mean total costs increased from the low to the high risk category (low $35,021 ± 
22,642 versus intermediate $46,101 ± 42,460 versus high $51,145 ± 31,655; p < 0.001). 
Mean total costs for the overall cohort were $37,559 ± 27,557.
COMMENT
In a statewide prospective registry of 2,530 SAVRs, 79% of the patients was at low risk 
(STS-PROM 0-4%), 16% at intermediate risk (STS-PROM 4-8%), and 5% at high risk (STS-
PROM>8%). Not surprisingly, clinical outcomes were worse in the higher risk categories 
and more resources were used. This resulted in a stepwise increase in costs from the low 
to the intermediate and high risk categories. Patients at high operative risk had increased 
30-day mortality (low 1.2%, versus intermediate 2.7% versus high risk 6.2%), more 
post-operative complications (low 34% versus intermediate 48% versus high risk 53%), 
and longer hospitalization (low 6.8 days versus intermediate 10.2 days versus high risk 
11.3 days). Mean total costs for the overall cohort were $37,559 ± 27,557. The total costs 
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Table 3. Resource Use and Cost Outcomes
Overall Cohort
(n=2,530)
Low risk
(n=2,002)
Intermediate risk
(n=415)
High risk
(n=113)
p-value
Length of stay 7.6 ± 6.5 (6) 6.8 ± 5.1 (5) 10.2 ± 10.2 (7) 11.3 ± 7.4 (9) <0.001a
Admission-
surgery
0.6 ± 2.0 (0) 0.4 ± 1.6 (0) 0.9 ± 2.5 (0) 1.7 ± 3.8 (0) <0.001b
Surgery-
discharge
7.0 ± 6.1 (5) 6.3 ± 4.8 (5) 9.3 ± 9.9 (2) 9.6 ± 6.5 (8) <0.001a
Readmission 
within 30 days
248 (9.8) 191 (9.5) 43 (10.4) 14 (12.4) 0.44
Total stay 9,924 ± 11,779 (7,087) 8,724 ± 8,968 (6703) 14,067 ± 19,276 (8,667) 15,962 ± 14,019 (10,991) <0.001b
Emergency room 12 ± 85 (0) 10 ± 78 (0) 15 ± 85 (0) 40 ± 158 (0) 0.001c
ICU/CCU 8,538 ± 11,341 (5,959) 7,365 ± 8,629 (5,638) 12,689 ± 18,507 (7,701) 14,092 ± 13,742 (10,475) <0.001b
Regular room 1,373 ± 2,865 (0) 1,350 ± 2,635 (0) 1,363 ± 3,474 (0) 1,830 ± 4,060 (0) 0.22
Diagnostics 2,947 ± 2,968 (2,217) 2,669 ± 2,439 (2095) 3,857 ± 4,406 (2,757) 4,532 ± 3,724 (3,812) <0.001b
Radiology 358 ± 583 (196) 302 ± 443 (183) 544 ± 918 (274) 668 ± 888 (448) <0.001b
Lab 2,070 ± 2,153 (1,566) 1,885 ± 1,799 (1,497) 2,695 ± 319 (1,790) 3,062 ± 2,715 (2,287) <0.001b
Cardiac 
diagnostics
512 ± 597 (379) 477 ± 556 (353) 609 ±716 (429) 790 ± 710 (686) <0.001b
Peripheral 
vascular lab
6 ± 46 (0) 5 ± 42 (0) 10 ± 62 0) 12 ± 51 (0) 0.07
Intervention 18,266 ± 9,750 (16,272) 18,249 ± 9,885 (16,199) 18,683 ± 9,396 (16,756) 17,041 ± 8,514 (15,026) 0.28
Anesthesia 519 ± 374 (636) 511 ± 607 (372) 537 ± 664 (369) 576 ± 959 (405) 0.47
Operating Room 7,446 ± 6,756 (4,242) 7,516 ± 4,173 (6,851) 7,426 ± 4,482 (6,647) 6,291 ± 4,410 (4,679) 0.01d
Recovery room 122 ± 279 (0) 129 ± 283 (0) 96 ± 275 (0) 93 ± 209 (0) 0.05
Blood products 726 ± 1,339 (223) 601 ± 1,114 (118) 1,172 ± 1,982 (552) 1,305 ± 1,570 (865) <0.001b
Implants (pacers, 
ICD, valve)f
289 ± 1,830 (0) 302 ± 1,914 (0) 216 ± 1,401 (0) 312 ± 1,702 (0) 0.67
General Supplies 9,165 ± 8,021 (8047) 9,190 ± 8,231 (8,016) 9,237 ± 7,500 (8,213) 8,463 ± 5,810 (7,950) 0.63
General care 3,685 ± 6,449 (2295) 3,127 ± 4,636 (2,189) 5,692 ± 11,301 (2,791) 6,196 ± 7,488 (3,645) <0.001b
Dialysis 111 ± 1,389 (0) 34 ± 608 (0) 300 ± 2,931 (0) 769 ± 2,132 (0) <0.001a
Therapies (PT, 
OT, cardiac 
rehabilitation)
569 ± 1784 (257) 431 ± 1,099 (223) 1,010 ± 3,022 (390) 1,388 ± 3,849 (490) <0.001b
Pharmacy 2,062 ± 3,179 (1414) 1,873 ± 2,602 (1,376) 2,821 ± 5,040 (1,559) 2,626 ± 3,192 (1,681) <0.001e
Cardiac 
catheterization 
lab
116 ± 518 (0) 97 ± 472 (0) 179 ± 684 (0) 220 ± 553 (0) 0.001e
Respiratory 
therapy
820 ± 1,892 (410) 686 ± 1,381 (395) 1,362 ± 3,391 (487) 1,188 ± 1,634 (656) <0.001
Intravenous 7 ± 136 (0) 5 ± 83 (0) 19 ± 280 (0) 4 ± 43 (0) 0.15
Other 2,737 ± 6,959 (840) 2,252 ± 8,385 (618) 3,802 ± 8,842 (1,344) 7,414 ± 15,997 (2,714) <0.001a
TOTAL COSTS 37,559 ± 27,557 (31,183) 35,021 ± 22,642 (30,289) 46,101 ± 42,460 (35,327) 51,145 ± 31,655 (42,965) <0.001b
Values are mean ± standard deviation (median) in U.S. dollars for year 2012. a signifi cant diff erence be-
tween all risk categories. b signifi cant diff erence between low and intermediate/high risk categories. c sig-
nifi cant diff erence between low/intermediate and high risk categories. d signifi cant diff erence between 
low and high risk category. e signifi cant diff erence between low and intermediate risk category. f additional 
implants.
ICU, Intensive care unit; CCU, cardiac care unit; MI, myocardial infarction; OT, occupational therapy; PT, 
physical therapy; STS-PROM, Society of Thoracic Surgery Predicted Risk Of Mortality.
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for SAVR in the diff erent risk categories were $35,021, $46,101, and $51,145 in the low, 
intermediate and high risk categories, respectively.
Costs according Risk Categories
While the diff erence in mean total costs between the low risk category and intermedi-
ate risk category was more than $10,000, the diff erence between the intermediate and 
high risk category was less evident. Apparently, total costs are infl uenced in particular 
by the diff erence of having few (low risk) or more (intermediate risk) comorbidities. 
Subsequently, the severity or multiplicity of comorbidities (intermediate versus high risk 
category) have less impact on the total costs.
An explanation might be that for patients with more comorbidities, extra care and pre-
cautions are taken in any case, leading to higher costs. This might be explained by the 
larger diff erence in patients with any complication between the low and intermediate 
risk category (14%) as compared with the diff erence between the intermediate and high 
risk category (4%). As a supportive example, we found that general care costs, largely 
consisting of supplementary supporting therapies, were only slightly (approximately 
Figure 2. Total Costs of Surgical Aortic Valve Replacement
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$500) higher in the high risk category as compared with the intermediate category. 
The diff erence between the low and intermediate category for this cost component is 
considerably higher (approximately $2,500).
Limitations of risk assessment are another potential explanation for the small diff erence 
in costs between intermediate and high risk patients. Risk factors, such as frailty, are not 
captured in the present risk models, but are increasingly important in the elderly.14, 15 
These factors are more often present in intermediate patients, and when not captured in 
the risk score, some patients might be categorized as intermediate risk, while in fact they 
are at high operating risk. In the low risk category, this is less of an issue because these 
patients are younger and have less comorbidities leading to frailty and lower activity.
Frailty and other risk factors that are not included in current risk scores might also lead 
to selection bias in the high risk category, thereby causing the small diff erence in costs 
between intermediate and high risk patients. Patients at high risk in whom SAVR does not 
seem appropriate are fi ltered out and only those patients that are able to undergo SAVR 
represent a selected group. This leads to relatively moderate and similar costs in the high 
risk group as compared with the intermediate risk group.
Costs in the Literature
Few other studies have investigated the costs of SAVR in everyday practice. Moreover, the 
methodology of these studies varied signifi cantly.2, 16-19 One study also used charge data 
and found that in 1997 the mean costs of SAVR were approximately $22,000, a result that 
corresponds well with the $38,000 in our study when infl ation is taken into account.12, 16 
Another study used the 5%-Medicare Standard Analytic Files in 2001-2008 for extract-
ing cost data, and interpreted ICD9 codes to identify risk factors that were used as inputs 
for calculating the logistic EuroSCORE.2 Subsequently patients were classifi ed into high 
risk and non-high risk using a logistic EuroSCORE of 20% as the cutoff  value. The costs 
of SAVR were $58,452 in the high risk group and $50,821 in the non-high risk group. The 
slightly higher outcomes than in our study could be the result of the three-month follow-
up after SAVR, and the risk stratifi cation in two EuroSCORE categories instead of the three 
STS-PROM categories in our study. Also, the STS and EuroSCORE models have shown a 
lack of correlation. It may therefore be unclear what the representative STS-PROM was 
for patients with >20% EuroSCORE values and in which study the risk, and consequently 
the costs, was higher. On the other hand, a recent study estimated costs of TAVR and SAVR 
procedures in intermediate risk patients, as defi ned by EuroSCORE, and found that the 
costs of SAVR were remarkably similar to our results in the intermediate risk category as 
defi ned by STS-PROM (both approximately $46,000).18
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The current data, combined with the high burden of disease of AS, represent a large 
impact on the health care budget. The estimated 67,500 SAVRs and the costs of SAVR 
in this cohort stand for yearly health care expenditures of $2.5 billion. Currently more 
than 20% of the population in developed countries is over 60 years old, and a rise to 
approximately 28% in 2025 and 34% in 2050 is anticipated.20 Since AS is primarily 
a disease of the elderly, it is expected that the burden and budget impact of AS will 
continue to increase.
Implications for TAVR
The results of the present study provide a benchmark for the cost of TAVR in everyday 
practice. The costs of high risk SAVRs in the present study are more than $20,000 lower 
than in the PARTNER trial.8 Apparently, real-life index admission costs are lower than the 
costs in the trial ($51,145 ± 31,655 versus $74,067 ± 40,596, respectively). The costing 
method in the PARTNER trial was based on a combination of resource-based accounting 
and hospital bills. The strict selection criteria of the PARTNER trial are another potential 
cause of the disparity with our results. Only 12% of the screened severe AS patients 
were ultimately randomized in the trial resulting in limited generalizability of both clini-
cal and economic outcomes.5 With the costs from our study, TAVR is less likely to be an 
economically attractive treatment. This demonstrates the value of real-life observational 
studies complementary to randomized trials to establish treatment recommendations. 
Therefore, the fi nal answer on the comparative cost-eff ectiveness of TAVR will be pro-
vided by ongoing registries with TAVR cost data from everyday practice.21
The SURTAVI and PARTNER II clinical trials evaluate TAVR versus SAVR in intermediate 
(STS-PROM 4-8) risk patients.15 It will be interesting to see what the clinical and quality-
of-life outcomes in these trials will be and how the economic outcomes compare to the 
$46,000 benchmark for SAVR in patients at intermediate operating risk from the current 
study.
Study Limitations
There are several limitations to this study. First, we did not have long-term follow-up 
data. A recent study showed that the 5-year follow-up costs after SAVR are considerably 
higher in high risk patients than in non-high risk patients.2 However, our study is more 
detailed with regard to clinical characteristics and is unique by reporting costs stratifi ed 
by STS-PROM risk categories that are used by the Centers for Medicare and Medicaid 
Services, current consensus documents, clinical guidelines and ongoing trials (ClinicalTri-
als.gov Identifi ers: NCT01314313 and NCT01586910).4, 15, 22, 23
Second, there might be diff erences between cost items from one provider to another 
due to unique individual hospital coding and billing patterns. However, in a close state-
wide collaboration as VCSQI, disparities are minimized. Moreover, these diff erences will 
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particularly infl uence the categorization of costs and not the total costs on the hospital 
bill.
Third, there were relatively few patients in the high risk category, which may have caused 
the lack of statistically signifi cant diff erences. This resulted in moderate power to detect 
diff erences between the intermediate and high risk categories. On the other hand, this 
study reported on all elective, fi rst-time isolated SAVR in the state of Virginia during a 10 
year timeframe and apparently this high risk category is relatively small.
Conclusions
Higher STS-PROM was signifi cantly associated with higher costs, post-operative mortal-
ity, complications, and length of stay. These important data are complimentary to data 
from randomized trials. The SAVR cost data in the intermediate and high category provide 
a basis for the analysis of TAVR cost-eff ectiveness.
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Supplementary Table 1. Cost Categories and ICD-9 Revenue Codes
Cost Category Revenue Codes
Emergency room 450-459
ICU/CCU 200-219
Regular room 100-179
Radiology 320-359, 400-409
Lab 300-319
Cardiac diagnostics 480, 482-489, 730-731, 739
Peripheral vascular lab 921
Anesthesia 370-379
Operating Room 360-369, 490-499
Recovery room 710-719
Blood products 380-399
Implants (pacers, ICD, valve) 275, 278
General Supplies 270-274, 276-277, 279
Pharmacy 250-259
Intravenous 260-269
Respiratory therapy 410-419
Cardiac catheterization lab 481
Therapies (PT, OT, cardiac rehabilitation) 420-449
Dialysis 800-809, 820-859, 880-889
Other
180-199, 220-249, 280-299, 470-479, 500-679, 
700-709, 740-799, 901-920, 922-942, 944-999
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ABSTRACT
Background
Transcatheter aortic valve replacement (TAVR) off ers a new treatment option for patients 
with aortic stenosis, but costs may play a decisive role in decision-making. Current stud-
ies are evaluating TAVR in an intermediate-risk population. We assessed the in-hospital 
and 1-year follow-up costs of patients undergoing TAVR and surgical aortic valve replace-
ment (SAVR) at intermediate operative risk and identifi ed important cost components.
Methods
We prospectively collected clinical data on 141 patients undergoing TAVR and 405 
undergoing SAVR. Propensity score matching yielded 42 matched pairs at intermediate 
risk. Costs were assessed using a detailed resource-use approach and compared using 
bootstrap methods.
Results
In-hospital costs were higher in TAVR patients than in SAVR patients (€40802 vs. €33354, 
respectively; p = 0.010). The total costs at 1 year were €46217 vs. €35511, respectively 
(p = 0.009). The TAVR was less costly with regard to blood products, operating room use, 
and length of stay.
Conclusions
For intermediate-risk patients with severe aortic stenosis the costs at 1 year are higher 
for TAVR than for SAVR. The diff erence was mainly caused by the higher costs of the 
transcatheter valve and was not compensated by the lower costs for blood products 
and hospital stay in TAVR patients. Therefore, SAVR remains a clinically and economically 
attractive treatment option.
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INTRODUCTION
Surgical aortic valve replacement (SAVR) is the standard treatment for patients with 
symptomatic aortic stenosis. However, transcatheter aortic valve replacement (TAVR) has 
rapidly emerged as a less invasive treatment option. A TAVR reduces mortality by 20% 
as compared with medical treatment in patients with severe aortic stenosis who are not 
eligible for surgery due to comorbidities and cardiovascular abnormalities.1 Moreover, 
TAVR is equivalent to SAVR in terms of 1-year survival for patients at high risk.2
Therefore, considerations such as quality-of-life and costs are crucial in the decision-
making process.3 The only randomized controlled trial that reported quality-of-life in 
high-risk patients undergoing TAVR demonstrated a small increase in quality-adjusted 
life years at 1 year.4 With equipoise in quality-of-life and survival, costs may play a piv-
otal role in the decision to perform TAVR or SAVR and therefore merit analysis.
Current studies evaluate TAVR in intermediate-risk populations, making the procedure 
more widely available. For these reasons our study assessed the in-hospital and 1-year 
follow-up costs of TAVR and SAVR in intermediate-risk patients with aortic stenosis using 
a detailed resource-use approach. A second objective was to identify important cost 
components.
PATIENTS AND METHODS
Study Population
Between January 2006 and November 2010 we prospectively collected data on consecu-
tive patients with aortic stenosis who underwent self-expanding transfemoral TAVR or 
SAVR at the Erasmus MC, Rotterdam, the Netherlands. All patients were discussed among 
cardiologists, interventional cardiologists, and cardiac surgeons during heart team meet-
ings, considering risk scores and additional factors such as frailty, porcelain aorta, and 
patient's preferences.5,6 Patients underwent either TAVR (n = 141) or SAVR (n = 405). After 
propensity score matching 42 TAVR and 42 SAVR patients remained for the cost analysis 
(Table 1). One-year follow-up data was collected for all 84 propensity-matched patients. 
The study was approved by the Institutional Research Ethics Committee.
Resource Use and Costs
We retrospectively collected in-hospital diagnostic, procedural, and postprocedural 
resource use data from electronic patient records. All patients had at least 1 outpatient 
clinic visit prior to the procedure and several diagnostic and preprocedural tests; 
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laboratory tests, chest X-rays, a dental consult, electrocardiography, cardiac ultrasound, 
coronary angiography, and lung function tests. We assumed that all patients had this 
standard clinical workup and that every TAVR patient underwent computed tomography. 
Associated costs were retrieved from the hospital's fi nancial unit and subunits in the 
departments of cardiology, cardiothoracic surgery, and radiology.
The self-expanding third generation CoreValve (Medtronic, Minneapolis, MN; €17,590) 
was used for TAVR and SAVR was performed with the bioprosthetic Carpentier-Edwards 
PERIMOUNT Magna Valves (Edwards Lifesciences, Irvine, CA; €2,700). All TAVR valves were 
inserted through a transfemoral approach. Other materials included disposables, sutures, 
needles, anesthesia, sterilized gauzes, and disposables for the heart-lung machine. We re-
trieved these costs from the electronic ordering system and hospital pharmacy. Procedural 
and postprocedural blood products comprised packaged cells, fresh frozen plasma, and 
platelets and were priced according to The Dutch Manual for Cost-Analysis in Health Care.7
Interventional rooms or operating room costs were calculated as costs per minute by 
using a micro-costing approach. A typical surgical team that carried out SAVR consisted 
Table 1. Baseline characteristics
Parameter
Before Propensity Score Matching After Propensity Score Matching
TAVR
(n=141)
SAVR
(n=405)
p-value TAVR
(n=42)
SAVR
(n=42)
p-value
Age, mean±SD (y) 81.3±6.7 70.1±9.0 <.0001 78.8±6.6 79.3±5.5 0.66
Male sex 78 (55.3) 240 (59.3) 0.41 21 (50.0) 22 (52.4) >0.99
Logistic EuroSCORE, 
mean±SD
16.2±10.9 6.2±5.5 <.0001 12.9±6.8 (11.1) 12.5 ±6.4 (10.7) 0.77
Diabetes mellitus 31 (22.0) 97 (24.0) 0.64 11 (26.2) 8 (19.0) 0.61
Coronary artery disease 56 (39.7) 167 (41.2) 0.75 20 (47.6) 20 (47.6) >0.99
LVEF
 >50%
 30-50%
 <30%
73 (51.8)
55 (39.0)
13 (9.2)
371 (91.6)
29 (7.2)
5 (1.2)
<.0001
27 (64.2)
14 (33.3)
1 (2.4)
30 (71.4)
10 (23.8)
2 (4.8)
0.68
Cerebrovascular accident 34 (24.1) 18 (4.4) <.0001 2(4.8) 2 (4.8) >0.99
Peripheral vascular disease 12 (8.5) 31 (7.7) 0.75 3 (7.1) 4 (9.5) >0.99
COPD 36 (25.5) 54 (13.3) 0.001 10 (23.8) 8 (19.0) 0.77
Pulmonary hypertension 17 (12.1) 16 (3.9) 0.001 2 (4.8) 3 (7.1) >0.99
Serum creatinine, 
mean±SD (μmol/l)
116.6 (94.3) 99.7 (55.7) 0.011 104.7 (92.2) 102.8 (64.6) 0.92
MI within 90 days before 
procedure
31 (22.0) 12 (3.0) <.0001 0 (0.0) 4 (9.5) 0.13
COPD, chronic obstructive pulmonary disease; LVEF, Left ventricular ejection fraction; MI, Myocardial infarc-
tion; SAVR, Surgical Aortic Valve Replacement; TAVR, Transcatheter Aortic Valve Replacement.
N(%) of patients unless stated otherwise.
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of 1 cardiothoracic surgeon, 1 anesthesiologist, 1 anesthesia assistant, 1 resident, 2 
nurses, and 2 technicians. Interventional teams were composed similarly, except that the 
team also comprised 2 interventional cardiologists, while no resident was involved. We 
assumed the standby time of the cardiothoracic surgeon during TAVR to be 50% of the 
total procedure time as he was unavailable for other surgeries. Salaries were obtained 
from the Manual and where necessary from collective agreements.7
Post-operative diagnostic tests included electrocardiography, laboratory tests, chest 
X-ray, cardiac ultrasound, coronary angiography, computed tomographic imaging, and 
lung scintigraphy. Additional procedures included chest drain placement, tracheostomy, 
reinterventions for pacemaker implantation, postdilatation of the transcatheter aortic 
valve, paravalvular leakage, sternal wound infection, and bleeding. Associated costs were 
retrieved using a micro-costing approach with data from fi nancial subunits.
Data on length of stay (LOS), 1-year follow-up visits, and readmissions to the cardiol-
ogy and neurology departments were collected through our electronic databases or 
databases from readmitting hospitals; where necessary the general practitioner was 
contacted. While TAVR patients were monitored in the academic hospital, SAVR patients 
were discharged to a general hospital to recover from surgery. After that, patients were 
usually discharged home. For TAVR patients, physician visits and tests were scheduled at 
1 and 4 months after the initial procedure. Patients who underwent SAVR were referred 
to a general hospital for further follow-up. Hospital stay (€2,241, €591, and €447 per 
night for intensive care, academic ward stay, and general hospital ward stay, respectively) 
and follow-up costs were retrieved from the Manual.7 These general average costs were 
based on various micro-costing studies and include physician consultations, nursing, 
nutrition, materials, equipment, overhead, and housing.7
For the individual patient costs we combined the Manual with actual costs of tests, pro-
cedures and materials as described because in the Netherlands individually specifi ed 
charge data are not available. No adjustment with a cost-to-charge ratio was needed as 
all costs were actual costs. Furthermore, administration and overhead, maintenance of 
the building, and equipment were taken into account. The health care perspective was 
applied and consumer price indices were used to convert all costs to the year 2011.8 The 
total costs at 1 year comprise the total in-hospital and follow-up costs.
Propensity Score Matching and Statistical Analysis
Comparison of the patient characteristics in the unmatched cohort was done using an un-
paired t-test for continuous variables and using a χ2 test or Fisher exact test for categorical 
variables. In the matched cohort, comparisons were performed using McNemar tests and 
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paired sample t-tests. Normality of the data was assessed using the Kolmogorov-Smirnov 
test and, if non-normality was proven, the Wilcoxon rank sum test was used. All tests 
were 2-sided with an α-level of 0.05.
The propensity score of a patient is defi ned as the probability to receive the experimen-
tal treatment conditional on pretreatment covariables.9 After propensity score matching 
we expect TAVR and SAVR cohorts to have comparable baseline characteristics, provid-
ing a fair comparison between groups.10 The propensity score for receiving TAVR was 
estimated using a multivariable probit (probability unit) model at a p-value less than 
0.10, including gender, age, and other baseline characteristics such as logistic Euro-
pean system for cardiac operative risk evaluation (EuroSCORE), diabetes, coronary artery 
disease, left ventricular ejection fraction, creatinine level, pulmonary hypertension, 
peripheral vascular disease, cerebrovascular disease, and chronic obstructive pulmonary 
disease. Subsequently, we performed Mahalanobis 1:1 matching, where a SAVR patient 
is matched to a randomly chosen TAVR patient using a caliper width of 0.05.11 The SAVR 
patients who were matched to a TAVR patient were no longer considered as a possible 
match. The resulting 42 matched pairs were used for the cost analysis.
Missing values were LOS in the intensive care unit (missing in 1 of 84 patients), length 
of ward stay (missing in 3), procedure time (missing in 3), and number of visits (missing 
in 1). The missing values were imputed by assuming they were the mean value of the 
non-missing values for that variable.12
Consistent with intention-to-treat analysis, in-hospital and follow-up costs were calcu-
lated by taking all patients (n = 84) into account, including those who died. To account 
for the skewed distribution of costs, we used bootstrap resampling to construct standard 
errors and confi dence intervals of the mean costs for TAVR, SAVR, and the diff erence 
between treatments.13
Outliers in total costs at 1 year were defi ned by a Cook distance larger than 4/n, where 
n is the number of data points. We performed sensitivity analysis excluding outliers and 
their matched partners.14 We also performed sensitivity analysis in a restricted dataset of 
matched pairs who did not undergo revascularization to deal with the unbalanced num-
ber of coronary revascularizations in the treatment groups. Analyses were performed 
by using Excel 2007 (Microsoft, Redmond, WA), SPSS for Windows (version 17.0.2; SPSS, 
Chicago, IL), and STATA 11.1 (Stata Corp, College Station, TX).
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RESULTS
Patients and Clinical Outcomes
Baseline characteristics of the unmatched and matched cohorts are given in Table 1. 
The logistic EuroSCORE was 12.9 in the TAVR and 12.5 in the SAVR group, which refl ects 
the intermediate operative risk. During SAVR, 20 patients underwent a concomitant 
coronary artery bypass grafting (CABG), whereas a concomitant percutaneous coronary 
intervention (PCI) during TAVR or as a staged procedure within the same hospital stay was 
performed in 3 patients (Table 2). There were no conversions from TAVR to SAVR. Proce-
dure duration and total LOS was shorter after TAVR than after SAVR (11.3 vs. 18.8 days, 
respectively; Table 2). This was true for both intensive care unit stay and ward stay, taking 
into account the stay in our academic hospital and in the general hospital to which the 
patient was discharged for recovery. In our propensity matched cohort no patients were 
discharged to a skilled nursing facility. We found no statistically signifi cant diff erence in 
complications, mortality at 1 year, follow-up duration, readmissions, and outpatient clinic 
visits (Table 2 and Table 3).
Table 2. Initial hospital stay
Parameter TAVR (n=42) SAVR (n=42) p-value
Procedure duration, mean±SD (min) 229±79 294±76 <0.001
Concomitant PCI/CABG 3 (7.1) 20 (47.6) <0.001
Length of post-operative stay, mean±SD (days)
 ICU
 Ward staya
  Ward academic hospital
  Ward general hospital
11.3±8.1
1.1±0.48
10.3±8.2
10.2±8.0
0.14±0.93
18.8±13.3
4.5±8.2
14.3±7.3
7.1±4.2
7.2±6.6
<0.001
<0.001
0.008
0.004
<0.001
In-hospital complicationsb
 Major stroke
 MI
 Major bleeding
 Major vascular
 Reintervention
 Infection
 PPI
 Pneumothorax
22 (52.4)
4 (9.5)
0
4 (9.5)
4 (9.5)
2 (4.8)
7 (16.7)
6 (14.3)
0 (0.0)
14 (33.3)
1 (2.4)
1 (2.4)
5 (11.9)
0 (0.0)
5 (11.9)
5 (11.9)
1 (2.4)
1 (2.4)
0.08
0.38
>0.99
>0.99
0.13
0.45
0.77
0.13
>0.99
In-hospital mortalityb 2 (4.8) 3 (7.1) >0.99
Abbreviations as previous; CABG, coronary artery bypass graft; ICU, Intensive Care Unit; PCI, percutaneous 
coronary intervention; PPI, permanent pacemaker implantation;
N(%) of patients unless stated otherwise.
aAll patients were operated in the academic center. Patients who underwent TAVR were usually discharged 
home, whereas patients who underwent SAVR were usually discharged to a general hospital for recovery.
bIn-hospital mortality is defi ned as death <30 days after procedure or death during initial hospital stay.
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In-Hospital Costs
The in-hospital costs were higher with TAVR than SAVR (€40,802 vs. €33,354, respec-
tively; Table 4). The largest diff erence was found in the procedure costs (€28,785 vs. 
€13,096, respectively) and in-hospital stay (€8,481 vs. €17,409, respectively). Procedural 
cost components that were signifi cantly diff erent between the treatment groups were 
operating room use, materials, and blood products (Table 4).
Table 4. In-Hospital Costs
Parameter (mean±SE) TAVR (n=42) SAVR (n=42) p-value
Pre-operative costs 2024±0 1538±0
Procedure costs 28785±1014 13096±315 <0.001
 Operating room use 1124±60 453±18 <0.001
 Personnel 2303±117 2431±90 0.41
 Materials 22055±869 5162±0 <0.001
 Blood products 176±41 1869±223 <0.001
 Overhead and housing 3127±48 3181±38 0.40
Total stay 8545±776 17409±3116 <0.001
 ICU stay 2458±168 9991±2820 0.008
 Ward staya 6087± 733 7418±544 0.087
  academic hospital 6023±715 4208±370 0.016
  general hospital 64±64 3210±446 <0.001
Post-operative tests 545±50 674±108 0.31
Post-operative blood products 136±43 63±27 0.17
Additional procedures 768±273 573±209 0.56
Total in-hospital costs 40802±1399 33354±3357 0.010
Euros for year 2011.
Abbreviations as previous.
aAll procedures were performed in the academic center. TAVR patients were usually discharged home, 
whereas SAVR patients were usually discharged to a general hospital for recovery. The subdivision of ward 
stay refl ects this diff erence.
Table 3. Follow-up
Parameter TAVR (n=42) SAVR (n=42) p-value
1 year follow-up death 7 (16.7) 5 (11.9) 0.73
Mean follow-up, mean±SD (days) 332.1±88 339.8±88 0.51
Outpatient clinic visits, n of patients (%) 33 (78.6) 35 (83.3) 0.75
Number of outpatient clinic visits per patient, n ±SD 1.8±1.8 2.0±1.6 0.24
Hospital readmission during follow-upa, n of patients 8 (19.0) 10 (23.8) 0.80
Hospital readmissiona, days ±SD 5.3±19.0 2.4±7.7 0.86
Abbreviations as previous.
aReasons for readmission included dyspnea, chest pain, endocarditis of the prosthesis, cardiac arrhythmias, 
additional dilatation of the valve, reoperation, transient ischemic attack and heart failure.
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Follow-Up Costs
The costs incurred during follow-up were nonsignifi cantly higher in the TAVR group than 
in the SAVR group (∆ costs = €3,258; Table 5). In addition, components of the follow-up 
costs were not signifi cantly diff erent. The total costs at 1 year were higher for TAVR than 
for SAVR (€46,217 vs. €35,511, respectively; p = 0.009; Fig 1).
Table 5. One-Year Follow-Up Costs
Parameter (mean±SE) TAVR (n=42) SAVR (n=42) p-value
Visit costs 182±28 135±16 0.10
Visit diagnostic tests 582±86 587±69 0.97
Readmission hospital stay 3336±1882 1086±528 0.25
Readmission procedures 1168±589 245±172 0.13
Readmission diagnostic tests 146±59 104±41 0.58
Total one-year follow-up 5414±2224 2157±627 0.17
Euros for year 2011.
Abbreviations as previous.
Figure 1. Total Costs at 1 Year
Euros for year 2011.
Blocks containing numbers represent cost components which diff er signifi cantly between treatment 
groups. ICCU, intensive cardiac care unit; SAVR, surgical aortic valve replacement; TAVR, transcatheter aor-
tic valve replacement.
Sensitivity Analyses
We identifi ed 3 outliers due to prolonged postprocedural or readmission hospital stay. In 
a sensitivity analysis of the remaining 39 pairs we found similar results as in the original 
analysis for in-hospital costs (€39,945 vs. €29,251; p < 0.001), follow-up costs (€3,426 
vs. €2,286; p = 0.37), and total costs at 1 year (€43,370 vs. €31,537; p < 0.001) for TAVR 
and SAVR, respectively.
Part II. Aortic Stenosis
176
In the sensitivity analysis of 22 matched pairs who did not undergo revascularization we 
found in-hospital costs of €40,154 (standard error of the mean [SE] = 1,504) for TAVR and 
€26,776 (SE = 1,087) for SAVR (∆ costs = €13,378; p < 0.001). The total costs at 1 year 
were, respectively, €48,102 (SE = 4,800) and €29,349 (SE = 1,608) (p < 0.001).
COMMENT
The results of our study suggest that TAVR is signifi cantly more expensive than SAVR 
for intermediate-risk patients with aortic stenosis. This conclusion refers to both the 
in-hospital costs and the total costs at 1 year. The diff erence is mainly explained by the 
costs of materials, which was roughly 4 times higher in TAVR than SAVR. The fact that the 
patients in the TAVR group were less costly with regard to blood products and LOS did 
not outweigh the diff erence in costs of materials (Fig 1). Furthermore, close monitoring 
of TAVR patients may explain the trend toward higher follow-up costs.
The costs of the procedure were higher for TAVR than for SAVR (Table 4), while procedure 
times with TAVR were shorter (Table 2). This can be explained by the more expensive 
equipment in intervention rooms than in the operating room (€1.54 vs. €4.91 per minute 
for TAVR and SAVR). However, room use is only a fraction of the overall procedural costs 
(Table 4).
We observed more revascularizations in patients undergoing SAVR because guidelines 
recommend concomitant CABG for patients with moderate to severe coronary artery 
disease;15 no such recommendations exist for TAVR. In the sensitivity analysis of matched 
pairs who did not undergo revascularization we found that the diff erence in costs be-
tween TAVR and SAVR was larger than in the original analysis. A concomitant procedure 
such as CABG is likely to make SAVR more expensive as the procedure and hospital stay 
may take longer and the complication rate is higher.16 However, PCI in addition to TAVR 
has shown to be of less infl uence on procedural and midterm outcomes.17 From an eco-
nomic perspective, an additional advantage for SAVR is to be expected if PCI and TAVR 
are performed as staged procedures.
The transcatheter valve is currently priced at €17,590, whereas the surgical aortic 
bioprosthesis costs only €2,700. With more valves being developed, market forces are 
likely to decrease the price of transcatheter valves, similar to the trend previously seen 
in coronary stents.18 Using the mean diff erence in costs at 1 year and the price of the 
transcatheter valve, we calculated that the valve would have to be priced at €6,884 to be 
a cost neutral alternative for SAVR.
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One other study reported the costs of TAVR, showing quite diff erent estimates compared 
with our results.19 The discordance with our study might be caused by diff erent cost 
calculation methods, which were briefl y described and partly based on a costing study of 
percutaneous pulmonary valves. In studies that used the in-hospital costs for SAVR, the 
estimates were also quite diff erent from our results.16,20 However, comparison is diffi  cult 
as none of these studies primarily focused on costs and therefore the methodology for 
assessing costs varied and was not very detailed.
We have found no published report that compared costs in TAVR versus SAVR in 
intermediate-risk patients. In the high-risk patients of the PARTNER (Placement of Aortic 
Transcatheter Valve) trial the total costs at 1-year follow-up were higher than the costs 
in our study.4 Moreover, there was no signifi cant diff erence in costs between TAVR and 
SAVR. In comparison with our results, the nonprocedural costs were higher, whereas the 
LOS and other resource use were similar. Diff erences might therefore be attributed to 
higher costs of hospital stay in the United States.21
Using our results we can make some crude statements on the cost eff ectiveness of TAVR 
versus SAVR. The PARTNER trial showed a quality-of-life gain of 0.068 at 1 year for TAVR 
as compared with SAVR [4]. Combining our cost results with this quality-of-life gain yields 
an ICER (incremental cost-eff ectiveness ratio) of around €150,000 per quality-adjusted 
life year saved, which in general is considered higher than the threshold willingness-to-
pay. Although ICERs should be calculated using life-time costs, 1-year follow-up costs in 
our study were similar for the 2 treatments and show that periprocedural costs will be 
the driver of cost eff ectiveness of TAVR. However, more elaborate analyses are needed 
to confi rm these results.
Limitations
Cost data were not based on a randomized trial but were retrospectively collected 
from a relatively small single-center observational study. However, economic data 
from well-performed observational studies are equally valuable to policy makers as 
such data refl ect the real-life economic consequences of new treatments.22 Moreover, 
industry sponsored economic evaluations alongside trials are more likely to report 
favorable results,23 increasing the value of independent economic observational 
studies.
To overcome the limitation that our study was not randomized, we used propensity score 
matching. This technique corrects for measured confounders but there may have been 
unmeasured confounding in our study. However, we used a very conservative caliper in 
the matching process while other studies have used wider margins.24 The statistically 
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similar clinical outcomes in the matched cohort allow for a valid cost comparison be-
tween the groups.
Because propensity score matching does not take into account procedural variables, it 
was possible that we found an imbalance in the concomitant revascularization rate. A 
regression model could adjust for this imbalance but makes assumptions on the distri-
bution of the outcome variable and would require more revascularizations in the TAVR 
group. Due to the skewed nature of cost variables and the small sample size, the distribu-
tion free bootstrap method is preferred.13
Since 2005 our center has performed roughly 250 TAVRs, whereas there is a multitude 
of experience with SAVR. This may result in longer procedures, more personnel being 
present, and longer hospital stay. As experience with TAVR in intermediate-risk patients 
develops, and with the refi nement of techniques and protocols, it is likely that costs, LOS, 
and complication rates will decrease.
The logistic EuroSCORE was used as a matching variable and indicator of operative 
risk. The score fails to include factors such as porcelain aorta, frailty, chest deformities, 
and malnutrition. Therefore we might have underestimated the operative risk of TAVR 
patients, leading to higher costs in this group. It is unlikely that this aff ected the main 
conclusion of our study as the cost of the transcatheter valve is the main cause of the 
diff erence in costs between the 2 groups.
In the current study the costs were specifi c for Dutch centers. However, our results may 
be translated to other countries using regression techniques.25 These models can adjust 
for diff erences in the cost of medical treatments due to demography, epidemiologic fac-
tors, and diff erences in medical practice, resource use, and funding of health care.
Conclusions
For intermediate-risk patients with severe aortic stenosis the costs at 1 year are higher 
for TAVR than for SAVR. The diff erence was mainly caused by the higher costs of the 
transcatheter valve and was not compensated by the lower costs for blood products 
and hospital stay in TAVR patients. Therefore, SAVR remains a clinically and economically 
attractive treatment option.
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TO THE EDITOR:
With great interest we read the commentary on transcatheter aortic valve implantion 
(TAVI) by Van Brabandt and colleagues in a recent issue of the Journal.1 The authors 
raised concerns regarding the continued access population and baseline imbalances in 
the PARTNER trial and the early termination of the STACCATO trial. They also commented 
on the approval process and concluded that the widespread use of TAVI is not supported 
by suffi  cient evidence. We acknowledge their thorough analysis, but some of their argu-
ments need to be put into perspective.
Van Brabandt et al. suggested adjustment for imbalances at baseline, but such analyses 
are hampered by covariate selection and rarely infl uence the overall conclusion of a 
clinical trial.2 Also, the randomisation process in the PARTNER trial was well done and 
with more extensively calcifi ed aorta in the TAVI group (19.0%) than in the standard 
treatment group (11.2%), it is not apparent that the baseline imbalances favoured TAVI. 
The steering committee consisted of both surgeons and cardiologists to balance poten-
tial diff erences in opinions and interests. Accusations that confl ict of interests infl uenced 
the results are easily made but should be substantiated.
It is conspicuous that the authors, despite their extensive eff orts, could not retrieve more 
details of the continued access population. However, the results of this relatively small 
patient group are unlikely to change the overall conclusion of PARTNER B with its 25% 
mortality reduction at two-year compared to standard treatment.3 Although an elaborate 
discussion with a large panel of experts is publicly available,4 we agree that publishing 
study design, patient characteristics and detailed results of the continued access popula-
tion would relieve concerns.
Van Brabandt et al. insinuated that one of the PARTNER investigators, commenting on 
the STACCATO trial, was more concerned with the fi eld than with his patients. With this 
bold statement, the authors ignored the serious methodological and ethical issues of the 
STACCATO trial. The only inclusion criterion (an age>70 years) led to TAVIs in the lowest 
risk category ever reported (STS score of 3.1) and fl awed power calculations put patients 
at risk while knowing that the trial would not be able to provide a reliable answer.5 Due to 
these issues, the STACCATO results contribute virtually nothing to the scientifi c appraisal 
of TAVI.
We agree with the authors that the uptake of TAVI has been rapid and that the European 
regulations for the introduction of high-risk medical devices seem outdated. Taking into 
account the mentioned issues, we believe that the evidence is hopeful for TAVI. This new 
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technique should be evaluated with scientifi c rigor and transparency and in light of the 
continuous refi nement of techniques. A major challenge is how to reduce the number 
of complications. The PARTNER trial however showed the results of the fi rst experience 
with the fi rst generation of TAVI. With newer techniques, like embolic protection devices, 
increased experience, and newer generation devices, the future looks promising.
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Many patients undergoing major non-cardiac surgery have a high risk of perioperative 
cardiovascular complications. Several studies have identifi ed variables that are as-
sociated with this increased perioperative cardiovascular risk,1-3 including arrhythmias, 
heart failure, recent myocardial infarction, and ischemic heart disease. Aortic stenosis 
(AS) is not always included in cardiac risk predictions models, because it is regularly 
underdiagnosed and therefore also underrepresented in databases and the resulting risk 
assessment tools. Nevertheless, severe AS is the most prevalent valvular heart disease in 
the elderly,4 of which many regularly require non-cardiac surgery.
Patients with AS have an obstruction in the outfl ow tract that gradually results in left 
ventricular myocardium hypertrophy. Initially, the cardiac output and left ventricular 
end-diastolic volumes are preserved, permitting patients to stay asymptomatic. Eventu-
ally however, the concentric left ventricular hypertrophy and reduced compliance of the 
myocardium leads to diastolic dysfunction. At that point, patients develop symptoms 
of dyspnea or chest pain due to the increased diastolic pressure of the left ventricle. In 
addition, the AS causes systemic hypotension and reduction of coronary fl ow reserve. 
When patients in this condition are exposed to the hemodynamic stress as in major 
surgical procedures, they are at higher risk of decompensated heart failure.
Therefore, the European Society of Cardiology (ESC), European Association of Cardio-
Thoracic Surgery (EACTS) and American College of Cardiology (ACC)/American Heart As-
sociation (AHA) Guidelines dedicate special sections describing decision-making in non-
cardiac surgery for patients with severe AS.5-7 These guidelines recommend to postpone 
or cancel non-cardiac surgery if severe AS is symptomatic and surgical or transcatheter 
aortic valve replacement prior to non-cardiac surgery should be considered. For asymp-
tomatic patients, the AHA guideline suggests postponing non-cardiac surgery if the valve 
has not been evaluated within 1 year.5 The ESC/EACTS guideline recommends to proceed 
with non-cardiac surgery in asymptomatic patients that are at low or moderate surgical 
risk for the non-cardiac surgery, whereas in high risk patients, the patients’ risk for surgi-
cal aortic valve replacement is decisive (Figure 1A).7 These recommendations are largely 
based on small and old observational studies.1, 8-11
In this edition of The Journal, Tashiro et al. present a large contemporary study of patients 
with severe AS undergoing moderate to high risk non-cardiac surgery.12 By linking more 
than 500,000 echocardiograms with their surgical database, the authors were able to 
identify 256 patients with severe AS. These patients were matched to patients without 
AS based on age-, gender and year of surgery. There was no signifi cant diff erence in 
30 day mortality (5.9% vs. 3.1%, p = 0.13). The rate of MACE (death, stroke, myocardial 
infarction, ventricular tachycardia/fi brillation, and heart failure) was higher in the severe 
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Figure 1. Decision-Making in Severe Aortic Stenosis for Patients who require Non-Cardiac Surgery
Panel A: based on the current ESC/EACTS guidelines.7
Panel B: suggested decision-making fl owchart when the study by Takashiro is incorporated.12
AS, aortic stenosis; BAV, balloon aortic valvuloplasty; SAVR, aortic valve replacement; TAVI, transcatheter 
aortic valve implantation
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AS group (18.8% vs. 10.5%, p = 0.01), mainly due to higher rates of heart failure. In ad-
dition, emergency surgery was shown to be the strongest predictor of 30 day mortality.
This important study has several implications for perioperative management of patients 
with severe AS and may even lead to revision of aforementioned guidelines. The periop-
erative mortality rate was lower than previously reported. Therefore the authors speculate 
that the threshold to proceed with the non-cardiac surgical procedure without treating a 
severe AS could be lowered.12 There are several potential reasons for the relatively low 
rate of mortality in the current study, including improvements in surgical and anesthesia 
techniques compared to earlier studies. However, outcomes in the symptomatic group 
(n = 106) were markedly worse than in the asymptomatic group (n = 150). In asymptom-
atic patients and their matched controls, mortality and MACE rates were practically equal 
(around 3% and 10-12% in both patients with and without AS). On the other hand, 
in the patients with symptoms, MACE at 30 days was signifi cantly higher compared to 
their controls (28.3% vs. 8.5%, p < 0.001), although the diff erence in mortality (9.4% vs. 
3.8%) did not reach statistical signifi cance (p = 0.097). This suggests that the excellent 
outcomes of patients with severe AS might be restricted to asymptomatic patients. This 
strengthens the guidelines noting that the non-cardiac surgical management of patients 
with severe AS mainly depends on the presence of symptoms.5, 7 This is further supported 
by a recent study that found that the presence of symptoms was a predictor of worse 
outcomes.13 Only when the prolonged AS results in considerable physiologic changes 
and apparent symptoms of dyspnea or chest pain, clinicians should consider treatment 
of this condition prior to non-cardiac surgery. In those patients with symptomatic severe 
AS, TAVI could serve as an alternative to surgical aortic valve replacement and should 
be preferred over balloon aortic valvuloplasty.14 Careful intraoperative monitoring and 
an intensive team eff ort with the anesthesiologist is recommended in these severe AS 
patients undergoing non-cardiac surgery.
In a fi eld where randomized trials are unlikely and observational evidence is scarce, 
the current study shows that moderate or high-risk non-cardiac surgery in patients with 
severe, asymptomatic AS can be performed safely. Until now, the existing evidence on 
non-cardiac surgery in patients with severe asymptomatic AS was largely based on one 
study describing low to moderate non-cardiac surgical procedures.15 With the results of 
the study by Tashiro et al. non-cardiac surgery of any risk should rarely be postponed be-
cause of the presence of asymptomatic severe AS (Figure 1B). With these new important 
insights, it might be time to revise the guidelines.
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ABSTRACT
Background
The SYNTAX trial demonstrated that in patients with 3-vessel or left-main CAD, CABG 
was associated with a lower rate of cardiovascular death, MI, stroke, or repeat revascu-
larization compared with DES-PCI. The long-term cost-eff ectiveness of these strategies 
is unknown.
Methods and Results
Between 2005 and 2007, 1800 patients with left-main or 3-vessel CAD were randomized 
to CABG (n = 897) or DES-PCI (n = 903). Costs were assessed from a US perspective, and 
health state utilities were evaluated with the EuroQOL questionnaire. A patient-level 
micro-simulation model based on the 5-year in-trial data was used to extrapolate costs, 
life expectancy, and quality-adjusted life expectancy over a lifetime horizon.
Although initial procedural costs were $3415/patient lower with CABG, total hospi-
talization costs were $10,036/patient higher. Over the next 5 years, follow-up costs 
were higher with DES-PCI, owing to more frequent hospitalizations, revascularization 
procedures, and higher medication costs. Over a lifetime horizon, CABG remained more 
costly than DES-PCI but the incremental cost-eff ectiveness ratio was favorable ($16,537/ 
QALY gained) and remained <$20,000/QALY in most bootstrap replicates. Results were 
consistent across a wide range of assumptions regarding the long-term eff ect of CABG 
vs. DES-PCI on events and costs. In patients with left-main disease or a SYNTAX Score 
≤22, however, DES-PCI was economically dominant compared with CABG although these 
fi ndings were less certain.
Conclusions
For most patients with 3-vessel or left-main CAD, CABG is a clinically and economically 
attractive revascularization strategy compared with DES-PCI. However, among patients 
with less complex disease, DES-PCI may be preferred on both clinical and economic 
grounds.
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INTRODUCTION
Approximately 6% of all American adults suff er from coronary artery disease (CAD) with 
estimated total annual costs in excess of $200 billion.1 Coronary revascularization pro-
cedures including percutaneous coronary intervention (PCI) and coronary artery bypass 
graft surgery (CABG) account for nearly $12 billion/year in direct costs alone. Over the 
past 2 decades, numerous clinical trials have compared the clinical outcomes of PCI vs. 
CABG for patients with multivessel CAD. In general, these studies have demonstrated 
similar short- and long-term mortality with either procedure (with the exception of dia-
betic patients) but substantial advantages of CABG in terms of angina relief and the need 
for subsequent revascularization procedures.2-8 Economic evaluations performed in both 
the balloon angioplasty and bare metal stent eras, have consistently demonstrated early 
cost savings with PCI but similar long-term costs for the 2 strategies.7, 9, 10
The most recent study to compare PCI with CABG in a broad population was the SYNTAX 
trial.11 In contrast to previous studies, SYNTAX included patients with more complex CAD 
(3-vessel and left main disease), had few exclusion criteria, and used drug-eluting stents 
(DES) for all PCI procedures. At 5-year follow-up, SYNTAX demonstrated that CABG was 
associated with a lower rate of the composite of cardiovascular death, MI, stroke, or repeat 
revascularization compared with DES-PCI—driven mainly by reductions in non-fatal MI and 
repeat revascularization.12 However, DES-PCI was associated with a lower rate of stroke in 
the overall population and similar overall clinical outcomes in certain patient subsets.12, 13 
Given the current economic challenges facing virtually all healthcare systems, understand-
ing both the long-term clinical benefi ts and cost-eff ectiveness of these alternative revas-
cularization strategies is critical for both clinical guideline development and health care 
policy. We therefore performed a prospective health economic evaluation alongside the 
SYNTAX trial. Although the SYNTAX trial included only 5-year follow-up, we used disease-
simulation techniques to extrapolate the 5-year trial results to a lifetime horizon.
METHODS
The design and methods of the SYNTAX trial have been described previously.11, 12, 14 Be-
tween March 2005 and April 2007, 1800 patients with 3-vessel or left main CAD without 
recent MI who were considered equally suitable for PCI with DES and CABG by both a 
cardiac surgeon and an interventional cardiologist were randomized to either procedure. 
CABG was performed using standard techniques, and PCI procedures utilized paclitaxel-
eluting stents (TAXUS Express, Boston Scientifi c, Natick, MA, USA). The institutional review 
board at each participating site approved the protocol and all patients provided written 
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informed consent. The trial complies with the Declaration of Helsinki and is registered 
at the National Institutes of Health website (http://www.clinicaltrials.gov; identifi er 
NCT00114972).
Estimation of Medical Care Costs
Costs for the initial hospitalization and the 5-year follow-up period were assessed by 
a combination of resource-based and event-based methods as described below. These 
methods were virtually identical to those used for a recent health economic assessment 
of DES-PCI vs. CABG among diabetic patients.15 To maintain consistency with that previ-
ous report, all costs were assessed from the perspective of the U.S. health care system 
and are reported in 2010 U.S. dollars.
Procedural Costs
Detailed resource use was recorded for each initial and any subsequent revasculariza-
tion procedures, and the cost for each item was estimated on the basis of its mean 
hospital acquisition cost at 3 surveyed U.S. hospitals. Each DES was assigned a cost of 
$1500. Costs of antithrombotic therapy were based on the current wholesale acquisition 
cost obtained from Micromedex Red Book.16 Costs for additional disposable equipment, 
overhead and depreciation of the cardiac catheterization laboratory and operating room, 
and non-physician personnel were estimated using data from the micro-cost accounting 
systems of Saint Luke’s Mid America Heart Institute and adjusted for observed procedure 
duration. For the purposes of this report, initial and planned staged PCI procedures were 
combined for the calculation of index resource utilization and cost.
Post-Procedure Hospitalization Costs
Post procedure costs for each initial hospitalization were estimated using regression 
models based on SYNTAX-eligible patients who underwent either PCI (n = 113,921) or 
CABG (n = 43,866) and whose data were included in the 2010 Medicare Provider and 
Review (MEDPAR) database. Hospital charges were converted into costs using hospital- 
and cost center-specifi c cost-to-charge ratios.17, 18 Linear regression models were then 
developed, using total hospitalization costs as the outcome and sociodemographic 
factors, comorbidities, and in-hospital complications (identifi ed on the basis of ICD-9 
codes) as predictors (Supplementary Table 1). Because of substantial variability in length 
of stay for revascularization procedures across the enrolling countries, length of stay 
was not included as a predictor in these models. The fi nal models for PCI and CABG 
were then used to predict nonprocedural costs for each initial hospitalization as well 
as any subsequent hospitalizations that involved coronary revascularization. To avoid 
double-counting procedural costs, the intercept for each model was adjusted to remove 
the costs directly related to the revascularization procedures.
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For follow-up cardiovascular hospitalizations that did not involve a revascularization 
procedure, Medicare Severity-Diagnosis Related Groups (MS-DRGs) were assigned based 
on the primary indication for hospitalization and procedures performed during that ad-
mission. Costs were then assigned based on mean 2010 Medicare reimbursement rates 
for the MS-DRG obtained from the Medicare Part A data fi les.19
Physician Costs
Physician fees for PCI and CABG procedures (including those for the primary surgeon, 
surgical assistant, and anesthesiologist) were based on the 2010 national Medicare fee 
schedule. Non procedure-related physician fees for revascularization-related hospital-
izations were estimated for U.S. patients on the basis of post procedure ICU and non-ICU 
length of stay and Medicare payment rates. For non-U.S. patients, postprocedure length 
of stay after CABG and PCI was estimated from regression models developed using 2010 
MedPAR data and the same covariates as used in the cost models (Supplementary Table 
2), along with PCI and CABG-specifi c ratios of ICU vs. total post procedure length of 
stay estimated from the trial data for U.S. patients. Physician costs for all other hospi-
talizations were estimated as a percentage of hospital costs according to the Medicare 
Severity-Diagnosis Related Group.20, 21
Outpatient Costs
Costs for outpatient visits, tests and procedures, and inpatient rehabilitation and skilled 
nursing facility days were estimated using 2010 Medicare reimbursement rates. Outpa-
tient medication use was assessed at each follow-up visit, and costs were assigned using 
the most current average wholesale prices from Micromedex Red Book.16
Quality of Life
Quality of life was assessed directly from patients at baseline and at 1, 6, 12, 36, and 
60 months using the EuroQOL (EQ-5D) health status instrument and converted to utility 
weights (range 0-1) using an algorithm developed from the U.S. population.22
Statistical Analysis
To account for the slightly higher withdrawal rate among patients assigned to CABG, a 
modifi ed intention-to-treat (mITT) population was used as the primary population for eco-
nomic analysis. This population was defi ned as all randomized patients who underwent ≥1 
initial revascularization procedure (n = 1766), with patients categorized according to their 
assigned treatment. Since virtually all of the patients who did not undergo revasculariza-
tion withdrew from the trial within the fi rst 6 months of follow-up, the MITT approach is 
preferred because it includes initial revascularization costs for all patients while yielding 
survival estimates that are virtually identical to those for an ITT analysis using censored 
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data. A secondary analysis used the per protocol (PP) population and included only those 
patients who underwent the assigned revascularization procedure (n = 1739).
Categorical data are reported as frequencies, and continuous data are reported as mean 
± standard deviation. Discrete variables were compared using Fisher exact tests. Nor-
mally distributed continuous variables were compared using Student t-tests, and non-
normally distributed data were compared using the Wilcoxon rank-sum test. Treatment 
eff ects from Poisson regression models were used for the comparison of hospitalization 
rates. Kaplan-Meier estimates and log-rank tests were used for the comparison of 5-year 
clinical events. Cost data are reported as both mean and median values and were com-
pared using t-tests.23 Confi dence intervals for the diff erences in costs between treatment 
groups were obtained via bootstrapping (1000 replicates).24
Quality-adjusted life expectancy was calculated for each patient as the time-weighted 
average of his/her utility values. The mid-point between assessments was used as the 
transition between health states, starting at the 30-day visit. Missing utility values were 
estimated using multiple imputation, taking into account baseline patient characteristics, 
clinical events including hospitalizations, and previous utility values.
In-Trial Analysis of Costs, Life years, and Quality-Adjusted Life Years
Since not all patients had complete 5-year follow-up data, methods for the analysis of 
censored data were used to obtain estimates of cumulative costs and quality-adjusted 
Figure 1.
CONSORT diagram. Black boxes represent the modifi ed intention-to-treat (mITT) population that was the 
primary analytic population for the economic study. The grey boxes represent the per protocol (PP) popula-
tion. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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life-years (QALY) at each follow-up timepoint.25 We used Kaplan Meier methods to 
estimate survival at each follow-up timepoint, and life expectancy diff erences were 
estimated as the area between the 2 survival curves. For costs, an inverse probability-
weighted estimator was applied, whereby the time axis was divided into 3-month 
intervals, and costs for each interval were estimated as the observed costs during 
the interval for patients with complete data divided by the probability of not being 
censored within the interval. Similar methods were applied to estimate QALYs. The 
bootstrap method was used to calculate the confi dence limits for the mean cumulative 
cost, life-year, and QALY estimates for each treatment group, as well as the diff erence 
between groups.24
Cost-Eff ectiveness
The cost-eff ectiveness of CABG vs. PCI was assessed over a life-time horizon using 
QALYs as the measure of health benefi t for the primary analysis, and life-years for sec-
ondary analyses.26 Costs, life-years, and QALYs were discounted at 3% per year for all 
cost-eff ectiveness calculations.27 The lifetime analyses were based on a combination of 
(1) observed in-trial cost and quality of life data and (2) projections of post-trial costs, 
life expectancy and quality-adjusted life expectancy obtained from a Markov disease-
simulation model. In this model, each surviving patient was assumed to face a monthly 
risk of death, with estimates of this risk based on the age-, sex- and race specifi c risk of 
death obtained from U.S. life tables, which were calibrated to match the observed 5-year 
mortality for the SYNTAX PCI population.15, 28
For the CABG group an additional multiplicative factor was applied to project the benefi t 
of CABG vs. PCI on mortality. This multiplier was based on the hazard ratio (HR) derived 
from an analysis of all-cause mortality from the SYNTAX patients. In a sensitivity analysis, 
the separate impact of non-fatal myocardial infarction (MI) and stroke on long-term 
mortality was taken into account. For these secondary analyses, HRs were obtained from 
a Cox proportional hazards regression model fi t to the trial data, in which non-fatal MI 
and stroke were each modeled as time-dependent covariates, and baseline character-
istics (age, sex and diabetes) and treatment group were included as fi xed covariates. 
Patient-level costs and utility weights for each projected year of life beyond the trial 
observation period were derived from regression models developed from the in-trial 
data (Supplementary Tables 3 and 4).
Three sets of analyses were performed based on alternative assumptions regarding the 
duration of the prognostic benefi t of CABG relative to PCI. The base case analysis as-
sumed that the benefi t of CABG tapered in a linear fashion from year 5 to 10 and that 
there were no prognostic diff erences between PCI and CABG beyond year 10 (i.e. HR=1 
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after year 10). In sensitivity analyses, we assumed that (1) prognostic benefi ts of CABG 
would remain constant from year 5 to year 10, with no benefi t of CABG after 10 years; 
or 2) that there would be no further prognostic benefi t of CABG beyond the 5-year trial 
observation period (i.e. HR=1 after year 5).
Bootstrap methodology (1000 replicates) was used to estimate uncertainty in the joint 
distribution of lifetime cost, life-years, and QALYs for each treatment group. To maintain 
consistency of the within-trial and post-trial CABG eff ect within each bootstrap sample, 
the HRs for the eff ect of CABG vs. PCI on mortality were re-estimated for each bootstrap 
replicate. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC.).
Table 1. Baseline Characteristics (mITT population)
CABG (n=870) PCI (n=896) p-value
Sociodemographic characteristics
 Age, y 64.9 ± 9.8 65.3 ± 9.6 0.40
 Male, % 79.4 76.6 0.15
 Body mass index, kg/m2 27.9 ± 4.4 28.1 ± 4.8 0.26
 Enrolled in the US, % 13.7 13.6 0.19
Clinical characteristics
 Diabetes mellitus, % 27.6 28.3 0.72
  Insulin-dependent, % 10.1 9.9 0.90
 Current smoker, % 22.0 18.5 0.07
 Previous MI, % 33.3 32.1 0.59
 Peripheral vascular disease 10.5 9.2 0.36
 COPD, % 9.2 7.9 0.34
 Prior stroke or TIA, % 9.1 7.7 0.29
 History of CHF, % 5.2 4.0 0.27
Angiographic characteristics
 LVEF, % 58.3 ± 13.2 59.1 ± 12.9 0.31
 LM disease (any), % 39.4 39.3 0.98
  LM only 5.4 4.5 0.98
  1 other artery 8.1 7.5 0.36
  2 other arteries 12.2 12.4 0.65
  3 other arteries 13.7 15.0 0.90
 3-vessel disease (no LM), % 60.6 60.7 0.98
 SYNTAX Score 29.1 ± 11.3 28.4 ± 11.4 0.21
mITT indicates modifi ed intention to treat; CABG, coronary artery bypass grafting; CHF, congestive heart 
failure; COPD, chronic obstructive pulmonary disease; LM, left main; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; mITT, modifi ed intention-to-treat; PCI, percutaneous coronary intervention; TIA, 
transient ischemic attack.
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RESULTS
Patient Population
Overall, a total of 1800 patients with 3-vessel or left main CAD were randomized to either 
CABG (n = 897) or PCI (n = 903). Of these, 27 patients assigned to CABG and 7 patients 
assigned to PCI did not undergo any revascularization procedure and were excluded 
from the primary mITT population for this economic analysis (Figure 1). Baseline char-
acteristics for the mITT population are summarized in Table 1. There were no signifi cant 
diff erences in any observed characteristics between the CABG and PCI groups. Of the 
mITT patients, 13.6% were enrolled in the United States, 39% had left main CAD, and the 
median follow-up was 60 months.
Initial Treatment Costs
Among patients assigned to PCI, 98.8% underwent PCI and 1.2% underwent CABG. 
Among patients assigned to CABG, 98.2% underwent CABG and 1.8% underwent PCI. 
Resource utilization for the initial revascularization procedures is summarized in Table 2 
Table 2. Index Procedural Resource Utilization and Cost (per Protocol Population)
CABG (n=854) PCI (n=885) p-value
Number of PCI procedures, %
 1 - 85.9 (760/885)
 2 - 13.5 (124/885)
 3 or more - 0.1 (1/885)
Procedure duration, minutes 209±62 [205] 101±55 [90] <0.001
Guiding catheters - 2.1 ± 1.2
Guidewires - 3.5 ± 2.3
Paclitaxel-eluting stents - 4.5 ± 2.3
Bare metal stents - 0.0 ± 0.3
Angioplasty balloons - 3.7 ± 2.8
Rotablator burrs - 0.1 ± 0.3
IVUS catheters - 0.1 ± 0.4
Closure device - 0.4 ± 0.6
Contrast volume, ml - 415 ± 207.5 [380]
Antithrombotic agents used, %
 Bivalrudin - 7.2% (64/885)
 Abciximab - 15.6% (138/885)
 Eptifi batide - 9.5% (84/885)
 Tirofi ban - 10.7% (95/885)
Index procedure cost, $ 8504 ± 1972 [8356] 11,919 ± 6162 [11263] <0.001
Values in brackets represent medians. CABG, coronary artery bypass grafting; IVUS, intravascular ultra-
sound; PCI, percutaneous coronary intervention.
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(PP population). In the PCI group, 13.6% underwent staged procedures, with 13.5% re-
quiring 2 procedures and 0.1% requiring 3 procedures. On average, the initial PCI pro-
cedure required 2.1 guiding catheters, 3.5 guidewires, 3.7 angioplasty balloons, and 4.5 
drug-eluting stents. Although procedure duration was longer for CABG, initial procedure 
costs were ~$3500 lower with CABG as compared with PCI ($8504 vs. $11,919, p < 0.001), 
owing to the higher costs associated with consumable resources (including stents) for 
the PCI group. For the mITT population, the diff erence in initial procedural costs was 
slightly smaller ($8482 vs. $11,866, p < 0.001), as a result of the small proportion of 
patients who crossed over to the alternative treatment strategy.
Table 3. Index Hospitalization Events, Resource Utilization, and Costs (mITT population)
CABG (n=870) PCI (n=896) Diff erence (95% CI) p-value
Death, % 1.4 (12/870) 1.8 (16/896) −0.4 (−1.6, 0.8) 0.49
MI, % 2.4 (21/870) 2.7 (24/896) −0.3 (−1.7, 1.2) 0.72
Stroke, % 1.0 (9/870) 0.1 (1/896) 0.9 (0.2, 1.6) 0.01
Unplanned CABG, % 1.1 (10/870) 0.8 (7/896) 0.4 (−0.5, 1.3) 0.42
Unplanned PCI, % 0.5 (4/870) 1.8 (16/896) −1.3 (−2.3, −0.3) 0.008
Complications, %
 Major bleeding 4.8 (42/870) 4.5 (40/896) 0.4 (−1.6, 2.3) 0.72
 Respiratory failure 1.6 (14/870) 0.0 (0/896) 1.6 (0.8, 2.4) < 0.001
 Renal failure 2.4 (21/870) 0.7 (6/896) 1.7 (0.6, 2.9) 0.003
 Wound infection 4.1 (36/870) 0 (0/896) 4.1 (2.8, 5.5) < 0.001
 Other infection 6.2 (54/870) 0.4 (4/896) 5.8 (4.1, 7.4) < 0.001
 Atrial fi brillation 17.9 (156/870) 1.3 (12/896) 16.6 (13.9, 19.2) < 0.001
 Cardiac tamponade 0.8 (7/870) 0.3 (3/896) 0.5 (−0.2, 1.2) 0.22
Other procedures, %
 Permanent pacemaker 0.6 (5/870) 0.2 (2/896) 0.4 (−0.2, 0.9) 0.28
 ICD implantation 0.2 (2/870) 0.0 (0/896) 0.2 (−0.1, 0.5) 0.24
  Carotid 
endarterectomy
0.5 (4/870) 0.0 (0/896) 0.5 (0.0, 0.9) 0.06
Initial hospitalization costs, $
  Revascularization 
procedures
8580 ± 2231 [8340] 12,054 ± 6287 [8340] −3474 (−3917, −3032) < 0.001
  Hospital stay + 
ancillary services
19,511 ± 6655 [16,669] 8785 ± 5,464 [6216] 10,726 (10,159, 11,294) < 0.001
 Physician fees 5100 ± 853 [4956] 2315 ± 954.8 [1942] 2785 (2700, 2869) < 0.001
 Total
33,190 ± 7938 [30,903]
23,154 ± 10,379 
[20,279]
10,036 (9172, 10,901) < 0.001
Values in brackets are medians. CCU, cardiac care unit; CI, confi dence interval; ICD, implantable cardiovert-
er-defribillator; ICU, intensive care unit; mITT, modifi ed intention-to-treat.
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Clinical events, resource utilization, and costs during the initial hospitalization are sum-
marized in Table 3. Post-procedural hospital costs were greater for the CABG group than 
the PCI group ($19,511 vs. $8785, p < 0.001), as were physician fees ($5100 vs. $2315, 
p < 0.001). As a result, total initial hospitalization costs were ~$10,000/patient higher in 
the CABG group than in the PCI group ($33,190 vs. $23,154, p < 0.001).
Follow-up Resource Utilization and Costs
Follow-up clinical outcomes, resource utilization, and costs are summarized in Table 4. 
During each year of follow-up, the annual rates of repeat revascularization, diagnostic 
catheterization, hospitalization, and their associated costs were higher for the PCI group 
as compared with the CABG group. In addition, costs for outpatient services and medica-
tions were consistently higher for patients assigned to initial PCI vs. CABG. Rehabilitation 
costs were greater in the CABG group in the fi rst year and were similar between treat-
ments in the subsequent years. As a result, the diff erence in cumulative medical care 
costs between the CABG and PCI narrowed from $10,036 after the index hospitalization 
to $5619 after 5 years of follow-up (Table 5 and Figure 2).
Figure 2.
Mean cumulative medical costs (lines) and mean annual follow-up costs (bars) in 2010 dollars, for the PCI 
and CABG groups. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention. Note 
that the fi rst set of bars represent represents the costs of the index hospitalization.
Part III. Coronary Revascularization
210
Ta
bl
e 
4.
 F
ol
lo
w
-U
p 
Ev
en
ts
, R
es
ou
rc
e 
U
ti
li
za
ti
on
, a
nd
 C
os
ts
 (m
IT
T 
po
pu
la
ti
on
)
Ye
ar
 1
Ye
ar
 2
Ye
ar
 3
Ye
ar
 4
Ye
ar
 5
5-
ye
ar
 C
um
ul
at
iv
e
CA
BG
n=
87
0
PC
I
N
=8
96
CA
BG
n=
81
3
PC
I
N
=8
51
CA
BG
n=
79
1
PC
I
N
=8
32
CA
BG
n=
76
7
PC
I
N
=8
05
CA
BG
n=
73
3
PC
I
N
=7
71
CA
BG
n=
87
0
PC
I
N
=8
96
p-
va
lu
e
Cl
in
ic
al
 o
ut
co
m
es
D
ea
th
, %
1.
8
2.
6
1.
5
2.
0
1.
9
2.
6
2.
2
3.
2
2.
9
2.
3
10
.7
13
.6
0.
06
M
I, 
%
0.
9
2.
2
0.
1
1.
2
0.
3
1.
2
0.
3
1.
7
0.
0
1.
2
3.
7
9.
3
<0
.0
01
St
ro
ke
, %
1.
0
0.
6
0.
7
0.
7
0.
5
0.
6
0.
4
0.
2
0.
0
0.
1
3.
4
2.
2
0.
12
Re
so
ur
ce
 u
se
 (e
ve
nt
s/
10
0 
pt
s)
Re
pe
at
 re
va
sc
ul
ar
iz
at
io
n 
(a
ny
)
4.
8
14
.1
3.
9
6.
6
2.
5
3.
7
2.
2
5.
5
2.
6
4.
3
16
.6
35
.2
<0
.0
01
 
 PC
I p
ro
ce
du
re
s
4.
7
11
.9
3.
9
5.
6
2.
5
2.
8
2.
2
4.
8
2.
6
3.
1
15
.3
28
.9
<0
.0
01
 
 CA
BG
 p
ro
ce
du
re
s
0.
1
2.
1
0.
0
0.
9
0.
0
1.
0
0.
0
0.
6
0.
0
1.
2
1.
3
6.
3
<0
.0
01
D
ia
gn
os
ti
c 
ca
th
et
er
iz
at
io
n
3.
8
11
.6
2.
3
6.
5
1.
9
4.
1
0.
1
0.
2
1.
4
3.
4
10
.1
22
.3
<0
.0
01
Re
-h
os
pi
ta
liz
at
io
n
27
.7
41
.1
16
.6
20
.9
12
.9
15
.6
14
.5
18
.3
11
.5
13
.5
77
.5
10
3.
6
<0
.0
01
Co
st
 p
er
 p
at
ie
nt
, $
 
Re
ho
sp
ita
liz
at
io
ns
24
35
39
64
15
70
20
44
12
00
14
85
12
40
16
64
11
78
14
71
-
-
-
 
O
ut
pa
tie
nt
 s
er
vi
ce
s
32
3
33
3
91
16
7
83
11
0
14
1
17
1
11
8
16
5
-
-
-
 
 Re
ha
b/
sk
ill
ed
 n
ur
si
ng
 s
ta
ys
90
0
18
6
27
14
28
15
30
47
31
49
-
-
-
 
M
ed
ic
at
io
ns
15
78
21
36
17
87
21
86
18
37
22
36
18
66
22
04
19
52
23
00
-
-
-
 
M
D
 fe
es
72
4
10
27
43
9
55
8
34
8
42
1
38
4
44
6
32
1
38
1
-
-
-
To
ta
l
59
59
76
46
39
14
49
70
34
95
42
66
36
61
45
32
36
01
43
66
-
-
-
C
AB
G
; c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
ti
ng
; M
I, 
m
yo
ca
rd
ia
l i
nf
ar
ct
io
n;
 m
IT
T,
 m
od
ifi 
ed
 in
te
nt
io
n-
to
-t
re
at
; P
C
I, 
pe
rc
ut
an
eo
us
 c
or
on
ar
y 
in
te
rv
en
ti
on
211
Chapter 11. US Cost-Eff ectiveness of PCI versus CABG
11
Utility Weights and QALYs
Compared with baseline, utility weights improved substantially for both treatment 
groups over the course of the trial (Supplementary Table 5). At 1 month follow-up, utility 
weights were signifi cantly lower after CABG than PCI (0.77 vs. 0.85, p < 0.001), refl ecting 
the longer recovery period following CABG. This early utility benefi t of PCI was no longer 
apparent at 6 months, however. As a result of the early diff erence in favor of PCI, cumula-
tive quality-adjusted life-years were lower with CABG than with PCI through 3 years of 
follow-up (Table 5). By the end of year 5, however, life expectancy (4.70 vs. 4.60 years) 
and quality-adjusted life expectancy (3.91 vs. 3.87 QALYs) were both greater with CABG 
than with PCI.
Table 5. Cumulative Costs, QALYs, and Life-Years for Years 1 to 5, Adjusted for Censoring
Time Since 
Randomization
Cumulative Costs, $ Cumulative QALYs Cumulative Life-Years
CABG PCI ∆ CABG PCI ∆ CABG PCI ∆
1 year 39,241 30,797 8444 0.789 0.813 −0.025 0.975 0.965 0.009
2 years 43,053 35,520 7533 1.595 1.614 −0.018 1.933 1.912 0.022
3 years 46,428 39,567 6862 2.394 2.396 −0.002 2.877 2.832 0.045
4 years 49,890 43,702 6188 3.166 3.148 0.019 3.800 3.732 0.069
5 years 53,260 47,641 5619 3.914 3.870 0.044 4.701 4.601 0.100
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; QALY, quality-adjusted life-
years gained. ∆=diff erence between CABG and PCI group; ∆, diff erence between CABG and PCI group
Lifetime Cost-Eff ectiveness - Overall Population
Results from the lifetime cost-eff ectiveness analyses are summarized in Table 6. Based 
on the observed 5-year results, the estimated mortality hazard ratio for CABG vs. PCI was 
0.80 (95% CI, 0.61-1.05). When these results were used to project clinical and economic 
outcomes beyond the trial period (Figure 3), we estimated that CABG would be associ-
ated with lifetime incremental costs of $5081 (95%CI, $1802 to $8241) compared with 
PCI together with a gain in life expectancy of 0.412 years (95% CI, −0.060 to 0.831) and 
a gain in quality-adjusted life expectancy of 0.307 QALYs (95% CI, −0.105 to 0.378).
The resulting incremental cost-eff ectiveness ratio (ICER) for CABG vs. PCI was $16,537/
QALY gained, with 84.7% of bootstrap replicates falling below a societal willingness-to-
pay threshold of $50,000/QALY (Figures 4 and 5, and Table 6/row 1). When outcomes 
were assessed in life-years, CABG was associated with an ICER of $12,329/life-year 
gained (Table 6/row 2). When the analysis also accounted for the prognostic impact of 
non-fatal MI and stroke, the benefi t of CABG increased modestly to 0.338 QALYs, and the 
ICER improved to $15,758/QALY gained with 87.7% of bootstrap replicates falling below 
a societal willingness-to-pay threshold of $50,000/QALY (Figure 5, Table 6/row 4).
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Figure 3.
Observed survival through 5 years and predicted survival beyond 5 years for the CABG and PCI groups, 
according to the base case assumptions. CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention.
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Figure 4.
Joint distribution of projected lifetime incremental costs and quality-adjusted life expectancy for CABG vs. 
PCI based on bootstrap replication of the SYNTAX trial population, plotted on the cost-eff ectiveness plane.
The black circle represents the estimated mean values (incremental cost=$5081, incremental QA-
LYs=0.307). CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention; QALY, quality-
adjusted life-year.
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These results were robust across a wide range of alternative assumptions regarding 
the duration and magnitude of the benefi t of CABG over PCI on both survival and costs 
beyond the timeframe observed in the trial. When we assumed that the benefi ts of CABG 
would remain constant from year 5 to year 10, with no further benefi t beyond 10 years, 
the ICER for CABG vs. PCI improved to $10,695/QALY gained. Under the conservative 
assumption of no benefi t of CABG beyond the 5-year trial period, the ICER increased to 
$27,485/QALY gained with 74.8% of the bootstrap replicates below the $50,000 per 
QALY gained threshold. Results were also similar when the analysis incorporated the 
prognostic impact of non-fatal MI and stroke, or when eff ectiveness was expressed in 
life-years rather than QALYs (Supplementary Tables 7 and 8).
Subgroup Analyses
Results from prespecifi ed, subgroup analyses are summarized in Supplementary Table 
6 (observed 5-year results) and Table 7 (lifetime projections). For most subgroups, the 
results were consistent with those of the overall trial population albeit with greater 
uncertainty due to the reduced sample sizes. There were 2 subgroups with results that 
diff ered substantially from those of the overall trial, however. For patients with less 
complex coronary anatomy (SYNTAX Score ≤22), PCI was projected to improve increase 
Figure 5.
Cost eff ectiveness acceptability curve of CABG vs. PCI. The probability that CABG is cost-eff ective is calcu-
lated as the proportion of bootstrap-derived estimates falling below a given cost-eff ectiveness threshold 
and is plotted across a range of possible cost-eff ectiveness thresholds. The solid blue line represents the 
base-case analysis, while the dashed red line indicates the analysis in which the prognostic impact of MI 
and stroke were taken into account.
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quality-adjusted life expectancy and to reduce costs compared with CABG. For this sub-
group, the probability that CABG would be economically attractive at an ICER of $50,000/
QALY was only 18.3%. In contrast, for patients with SYNTAX Scores of 23-32 and ≥33, the 
ICERs for CABG vs. PCI were $36,790/QALY gained and $8219/QALY gained, respectively. 
PCI was also projected to be an economically dominant strategy for patients with left 
main CAD, whereas CABG appeared to be highly economically attractive compared with 
PCI for patients with 3-vessel disease (ICER $4905/QALY gained). For all other patient 
subgroups, CABG was projected to be economically attractive compared with PCI with 
ICERs <$35,000/QALY gained. Results for subgroups were largely unchanged under 
alternative assumptions regarding the duration and magnitude of the benefi t of CABG 
over PCI, and when we considered the impact of non-fatal MI and stroke on mortality 
(Supplementary Tables 7 and 9).
Impact of Stent Pricing and Productivity Losses
Since DES prices in the US continue to decrease each year, we performed a sensitivity 
analysis on the acquisition cost of DES (Figure 6). Although the ICER for CABG vs. PCI 
increased as the acquisition cost of DES decreased, even at a DES price of $0, the ICER 
for CABG vs. PCI in the overall study population remained <$40,000/QALY gained. When 
this sensitivity analysis was repeated within strata according to SYNTAX Score, only the 
intermediate SYNTAX Score tertile was sensitive to stent price (Supplementary Table 10). 
-50,000
-40,000
-30,000
-20,000
-10,000
0
10,000
20,000
30,000
40,000
50,000
60,000
70,000
80,000
90,000
100,000
0 200 400 600 800 1000 1200 1400 1600 1800 2000
IC
ER
 ($
/Q
AL
Y)
 
Stent price ($) 
Overall population
SYNTAX score ≤22 
SYNTAX score 23-32
SYNTAX score ≥33  
Figure 6.
Sensitivity analysis of the ICER for CABG vs. PCI as a function of the stent price in the overall population 
and according to the anatomic SYNTAX Score. The negative ICERs for the low SYNTAX Score population 
indicate that PCI was economically dominant over the full range of stent prices displayed.
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For patients with a SYNTAX Score ≤22, the PCI strategy remained economically attractive 
unless the stent price exceeded $4880/stent, while for patients with a SYNTAX Score ≥33, 
CABG remained economically attractive at all stent prices. Among patients with SYNTAX 
Scores between 23 and 32, however, the ICER for CABG vs. PCI remained <$50,000/QALY 
gained only if the stent price were >$1195.
Finally, we performed a sensitivity analysis to assess the impact of productivity loss on 
the cost-eff ectiveness of CABG vs. DES-PCI. Since no data on employment were collected 
from the SYNTAX trial patients, we used several external sources to estimate the pro-
portion of patients employed at baseline, the timing of return to work according to the 
type of revascularization procedure, and the average earning for a US worker.9, 29 With 
incorporation of these factors, the cost diff erence between the treatments increased 
by ~$1000 for the overall population, refl ecting the higher productivity loss with CABG 
compared to PCI, but the ICER for CABG vs. PCI remained <$20,000/QALY gained (Supple-
mentary Table 11). When this additional analysis was repeated for subgroups according 
to SYNTAX Score tertile and LM or 3-vessel disease subgroups, the outcomes were similar 
to the main analyses that did not incorporate productivity losses.
DISCUSSION
SYNTAX is the fi rst study to directly compare the long-term clinical and economic 
outcomes of DES-PCI vs. CABG for patients with 3-vessel or left main CAD. As such, 
this economic substudy provides a number of critical insights about the optimal re-
vascularization strategy for such patients. First, we found that despite substantially 
higher procedural costs, DES-PCI is substantially less costly than CABG in the short 
term. Second, although CABG was associated with improved clinical outcomes and 
reduced follow-up resource utilization, cumulative costs remained lower with DES-PCI 
(by ~$5000/patient) at 5 years and over a lifetime horizon. Third, although diff erences 
in life expectancy and quality-adjusted life expectancy were small over the 5-year 
timeframe of the trial (0.100 years and 0.044 QALYs, respectively), the incremental life 
expectancy and QALY gains with CABG increased considerably when projected over a 
patient’s lifetime. As a result, the lifetime incremental cost-eff ectiveness ratio for CABG 
vs. DES-PCI was ~$16,500/QALY gained and ~$12,500/LY gained—values that compare 
favorably with many other accepted therapies in the context of the US healthcare 
system.30, 31 Moreover, while SYNTAX did not demonstrate a “statistically signifi cant” 
diff erence in 5-year mortality between CABG and DES-PCI, these main fi ndings were 
robust to both stochastic uncertainty analyses (i.e., bootstrapping) and to a variety of 
alternative assumptions regarding the durability of benefi t, the prognostic impact of 
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non-fatal events, and stent pricing. In general, the economic outcomes of the SYNTAX 
trial mirrored the clinical results.
Although the results of the overall trial were robust, subgroup analyses demonstrated 
several key cohorts with results that diverged from those of the main SYNTAX population. 
Specifi cally, among patients with left main disease or SYNTAX Score ≤22, DES-PCI was 
projected to be an economically dominant strategy that resulted in similar or greater 
quality-adjusted life expectancy and lower lifetime costs compared with CABG. Although 
these results were not defi nitive (due mainly to uncertainty with respect to long-term 
survival diff erences), these fi ndings suggest that DES-PCI may be the preferred strategy 
for patients with less anatomically complex CAD on both clinical and economic grounds. 
In contrast, among patients with 3-vessel disease or with anatomic SYNTAX Scores ≥32, 
CABG was strongly favored on economic grounds with ICERs <$10,000/QALY gained and 
a <6% probability that the ICER exceeds $50,000/QALY gained. While subgroup analyses 
are typically considered “hypothesis generating” when interpreting clinical trial results, 
cost-eff ectiveness analysis is driven by measures of absolute cost and benefi t that 
may be more susceptible to meaningful interactions. As such, subgroup eff ects in cost-
eff ectiveness analysis are frequently considered to be valid considerations for guideline 
development and health care policy—particularly when the results are supported by ap-
propriate uncertainty analyses and are consistent with the underlying pathophysiology.32
The fi nding that our results were only minimally sensitive to stent pricing was somewhat 
surprising. Although device prices are commonly perceived to be an important determi-
nant of their cost-eff ectiveness,33 when comparing DES-PCI vs. CABG, we found that the 
major determinant of cost-eff ectiveness was the gain in life expectancy rather than the 
cost diff erence, per se. Consequently, there was no device cost at which DES-PCI would 
be economically attractive compared with CABG in either the overall trial population or 
in patients with a high SYNTAX Score. Only among patients with an intermediate SYNTAX 
Score (where the gain in quality-adjusted life expectancy with CABG was minimal) would 
DES-PCI become the economically preferred therapy if the device cost were reduced by 
~20% from current levels.
Comparison with Previous Studies
These fi ndings contrast with those from our previous cost-eff ectiveness analysis of DES-
PCI vs. CABG based on the 1-year SYNTAX trial results, in which we reported that DES-PCI 
was an economically dominant strategy.34 Compared with that previous report, the initial 
cost diff erence in favor of DES-PCI has increased from ~$5000/patient to ~$10,000/
patient—changes driven largely by the substantial reduction in DES prices over the last 
4-5 years (from $2200/stent to $1500/stent). Another important diff erence between 
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the 2 studies is the cost diff erence in the fi rst year of follow-up, which decreased from 
~$2300 in the original study to ~$1700 in the current study— due mainly to reductions 
in the cost of dual antiplatelet therapy with the approval of generic clopidogrel. The most 
important diff erence between the 2 studies was that in the 1-year study, quality-adjusted 
life expectancy favored DES-PCI (refl ecting the early QOL and survival advantage), 
whereas in the current study, quality-adjusted life expectancy was greater with CABG. 
These diff erences highlight the importance of basing policy decisions on clinical trials 
with suffi  ciently long follow-up to allow prognostically important benefi ts to emerge. 
Although many third-party payers in the US are more concerned with a 1-3 year time 
horizon than a lifetime horizon, the results of our study demonstrate how analyses that 
focus solely on short-term economic and clinical outcomes may fail to incorporate the 
full benefi ts of the more eff ective therapy and arrive at misleading conclusions.
Numerous previous studies have sought to evaluate the relative cost-eff ectiveness of PCI 
vs. CABG for patients with multivessel CAD.7, 9, 15, 28, 35-39 However, most of these studies 
are limited by relatively short follow-up durations,7, 34, 36, 39 or by focusing solely on costs 
without performance of a formal cost-eff ectiveness analysis.35 In addition, no studies to 
date have examined the cost-eff ectiveness of PCI vs. CABG for patients with left main 
disease. With respect to methodology and duration of follow-up, our study is most com-
parable to economic evaluations performed alongside the BARI and FREEDOM trials. In 
BARI, the ICER for CABG vs. balloon angioplasty was ~$14,000/life-year gained over a 12 
year follow-up period28—results that are quite similar to those from the SYNTAX trial. In 
contrast to SYNTAX, however, BARI found that for patients with 3-vessel CAD costs were 
actually lower with CABG than PCI over 5 years of follow-up.9 It is likely that these diff er-
ences between trials refl ect the much lower rate of repeat revascularization procedures 
after PCI seen in SYNTAX as compared with BARI with the introduction of eff ective drug-
eluting stents (26% vs. 54%).3, 12
FREEDOM is the only other trial to compare the cost-eff ectiveness of PCI vs. CABG in the 
DES era and demonstrated that for patients with diabetes and multivessel CAD, CABG 
is highly cost-eff ective compared with DES-PCI with an ICER of ~$8000/QALY gained.15 
Although these overall results are relatively similar to those seen in SYNTAX, in FREEDOM 
CABG was economically attractive across the full range of SYNTAX Scores whereas in 
SYNTAX, CABG was only attractive for patients moderate to high degrees of angiographic 
complexity (SYNTAX Score >22). These fi ndings may relate to underlying diff erences in 
atherosclerosis between patients with vs. without diabetes or may refl ect the fact that 
diabetic patients often have additional conditions (e.g. renal dysfunction, peripheral 
artery disease) that confer higher cardiovascular risk.13 Of note, patients with left main 
coronary disease were not studied in either BARI or FREEDOM.
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Limitations
Our study has several important limitations. First, our economic analysis was performed 
from the perspective of the U.S. healthcare system, although the SYNTAX trial enrolled 
patients from 18 countries. To address this issue, costs associated with the index pro-
cedures were estimated from detailed resource use, which would not be expected to 
diff er by geography. Since hospital length of stay diff ers across countries, all other costs 
were estimated using methods that were independent of length of stay and depend 
only the assumption that clinical outcomes and procedural complications are similar 
across healthcare systems.40 Although it would have been possible to exclude all non-US 
patients from our analysis, this would have markedly reduced our sample size and added 
considerable variability to the results. It is nonetheless reassuring that our main results 
were consistent between patients enrolled in the US compared with other countries.
Second, the need for lifetime extrapolations required several assumptions regarding the 
impact of CABG on long-term survival, health care costs, and quality-of-life. To the great-
est extent possible, we used empirical data from the trial to inform these assumptions 
and examined the impact of plausible alternatives in sensitivity analyses, the results of 
which were similar to our primary results. Third, all DES patients in the SYNTAX trial were 
treated with paclitaxel-eluting DES. Recently, second-generation DES have demonstrated 
lower rates of MI, target vessel revascularization, and stent thrombosis as compared 
with fi rst-generation DES.41 Therefore, the cost results of the current study may not be 
generalizable to patients treated with second-generation DES. It is unlikely that the main 
results of our analysis would change substantially with use of second generation DES, 
however, since there is no evidence that these devices reduce mortality compared with 
the paclitaxel-eluting stents that were used in SYNTAX.41 Finally, PCI in the SYNTAX trial 
did not incorporate routine use of physiologic guidance—a technique that has recently 
been shown to both improve clinical outcomes and lower long-term costs compared with 
angiographic guidance.42, 43 Future trials comparing physiologically-guided PCI vs. CABG 
will be required to determine the overall cost-eff ectiveness of this strategy.
Conclusions
Based on the results of the SYNTAX trial, for most patients with 3-vessel or left main 
CAD without recent MI, CABG is a clinically and economically attractive revascularization 
strategy compared with DES-PCI. However, among patients with less complex disease, 
DES-PCI may be preferred on both clinical and economic grounds. These fi ndings provide 
additional support for existing guidelines and underscore the importance of ongoing 
studies to defi ne the optimal revascularization strategy for patients with left main 
disease.
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Supplementary Table 1. Linear Regression Models developed from MedPAR Data for the Prediction of 
Post-Procedure Costs
Model variable CABG (n=43,866) PCI (n=113,921)
Intercept* (uncomplicated hospitalization, non-procedure costs) 16,669 6216
Demographics
 Age≥80 years 2209 170
 Female 671 −8
Co-morbidities
 Congestive heart failure 3294 1752
 COPD −340 614
 Chronic renal failure, without dialysis −850 226
 Chronic renal failure, with dialysis 9569 3192
 Gastro-intestinal bleeding - 1673
Complications
 Death 12,519 3200
 Stroke 9674 6580
 Myocardial infarction 9688 6258
 Additional PCI 11,070 9285
 Additional CABG - 21,992
 Major vascular complication 8457 2541
 Transfusion - 3829
 Cardiogenic shock 16,739 7002
 Post-operative hypotension - 1308
 Respiratory failure 9009 9946
 Renal failure 10,068 5477
 Post-operative infection 14,802 9211
 Post-operative atrial fi brillation 903 2861
 Post-operative ventricular arrhythmia - 3316
 Pacemaker insertion 10,087 5984
 Cardiac Tamponade 7555 6122
 Pulmonary embolus 9717 8975
R2 0.21 0.18
The impact of interactions for age with complications was tested, but did not improve the model. *Inter-
cepts haven been adjusted to exclude the cost of otherwise uncomplicated procedures. CABG, coronary 
artery bypass grafting; PCI, percutaneous coronary intervention
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Supplementary Table 2. Linear Regression Models developed from MedPAR Data for the Prediction of 
Post-Procedure Length of Stay
Model variable CABG (n=43,866) PCI (n=113,921)
Intercept* (uncomplicated hospitalization, non-procedure costs) 6.79 1.61
Demographics
 Age≥80 years 0.94 0.23
 Female 0.81 0.31
Co-morbidities
 Congestive heart failure 1.50 1.35
 COPD 0.14 0.46
 Chronic renal failure, without dialysis −0.01 0.43
 Chronic renal failure, with dialysis 3.18 1.46
 Gastro-intestinal bleeding - 1.46
Complications
 Death 0.07 −0.34
 Stroke 4.33 3.07
 Myocardial infarction 3.05 2.53
 Additional PCI 1.03 1.52
 Additional CABG - 5.34
 Major vascular complication 1.81 1.09
 Transfusion - 2.31
 Cardiogenic shock 3.29 2.37
 Post-operative hypotension - 0.22
 Respiratory failure 2.99 4.33
 Renal failure 4.29 3.80
 Post-operative infection 7.92 5.10
 Post-operative atrial fi brillation 0.61 1.62
 Post-operative ventricular arrhythmia - 1.63
 Pacemaker insertion 1.98 0.95
 Cardiac Tamponade 3.70 1.01
 Pulmonary embolus 4.39 4.68
R2 0.21 0.27
The impact of interactions for age with complications was tested, but did not improve the model. *Inter-
cepts haven been adjusted to exclude the cost of otherwise uncomplicated procedures. CABG, coronary 
artery bypass grafting; PCI, percutaneous coronary intervention.
229
Chapter 11. US Cost-Eff ectiveness of PCI versus CABG
11
Supplementary Table 3. Regression Model developed from SYNTAX Follow-Up Cost for the Prediction 
of Long-Term costs
Parameter Coeffi  cient Estimate ($) p-value
Intercept 4367 <0.001
CABG −897 <0.001
Age 5 0.586
Male −655 0.003
SYNTAX Score 23-32 −486 0.029
SYNTAX Score ≥33 −190 0.396
Left main disease 329 0.077
Peripheral vascular disease 2449 <0.001
Myocardial Infarction during trial 3807 <0.001
Stroke during trial 3898 <0.001
Supplementary Table 4. Regression Model developed from SYNTAX Follow-Up Utility data for the Pre-
diction of Long-Term Utility Weights
Parameter Coeffi  cient Estimate p-value
Intercept 0.78900 <0.001
Male 0.08641 <0.001
SYNTAX Score 23-32 0.00058821 0.894
SYNTAX Score ≥33 −0.01156 0.009
History of Stroke −0.02188 0.001
Peripheral vascular disease −0.03754 <0.001
Carotid artery disease −0.03080 <0.001
Myocardial Infarction during trial −0.01542 0.086
Stroke during trial −0.08218 <0.001
Supplementary Table 5. EQ-5D Utility Scores by Treatment Assignment
Timepoint CABG PCI p-value
Baseline 0.741 ± 0.191 [0.800] 0.754 ± 0.187 [0.800]
1 month 0.769 ± 0.171 [0.816] 0.853 ± 0.156 [0.844] <0.001
6 months 0.847 ± 0.153 [0.827] 0.862 ± 0.150 [0.844] 0.09
12 months 0.850 ± 0.158 [0.827] 0.854 ± 0.157 [0.844] 0.98
36 months 0.850 ± 0.161 [0.843] 0.847 ± 0.164 [0.833] 0.62
60 months 0.846 ± 0.173 [0.838] 0.843 ± 0.174 [0.843] 0.83
Values in brackets are medians. CABG, coronary artery bypass graft; PCI, percutaneous coronary interven-
tion. P-values are derived from ANCOVA, adjusted for baseline.
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Supplementary Table 10. Sensitivity Analysis on Stent Price in Overall Population and SYNTAX Score
Population
Base case with 
stent price of 
$1500
Required stent price 
at which the ICER of 
CABG vs. PCI equals 
$50,000/QALY 
gained
Interpretation of sensitivity 
analysis (other things equal)
Overall (n=1766)
CABG 
economically 
attractive
$ −775
Stent price does not infl uence 
economic attractiveness
SYNTAX Score ≤22 (n=562) PCI dominant $ 4880
Stent price above this threshold 
will make PCI economically 
unattractive
SYNTAX Score 23-32 (n=600)
CABG 
economically 
attractive
$ 1195
Stent price below this threshold 
would make PCI economically 
attractive
SYNTAX Score ≥33 (n=595)
CABG 
economically 
attractive
$ −7850
Stent price does not infl uence 
economic attractiveness
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ABSTRACT
Aims
Recent cost-eff ectiveness analyses of percutaneous coronary intervention (PCI) vs. coro-
nary artery bypass grafting (CABG) have been limited by a short time-horizon or were 
restricted to the U.S. healthcare perspective. We therefore used individual patient-level 
data from the SYNTAX trial to evaluate the cost-eff ectiveness of PCI vs. CABG from a 
European (Dutch) perspective.
Methods and Results
Between 2005 and 2007, 1800 patients with three-vessel or left main CAD were ran-
domized to either CABG (n = 897) or PCI with DES (n = 903). Costs were estimated for all 
patients based on observed healthcare resource utilization over 5 years of follow-up. 
Health state utilities were evaluated with the EuroQOL questionnaire. A patient-level 
microsimulation model based on Dutch life-tables was used to extrapolate the 5-year 
in-trial data to a lifetime horizon.
Although initial procedural costs were lower for CABG, total initial hospitalisation costs 
per patient were higher (€17506 vs. €14037, p < 0.001). More frequent hospitalisations, 
repeat revascularization procedures, and higher medication costs made PCI more costly 
over the next 5 years. Nevertheless, total 5 year costs remained €2465/patient higher 
with CABG. When the in-trial results were extrapolated to a lifetime horizon, CABG was 
projected to be economically attractive relative to DES-PCI, with gains in both life ex-
pectancy and quality-adjusted life expectancy. The incremental cost-eff ectiveness ratio 
(€5390/QALY gained) was favourable and remained <€80000/QALY in >90% of the 
bootstrap replicates. Outcomes were similar when incorporating the prognostic impact 
of non-fatal MI and stroke, as well as across a broad range of assumptions regarding 
the eff ect of CABG on post-trial survival and costs. However, DES-PCI was economically 
dominant compared with CABG in patients with a SYNTAX Score ≤22 or in those with left 
main disease. In patients for whom the SYNTAX Score II favoured PCI based on lower pre-
dicted 4 year mortality, PCI was also economically dominant, whereas in those patients 
for whom the SYNTAX Score II favoured surgery, CABG was highly economically attractive 
(ICER range, €2967 to €3737/QALY gained).
Conclusions
For the broad population with three-vessel or left main disease who are candidates 
for either CABG or PCI, we found that CABG is a clinically and economically attractive 
revascularization strategy compared with DES-PCI from a Dutch healthcare perspective. 
The cost-eff ectiveness of CABG vs. PCI diff ered according to several anatomic factors, 
however. The newly developed SYNTAX Score II provides enhanced prognostic discrimi-
nation in this population and may be a useful tool to guide resource allocation as well.
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INTRODUCTION
Approximately 2% of the total healthcare expenditure in the European Union is spent on 
the treatment of coronary artery disease (CAD).1 Percutaneous coronary intervention (PCI) 
and coronary artery bypass grafting (CABG) for multivessel CAD have been compared in 
several studies. For patients without diabetes mellitus, these studies have demonstrated 
similar short- and long-term survival with either procedure, but CABG provided better 
angina relief and led to less frequent repeat revascularisation procedures.2-8 Long-term 
economic evaluations have found that while PCI is cost-saving in the short term, CABG is 
an economically attractive treatment option compared with balloon angioplasty or PCI 
using bare metal stents.9
The Synergy between PCI with TAXUS and Cardiac Surgery (SYNTAX) trial is the largest 
trial to date to compare PCI with CABG in a broad patient population. In contrast to earlier 
studies, the SYNTAX trial recruited patients with complex CAD (three-vessel or left main 
disease), used drug-eluting stents (DES), and applied an all-comers design, with minimal 
exclusion criteria. At 5-year follow-up, CABG had a lower rate of the composite endpoint 
of all-cause death, myocardial infarction, stroke or repeat revascularisation compared 
with DES-PCI-- driven mainly by lower rates of non-fatal myocardial infarction (MI) and 
repeat revascularisation with CABG. Based on the SYNTAX trial data, the SYNTAX Score 
II was recently developed and validated as a tool for weighing anatomical and clinical 
factors to establish the optimal revascularisation strategy for individual patients with 
complex CAD.10, 11
Since healthcare spending outpaces the growth of the overall economy in virtually all 
Western countries, long-term clinical outcomes and lifetime cost-eff ectiveness analy-
ses of the two alternative revascularisation strategies are crucial for clinical guideline 
development and healthcare policy. Although the U.S. and European healthcare systems 
diff er signifi cantly with respect to clinical practice patterns, availability of resources and 
prices, few economic evaluations of CABG vs. PCI have been performed from a European 
perspective.7, 12 Moreover, the available European economic substudies are >10 years old 
and have incorporated only a brief time horizon. We therefore performed a prospective 
health economic study alongside the SYNTAX trial, adopting a Dutch perspective and 
disease-simulation techniques to extrapolate the 5-year trial results to a lifetime horizon. 
In addition, we analysed the economic outcomes in subgroups defi ned on the basis of 
the new SYNTAX Score II,10 hypothesizing that this tool would be a good discriminator of 
economic outcomes and healthcare value.
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METHODS
Trial Design
The design and methods of the SYNTAX trial have been described previously.13-15 A heart 
team, consisting of a cardiac surgeon and interventional cardiologist screened consecu-
tive patients with de novo three-vessel or left main (isolated or associated with 1, 2 or 
3-vessel disease) CAD. Between March 2005 and April 2007, 1800 patients who were 
considered by the Heart Team to be equally suitable for revascularisation using DES-PCI 
or CABG, were randomized. Patients were enrolled in 85 centres in 17 European coun-
tries and the United States. CABG was performed using standard techniques, and PCI 
procedures utilised paclitaxel-eluting stents (TAXUS Express, Boston Scientifi c, Natick, 
MA, USA). The institutional review board at each participating site approved the protocol, 
and all patients provided written informed consent. The trial complies with the Declara-
tion of Helsinki and is registered at the National Institutes of Health website (http://www.
clinicaltrials.gov; identifi er NCT00114972).
Clinical Outcomes, Resource Utilisation and Medical Cost Estimation
Research coordinators at each site collected patient characteristics, procedural details, 
resource utilisation and clinical outcomes during the initial hospitalisation and 5-year 
follow-up period. A blinded clinical events committee reviewed all components of the 
primary clinical endpoint (death, MI, stroke, repeat revascularisation), while other clinical 
outcomes and measures of resource utilisation (e.g. length of stay) were collected on-site 
and were independently monitored.
Costs for the index hospitalisation and the fi ve-year follow-up period were assessed by 
combining resource-based and event-based methods as described below. All costs were 
assessed from the perspective of the Dutch healthcare system and are reported in Euros. 
The Dutch Manual for Cost-analysis in Healthcare was utilised,16 and where necessary 
the consumer price index was used to convert costs to the year 2012.17 As recommended 
by the Dutch Council for Public Health, a willingness-to-pay (WTP) threshold level of 
€80 000/QALY was used to assess cost eff ectiveness.18
Procedural Costs
Detailed resource use was recorded for each revascularisation procedure, and the cost 
for each item was estimated using hospital acquisition costs at the Erasmus Medical Cen-
ter, Rotterdam, the Netherlands. The cost of DES and bare metal stents were €935 and 
€738, respectively. Costs of antithrombotic therapy were based on acquisition costs for 
Dutch pharmacies.19 Costs for non-physician personnel, disposables, perfusion (CABG), 
overhead and depreciation of the cardiac catheterization laboratory and the operating 
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room were estimated using a detailed micro-costing approach at the Erasmus Medi-
cal Centre. Costs for each procedure were adjusted for procedure duration. Initial and 
planned staged PCI procedures were combined in the calculation of the index resource 
utilisation and procedure cost.
Post-Procedure Hospitalisation Costs
All other hospitalisation costs associated with coronary revascularisation were estimated 
using costs for hospital stay (€2198 and €485 per night for intensive care and normal 
ward stay, respectively). These costs were based on multiple Dutch micro-costing stud-
ies and incorporate nursing, nutrition, materials, equipment, overhead and housing.16 
In order to apply the same costs to other countries with diff erent practice patterns, 
we used regression models to adjust length of stay after PCI or CABG to Dutch norms. 
Separate linear regression models for PCI and CABG were developed; for each model, 
total length of stay was the dependent variable and independent variables included 
socio-demographic factors, comorbidities, in-hospital complications, and the enrolling 
country. Details of the models are provided in the Appendix, Supplementary Table 1.
For follow-up cardiovascular hospitalisations that did not involve a revascularisation 
procedure, the hospital admission was assigned to the appropriate diagnosis-related 
group (DRG) based on the principal diagnosis and any procedures performed during that 
admission. Costs were assigned based on the mean reimbursement rate for that DRG 
across three Dutch hospitals.
Physician Costs
Physician fees for PCI and CABG procedures were based on honoraria for these pro-
cedures set by the Dutch National Health Tariff s Authority.16 Non-procedure related 
physician fees were assigned based on a fi xed proportion of the costs per night in the 
intensive care ward.16 Physician fees for all other hospitalisations were DRG-based and 
calculated as the mean honorarium across three Dutch hospitals.
Outpatient Costs
Costs for outpatient visits, tests and procedures were based on tariff s set by the Dutch 
National Health Tariff s Authority, and the Dutch Manual for Cost-analysis in Healthcare.16 
Medication costs were based on the acquisition costs for Dutch pharmacies.19
Quality of Life
Quality of life was assessed directly from patients at baseline, 1, 6, 12, 36, and 60 months 
using the EuroQOL (EQ-5D) health status instrument and converted to utility weights 
(range 0-1) using an algorithm developed for the Dutch population.20
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Statistical Analysis
To account for the higher rate of withdrawal prior to treatment among patients assigned 
to CABG, we used the modifi ed intention-to-treat (mITT) population as the primary 
population for the economic analysis. This mITT population was defi ned as all 1766 
randomized patients who underwent ≥1 initial revascularisation procedure, with patients 
categorized according to their assigned treatment. A secondary analysis used the per 
protocol (PP) population and included only those patients who underwent the assigned 
revascularisation procedure (n = 1739).
Categorical data are reported as frequencies, and continuous data are reported as mean 
± standard deviation. Discrete variables were compared using Fisher exact tests. Nor-
mally distributed continuous variables were compared using Student t-tests, and non-
normally distributed data were compared using the Wilcoxon rank-sum test. Treatment 
eff ects from Poisson regression models were used for the comparison of hospitalisation 
rates. Kaplan-Meier survival curves and log-rank tests were used for the comparison of 
fi ve-year clinical events. Cost data are reported as both mean and median values and 
were compared using t-tests, which are appropriate given our focus on comparing mean 
costs between groups (rather than the underlying distributions).21 Confi dence intervals 
for the diff erences in costs between treatment groups were obtained via bootstrapping.22
854 initial 
CABG 
16 initial  
PCI 
885 initial 
PCI 
11 initial  
CABG 
27 no procedure 
(withdrawn) 
7 no procedure 
(withdrawn) 
870 underwent 
revascularization 
896 underwent 
revascularization 
897 assigned to CABG 
1800 patients randomized 
903 assigned to PCI 
Figure 1.
CONSORT diagram. Black boxes represent the modifi ed intention-to-treat (mITT) population that was the 
primary analytic population for the economic study. The grey boxes represent the per protocol (PP) popula-
tion. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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Quality-adjusted life expectancy was calculated for each patient as the time-weighted 
average of his/her utility values, using the mid-point between assessments as the transi-
tion between health states, starting at the 30-day visit. The baseline utility was applied 
to the time from randomization to the index procedure, and the 30-day utility value was 
applied to the period from the procedure through the midpoint between the 30-day 
and 6-month follow-up. Missing utility values were estimated using multiple imputation, 
taking into account baseline patient characteristics, antecedent clinical events, previous 
utility values and number of hospitalisations.
In-Trial Analysis of Costs, Life Years and Quality-Adjusted Life Years
To accommodate diff erential follow-up duration, methods for the analysis of censored 
data were used to obtain estimates of cumulative costs and quality-adjusted life-years 
gained (QALY) over time. An inverse probability-weighted estimator was applied, whereby 
the time axis was divided into 3-month intervals, and costs for each interval were esti-
mated as the observed costs during the interval for patients with complete data divided 
by the probability of not being censored within the interval.23 Similar methods were 
applied to estimate quality-adjusted life expectancy. Life-years gained at annual time 
points were estimated as the diff erence in the area between the Kaplan-Meier survival 
curves for the two treatment groups. The confi dence limits for the mean cumulative cost, 
life-year, and QALY estimates for each treatment group, as well as the diff erence between 
groups were calculated using the bootstrap method.22
Cost-Eff ectiveness
The cost-eff ectiveness of CABG vs. PCI was assessed over a life-time horizon. Health 
benefi ts were expressed in QALYs gained in the primary analysis and as life-years gained 
in secondary analyses.16, 24 Life-years and QALYs were discounted at 1.5% annually, and 
costs at 4% annually, as recommended by the Dutch Manual for Cost-analysis in Health-
care.22 The analyses were based on a combination of (1) observed in-trial cost and quality 
of life data and (2) projections of post-trial costs, life expectancy and quality-adjusted 
life expectancy obtained from a Markov disease-simulation model. In this model, each 
surviving patient was assumed to encounter a monthly risk of death, based on age-, and 
sex-matched risk of death obtained from Dutch life tables, which were calibrated to the 
observed fi ve-year mortality for the trial population.25, 26
For the PCI group, the comparison of the observed fi ve-year mortality for the trial popula-
tion with that of an age-, and sex-matched Dutch population, yielded a multiplier of 1.30. 
To incorporate the prognostic benefi t of CABG vs. PCI, an additional multiplicative factor 
was applied, based on the hazard ratio (HR) derived from an analysis of all-cause mortal-
ity from the SYNTAX patients. In sensitivity analyses, the independent impact of non-fatal 
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events (myocardial infarction [MI] and stroke) on long-term mortality was taken into ac-
count. For these secondary analyses, events were used as time-varying covariates and 
analyses were adjusted for baseline characteristics (age, sex and diabetes) and treatment 
group. The resulting mortality HRs were used as multipliers for patients with a non-fatal 
MI and non-fatal stroke. Patient-level costs and utility weights for each projected year of 
life beyond the trial observation period were derived from regression models developed 
from the in-trial data (Appendix, Supplementary Tables 3 and 4).
Three sets of analyses were performed based on diff erent assumptions regarding the 
duration of the prognostic benefi t of CABG compared with PCI. The base case analysis 
assumed that the benefi t of CABG tapered in a linear fashion from years 5 to 10 and that 
there were no prognostic diff erences between PCI and CABG beyond year 10 (i.e. HR=1 
after year 10). In sensitivity analyses, we assumed (1) a constant prognostic benefi t of 
CABG from year 5 to year 10, with no benefi t of CABG after 10 years; or (2) no prognostic 
benefi t of CABG beyond the 5-year trial period (i.e. HR=1 after year 5).
In addition to the overall analysis and sensitivity analyses, subgroup analyses were per-
formed to examine the cost-eff ectiveness of CABG vs. DES in prespecifi ed patient sub-
sets stratifi ed according to age (≤60, 61-70, >70), diabetes, left main or 3-vessel disease, 
and the anatomic SYNTAX score. Finally, we used the recently developed SYNTAX score 
II that incorporates both anatomic and clinical factors to calculate a predicted 4-year 
mortality for patients with CAD when treated with either DES-PCI or CABG.10 To use this 
as a stratifi cation factor, patients were assigned to 5 diff erent categories according to the 
predicted diff erence in 4-year survival with DES-PCI vs. CABG.
Bootstrap methodology (1000 repetitions) was used to estimate uncertainty in the joint 
distribution of lifetime cost, life-years, and QALYs for each treatment group. To maintain 
consistency of the within-trial and post-trial CABG eff ect within each bootstrap sample, 
the HRs for the eff ect of CABG vs. PCI on mortality were re-estimated for each bootstrap 
replicate. All analyses were performed using SAS 9.3 (SAS Institute, Cary, NC).
RESULTS
Patient Population
In SYNTAX, 1800 patients with de novo three-vessel or left main CAD were randomized to 
either CABG (n = 897) or PCI (n = 903). Of the randomized patients, 27 assigned to CABG 
and 7 assigned to PCI did not undergo any revascularisation procedure and were ex-
cluded from the primary mITT population (Figure 1). There were no signifi cant diff erences 
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in any observed baseline characteristics between the CABG and PCI groups for the mITT 
population (Table 1). Of the mITT patients, 148 (8.4%) were enrolled in the Netherlands, 
39% had left main CAD, and the median follow-up was 60 months.
Initial Treatment Costs
Of the patients that were randomized to PCI, 885 (98.8%) underwent PCI and 11 (1.2%) 
underwent CABG. Among patients assigned to CABG, 854 (98.2%) underwent CABG, and 
16 (1.8%) underwent PCI. Resource utilisation for the initial revascularisation procedures 
is summarised in Table 2 (PP population). In the PCI group, 13.6% underwent staged pro-
cedures. On average, 2.1 guiding catheters, 3.5 guidewires, 3.7 angioplasty balloons, and 
4.5 drug-eluting stents were used during the initial PCI procedure. Although procedure 
Table 1. Baseline Characteristics (mITT Population)
CABG (n=870) PCI (n=896) p-value
Sociodemographic characteristics
Age, y 64.9 ± 9.8 65.3 ± 9.6 0.40
Male, % 79.4 76.6 0.15
Body mass index, kg/m2 27.9 ± 4.4 28.1 ± 4.8 0.26
Enrolled in the Netherlands, % 8.5 8.3 0.85
Clinical characteristics
Diabetes mellitus, % 27.6 28.3 0.72
Insulin-dependent, % 10.1 9.9 0.90
Current smoker, % 22.0 18.5 0.07
Previous MI, % 33.3 32.1 0.59
Peripheral vascular disease 10.5 9.2 0.36
COPD, % 9.2 7.9 0.34
Prior stroke or TIA, % 9.1 7.7 0.29
History of CHF, % 5.2 4.0 0.27
Angiographic characteristics
LVEF, % 58.3 ± 13.2 59.1 ± 12.9 0.31
LM disease (any), % 39.4 39.3 0.98
LM only 5.4 4.5 0.98
1 other artery 8.1 7.5 0.36
2 other arteries 12.2 12.4 0.65
3 other arteries 13.7 15.0 0.90
Three-vessel disease (no LM), % 60.6 60.7 0.98
SYNTAX Score 29.1 ± 11.3 28.4 ± 11.4 0.21
mITT indicates modifi ed intention to treat; CABG, coronary artery bypass grafting; CHF, congestive heart 
failure; COPD, chronic obstructive pulmonary disease; LM, left main; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; mITT, modifi ed intention-to-treat; PCI, percutaneous coronary intervention; TIA, 
transient ischemic attack.
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duration was longer for CABG, initial procedure costs were ~€1351 lower with CABG as 
compared with PCI (€6472 vs. €7823, p < 0.001), owing to higher costs associated with 
disposable resources in the PCI group. For the mITT population, the diff erence in initial 
procedural costs was similar (€1354; €6444 vs. €7798, p < 0.001).
Clinical events, resource utilisation, and costs during the initial hospitalisation are sum-
marized in Table 3. Post-procedural hospital costs were higher for the CABG group com-
pared with the PCI group (€8725 vs. €3996, p < 0.001), as were physician fees (€2264 
vs. €2111, p < 0.001). As a result, total initial hospitalisation costs were ~€3500/patient 
higher in the CABG group compared with the PCI group (€17506 vs. €14037, p < 0.001).
Follow-up Resource Utilisation and Costs
Follow-up clinical outcomes, resource utilisation, and costs are summarised in Table 4. 
During each year of follow-up, the annual rates of diagnostic catheterisation, repeat 
revascularisation, hospitalisation, and their associated costs were higher for patients 
Table 2. Index Procedural Resource Utilisation and Cost (Per Protocol Population)
CABG (n=854) PCI (n=885) p-value
Number of PCI procedures, %
 1 - 85.9 (760/885)
 2 - 13.5 (124/885)
 3 or more - 0.1 (1/885)
Procedure duration, minutes 209±62 [205] 101±55 [90] <0.001
Guiding catheters - 2.1 ± 1.2
Guidewires - 3.5 ± 2.3
Paclitaxel-eluting stents - 4.5 ± 2.3
Bare metal stents - 0.0 ± 0.3
Angioplasty balloons - 3.7 ± 2.8
Rotablator burrs - 0.1 ± 0.3
IVUS catheters - 0.1 ± 0.4
Closure device - 0.4 ± 0.6
Contrast volume, ml - 415 ± 207.5 [380]
Antithrombotic agents used, %
 Bivalrudin - 7.2% (64/885)
 Abciximab - 15.6% (138/885)
 Eptifi batide - 9.5% (84/885)
 Tirofi ban - 10.7% (95/885)
Index procedure cost, € 6472 ± 1500 [6359] 7823 ± 4324 [7330] <0.001
Values in brackets represent medians. CABG, coronary artery bypass grafting; IVUS, intravascular ultra-
sound; PCI, percutaneous coronary intervention.
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assigned to initial PCI. In addition, costs for outpatient services and medications were 
consistently higher in the PCI group compared to the CABG group. Rehabilitation costs 
were greater in the fi rst year after CABG and were similar between treatments in the 
subsequent years. Overall, the diff erence in cumulative medical care costs between the 
CABG and PCI narrowed from €3469 after the index hospitalisation to €2465 after 5 
years of follow-up (Table 5 and Figure 2).
Table 3. Index Hospitalisation Events, Resource Utilisation, and Costs (mITT Population)
CABG (n=870) PCI (n=896) Diff erence (95% CI) p-value
Death, % 1.4 (12/870) 1.8 (16/896) −0.4 (−1.6, 0.8) 0.49
MI, % 2.4 (21/870) 2.7 (24/896) −0.3 (−1.7, 1.2) 0.72
Stroke, % 1.0 (9/870) 0.1 (1/896) 0.9 (0.2, 1.6) 0.01
Unplanned CABG, % 1.1 (10/870) 0.8 (7/896) 0.4 (−0.5, 1.3) 0.42
Unplanned PCI, % 0.5 (4/870) 1.8 (16/896) −1.3 (−2.3, −0.3) 0.008
Complications, %
Major bleeding 4.8 (42/870) 4.5 (40/896) 0.4 (−1.6, 2.3) 0.72
Respiratory failure 1.6 (14/870) 0.0 (0/896) 1.6 (0.8, 2.4) < 0.001
Renal failure 2.4 (21/870) 0.7 (6/896) 1.7 (0.6, 2.9) 0.003
Wound infection 4.1 (36/870) 0 (0/896) 4.1 (2.8, 5.5) < 0.001
Other infection 6.2 (54/870) 0.4 (4/896) 5.8 (4.1, 7.4) < 0.001
Atrial fi brillation 17.9 (156/870) 1.3 (12/896) 16.6 (13.9, 19.2) < 0.001
Cardiac tamponade 0.8 (7/870) 0.3 (3/896) 0.5 (−0.2, 1.2) 0.22
Other procedures, %
Permanent 
pacemaker
0.6 (5/870) 0.2 (2/896) 0.4 (−0.2, 0.9) 0.28
ICD implantation 0.2 (2/870) 0.0 (0/896) 0.2 (−0.1, 0.5) 0.24
Carotid 
endarterectomy
0.5 (4/870) 0.0 (0/896) 0.5 (0.0, 0.9) 0.06
Length of stay*
ICU/CCU 3.0 ± 5.2 (870) 1.6 ± 2.9 (896) 1.5 (1.1, 1.9) < 0.001
Total 13.9 ± 10.1 (870) 6.7 ± 7.7 (896) 7.2 (6.4, 8.0) < 0.001
Initial hospitalisation costs, €
Revascularization 
procedures
6517 ± 1691 [6347] 7930 ± 4404 [7374] −1413 (−1726, −1100) < 0.001
Hospital stay + 
ancillary services
8725 ± 4818 [7117] 3996 ± 3816 [2143] 4729 (4324, 5134) < 0.001
Physician fees 2264 ± 370 [2126] 2111 ± 587 [1887] 153 (107, 199) < 0.001
Total 17506 ± 5621 [16214] 14037 ± 6850 [12597] 3469 (2883, 4054) < 0.001
Values in brackets are medians. CCU, cardiac care unit; CI, confi dence interval; ICD, implantable cardiovert-
er-defribillator; ICU, intensive care unit; mITT, modifi ed intention-to-treat. * Length of stay in the diff erent 
countries was converted to the Dutch perspective using a regression modeling approach (Supplementary 
Table 1).
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Utility Weights and QALYs
For both treatment groups, utility weights improved substantially over the course of the 
trial (Supplementary Table 2). At 1 month follow-up, utility weights were signifi cantly 
lower after CABG than PCI (0.74 vs. 0.83, p < 0.001), refl ecting longer recovery after CABG. 
However, this early utility benefi t of PCI was no longer signifi cant at 6 months and longer 
follow-up. As a result of the early utility benefi t of PCI, cumulative quality-adjusted life-
years were higher with PCI than with CABG through 3 years of follow-up (Table 5). At 5 
Table 5. Cumulative In-Trial Costs, QALYs, and Life-Years, Adjusted for Censoring
Time Since
Randomization
Cumulative Costs, € Cumulative QALYs Cumulative Life-Years
CABG PCI ∆ CABG PCI ∆ CABG PCI ∆
1 year 20868 17495 3373 0.762 0.791 −0.029 0.975 0.965 0.009
2 years 22193 19156 3037 1.547 1.600 −0.022 1.933 1.912 0.022
3 years 23364 20507 2857 2.323 2.329 −0.005 2.877 2.832 0.045
4 years 24454 21879 2575 3.074 3.058 0.016 3.800 3.732 0.069
5 years 25680 23215 2465 3.802 3.762 0.040 4.701 4.601 0.100
CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; QALY, quality-adjusted life-
years gained. ∆=diff erence between CABG and PCI group; D, diff erence between CABG and PCI groups
€0 
€5000 
€10000 
€15000 
€20000 
€25000 
€30000 
Index Year 1 Year 2 Year 3 Year 4 Year 5
CABG Annual Cost
PCI Annual Cost
CABG Cumulative Cost
PCI Cumulative Cost
Figure 2.
Mean cumulative medical costs (lines) and mean annual follow-up costs (bars) in 2012 euros, for the PCI 
and CABG groups. CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention. Note 
that the fi rst set of bars represent represents the costs of the index hospitalisation.
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years, however, life expectancy (4.70 vs. 4.60 years) and quality-adjusted life expectancy 
(3.80 vs. 3.76 QALYs) were both greater with CABG than with PCI.
Lifetime Cost-Eff ectiveness - Overall Population
Results from lifetime cost-eff ectiveness analyses are shown in Table 6. Despite reductions 
in annual follow-up costs over the fi rst 5 years of follow-up, patients in the CABG group 
were projected to incur €1929 higher overall healthcare costs over a lifetime horizon. 
Although CABG was only associated with a small gain in life expectancy (0.100 life-years) 
and quality-adjusted life expectancy (0.040 QALY) over the fi rst 5 years of follow-up, 
extrapolation of the observed benefi ts over a lifetime horizon resulted in an increase 
in life expectancy of 0.488 years and an increase in quality-adjusted life expectancy of 
0.358 QALYs with CABG as compared with PCI.
The resulting incremental cost-eff ectiveness ratio (ICER) for CABG vs. PCI was €5390/
QALY gained, with 92.8% of bootstrap replicates falling below a societal willingness-to-
pay threshold of €80000/QALY (Figures 4 and 5, and Table 6/row 1). When outcomes were 
expressed in life-years, CABG was associated an ICER of €3953/life-year gained (Table 
6/row 2). In the analysis accounting for the prognostic impact of non-fatal MI and stroke, 
the benefi t of CABG increased moderately to 0.399 QALYs, and the ICER was €5092/QALY 
Figure 3.
Observed survival through 5 years and predicted survival beyond 5 years for the CABG and PCI groups, 
according to the base case assumptions. CABG, coronary artery bypass grafting; PCI, percutaneous coronary 
intervention.
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gained with 94.2% of bootstrap replicates below a societal willingness-to-pay threshold 
of €80,000 (Figure 5, Table 6/row 4).
Results were robust across a wide range of alternative assumptions regarding the dura-
tion and magnitude of the benefi t of CABG over PCI on both costs and survival beyond 
the 5 year timeframe observed in the trial. Assuming that the benefi ts of CABG would 
remain constant from year 5 to year 10, with no further benefi t beyond 10 years, the 
ICER for CABG vs. PCI was €3505/QALY gained. When we conservatively assumed that 
there would be no benefi t of CABG beyond the 5-year trial period, the ICER increased 
to €8815/QALY gained with 90.7% of the bootstrap replicates below the €80000/QALY 
threshold. Results were similar when the analysis incorporated the prognostic impact of 
non-fatal MI and stroke, or when eff ectiveness was expressed in life-years rather than 
QALYs (Supplementary Tables 6 and 7).
-€10000 
-€5000 
€0 
€5000 
€10000 
-2 -1 0 1 2
 Δ QALYs (CABG-PCI)   
Δ 
Lo
ng
-te
rm
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os
t (
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BG
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p Cost 
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Figure 4.
Joint distribution of projected lifetime incremental costs and quality-adjusted life expectancy for CABG vs. 
PCI based on bootstrap replication of the SYNTAX trial population, plotted on the cost-eff ectiveness plane. 
The red circle represents the estimated mean values (incremental cost=€1929, incremental QALYs=0.358). 
The green line represents the €80000/QALY cost-eff ectiveness threshold. CABG, coronary artery bypass 
grafting; PCI, percutaneous coronary intervention; QALY, quality-adjusted life-year.
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Subgroup Analyses and the Impact of Stent Pricing
Results from the pre-specifi ed subgroup analyses are summarised in Table 7. For most 
subgroups, the results were similar to those of the overall trial population albeit with 
greater uncertainty due to the reduced sample sizes. However, the results in 4 subgroups 
diff ered substantially from those of the overall trial. For patients with less complex coro-
nary anatomy (SYNTAX Score ≤22), PCI was projected to increase quality-adjusted life 
expectancy and to reduce costs compared with CABG. For this subgroup, CABG was only 
economically attractive in 28.7% of the bootstrap replicates at an ICER of €80000/QALY. 
Conversely, for patients with SYNTAX Scores of 23-32 and ≥33, the ICERs for CABG vs. PCI 
were €54475/QALY gained and €1787/QALY gained, respectively.
PCI was an economically dominant strategy for patients with left main CAD, whereas 
CABG was highly economically attractive compared with PCI for patients with three-ves-
sel disease (ICER €1174/QALY gained). For all other subgroups, CABG was economically 
attractive compared with PCI with ICERs <€20,000/QALY gained. Importantly, results for 
the population of patients enrolled in the Netherlands (n = 148) were consistent with 
0%
20%
40%
60%
80%
100%
€0 €50000 €100000 
Base case
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non-fatal events
Pr
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Figure 5.
Cost eff ectiveness acceptability curve of CABG vs. PCI. The probability that CABG is cost-eff ective is calcu-
lated as the proportion of bootstrap-derived estimates falling below a given cost-eff ectiveness threshold 
and is plotted across a range of possible cost-eff ectiveness thresholds. The solid blue line represents the 
base-case analysis, while the dashed red line indicates the analysis in which the impact of MI and stroke 
were taken into account.
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those for the overall population as well. Results for subgroups were unchanged when we 
considered the impact of non-fatal MI and stroke on mortality (Supplementary Table 5).
When stratifi ed according to diff erences in predicted 4-year mortality based on the 
SYNTAX score II, we found that the tool not only discriminates well for 4-year mortal-
ity but also for long-term economic outcomes (Figure 6). For patients in whom PCI was 
estimated to result in better 4-year survival, PCI was also economically dominant. For 
patients in whom CABG was predicted to result in better 4 year survival, CABG was also 
highly economically attractive (ICERs ranging from €2967 to €3737 per QALY gained). 
In the SYNTAX Score II groups where CABG was preferred, the probability that CABG was 
economically dominant ranged from 71.7% to 99.8%.
We also performed a sensitivity analysis varying the acquisition cost of DES (Figure 7). 
Although the ICER for CABG vs. PCI increased as the acquisition cost of DES decreased, 
even at a DES price of €0, the ICER for CABG remained <€20,000/QALY gained in the 
overall population. When this analysis was repeated within strata according to SYNTAX 
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-2 -1 0 1 2
≥2% in favor of PCI 0-2% in favor of PCI 
-2 -1 0 1 2
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-€5000 
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€10000 
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0-2% in favor of CABG 2-5% in favor of CABG ≥5% in favor of CABG 
-2 -1 0 1 2 -2 -1 0 1 2
Figure 6.
Joint distribution of projected lifetime incremental costs and quality-adjusted life expectancy for CABG vs. 
PCI within subgroups stratifi ed according to diff erences in predicted 4-year mortality based on the SYNTAX 
Score II. For each stratum, the red circle represents the estimated mean values. The green line represents 
the €80000/QALY cost-eff ectiveness threshold. Horizontal axes: diff erence in quality-adjusted life years 
(CABG-PCI). CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention.
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Score, only the intermediate SYNTAX Score tertile was sensitive to stent price (Figure 
7 and Supplementary Table 7). For patients with a SYNTAX Score ≤22, the PCI strategy 
remained economically attractive unless the stent price exceeded €1400/stent, while 
for patients with a SYNTAX Score ≥33, CABG remained economically attractive at all stent 
acquisition costs. However, among patients with SYNTAX Scores between 23 and 32, the 
ICER for CABG vs. PCI remained <€80,000/QALY gained only if the DES acquisition cost 
was >€675/stent.
DISCUSSION
This economic substudy of the SYNTAX trial is the fi rst to directly compare long-term 
clinical and economic outcomes of DES-PCI vs. CABG among patients with three-vessel 
or left main CAD from a Dutch healthcare perspective. Our results reveal that initial 
hospitalisation costs were higher with CABG, and these up-front costs were only partially 
off set by improved clinical outcomes and lower resource use utilisation during follow-up. 
Over the fi rst 5 years of follow-up, CABG improved life expectancy and quality-adjusted 
life expectancy (by 0.10 years and 0.040 QALYs, respectively) while increasing costs by 
~€2500 compared with DES-PCI. These in-trial life expectancy results were magnifi ed 
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Figure 7.
Sensitivity analysis of the ICER for CABG vs. PCI as a function of the stent price in the overall population 
and according to the anatomic SYNTAX Score. The green line represents a cost-eff ectiveness threshold of 
€80,000/QALY. The negative ICERs for the low SYNTAX Score population indicate that PCI was economically 
dominant over the full range of stent prices displayed.
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when extrapolated over a patient’s lifetime (0.358 QALYs and 0.488 life years gained with 
CABG vs. DES-PCI), while the cost diff erence narrowed further (~€1900 higher costs with 
CABG vs. DES-PCI). In the base case analysis, the resulting lifetime cost-eff ectiveness 
ratios for CABG vs. DES-PCI were €5390/QALY gained and €3953/life year gained, values 
that are considered highly cost-eff ective from a Dutch perspective. These results were 
robust to a variety of alternative assumptions regarding the duration and magnitude 
of the benefi t of CABG over PCI, stent pricing, and the prognostic impact of non-fatal 
myocardial infarction and stroke.
For most subgroups, the results were similar to those of the overall trial population albeit 
with more uncertainty due to the reduced sample sizes. In patients with a SYNTAX Score 
≤22, however, DES-PCI was associated with a small lifetime gain of 0.004 QALY compared 
with CABG, resulting in an economically dominant position compared with CABG. These 
results suggest that for patients with relatively straightforward 3-vessel or left main CAD, 
DES-PCI might be the preferred revascularization strategy on both clinical and economic 
grounds. In contrast, in the subgroup with highly complex CAD (SYNTAX Score ≥32), CABG 
was strongly favoured on clinical and economic grounds (1.109 QALY gain, €1982 higher 
costs compared with DES-PCI). In the intermediate SYNTAX Score group, CABG was as-
sociated with a small 0.049 QALY gain, surrounded by large uncertainty. We also found 
that by incorporating both clinical and anatomic factors, the SYNTAX Score II can be a 
valuable discriminator of health care value for patients with complex CAD.
While device prices are often perceived to be an important driver of cost-eff ectiveness,27 
our results were not sensitive to the stent price. Indeed, the major determinant of cost-
eff ectiveness in our DES-PCI vs. CABG comparison was the gain in (quality-adjusted) life 
expectancy rather than the cost diff erence. Therefore, we found no device cost at which 
DES-PCI would have been an economically attractive treatment option in the overall 
population, or in patients with a SYNTAX Score ≥32. Only in the intermediate SYNTAX 
Score group did stent price aff ect the ICER materially; indeed, for that subgroup, reducing 
the stent price by ~25% from current levels would make DES-PCI the preferred treatment 
option on economic grounds.
Role of the SYNTAX Score II
Our paper is the fi rst to examine the economic implications of the SYNTAX Score II. The 
SYNTAX Score II was recently introduced to provide an objective, evidence-based tool 
to enhance individualized decision-making for patients with complex CAD.10 This score 
predicts 4-year mortality with PCI or CABG and was constructed using both anatomical 
predictors (i.e. the anatomical SYNTAX Score) and clinical factors including age, gender, 
renal function, left ventricular ejection fraction, chronic obstructive pulmonary disease 
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and peripheral vascular disease. In this analysis, we found that selecting patients for PCI 
vs. CABG based on 4-year mortality projections leads to treatment decisions that are 
both clinically and economically attractive.
Comparison with Previous Studies
Our results are remarkably diff erent from the cost-eff ectiveness of DES-PCI vs. CABG 
based on the 1-year SYNTAX data.28 In that early analysis, DES-PCI was associated with 
a small QALY gain and ~$3600 lower costs, suggesting that DES PCI was economically 
dominant compared with CABG. In the current study however, quality-adjusted life ex-
pectancy was higher with CABG such that the surgical option was highly cost-eff ective for 
most patients despite higher short- and long-term costs. This discrepancy between the 
1-year and lifetime cost-eff ectiveness of DES-PCI and CABG, emphasizes the importance 
of basing policy decisions on trials with long-term follow-up in order to capture benefi ts 
that emerge at later time points.
To date, few studies on the cost-eff ectiveness of CABG vs. PCI have been performed from 
a European country perspective.9 The economic substudy of the Arterial Revasculariza-
tion Therapy Study (ARTS) found that after 3-year follow-up CABG was associated with 
€1798 higher costs than PCI using bare metal stents, but did not use QALYs to express 
benefi ts and did not project their fi ndings over a lifetime horizon.29 Recently, a small 
(n = 199) observational study applied an Austrian healthcare perspective to assess the 
cost-eff ectiveness of CABG vs. DES-PCI. They found that CABG was associated with €5400 
higher costs at 5-years, leading to an ICER of €45615 per death, myocardial infarction, 
stroke or repeat revascularization avoided.30 Although results were not expressed in 
euros/QALY, similar to our results, the ICER (expressed in cost per event avoided) was 
more favourable for CABG in those subgroups with a higher SYNTAX Score.
Country-Specifi city of Cost-Eff ectiveness Results
There are many reasons why cost-eff ectiveness results may vary across countries, in-
cluding diff erences in severity of disease, epidemiological context, healthcare system 
characteristics, clinical practice patterns, and diff erent prices for resources and labour. 
Therefore guidelines for economic evaluations strongly recommend the application of 
local costing methodology.16, 31, 32 It is nonetheless instructive to compare the results of 
the current Dutch perspective analysis with those from the recently published US per-
spective analysis.33 Although costs, EQ-5D utilities, and calibration factors for the lifetime 
model diff ered, the overall results of the 2 studies are nonetheless quite similar. In the 
US analysis, the base case ICER for CABG vs. DES-PCI was $16,537/QALY gained, a result 
that corresponds (after application of purchasing power parity conversion factors34) to 
€10569/QALY gained from a Dutch perspective. Some diff erences in the ICERS are to 
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be expected since purchasing power parities are generic conversion factors that are not 
tailored to highly specifi c analyses of any specifi c procedure or treatment as performed 
in this study.
Limitations
This study has several limitations. Although the SYNTAX trial enrolled patients from 18 
countries, the current analysis was performed from a Dutch healthcare perspective. Al-
though we were careful to assign costs at levels of resource utilization that were unlikely 
to diff er by country, this was not possible for length of stay. We therefore used regression 
modeling to adjust length of stay at the individual country level to Dutch norms. Follow-
ing existing recommendations for economic analyses alongside multinational trials, all 
clinical outcomes were assumed to be similar across countries.35 Restricting our analysis 
to Dutch patients only would have severely reduced our sample size and increased 
uncertainty in the results. Nonetheless, it is reassuring that our results were very similar 
when restricted to only Dutch trial participants.
In addition, our study was limited by the need to extrapolate results from 5-years to a 
lifetime horizon, necessitating assumptions with respect to the impact of CABG on long-
term survival, quality-of-life and healthcare costs. We used all possible data from the 
trial to inform these extrapolations and varied assumptions in sensitivity analyses, which 
produced similar results as our base case analysis. Finally, DES-PCI was performed using 
fi rst generation (paclitaxel-eluting) DES. Therefore, our results may not be generalisable 
to settings where second generation DES are used. However, to date, there is no evidence 
that these newer generation stents reduce mortality compared with paclitaxel eluting 
stents.36
Conclusions
In the SYNTAX trial, the largest randomized comparison between CABG and DES-PCI in 
a broad population of patients with three-vessel or left main disease, we found that 
CABG is an economically attractive revascularization strategy compared with DES-PCI. 
However, among patients with anatomically less complex disease, DES-PCI appears to 
be preferred on both clinical and economical grounds. Finally, we found that the newly 
developed SYNTAX Score II is a useful discriminator of economic value for revascularisa-
tion decisions, providing further support for its incorporation in both clinical guidelines 
and economic policies.
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Supplementary Table 1. Linear Regression Model for the Prediction of Post-Procedural Length of Stay 
after Revascularization
Model variable CABG (n=870) PCI (n=896)
Intercept 10.2 3.42
Demographics
Age≥80 years 2.63 -
Female 0.60
Co-morbidities
Congestive heart failure 3.30 4.79
COPD - -
Chronic renal failure, without dialysis - 8.24
Gastrointestinal bleed or peptic ulcer disease - 3.17
Complications
Death 5.11 −4.49
MI 0.57 1.83
Major vascular complications 5.54 0.57
Additional PCI 6.34 2.52
Additional CABG - 7.85
Pacemaker insertion 9.81 18.86
Post-operative atrial fi brillation 2.84 −1.00
Post-operative infection 3.29 14.08
Post-operative ventricular arrhythmia - 3.27
Renal failure 5.04 1.27
Respiratory failure 1.84 -
Stroke 3.91 31.7
Cardiogenic shock - 8.85
Cardiac tamponade - −3.49
Transfusion - 4.42
CABG, coronary artery bypass grafting; PCI, percutaneous coronary intervention
Supplementary Table 2. EQ-5D Utility Scores by Treatment Assignment
Time Point CABG PCI p-value
Baseline 0.693 ± 0.240 [0.729] 0.708 ± 0.242 [0.775]
1 month 0.737 ± 0.217 [0.807] 0.829 ± 0.198 [0.843] <0.001
6 months 0.823 ± 0.191 [0.843] 0.840 ± 0.189 [0.843] 0.13
12 months 0.826 ± 0.201 [0.843] 0.832 ± 0.197 [0.843] 0.89
36 months 0.827 ± 0.204 [0.843] 0.821 ± 0.207 [0.843] 0.55
60 months 0.824 ± 0.213 [0.843] 0.822 ± 0.216 [0.843] 0.95
Values in brackets are medians. CABG, coronary artery bypass graft; PCI, percutaneous coronary interven-
tion. P-values are derived from ANCOVA, adjusted for baseline.
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Supplementary Table 3. Regression Model developed from SYNTAX Follow-Up Cost for the Prediction 
of Long-Term Costs
Parameter Coeffi  cient Estimate (€) p-value
Intercept 771 0.11
CABG −348 0.006
Age 10 0.12
Male −169 0.27
SYNTAX Score 23-32 −361 0.02
SYNTAX Score ≥33 −168 0.28
Left main disease 326 0.01
Peripheral vascular disease 1878 <0.001
Myocardial Infarction during trial 2524 <0.001
Stroke during trial 1705 <0.001
Supplementary Table 4. Regression Model developed from SYNTAX Follow-Up Utility Data for the Pre-
diction of Long-Term Utility Weights
Parameter Coeffi  cient Estimate p-value
Intercept 0.75337 <0.001
Male 0.10223 <0.001
SYNTAX Score 23-32 0.00277 0.613
SYNTAX Score ≥33 −0.01283 0.02
History of Stroke −0.02335 0.006
Peripheral vascular disease −0.04119 <0.001
Carotid artery disease −0.03535 <0.001
Myocardial Infarction during trial −0.01307 0.2402
Stroke during trial −0.08268 <0.001
267
Chapter 12. Dutch Cost-Eff ectiveness of PCI versus CABG
12
Su
pp
le
m
en
ta
ry
 T
ab
le
 5
. L
if
et
im
e 
Co
st
-E
ff 
ec
ti
ve
ne
ss
 R
es
ul
ts
, i
nc
or
po
ra
ti
ng
 th
e 
Im
pa
ct
 o
f 
M
I a
nd
 S
tr
ok
e
Co
st
, €
Q
AL
Ys
IC
ER
 (€
/Q
AL
Y)
%
D
om
in
an
t
%
D
om
in
at
ed
%
 <
€8
0K
CA
BG
PC
I
∆ 
(C
AB
G
-P
CI
)
(9
5%
 C
I)
CA
BG
PC
I
∆ 
(C
AB
G
-P
CI
)
(9
5%
 C
I)
Ba
se
 c
as
e 
lif
et
im
e 
an
al
ys
is
 (n
=1
76
6)
37
82
7
35
79
6
20
31
 (3
57
, 3
49
9)
11
.6
77
11
.2
79
0.
39
9 
(−
0.
06
2,
 0
.8
00
)
50
92
0.
8
4.
6
94
.2
LM
 d
is
ea
se
 (n
=6
94
)
39
85
3
36
64
1
32
12
 (7
42
, 6
15
5)
10
.9
07
11
.3
50
−0
.4
43
 (−
1.
12
2,
 0
.4
30
)
PC
I d
om
in
an
t
0.
1
79
.8
16
.8
Th
re
e-
ve
ss
el
 d
is
ea
se
, n
o 
LM
 (n
=1
07
2)
36
45
5
35
25
7
11
99
 (−
92
0,
 3
18
3)
12
.1
66
11
.2
33
0.
93
3 
(0
.2
83
, 1
.3
06
)
12
84
0.
1
14
.8
99
.8
SY
N
TA
X 
Sc
or
e 
≤2
2 
(n
=5
62
)
38
90
7
37
24
5
16
62
 (−
16
60
, 4
70
1)
12
.4
00
12
.3
50
0.
05
0 
(−
0.
98
9,
 0
.6
18
)
33
23
1
5.
9
52
.6
33
.0
SY
N
TA
X 
Sc
or
e 
23
-3
2 
(n
=6
00
)
36
10
8
33
53
8
25
70
 (−
32
8,
 5
30
7)
11
.3
42
11
.2
56
0.
08
6 
(−
0.
59
6,
 0
.9
51
)
29
96
9
2.
7
30
.8
65
.5
SY
N
TA
X 
Sc
or
e 
≥3
3 
(n
=5
95
)
38
64
9
36
59
5
20
54
 (−
67
6,
 4
62
3)
11
.3
66
10
.2
27
1.
13
9 
(0
.3
86
, 1
.7
76
)
18
03
6.
4
0.
1
99
.8
D
iff
 e
re
nc
e 
in
 4
 y
ea
r p
re
di
ct
ed
 m
or
ta
lit
y 
(S
YN
TA
X 
Sc
or
e 
II)
 
≥2
%
 in
 fa
vo
r o
f P
CI
 (n
=2
81
)
35
74
4
35
84
6
−1
02
 (-
46
62
, 4
57
8)
7.
99
1
9.
26
5
−1
.2
73
 (-
2.
48
7,
 0
.1
38
)
PC
I d
om
in
an
t
1.
3
48
.4
3.
6
 
0-
2%
 in
 fa
vo
r o
f P
CI
 (n
=2
35
)
37
12
4
33
90
9
32
15
 (-
12
86
, 7
86
2)
11
.4
20
12
.3
67
−0
.9
47
 (-
2.
81
6,
 0
.5
64
)
PC
I d
om
in
an
t
0.
5
80
.5
12
.4
 
0-
2%
 in
 fa
vo
r o
f C
AB
G
 (n
=4
67
)
34
85
4
33
96
5
88
9 
(-
15
06
, 3
56
0)
13
.9
81
13
.6
89
0.
29
1 
(-
0.
59
7,
 1
.2
68
)
30
55
18
.0
14
.1
81
.3
 
2-
5%
 in
 fa
vo
r o
f C
AB
G
 (n
=3
20
)
39
77
9
36
79
0
29
89
 (-
11
18
, 6
70
5)
13
.4
70
12
.6
80
0.
79
0 
(-
0.
37
5,
 1
.2
94
)
37
83
6.
5
10
.5
86
.7
 
≥5
 in
 fa
vo
r o
f C
AB
G
 (n
=4
63
)
40
70
4
37
74
8
29
56
 (-
30
1,
 6
90
8)
9.
71
9
8.
70
8
1.
01
1 
(0
.3
56
, 2
.0
02
)
29
23
3.
3
0.
3
99
.7
C
AB
G
, c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
ti
ng
; C
I, 
co
nfi
 d
en
ce
 in
te
rv
al
; I
C
ER
, i
nc
re
m
en
ta
l c
os
t-
eff
 e
ct
iv
en
es
s 
ra
ti
o;
 L
M
, l
ef
t 
m
ai
n;
 P
C
I, 
pe
rc
ut
an
eo
us
 c
or
on
ar
y 
in
te
rv
en
ti
on
; Q
AL
Y,
 
qu
al
it
y-
ad
ju
st
ed
 li
fe
-y
ea
r g
ai
ne
d.
 C
os
ts
 a
re
 d
is
co
un
te
d 
at
 4
%
, l
ife
-y
ea
rs
 a
nd
 Q
AL
Ys
 a
t 1
.5
%
 p
er
 y
ea
r.
Part III. Coronary Revascularization
268
Su
pp
le
m
en
ta
ry
 T
ab
le
 6
. L
if
et
im
e 
Co
st
-E
ff 
ec
ti
ve
ne
ss
 R
es
ul
ts
 fo
r B
as
e 
Ca
se
 a
nd
 S
en
si
ti
vi
ty
 A
na
ly
se
s,
 e
xp
re
ss
ed
 in
 T
er
m
s 
of
 C
os
t p
er
 L
if
e 
Ye
ar
 g
ai
ne
d 
(i
ns
te
ad
 o
f Q
A
LY
)
Co
st
, €
LY
s
IC
ER
 (€
/L
Y)
%
D
om
in
an
t
%
D
om
in
at
ed
%
<€
80
K
CA
BG
PC
I
∆ 
(C
AB
G
-P
CI
)
(9
5%
 C
I)
CA
BG
PC
I
∆ 
(C
AB
G
-P
CI
)
(9
5%
 C
I)
Ta
pe
re
d 
CA
BG
 e
ff 
ec
t b
et
w
ee
n 
5 
an
d 
10
 y
Li
fe
-y
ea
rs
 in
st
ea
d 
of
 Q
AL
Ys
38
16
4
36
23
5
19
29
 (2
52
, 3
59
1)
14
.3
59
13
.8
71
0.
48
8 
(−
0.
05
2,
 0
.9
71
)
39
53
1.
3
3.
4
96
.3
U
nd
is
co
un
te
d 
co
st
 a
nd
 Q
AL
Ys
38
16
4
36
23
5
19
29
 (2
52
, 3
59
1)
17
.0
14
16
.4
04
0.
60
9 
(−
0.
04
2,
 1
.2
00
)
31
67
7.
6
2.
5
96
.6
In
co
rp
or
at
e 
eff
 e
ct
 o
f M
I a
nd
 S
tr
ok
e
37
82
7
35
79
6
20
31
 (3
57
, 3
49
9)
14
.2
22
5
13
.6
89
9
0.
53
3 
(0
.0
30
, 1
.2
64
)
38
11
0.
8
2.
7
96
.8
Fi
xe
d 
CA
BG
 e
ff 
ec
t b
et
w
ee
n 
5 
an
d 
10
 y
Li
fe
-y
ea
rs
 in
st
ea
d 
of
 Q
AL
Ys
37
82
3
36
23
5
15
88
 (−
11
8,
 3
29
6)
14
.4
75
13
.8
71
0.
60
4 
(−
0.
08
7,
 1
.2
08
)
26
29
3.
7
3.
4
96
.2
U
nd
is
co
un
te
d 
co
st
 a
nd
 L
Ys
37
82
3
36
23
5
15
88
 (−
11
8,
 3
29
6)
17
.1
59
1
16
.4
04
4
0.
75
5 
(−
0.
08
8,
 1
.4
90
)
21
03
14
.8
1.
7
96
.6
In
co
rp
or
at
e 
eff
 e
ct
 o
f M
I a
nd
 S
tr
ok
e
37
49
2
35
79
6
16
95
 (−
29
, 3
20
8)
14
.3
40
13
.6
90
0.
65
0 
(−
0.
03
6,
 1
.2
35
)
26
08
2.
6
3.
0
96
.6
N
o 
eff
 e
ct
 o
f C
AB
G
 b
ey
on
d 
5 
y
Li
fe
-y
ea
rs
 in
st
ea
d 
of
 Q
AL
Ys
38
55
0
36
23
5
23
15
 (6
41
, 3
97
5)
14
.2
42
13
.8
71
0.
37
1 
(−
0.
03
2,
 0
.7
46
)
62
40
0.
3
3.
2
95
.4
U
nd
is
co
un
te
d 
co
st
 a
nd
 L
Ys
37
82
3
36
23
5
15
88
 (−
11
8,
 3
29
6)
16
.8
70
16
.4
04
0.
46
6 
(−
0.
01
6,
 0
.9
31
)
34
08
2.
7
2.
8
96
.1
In
co
rp
or
at
e 
eff
 e
ct
 o
f M
I a
nd
 S
tr
ok
e
38
20
5
35
79
6
24
09
 (7
79
, 3
85
4)
14
.1
03
9
13
.6
89
9
0.
41
4 
(0
.0
17
, 0
.7
87
)
58
19
0.
1
2.
0
96
.9
C
AB
G
, c
or
on
ar
y 
ar
te
ry
 b
yp
as
s 
gr
af
ti
ng
; C
I, 
co
nfi
 d
en
ce
 in
te
rv
al
; I
C
ER
, i
nc
re
m
en
ta
l c
os
t-
eff
 e
ct
iv
en
es
s 
ra
ti
o;
 P
C
I, 
pe
rc
ut
an
eo
us
 c
or
on
ar
y 
in
te
rv
en
ti
on
; L
Y,
 q
ua
lit
y-
ad
ju
st
ed
 
lif
e-
ye
ar
 g
ai
ne
d.
 C
os
ts
 a
re
 d
is
co
un
te
d 
at
 4
%
, l
if
e-
ye
ar
s 
an
d 
Q
AL
Ys
 a
t 1
.5
%
 p
er
 y
ea
r.
269
Chapter 12. Dutch Cost-Eff ectiveness of PCI versus CABG
12
Supplementary Table 7. Sensitivity Analysis on Stent Price in Overall Population and SYNTAX Score
Population
Base case with 
stent price of 
€935
Required stent price 
at which the ICER of 
CABG vs. PCI equals 
€80,000/QALY 
gained
Interpretation of sensitivity 
analysis (other things equal)
Overall (n=1766)
CABG 
economically 
attractive
€ −4209
Stent price does not infl uence 
economic attractiveness
SYNTAX Score ≤22 (n=562) PCI dominant € 1400
Stent price above this threshold 
will make PCI economically 
unattractive*
SYNTAX Score 23-32 (n=600)
CABG 
economically 
attractive
€ 675
Stent price below this threshold 
would make PCI economically 
attractive
SYNTAX Score ≥33 (n=595)
CABG 
economically 
attractive
€ −18340
Stent price does not infl uence 
economic attractiveness
* because of the small diff erence in QALYs between CABG and PCI, the ICER in the low SYNTAX Score group 
is strongly depending on the diff erence in costs.
CABG, coronary artery bypass grafting; ICER, incremental cost-eff ectiveness ratio; PCI, percutaneous coro-
nary intervention; QALY, quality-adjusted life-year gained.
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ABSTRACT
Background
Although more than 200,000 bypass operations are performed in the U.S. annually, little 
data exist on the predictors of costs and resource use for this procedure. Questions 
related to clinical outcomes, costs and resource use in coronary artery bypass grafting 
(CABG) were addressed.
Methods
In a multi-institutional statewide database, patient level data from 42,839 patients 
undergoing isolated CABG were combined with cost data. After adjusting for cost-to-
charge ratios and infl ation, the association of length of stay and costs with the Society of 
Thoracic Surgeons-Predicted Risk of Mortality (STS-PROM) was analyzed. Patients were 
randomly divided into a development (60%) and validation (40%) cohort. Regression 
models were developed to analyze the impact of patient characteristics, comorbidities 
and complications on post-operative length of stay and total costs.
Results
Post-operative length of stay and total direct costs for CABG averaged 6.9 days and 
$38,847. Length of stay and costs increased from 5.4 days and $33,275 in the lowest 
risk decile (mean STS-PROM of 0.6%) to 13.8 days and $69,122 in the highest risk decile 
(mean STS-PROM 19%). Compared with complications, patient characteristics had little 
impact on length of stay and costs. Upon validation, the models that combined pre- and 
post-operative variables explained variance better (R2 = 0.51 for length of stay; R2 = 0.47 
for costs) and were better calibrated than the pre-operative models (R2 = 0.10 for length 
of stay; R2 = 0.14 for costs).
Conclusions
The STS-PROM and pre-operative regression models are useful for pre-operative predic-
tion of costs and length of stay for groups of patients, case-mix adjustment in hospital 
benchmarking, and pay-for-performance measures. The combined pre- and post-opera-
tive models identify incremental costs and length of stay associated with complications 
and are more suitable for prioritizing quality improvement eff orts.
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INTRODUCTION
Health care expenditures have increased substantially over the past decades and policy 
makers try to maintain costs with various measures such as the Aff ordable Care Act. 
With the increasing emphasis on effi  cient medical practice, cardiac surgeons, operating 
room managers and hospital administrators need to know the implications and predic-
tive power of patient characteristics, comorbidities, and complications on the costs and 
resource use of open heart surgery. Such information is helpful in planning resource use 
and can be used for prioritizing quality improvement eff orts in high-volume procedures. 
With almost 1100 procedures per million American adults, coronary artery bypass graft-
ing (CABG) is among the most common performed operations in the world and accounts 
for more resources expended in cardiovascular medicine than any other single surgical 
procedure.1 Little data exist on the predictors of the costs and resource use associated 
with this procedure.
In this study, clinical data were combined with patient-specifi c costs for CABG in the 
Commonwealth of Virginia. Three questions were addressed related to clinical outcomes, 
costs and resource use. First of all, what are the mean direct costs and length of stay as-
sociated with CABG and how is this aff ected by the predicted risk of operative mortality? 
Second, how do patient characteristics and specifi c comorbidities infl uence the length 
of stay and direct costs of patients undergoing CABG? And lastly, what is the impact of 
post-procedural complications on length of stay and total directs costs?
PATIENTS AND METHODS
Study Population
The clinical records of patients undergoing cardiac surgery were prospectively collected 
in the Virginia Cardiac Surgery Quality Initiative (VCSQI) database. For this project, all 
isolated, CABGs between January 2003 and April 2013 were selected.
VCSQI is a voluntary consortium of 17 cooperating cardiac surgery centers in the Com-
monwealth of Virginia.2 The aim of the collaboration is to improve the quality of cardiac 
surgical care, while controlling costs. The database captures 99% of all cardiac surgical 
procedures in the state. VCSQI members contributed their data to The Society of Tho-
racic Surgeons (STS) Adult Cardiac Database. Each of VCSQI’s hospital members agreed 
in advance to share de-identifi ed patient data for secondary research purposes. This 
investigation was exempt from formal institutional board review at each participating 
center because it represents a secondary analysis of the VCSQI data registry in absence 
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of Health Insurance Portability and Accountability Act patient identifi ers. Business As-
sociates Agreements are in place between VCSQI, its 17 member hospitals, and database 
vendor (ARMUS Corporation, San Mateo CA).
Clinical Data
Clinical data consisted of all the data routinely collected in the STS database. Post-opera-
tive outcomes included death, stroke, renal failure, atrial fi brillation, deep sternal wound 
infection, permanent stroke, prolonged ventilation, and reoperations for bleeding, graft 
occlusion and other reasons, all defi ned according to the STS database defi nitions.3 In-
hospital death was defi ned as death within 30 days after discharge or within the hospital. 
Pre-operative risk was assessed with the STS-predicted risk of mortality (STS-PROM). Each 
institution was accountable for coding and submitting its data to VCSQI’s repository and 
agreed on the defi nitions, data collection, and timely submission.
Cost and Length of Stay Data
The process of combining clinical and fi nancial data in the VCSQI database has been 
described elsewhere.4, 5 Briefl y, STS patient records were matched with uniform billing 
(UB) discharge records, which are used by institutional health care providers throughout 
the U.S. The UB-04 form replaced its predecessor UB-92 in 2007 and represents the 
patient’s fi nal bill. Charges for all of the ICD-9 (International Classifi cation of Diseases, 9th 
revision) revenue codes were grouped into 20 logical cost categories (see list in the Ap-
pendix). Since charges refl ect institutional pricing decisions and other factors unrelated 
to resource use, we applied cost-to-charge ratios. These ratios were yearly updated and 
specifi c for each participating institution and category within that institution. The total 
costs estimate was the sum of all 20 categories. The medical care service component of 
the U.S. consumer price index was used to convert all costs to U.S. dollars for the year 
2013.6
Statistical Analysis
The total cohort consisted of 42,839 patients. Patients were randomly divided into a 
model development (60%) or model validation (40%) cohort. The two cohorts were 
analyzed for diff erences in baseline characteristics, clinical outcomes, and length of 
stay. Variables were tested for normality using the Kolmogorov-Smirnov test; normally 
distributed variables were compared using t-tests for numerical variables and using chi-
squared tests for categorical variables.
Multiple linear regression models with total hospital costs or post-operative length 
of stay as the dependent variable were built. Separate models were developed: the 2 
pre-operative models included only independent variables that were known before the 
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procedure, whereas the 2 combined models incorporated not only the pre-operative 
variables, but also outcomes of the procedure, including complications and in-hospital 
mortality. Given the iterative modeling process and the large number of variables includ-
ed, only those variables that were signifi cant with a p ≤ 0.01 were retained in the models. 
Additionally, the variables age, gender, and race were forced into the models. Regressions 
were estimated in log and linear form, and reported in linear form, since there were no 
substantial diff erences in the results and linear regression coeffi  cients are more easily 
interpretable. Performance of the models was assessed using the R2 in the development 
cohort and by calibration plots in the validation cohort. Trends in plots were presented 
using polynomials fi tted on the entire dataset. Analyses were performed with Excel 2010 
(Microsoft, Redmond, WA, USA) and SPSS version 20.0.0 (SPSS, Chicago, IL).
RESULTS
Patient Characteristics, Clinical Outcomes and Costs
Patient characteristics, risk factors, and complications for the development and valida-
tion cohort are presented in Table 1. Most CABGs were performed on males that were 
Table 1. Variables in the Development and Validation Cohort
Description Development
(n=25,631)
Validation
(n=17,208)
p-value
Age, yr 64.0±10.7 64.0±10.6 0.70
Male sex 73.7 73.8 0.82
STS-PROM 2.16±3.5 2.19±3.9 0.49
STS-PROMM 13.8±10.5 13.8±10.7 0.93
Race, %
 Caucasian
 African American
 Hispanic
 Asian
 Native American
 Other
81.4
14.0
0.9
2.3
0.1
1.3
81.8
13.4
0.8
2.5
0.2
1.5
0.04
Body mass index, kg/m2 29.4±5.8 29.3±5.6 0.06
Heart failure ≤2 weeks before, % 12.0 12.0 0.99
Renal failure requiring dialysis, % 2.3 2.3 0.78
Creatinine, mg/dl 1.20±1.0 1.19±1.0 0.77
Left ventricular ejection fraction (SD) 51.3±12.4 51.3±12.5 0.52
Chronic lung disease, %
 No
 Mild
 Moderate
 Severe
82.6
10.0
4.9
2.4
82.1
10.1
5.1
2.7
0.21
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Table 1. Variables in the Development and Validation Cohort (continued)
Description Development
(n=25,631)
Validation
(n=17,208)
p-value
Cerebrovascular Disease, % 13.6 13.2 0.24
Pre-operative cardiogenic shock, % 1.6 1.6 0.84
Urgency status, %
 Elective
 Urgent
 Emergent
41.7
54.6
3.7
41.1
55.3
3.5
0.24
On inotropic medication, % 1.6 1.6 0.72
Arrhythmia, % 7.5 7.4 0.93
Myocardial infarction ≤21 days, % 28.9 29.2 0.49
Peripheral arterial disease, % 13.7 13.6 0.46
Hypertension, % 81.1 81.8 0.10
Diabetes Mellitus, % 39.7 39.4 0.52
Immunocompromised status, % 2.1 2.0 0.53
Previous CABG, % 3.1 3.3 0.23
Previous valve operation, % 0.2 0.3 0.15
Previous PCI, % 18.6 18.7 0.82
No. of diseased vessels, %
 One
 Two
 Three
4.3
17.8
77.9
4.4
17.2
78.4
0.45
IABPe, %
 None
 Pre-operative
 Intraoperative
 Post-operative
91.5
7.1
1.2
0.2
91.8
6.7
1.2
0.2
0.40
Post-operative length of stay, days 6.9±7.3 6.9±.6.7 0.32
Total length of stay, days 9.3±8.1 9.3±7.7 0.84
Post-operative ventilation >24 hours, % 9.3 9.4 0.71
Post-operative renal failure, % 3.5 3.5 0.95
Post-operative pneumonia, % 2.9 2.8 0.47
Post-operative atrial fi brillation, % 17.6 16.8 0.04
Post-operative stroke, % 1.3 1.4 0.47
Post-operative deep sternal wound infection, % 0.5 0.3 0.11
Reoperation bleeding, % 1.7 1.8 0.48
Reoperation other cardiac reasons, % 0.7 0.8 0.42
Reoperation non-cardiac reasons, % 2.0 2.0 0.56
In-hospital mortality, % 1.7 1.8 0.32
In-hospital mortality or morbidity, % 14.4 14.5 0.93
Data defi ned as mean±SD, or % of patients. IABP, intra-aortic balloon pump; SD, standard deviation; STS-
PROM, Society of Thoracic Surgeons-Predicted Risk of Mortality; STS-PROMM, Society of Thoracic Surgeons-
Predicted Risk of Mortality or Morbidity; yr, years.
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>60 years old. Atrial fi brillation, prolonged ventilation, renal failure and pneumonia 
were the most common post-operative complications (17.2%, 9.3%, 3.5% and 2.9%, 
respectively). There were no clinically important diff erences in patient characteristics, 
comorbidities or outcomes between the development and validation cohorts.
Mean length of stay and total direct costs for CABG averaged 6.9 days and $38,847, 
respectively. Length of stay and costs increased from 5.4 days and $33,275 in the lowest 
risk decile (mean STS-PROM of 0.6%) to 13.8 days and $69,122 in the highest risk decile 
(mean STS-PROM 19%; Figure 1). In lower risk patients, length of stay and costs show a 
similarly increasing trend. In higher risk patients, however, costs increase more rapidly 
than length of stay.
Length of Stay Regression Models
Multivariable regression results for length of stay are reported in Figure 2A. Of the 
pre-operative patient characteristics and comorbidities, only 4 out of 30 possible de-
mographic and clinical factors increased length of stay with ≥2 days. A previous valve 
operation, pre-operative cardiogenic shock, urgent status, and inotropic medication are 
independently associated with the highest additional length of stay after CABG in the 
pre-operative model (3.10, 2.49, 2.42 and 2.18 additional days, respectively). In the 
combined model, predominantly the post-operative complications were associated with 
considerably longer hospital stay. In this model, the pre-operative variables had either 
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Figure 1. Total Costs and Length of Stay after Isolated CABG according to STS Score
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CABG, coronary artery bypass grafting; STS, Society of Thoracic Surgeons.
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a small impact or failed to be statistically signifi cant predictors of length of stay. Re-
operation for non-cardiac reasons, deep sternal wound infection, and pneumonia were 
independently associated with the highest additional days in the hospital (12.81, 11.77, 
and 7.61 additional days, respectively).
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Figure 2. Regression Covariates for Isolated CABG
Multivariable regression results for total costs (A) and length of stay after the procedure (B).
Reference categories are: Caucasian race; no lung disease; elective surgery; one vessel disease; no IABP.
BMI; body mass index; CABG, coronary artery bypass grafting; DM, diabetes mellitus; DSWI, deep sternal 
wound infection; fi b, fi brillation; IABP, intra-aortic balloon pump; LVEF, left ventricular ejection fraction; 
MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; Postop, 
post-operative; Reop, reoperation; yr, years.  * defi ned as death within 30 days after discharge or within 
the hospital.
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Cost Regression Models
Multivariable regression results for costs are reported in Figure 2B. With respect to the 
cost prediction models, we observed several relationships similar to those for length of 
stay. Although a variety of pre-operative variables was associated with higher hospital 
costs, these variables had a smaller impact when also post-operative complications were 
taken into account. Pre-operative cardiogenic shock, a previous valve operation and se-
vere lung disease were independently associated with the highest additional costs after 
CABG in the pre-operative model (additional costs $14,114, $11,597, and $11,376, re-
spectively). For the combined model, complications that were independently associated 
with the highest additional costs were reoperation for non-cardiac reasons, prolonged 
ventilation, pneumonia, and deep sternal wound infection ($37,315, $23,127, $21,964, 
and $19,222 respectively). Except for mortality, which was associated with $4,449 higher 
costs but 3.64 fewer days in the hospital, there is a large overlap in predictors between 
the length of stay and cost regression models.
Validation
The R2 values of the models that only considered pre-operative variables were lower 
(0.10 and 0.14 for length of stay and costs, respectively) than the R2 coeffi  cients for 
models that considered both pre-operative and post-operative variables (0.51 and 0.47 
for length of stay and costs, respectively). As expected, the explanatory power of the 
post-operative models was higher, but a 4- to 5-fold increase in R2 is perhaps surprising. 
This suggests that although patient characteristics and comorbidities are important, they 
are generally not the major drivers of hospital stay and costs.
In the validation cohort, all models showed that they were well calibrated (Figure 3). 
The absolute diff erence between observed and predicted length of stay was small across 
deciles (range 0.0005-0.51 and 0.03-1.02 days for the pre-operative and combined 
model, respectively). Similarly, the diff erence between predicted and observed costs 
was small ($347-$5100 and $10-$5227 for the pre-operative and combined model, 
respectively). The combined models were slightly better calibrated as they were more 
consistent with the calibration line (Figure 3).
DISCUSSION
The current study found that the costs (mean $38,847) and post-operative length of 
stay (mean 6.9 days) associated with CABG are considerable. Length of stay and costs 
increased from 5.4 days and $33,275 in the lowest risk decile (mean STS-PROM of 0.6%) 
to 13.8 days and $69,122 in the highest risk decile (mean STS-PROM 19%). To assess 
how patient characteristics and specifi c comorbidities infl uence the length of stay and 
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direct costs of patients undergoing CABG, 2 length of stay and 2 cost-prediction models 
for patients undergoing CABG were presented. The pre-operative models were based 
on patient characteristics and comorbidities known before the procedure; the combined 
models also incorporated outcomes, complications, and in-hospital mortality. Validation 
of the models showed that the combined models had 4-5 times more explanatory power 
but calibration was reasonable in both pre-operative and combined models.
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Figure 3. Calibration Plot for Pre-operative and Post-operative Cost (A) and Length of Stay (B) Predic-
tion Models
The green and dashed orange lines represent polynomial trend curves. Error bars represent the standard 
error of the mean costs of the observed costs (A) or length of stay (B).
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The advantage of the current models is that it presents post-operative hospital length 
of stay as a continuous variable. Other studies built prediction models only for intensive 
care stay,5, 7-10 and categorized their outcome as ‘standard’ versus ‘prolonged’, using 
diff erent defi nitions. Despite inconsistencies in defi nitions, variables describing renal 
function, critical pre-operative state, ejection fraction, inotropic support, and emergen-
cies are important predictors for prolonged intensive care stay. The importance of these 
predictors is consistent with our models for the prediction of post-operative length 
of stay.
Few other studies have identifi ed predictors of total hospital costs after cardiac sur-
gery.11-15 One large retrospective study used Medicare Provider Analysis and Review 
fi le data and found a mean cost of $32,201 for CABG in more than 100,000 patients in 
2005,11 but solely focused on the incremental costs of post-operative outcomes. Another 
study found that both pre-operative and intraoperative variables were predictors of costs 
in cardiac surgical patients. A model based on pre-operative parameters alone could 
not explain a reasonable proportion of costs. However, the study consisted of only 201 
patients and the fi nancial data seem to be based on charges instead of costs.13 Riordan 
and colleagues concluded from their single center study based on of 628 CABG patients 
from 1997 that contemporary surgical risk models based on pre-operative data were not 
suitable for cost prediction in individual patients.12 A recent paper using data from the 
Nationwide Inpatient Sample on 183,973 CABGs at 633 hospitals between 2005 and 
2008 found a very similar mean cost of CABG ($37,924) as in the current manuscript.15 
The study found lower incremental cost of complications, since they included other 
covariates in their model, such as hospital region, individual hospital eff ect and length 
of hospitalization.
The models in this study that combined pre- and post-operative variables have 4-5 times 
more explanatory power than the pre-operative models. This is refl ected by the low R2 
coeffi  cient for the pre-operative model and the fact that many pre-operative variables 
were no longer signifi cant predictors in the combined model. Complications explained 
the largest portion of the variation in length of stay and total hospital costs. However, 
the combined models can only be applied post-hoc and are therefore more suitable 
for prioritizing quality improvement eff orts and assessing the costs of complications. 
Although the explanatory power of the pre-operative models is smaller and predictions 
in individual patients inaccurate, the calibration plots show that the pre-operative mod-
els can be used to reliably predict the length of stay and costs for cohorts of patients. 
Figure 1 provides an even easier-to-use tool to instantly estimate the expected length 
of stay and costs based on the STS-PROM of a group of patients, but also lacks ability for 
individual patients.
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Given the high annual volume of CABG procedures, this type of surgery is a natural target 
for cost containment and process improvement. For this objective, risk-adjusted length 
of stay and costs are excellent measures. The pre-operative model will be a useful tool 
for hospital benchmarking and pay-for-performance measures, better than the combined 
models since prediction should be adjusted for diff erences in risk factors and not diff er-
ences in outcomes.16, 17
The ability to identify factors that are the biggest contributors to a long hospital stay and 
high costs can help clinicians and administrators to focus on areas in which their quality 
improvement eff orts will have the greatest impact. In our models, patient characteristics 
and comorbidities explained only a small portion of length of stay and costs. Clinicians 
and hospital management should fi rst focus on reduction of high-frequent, high-cost 
complications. When prioritizing quality improvement eff orts, not only the incremental 
costs or length of stay of specifi c complications need to be evaluated (Figure 2), but also 
the frequency in which they occur (Table 1). Sternal wound infection is a costly (~$19,000) 
but rare (0.4%) complication, whereas post-operative atrial fi brillation is associated 
with moderate incremental costs (~$5,000), but occurs much more frequent (17.2%). 
Consequently, over a 10-year period, the total costs associated with atrial fi brillation 
were approximately 10 times higher than the costs associated with deep sternal wound 
infections ($39 million versus $3.4 million, respectively). Other high cost, high frequent 
complications are prolonged ventilation (~$23,000, 9.3%), pneumonia (~$22,000, 2.9%), 
and renal failure (~$17,000, 3.5%). Lower complication rates and effi  cient treatments of 
these complications will decrease costs.
There are some potential limitations in this study. There might be diff erences in cost 
methodology across hospitals, regions and states, since hospital accounting methods, 
coding and billing patterns diff er. By applying category specifi c, yearly updated cost-
to-charge ratios from each participating institution and continuous collaboration within 
VCSQI, the variation across centers in the Commonwealth of Virginia was minimized. In 
addition, the current study does not compare outcomes across centers but rather reports 
summary estimates for all the centers within the state.
In conclusion, CABG is a natural target for cost containment and process improvement, 
since the annual volume, costs and post-operative length of stay are high. In total, 2 length 
of stay and 2 cost-prediction models for patients undergoing CABG were presented. The 
STS-PROM and pre-operative models, which included patient characteristics and comor-
bidities, are useful for group estimates, case-mix adjustment in hospital benchmarking 
and pay-for-performance measures. The combined models identify incremental costs as-
sociated with complications and can be used for prioritizing quality improvement eff orts.
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Supplementary Table 1. Cost Categories and ICD-9 Revenue Codes
Cost Category Revenue Codes
Emergency room 450-459
ICU/CCU 200-219
Regular room 100-179
Radiology 320-359, 400-409
Lab 300-319
Cardiac diagnostics 480, 482-489, 730-731, 739
Peripheral vascular lab 921
Anesthesia 370-379
Operating Room 360-369, 490-499
Recovery room 710-719
Blood products 380-399
Implants (pacers, ICD, valve) 275, 278
General Supplies 270-274, 276-277, 279
Pharmacy 250-259
Intravenous 260-269
Respiratory therapy 410-419
Cardiac catheterization lab 481
Therapies (PT, OT, cardiac rehabilitation) 420-449
Dialysis 800-809, 820-859, 880-889
Other
180-199, 220-249, 280-299, 470-479, 500-679, 
700-709, 740-799, 901-920, 922-942, 944-999
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ABSTRACT
Objective
Pay-for-performance measures, part of the Aff ordable Care Act, aim to reduce health care 
costs by linking value with Medicare payments, but until now the concept of value has 
not been applied to specifi c procedures. We sought to defi ne value in coronary artery 
bypass grafting (CABG) and provide a framework to identify high-value centers.
Methods
In a multi-institutional statewide database, clinical patient-level data from 42,839 pa-
tients undergoing CABG were matched with cost data. Hierarchical models adjusting for 
relevant pre-operative patient characteristics and comorbidities were used to estimate 
center-specifi c risk-adjusted costs and risk-adjusted post-operative length of stay. 
Variation in value across centers was assessed by the correlation between risk-adjusted 
measures of quality (mortality, morbidity/mortality) and resource use (costs and length 
of stay).
Results
There were no signifi cant correlations between risk-adjusted costs and risk-adjusted 
mortality (r = 0.20, p = 0.45) or morbidity/mortality (r = 0.15, p = 0.57) across centers. Risk-
adjusted costs and length of stay were not signifi cantly associated (r = 0.23, p = 0.37), 
because of cost accounting diff erences across centers. This may explain the lack of 
correlation between risk-adjusted quality and risk-adjusted cost measures. When risk-
adjusted length of stay and morbidity/mortality were used for the framework, there was 
a strong positive correlation (r = 0.67, p = 0.003), indicating that higher risk-adjusted 
quality is associated with shorter risk-adjusted length of stay.
Conclusions
Risk-adjusted length of stay and risk-adjusted combined morbidity/mortality are impor-
tant outcome measures for assessing value in cardiac surgery. The proposed framework 
can be used to defi ne value in CABG and identify high-value centers, thereby providing 
information for quality improvement and pay-for-performance initiatives.
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INTRODUCTION
The soaring costs of the U.S. health care system form an increasing burden on society and 
threaten the fi nancial stability of the government. Currently, health care expenditures 
represent 10-12% of the gross domestic product in many western European countries 
and Canada, while this proportion is nearly 18% (almost $3 trillion) in the United 
States.1, 2 There is wide consensus that we must contain health care expenditure, while 
improving quality and numerous approaches focusing on value have been proposed.3, 4 
Pay-for-performance measures and value-based payment modifi ers, to be implemented 
in 2015 as part of the Aff ordable Care Act, aim to reduce health care costs by linking 
quality and resource use performance measures with Medicare payments to physicians 
and hospitals. Physicians will be held accountable for resource utilization and costs for 
their hospitalized patients.
With more than 200,000 costly procedures performed in the U.S. annually, coronary 
artery bypass grafting (CABG) is an important procedure for improving health care value.5 
Value can be defi ned by a combination of clinical quality and resource use and should 
use risk-adjusted measures.4, 6 Although comparisons in effi  ciency exist7 and quality 
assessment measures have been proposed,8-10 the concept of value (combining risk ad-
justed measures of resource use and quality) has not been applied to specifi c procedures 
like CABG.
We conducted a study to defi ne value in CABG and to provide a framework to identify 
high-value centers. By adjusting for relevant pre-operative patient characteristics and 
comorbidities, we derived measures of risk-adjusted resource use and risk-adjusted 
quality after CABG. Subsequently, we tested whether higher risk-adjusted quality was 
correlated with shorter risk-adjusted length of stay and lower risk-adjusted costs.
METHODS
The Virginia Cardiac Surgery Quality Initiative (VCSQI) database was used for this analysis. 
Clinical records of patients undergoing cardiac surgery that were prospectively collected 
and for the current study all primary, isolated CABGs between January 2003 and April 
2013 were selected.
VCSQI is a voluntary group of 17 cooperating cardiac surgery centers in the Common-
wealth of Virginia.11 The aim of the consortium is to improve the quality of cardiac surgical 
care, while reducing costs. The database covers ~100% of all cardiac surgical procedures 
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in the state. VCSQI members contribute their data to The Society of Thoracic Surgeons 
(STS) Adult Cardiac Database. Each of VCSQI’s center agreed to share de-identifi ed patient 
data for secondary research and quality improvement. Institutional review boards at each 
participating center exempted this study because it represents a secondary analysis of 
the VCSQI data registry in absence of Health Insurance Portability and Accountability Act 
patient identifi ers. Business Associates Agreements are in place between VCSQI, its 17 
members, and database vendor (ARMUS Corporation, San Mateo CA).
Clinical Data
Post-operative outcomes were routinely collected in the STS database and included death, 
stroke, renal failure, atrial fi brillation, deep sternal wound infection, permanent stroke, 
prolonged ventilation, and reoperations for bleeding, graft occlusion and other reasons, all 
defi ned according to the STS database defi nitions.12 Operative death was defi ned as death 
within 30 days after discharge or within the hospital stay. Pre-operative risk was assessed 
using the STS-predicted risk of mortality (STS-PROM) and the STS-predicted risk of morbid-
ity or mortality (STS-PROMM). Each center was responsible for coding and submitting its 
data to VCSQI and agreed on the defi nitions, data collection, and timely submission.
Cost Data
Patient-level clinical and fi nancial data in the VCSQI database were combined as pre-
viously described.13, 14 Briefl y, STS patient records were matched with uniform billing 
(UB) discharge records. The UB-04 form is used throughout the U.S. and represents 
the patient’s fi nal hospital bill. Charges for all of the ICD-9 (International Classifi cation 
of Diseases, 9th revision) revenue codes were grouped into 20 logical cost categories 
(Supplementary Table 1). Since charges refl ect institutional pricing decisions and other 
factors unrelated to resource use, we applied cost-to-charge ratios.15 These ratios were 
yearly updated and specifi c for each participating institution and category within that 
institution. The total costs estimate was the sum of all 20 categories. The variation in 
total costs and post-operative length of stay as a result of post-operative complications 
was refl ected in the total estimate for the individual patient.14 The medical care service 
component of the U.S. consumer price index was used to convert all costs to U.S. dollars 
for the year 2013.13, 16
Statistical Analysis
We calculated risk-adjusted costs and post-operative length of stay for each of the 17 
centers by adjusting for diff erences in patient case-mix. Risk-adjusted estimates were 
derived from hierarchical models, which account for clustering of outcomes within 
hospitals, provide more stable estimates for hospitals with low volumes and adjust for 
multiplicity of comparisons. This approach to risk-standardization has been gaining in-
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creasing traction in recent years and has been adopted by CMS.17 We modeled cost and 
post-operative length of stay as dependent variables, applying hierarchical generalized 
linear models, with a gamma distribution for costs and a negative binomial distribution 
for length of stay.18 These models included a random eff ect for hospital and adjustment 
for pre-operative patient characteristics and comorbidities (Supplementary Table 2). 
Given the iterative modeling and large number of variables included, only variables that 
were signifi cant at a level of p ≤ 0.01 were preserved in the models.19 The variables age, 
gender, and race were forced into the models. The models were recently validated for 
prediction of post-operative length of stay and costs.19 Regressions were estimated in log 
and linear form, and reported in linear form, since there were no substantial diff erences 
in the results and linear regression coeffi  cients are more easily interpretable.
Hospital mean risk-adjusted costs were derived by calculating the ratio of average 
model-predicted costs for a given hospital to the expected costs based only on patient 
characteristics, and then multiplying this ratio by the overall population-average cost. 
Hospital mean risk-adjusted lengths-of-stay were calculated in a similar way.20-22 Risk-
adjusted measures of mortality and morbidity/mortality were also calculated per center, 
based on validated STS risk calculators.
Morbidity/mortality was defi ned as post-operative deep sternal wound infection, reop-
eration, permanent stroke, prolonged ventilation, renal failure or operative mortality.8, 9, 12 
Correlation between risk-adjusted quality and resource use measures were assessed 
with the Spearman’s correlation coeffi  cient. Analyses were performed with Excel 2010 
(Microsoft, Redmond, WA, USA), SPSS version 20.0.0 (SPSS, Chicago, IL) and the hierarchi-
cal models were fi tted using the GLIMMIX macro in SAS 9.3 (SAS Institute, Cary, NC.).
RESULTS
The patient characteristics and comorbidities of the 42,839 included CABG patients are 
presented in Table 1. The STS-PROM averaged 2.2% and the STS-PROMM was 13.8%. 
Post-operative clinical outcomes and resource use are presented in Table 2. Atrial fi brilla-
tion was the most common post-operative complication (17.2%), followed by prolonged 
ventilation (9.3%) and renal failure (3.5%). Mean total length of stay was 9.3 days of 
which the majority consisted of post-operative stay (6.9 days). The mean total costs for 
CABG were $38,848.
There was signifi cant variation in risk-adjusted costs ($27,380 to $55,296), risk-adjusted 
post-operative length of stay (6.26 to 8.77 days), risk-adjusted mortality (0.95% to 
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Table 1. Patient Characteristics
Characteristic N=42,839
Age, yr 64.0±10.7
Male sex 73.7
STS-PROM 2.17±3.7
STS-PROMM 13.80±10.6
Race, %
 Caucasian
 African American
 Hispanic
 Asian
 Native American
 Other
81.5
13.8
0.8
2.4
0.1
1.4
Body mass index, kg/m2 29.4±5.7
Heart failure ≤2 weeks before, % 12.0
Renal failure requiring dialysis, % 2.3
Creatinine, mg/dl 1.20±1.0
Left ventricular ejection fraction 51.3±12.5
Chronic lung disease, %
 No
 Mild
 Moderate
 Severe
82.4
10.0
5.0
2.5
Cerebrovascular Disease, % 13.5
Pre-operative cardiogenic shock, % 1.6
Urgency status, %
 Elective
 Urgent
 Emergent
41.5
54.9
3.6
On inotropic medication, % 1.6
Arrhythmia, % 7.5
Myocardial infarction ≤21 days, % 29.0
Peripheral arterial disease, % 14.2
Hypertension, % 81.4
Diabetes Mellitus, % 39.6
Immunocompromised status, % 2.1
Previous CABG, % 3.2
Previous valve operation, % 0.2
Previous PCI, % 18.7
No. of diseased vessels, %
 One
 Two
 Three
4.2
17.6
78.1
Data defi ned as mean±SD, or % of patients.
SD, standard deviation; STS-PROM, Society of Thoracic Surgeons-Predicted Risk of Mortality; STS-PROMM, 
Society of Thoracic Surgeons-Predicted Risk of Mortality or Morbidity; yr, years.
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2.13%) and risk-adjusted morbidity/mortality (10.78% to 19.44%) across centers. 
Figure 1A represents a plot of risk-adjusted costs vs. risk-adjusted mortality, showing 
that there was no statistically signifi cant correlation between risk-adjusted costs and 
risk-adjusted mortality (r = 0.20, p = 0.45). Also when complications were included in the 
risk-adjusted outcome, we found no statistically signifi cant correlation (risk-adjusted 
costs vs. risk-adjusted morbidity/mortality; r = 0.15, p = 0.57; Figure 1B).
Figure 2A represents a plot of risk-adjusted post-operative length of stay and risk-adjust-
ed mortality for the 17 cardiac surgical centers. The correlation between risk-adjusted 
length of stay and risk-adjusted mortality was not statistically signifi cant (r = −0.27, 
p = 0.30). This suggests that lower mortality is not associated with lower resource use, as 
measured by post-operative length of stay.
There was a signifi cant positive correlation between the more comprehensive quality 
outcome measure risk-adjusted morbidity/mortality and risk-adjusted length of stay 
(r = 0.67, p = 0.003; Figure 2B). Also when two centers with the highest risk-adjusted 
length of stay were excluded, the correlation remained positive and signifi cant (r = 0.60, 
p = 0.02). This suggests that higher quality (low risk-adjusted morbidity/mortality) coin-
cides with shorter post-operative length of stay. Those cardiac surgical centers represent 
high-value CABG. On the contrary, there were also centers in the upper right quadrant 
Table 2. Post-operative Clinical Outcomes and Resource Use
Variable N=42,839
Post-operative ventilation >24 hours 9.3
Post-operative renal failure 3.5
Post-operative pneumonia 2.9
Post-operative atrial fi brillation 17.2
Post-operative stroke 1.4
Post-operative deep sternal wound infection 0.4
Reoperation bleeding 1.7
Reoperation other cardiac reasons 0.8
Reoperation non-cardiac reasons 2.0
Operative mortality 1.8
Operative morbidity/mortality* 14.4
Total length of stay, days 9.3±7.9
Post-operative length of stay, days 6.9±7.0
Total costs [median] ($) 38,848 ± 29,299 [32,397]
Data defi ned as mean±SD, or % of patients. *defi ned as: operative deep sternal wound infection, reopera-
tion, permanent stroke, prolonged ventilation, renal failure or mortality.
SD, standard deviation.
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which combined high risk-adjusted morbidity/mortality with high risk-adjusted length 
of stay. This suggests that lower quality, as measured by higher than expected morbidity 
and mortality, leads to higher resource use, as measured by higher than expected post-
operative length of stay. It is these centers that represent low value.
There was no signifi cant correlation between risk-adjusted costs and risk-adjusted length 
of stay across centers (r = 0.23, p = 0.37; Figure 3). Although there were several centers for 
which the risk-adjusted costs and risk-adjusted length of stay showed a trend (centers 
A, O, B, I, J, P, L, E, N), there were also centers (C, K, D and M) that had risk-adjusted costs 
that was diff erent than would be expected based on risk-adjusted length of stay. Since 
length of stay is closely related with costs at a group level,23 a strong correlation between 
risk-adjusted cost and risk-adjusted length of stay was expected.
DISCUSSION
Even after adjusting for pre-operative patient characteristics and comorbidities, we 
found important variation in measures of quality (risk-adjusted mortality, risk-adjusted 
Figure 3. Risk-Adjusted Costs and Risk-Adjusted Length of Stay per Center
The dots represent the risk-adjusted costs (vertical axis) and risk-adjusted length of stay (horizontal axis) 
per cardiac surgical center.
Int, intermediate; LOS, length of stay; r, correlation coeffi  cient.
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morbidity/mortality) and resource use (risk-adjusted costs and risk-adjusted length of 
stay) across 17 centers performing CABG in the Commonwealth of Virginia. A signifi cant 
correlation existed between risk-adjusted morbidity/mortality and risk-adjusted length 
of stay. These fi ndings suggest that better quality leads to shorter post-operative length 
of stay and resource use. Substantial savings and better outcomes can be realized if all 
centers achieve the same performance of high-value centers.
This is the fi rst study to describe combined center-specifi c clinical and fi nancial outcomes 
for CABG. The over- and underperforming centers are shown in the lower left and upper 
right quadrants in Figure 2B, respectively. The study serves as a basis for discussions on 
health care value measurement and facilitates improvements of value in health care. 
Policy measures as pay-for-performance and the value-based payment modifi er provide 
fi nancial incentives to improve value (i.e. to keep costs low by improving outcomes 
and quality of care).24, 25 In general, policy measures will provide incentives that relate 
payment inversely with risk-adjusted clinical outcomes and risk-adjusted resource use. 
In the current study we found distinct variability in value when both quality and cost 
measures were combined, but the exact defi nitions of low/high performers require close 
collaboration with the physician community before this can lead to real-world payment 
implications.
Previous studies on pay-for-performance have been criticized for their performance met-
rics that focused on processes of care that were not clinically meaningful.26 For instance, 
measuring the proportion of heart failure patients receiving paper discharge instructions 
does not necessarily result in better patient outcomes.27 In general, physicians, patients, 
and CMS should work together to defi ne meaningful outcome measures. Clinically rel-
evant metrics will not only increase the potential of pay-for-performance but are also 
more likely to engage physicians than process-based metrics.28 In the current analyses 
we used risk-adjusted costs and risk-adjusted length of stay as measures of resource use, 
and risk-adjusted mortality and risk-adjusted morbidity/mortality as quality measures.
Outcome Measures for Assessing Value
Unexpectedly, we only found a strongly signifi cant correlation when risk-adjusted length 
of stay and risk-adjusted morbidity/mortality were used as outcome measures for re-
source use and quality, respectively. Since costs and length of stay are closely related 
at a group level,23 we also expected risk-adjusted costs and risk-adjusted morbidity/
mortality to be signifi cantly correlated. However, diff erent centers account cost diff er-
ently, particularly in the way how overhead costs are allocated.29 A center with brand new 
facilities and high real estate costs may allocate costs diff erently to a single procedure 
(CABG) than centers with depreciated facilities and a lower cost location. This is less of 
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an issue when the study-objective is to estimate overall costs of a procedure or model 
building for all centers combined,19 but using these cost data to compare centers is likely 
to refl ect the variation in accounting systems instead of true diff erences in the effi  ciency 
of performing CABG. Even with a uniform hospital bill (UB-04) and similar cost account-
ing systems, it is not clear that the accounting practices are comparable across each of 
the study centers, since also costs of similar resources (catheters, sutures, equipment) 
might diff er between centers. Ideally, standardized unit costs should be applied to each 
patient’s resource consumption,30 but these data were unavailable for this large dataset.
Our alternative measure of risk-adjusted resource use, length of stay, is widely available 
and easy to measure. Post-operative length of stay as an isolated performance measure 
(i.e. without a risk-adjusted quality measure) should be avoided, since this might lead 
to over-aggressive discharge protocols.31 Rather a balanced approach to effi  ciency and 
quality improvement will provide a patient centric and patient safe approach to health 
care. Also, factors beyond hospital’s direct control (e.g. the lack of post-acute facilities) 
might infl uence post-operative length of stay. On the other hand, risk-adjusted length of 
stay (in combination with risk-adjusted quality) provides incentives for centers to care-
fully evaluate their processes of care from a broad perspective, including improvements 
in post-discharge facilities.
We did not fi nd a correlation of risk-adjusted mortality with any measure of risk-adjusted 
resource use (costs or length of stay). Mortality alone may be an inadequate measure to 
compare quality across centers and our analyses show that complications are the real 
driver of the association. Mortality may or may not result in increased resource use since 
a patient who dies shortly after surgery consumes few resources. Complications on the 
other hand, always lead to higher resource use consumption. Therefore, the STS Quality 
Measurement Task Force (QMTF) proposes a comprehensive composite quality score, in 
which risk-adjusted morbidity/mortality is an important domain.8, 9
After high-value centers have been identifi ed, subsequent in-depth research and com-
parison with low-value centers is needed to identify factors that help explain how these 
centers achieved the exceptional performance on risk-adjusted quality and risk-adjusted 
resource use measures. This process of quality improvement could include qualitative 
research such as collaborative site visits and structured interviews between the partici-
pating centers.8, 9
Limitations
This study has some limitations. First, the results of this study may not be generalizable 
to other cardiac surgical centers in the U.S as data were used from 17 cardiac surgical 
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centers in one state. However, the key variables (STS-PROMM, length of stay) are well-
known and therefore, the framework developed in this study can be applied to all cardiac 
surgical centers in the United States performing CABG. Second, we used post-operative 
length of stay as a surrogate for resource use since diff erences in accounting methodol-
ogy hampered cost comparisons across centers. Ideally, standardized unit costs would 
have been applied to each patient’s resource consumption.30 However, these detailed 
individual resource consumption data were unavailable for this large dataset. Instead 
we used a single measure of resource use, risk-adjusted length of stay, which is closely 
related with costs at a group level.23 Third, the study is observational, and unmeasured 
confounding cannot be excluded. However, the risk-adjustment of length of stay and 
costs using the available variables was robust, and an observational design is best to 
evaluate actual clinical practice. Finally, it is important to realize that centers that treat 
markedly more frail or other special patients might unjustifi ably be categorized as a low-
value center.
Conclusions
Risk-adjusted length of stay and risk-adjusted combined morbidity/mortality are im-
portant outcome measures for assessing value in cardiac surgery. In high-value centers, 
lower rates of risk-adjusted morbidity/mortality outcomes were associated with shorter 
risk-adjusted length of stay. The proposed framework can be used to defi ne value in 
CABG and identify high-value centers, thereby providing useful information for quality 
improvement and pay-for-performance initiatives.
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Supplementary Table 1. Cost Categories and ICD-9 Revenue Codes
Cost Category Revenue Codes
Emergency room 450-459
ICU/CCU 200-219
Regular room 100-179
Radiology 320-359, 400-409
Lab 300-319
Cardiac diagnostics 480, 482-489, 730-731, 739
Peripheral vascular lab 921
Anesthesia 370-379
Operating Room 360-369, 490-499
Recovery room 710-719
Blood products 380-399
Implants (pacers, ICD, valve) 275, 278
General Supplies 270-274, 276-277, 279
Pharmacy 250-259
Intravenous 260-269
Respiratory therapy 410-419
Cardiac catheterization lab 481
Therapies (PT, OT, cardiac rehabilitation) 420-449
Dialysis 800-809, 820-859, 880-889
Other
180-199, 220-249, 280-299, 470-479, 500-679, 
700-709, 740-799, 901-920, 922-942, 944-999
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Supplementary Table 2. Pre-operative Patient Characteristics and Comorbidities for which the Cost and 
Length of Stay Outcomes were adjusted
Cost model Length of stay model
Age Age
Male sex Male sex
Race Race
Body mass index Body mass index
Heart failure ≤2 weeks before Heart failure ≤2 weeks before
Creatinine Creatinine mg/dl
Left ventricular ejection fraction Left ventricular ejection fraction
Chronic lung disease (Mild/Moderate/Severe) Chronic lung disease (Mild/Moderate/Severe)
Cerebrovascular Disease Cerebrovascular Disease
Pre-operative cardiogenic shock Pre-operative cardiogenic shock
Urgency status (Urgent/Emergent) Urgency status (Urgent/Emergent)
On inotropic medication On inotropic medication
Arrhythmia Arrhythmia
Myocardial infarction ≤21 days Myocardial infarction ≤21 days
Peripheral arterial disease Peripheral arterial disease
Hypertension -
Diabetes Mellitus Diabetes Mellitus
Immunocompromised status Immunocompromised status
Previous CABG Previous CABG
Previous valve operation Previous valve operation
Previous PCI -
No. of diseased vessels (Two/Three) No. of diseased vessels (Two/Three)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
C HAPTER 15
Appropriate Coronary Artery Bypass 
Grafting Use in the Percutaneous 
Coronary Intervention Era: are we 
fi nally making progress?
Osnabrugge RL, Head SJ, Bogers AJ, Kappetein AP.
Semin Thorac Cardiovasc Surg. 2012;24:241-3.
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ABSTRACT
Appropriate use criteria integrate guidelines, clinical trial evidence and expert opinion 
to be able to interpret the most appropriate care for a range of distinct clinical scenarios. 
Inappropriate use estimates cannot be neglected. Approximately 12-14 % of all percuta-
neous coronary interventions and 1-2% of all coronary artery bypass grafting procedures 
in patients with stable angina are deemed inappropriate. Several reasons for this strik-
ing diff erence are identifi ed. Continuous improvement of the criteria, multidisciplinary 
discussions and the correct fi nancial incentives will be essential in reducing the number 
of inappropriate procedures, improve patient outcomes and contain costs.
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The delivery of medical care exhibits substantial regional variations, which cannot be 
attributed solely to diff erences in disease prevalence, patient’s race or treatment prefer-
ences. This variation is present in a wide variety of surgical procedures and certainly 
exists in the cardiovascular fi eld.1 In addition, we have seen an unprecedented surge in 
new medical technologies and treatments for medicine in general, and for the cardio-
vascular domain in particular. While this opens up new opportunities, rapid adoption 
of technology is not always justifi ed. Some treatments are only benefi cial for selected 
patients and can be harmful to others. New treatment options often go hand in hand with 
increased costs and should only be off ered to patients who will benefi t from them. To 
ensure the best patient outcomes and keep costs under control, individual patient care 
has to be performed according to latest evidence and guidelines.
The selection of the best treatment option is not straightforward, since individual pa-
tients have a myriad of characteristics which do not completely align with the guidelines 
or with the selected patient groups in clinical trials. The method for determining ap-
propriateness aimed to overcome this by integrating guidelines, clinical trial evidence 
and expert opinion into an appropriateness scale of a certain procedure for a range of 
distinct clinical scenarios.2
Recently, the American College of Cardiology Foundation updated their appropriate use 
criteria (AUC) for coronary revascularization.3 Coronary revascularization was deemed 
appropriate when the expected benefi ts, in terms of survival or health outcomes, 
exceeded the expected negative consequences of the procedure.3 In more detail, the 
appropriateness of a procedure in distinct clinical scenarios was scored on a scale from 
1 to 9 by a technical panel. Procedures were deemed appropriate, uncertain or inap-
propriate. In the uncertain category more evidence or information on the patient was 
needed.
Several studies have used the AUC to assess the inappropriate use of PCI and CABG. 
Recent large registries found rates of inappropriateness of approximately 12% to 14% 
and rates of uncertain appropriateness of 38% to 50%.4, 5 Interestingly, the more PCI 
facilities there are available per number of inhabitants, the more PCIs are performed.6 For 
CABG, an early study showed that 16% of the procedures were inappropriate.7 More re-
cent evidence from large registries suggest a reduction in inappropriateness to 1-2%.5, 8 
Together the inappropriate revascularization procedures account US$1 to $10 billion ad-
ditional health care costs.9 A focus on eliminating inappropriate revascularization could 
therefore not only provide better outcomes for patients, but signifi cantly reduce costs in 
an era of increasing health care expenditures.
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The diff erence in rates of inappropriateness between CABG and PCI are striking and 
several reasons can be identifi ed. First of all, patients’ perceptions and the extensiveness 
of physicians’ explanations about the benefi ts and risks of the revascularization method 
may have an infl uence on rates of inappropriateness.10 The invasiveness of CABG might 
persuade patients to request PCI. Also, patients value the early and benefi t of PCI higher 
than the long term advantages of CABG (temporal discounting).11
A second reason might be that PCI can be performed as an ad-hoc procedure during 
the same visit as the diagnostic catheterization, leaving little opportunity for multidis-
ciplinary involvement and considerations.12 CABG on the other hand is often performed 
after referral and with more than one physician participating in the decision. Interest-
ingly, patients who were more suitable for CABG after coronary angiography were more 
likely to be recommended surgery when the angiography was performed at hospitals 
without the ability to perform ad hoc PCI.13 Also, the quality of life results of the Clinical 
Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial, 
led to reconsideration of medical therapy in patients with stable angina.14
It seems clear that pay-for-performance incentives might play a prominent role in 
inappropriate revascularization. While it may indeed be important, it is challenging to 
hypothesize that a physician focusses on his own interests when treating a patient. 
Moreover, ad-hoc stenting is performed more frequently in academic hospitals as com-
pared with general hospitals.12 A more important problem might be the fact that the 
guidelines and practicing cardiologists are not aligned. In a Medscape survey, 43% of the 
645 interviewed cardiologists stated that guidelines have a negative impact on patient 
care.15 Belief in AUC is even lower with 75% of the cardiologists stating that criteria and 
quality measures had either no or even a negative impact on patient care. These results 
should be an incentive to bring the practicing cardiologists and the societies who make 
the guidelines closer together.
In dealing with inappropriateness, a multidisciplinary heart team can play a crucial role. 
Such a team consists of at least a non-interventional cardiologist, an interventional cardi-
ologist and a cardiovascular surgeon and is currently recommended in the European and 
American revascularization guidelines, as well as in the AUC of the American College of 
Cardiology Foundation.3, 16, 17 With the joint eff ort of diff erent specialties and stakehold-
ers, the patient is more likely to undergo a treatment based on the guidelines and latest 
evidence. Patients will also be better informed and value the elaborate evaluation of 
their treatment. To fully benefi t from the heart team, clinical and fi nancial aspects of the 
decision-making process need to be aligned. For instance, in the Netherlands the heart 
team discussions are reimbursed and in academic hospitals the physician’s income is not 
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directly related to the number of procedures performed. In this way, decisions will be 
fully based on the evidence for the specifi c patient and fi nancial incentives do not get 
the chance of playing a role. Salaries should be based on the quality of care provided and 
not on the number of procedures.
Despite continuous eff orts to improve the criteria, some important limitations of AUC 
persist.18 Inappropriate indications show only moderate concordance between a range of 
cardiologists and the AUC technical panel.19 This makes the composition of the relatively 
small (n = 17) technical panel essential and weakens the validity of AUC studies. More-
over, the number of clinical scenarios is limited, the role of pre-procedural diagnostic 
testing is unclear and the interpretation of the uncertain and inappropriate categories 
is confusing.
On the other hand, the AUC have moderate to very good reliability and good construct 
validity.20 Care deemed appropriate was also a predictor of better outcomes as compared 
with care deemed inappropriate.20 Interestingly, there were eminent practice variations 
even within a New York State’s PCI registry. This means that even though AUC scenarios 
are criticized by interventional cardiologists.18 they do not seem to have consistency as a 
group with regard to how to treat patients.5
Altogether, inappropriate use cannot be neglected. Continuous improvement of the cri-
teria, multidisciplinary discussions and the correct fi nancial incentives will be essential 
in reducing the number of inappropriate procedures, improve patient outcomes and 
contain costs.
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ABSTRACT
Objective
Validation studies of the EuroSCORE II have been limited to European datasets. There-
fore, the aims of this study were to assess the performance of the EuroSCORE II in a large 
multicenter U.S. database, and compare it with the Society of Thoracic Surgery Predicted 
Risk of Mortality (STS-PROM). In addition, implications for patient selection for transcath-
eter aortic valve implantation (TAVI) were explored.
Methods
The EuroSCORE II and STS-PROM was calculated for 50588 patients from a multi-institu-
tional statewide database of all cardiac surgeries performed since 2003. Model perfor-
mance was assessed using the area under the receiver operator curve (AUC), observed 
versus expected (O:E) ratios and calibration plots. Analyses were performed for isolated 
CABG (n = 40871), AVR (n = 4107), AVR+CABG (n = 3480), mitral valve (MV) replacement 
(n = 1071) and MV repair (n = 1059).
Results
Overall in-hospital mortality was 2.1%. The EuroSCORE II was outperformed by the STS-
PROM in the overall cohort with regard to discrimination (AUC=0.77 versus 0.81, respec-
tively; p < 0.001) and calibration (O:E = 0.68 versus 0.80, respectively). Discrimination for 
CABG was worse with the EuroSCORE II (AUC=0.77 versus STS-PROM 0.81, p < 0.001). 
For other procedures discrimination was similar: AVR (AUC=0.71 versus STS-PROM 0.74, 
p = 0.40), AVR+CABG (AUC=0.72 versus STS-PROM 0.74, p = 0.47, MV repair (AUC=0.82 
versus STS-PROM 0.86, p = 0.55), and MV replacement (AUC=0.78 versus STS-PROM 
0.79, p = 0.69). Calibration of the EuroSCORE II was worse for CABG (O:E = 0.68 versus 
STS-PROM 0.80), similar in AVR+CABG (O:E = 0.76 versus STS-PROM 0.70) and MV Repair 
(O:E = 0.64 versus STS-PROM 0.67), while EuroSCORE II may be more accurate in AVR 
(O:E = 0.96 versus STS-PROM 0.76). Performance of both models improved when only re-
cent cases (after January 1st 2008) were used. Ongoing TAVI trials aimed at patients with 
an estimated 4-10% risk of mortality are enrolling patients with mean estimated risks of 
6.2% (EuroSCORE II) or 6.0% (STS-PROM), and an actual mortality of 4.6% (EuroSCORE 
II) or 4.8% (STS-PROM).
Conclusions
In a large U.S. multicenter database, the STS-PROM performs better than the EuroSCORE II 
for CABG. However, the EuroSCORE II is a reasonable alternative in low-risk CABG patients 
and in those undergoing other cardiac surgical procedures. Clinical trials and physicians 
that use these scores, recruit and treat patients that are at a lower risk than anticipated. 
This potentially leads to overtreatment with an investigational device. Decision-making 
should not solely be based on risk scores, but should comprise multidisciplinary heart 
team discussions.
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INTRODUCTION
Risk models are essential for clinical decision-making, benchmarking of clinical prac-
tices, and patient-selection in clinical trials. Several scores are currently used in cardiac 
surgery.1 The widely utilized EuroSCORE predicts 30-day mortality after cardiac surgery.2 
It was developed in 1999 using a dataset of almost 15000 patients and updated in 
2003.2, 3 Validation studies of the EuroSCORE have shown that the score over-predicts 
mortality, especially in high-risk patients.4, 5 The EuroSCORE II was introduced to improve 
performance and increase applicability to contemporary cardiac surgery.6 It was derived 
from a database of 23000 patients who underwent cardiac surgery in 43 countries in the 
year 2010.
The new score seems to perform better than the original score, but validation stud-
ies have been limited to European datasets.7-13 With increasing transatlantic research 
collaboration and the potential benefi ts of using the more parsimonious EuroSCORE II 
also in the U.S., knowledge on the performance and comparability of this score in North-
American patients is essential. For instance, two major multinational trials currently 
investigate transcatheter aortic valve implantation (TAVI) as an alternative to surgical 
aortic valve replacement (AVR) in intermediate risk patients (Clinicaltrials.gov identifi er: 
NCT01586910 and NCT01314313).
These trials use the Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) 
for patient selection, whereas the EuroSCORE is used in everyday practice in Europe. 
Therefore, the purpose of this study was to compare the performance of the EuroSCORE II 
with the STS-PROM model in a large multicenter U.S. database, and also explore implica-
tions for patient selection for TAVI.
METHODS
Study Population
Clinical records of patients undergoing cardiac surgery were prospectively collected 
from 2003 to 2012 in the Virginia Cardiac Surgery Quality Initiative (VCSQI) database. For 
this study, all patients who underwent isolated coronary artery bypass grafting (CABG), 
isolated AVR, isolated mitral valve (MV) replacement, isolated MV repair, or CABG+AVR 
were selected. VCSQI is a voluntary consortium of 17 cardiac surgical centers provid-
ing cardiac surgery in the Commonwealth of Virginia. The database captures 99% of all 
cardiac surgical procedures.14 VCSQI members contributed data to the STS Adult Cardiac 
Database. Data analyses were exempt from the University of Virginia Institutional Review 
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Board, because patients were de-identifi ed and the fact that the data were primarily 
collected for non-research purposes.
Defi nitions and Risk Score Calculation
Operative mortality was defi ned as i). death during initial hospital stay, or ii). death within 
30 days if the patient is discharged <30 days. The EuroSCORE II was built using death 
during the initial hospital stay,6 and therefore we performed additional analyses using 
that endpoint defi nition. Because EuroSCORE II performance was similar (discrimination) 
or better (calibration) using the operative mortality defi nition, we report all comparative 
analyses based on that defi nition. Moreover, using the same endpoint defi nition facili-
tates the comparison in this U.S. cohort of patients. Patient characteristics, risk factors and 
other variables were collected using STS database defi nitions. Some defi nitions were not 
totally equivalent to the EuroSCORE defi nitions. Critical pre-operative state was assessed 
combining the variables resuscitation, inotropes use, ventricular tachycardia or fi brilla-
tion and pre-operative intra-aortic balloon pump for hemodynamic instability. Creatinine 
clearance was calculated using the Cockroft-Gault formula,15 and where only the mean 
pulmonary artery pressure was collected, we calculated the systolic pulmonary pressure 
using the formula reported by Kind et al.16 No data was available for poor mobility due to 
musculoskeletal dysfunction and consequently the EuroSCORE II risk factor ‘poor mobil-
ity’ was based on neurological dysfunction only.11 The Canadian Cardiovascular Society 
(CCS) class was not scored for each individual patient and therefore we used the variable 
unstable angina as a proxy. Patients were assumed to be New York Heart Association 
(NYHA) class 1 if congestive heart failure was absent. Subsequently, the logistic EuroS-
CORE and EuroSCORE II were calculated for each patient,3, 6 while the STS-PROM had been 
routinely calculated at the time of data entry in the database. Since patient risk factors 
and case-mix in adult cardiac surgery change dynamically over time,17, 18 sensitivity analy-
ses were performed to investigate whether model performance was better in more recent 
procedures. Based on an analysis of predicted risk and mortality profi les over time, recent 
cases for the sensitivity analyses were defi ned as procedures after January 1st 2008.
Statistical Analysis
Baseline characteristics are displayed as proportions or means ± standard deviation for 
discrete and continuous variables, respectively. The risk models were evaluated in terms 
of discrimination and calibration, using the area under the receiver operator curve (AUC) 
and calibration plots. An AUC of 1.0 indicates perfect discriminative power, whereas 0.5 
indicates no discriminative abilities. AUCs were compared using the method proposed 
by Hanley et al.19 Calibration represents the agreement between observed outcome and 
predicted outcome. The Hosmer-Lemeshow test was not used, since it is not informative 
in large samples. Instead, we compared observed in-hospital mortality with expected 
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in-hospital mortality. We constructed calibration plots of observed versus expected 
mortality, displaying the trend using Friedman’s super-smoother methodology on the 
ungrouped data.20 In addition, we divided the cohort into 10 equally sized groups based 
on the ranked predicted risk.
Analyses were performed for all procedures combined, as well as per procedure. Patients 
who underwent AVR were also classifi ed into low, intermediate or high operative risk, 
according to their predicted risk of mortality (0-4%, 4-10% and >10%, respectively). 
These STS-PROM cutoff s are used in ongoing TAVI vs. surgical AVR trials (Clinicaltrials.gov 
identifi ers: NCT01586910 and NCT01314313). Analyses were performed with SPSS for 
Windows (version 20.0.0.1; IBM, Armonk, NY, USA) and R software (version 2.15.3).
RESULTS
Patients
Full patient characteristics are presented in Table 1. The mean age of the population was 
64.7 years and 14622 patients (28.9%) were women. The majority (40871) of the 50588 
patients included during the study period underwent CABG. Other procedures were iso-
lated aortic valve replacements (AVR, 4107 patients), combined AVR+CABG (3480) proce-
dures, isolated MV repairs (1059 patients), and isolated MV replacements (1071 patients). 
The mean values of the STS-PROM, EuroSCORE II, and logistic EuroSCORE were 2.7%, 
3.2%, and 6.9%, respectively. Overall operative mortality was 2.1% (1071 patients).
Overall Performance of the Scores
Figure 1 presents the AUC of the diff erent risk prediction models in the overall cohort 
of patients. The STS-PROM had better discriminatory power compared to the EuroSCORE 
II (AUC=0.81 versus 0.77, respectively; p < 0.001) and logistic EuroSCORE (AUC=0.81 
versus 0.78, respectively; p = 0.003). The AUC of the EuroSCORE II and logistic EuroSCORE 
were similar (AUC=0.77 versus 0.78, respectively; p = 0.16).
The calibration curves of the STS-PROM, EuroSCORE II and logistic EuroSCORE are pre-
sented in Figure 2. All scores showed a relatively linear relationship between predicted 
and observed mortality. The scores were below the perfect prediction line, meaning that 
they over-predicted mortality. In patients with a predicted risk of mortality above ap-
proximately 5%, the STS-PROM was better calibrated than the EuroSCORE II. The logistic 
EuroSCORE considerably over-predicted in-hospital mortality in all patients. Expressed 
numerically, the EuroSCORE II, STS-PROM and logistic EuroSCORE had an observed versus 
expected (O:E) ratio of 0.68, 0.80, and 0.32, respectively (Table 2).
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Table 1. Patient Characteristics
Characteristic N=50 588
Age (mean ± SD) 64.6 ± 11.2
Female 14 622 (28.9)
Body mass index (mean ± SD) 29.7 ± 7.9
Renal function
 Moderately impaired (CC 50-85 ml/min)
 Severely impaired (CC <50 ml/min)
 On dialysis
19 152 (37.9)
7 032 (13.9)
1 256 (2.5)
Extracardiac arteriopathy 6 887 (13.6)
Poor mobility 1 700 (3.4)
Previous cardiac surgery 3 544 (7.0)
Chronic pulmonary disease 3 948 (7.8)
Active endocarditis 312 (0.6)
NYHA class
 NYHA 1
 NYHA 2
 NYHA 3
 NYHA 4
19 852 (39.3)
9 274 (18.3)
14 875 (29.4)
6 587 (13.0)
Pulmonary hypertension
 Moderate (31-55 mm Hg)
 Severe (>55 mm Hg)
7 280 (14.4)
1 620 (3.2)
Recent myocardial infarction 19 001 (37.6)
Critical pre-operative state 1 904 (3.8)
Diabetes on insulin 5 571 (11.0)
CCS class 4 angina 18 169 (35.9)
Left ventricular ejection fraction
 Moderate (31-50%)
 Poor (21-30%)
 Very poor (≤20)
10 284 (20.3)
3 030 (6.0)
1 274 (2.5)
Type of procedure
 Isolated CABG
 Isolated AVR
 Isolated MV replacement
 Isolated MV repair
 CABG + AVR
40 871 (80.8)
4 107 (8.1)
1 071 (2.1)
1 059 (2.1)
3 480 (6.9)
STS-PROM score (mean ± SD) 2.7 ± 4.2
EuroSCORE II (mean ± SD) 3.1 ± 5.0
Logistic EuroSCORE (mean ± SD) 6.7 ± 8.3
Values are number of patients (%) unless otherwise indicated. AVR, aortic valve replacement; CABG, cor-
onary artery bypass grafting; CC, creatinine clearance; CSS, Canadian Cardiovascular Society; MV, Mitral 
Valve; NYHA, New York Heart Association; SD, standard deviation; STS-PROM, Society of Thoracic Surgery 
Predicted Risk of Mortality.
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Figure 1. Receiver-Operating Curves of Risk Models for the Overall Cohort
The diagonal line represents no discriminatory power (AUC = 0.50). The higher the AUC, the better is the 
discriminatory power. AUC: area under the curve; CI: confi dence interval; log: logistic.
Figure 2. Calibration Plots of Risk Models for the Overall Cohort
The diagonal line represents perfect calibration. Calibration of EuroSCORE II and the STS-PROM is good and 
similar up until a predicted in-hospital mortality rate of 5%. For patients with a predicted morality >5%, 
the STS-PROM is better calibrated. The logistic EuroSCORE over-predicts mortality across all patients. Verti-
cal bars represent 95% CIs. Log: logistic
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Performance according to Type of Procedure
The calibration of the STS-PROM and EuroSCORE II according to the type of procedure is 
presented numerically in Table 2 and graphically in Figure 3. Isolated CABG was the most 
common procedure and performance of the STS-PROM and EuroSCORE II was similar to 
their performance in the ‘all procedure’ category. Both scores showed good calibration 
up until approximately 5% of the predicted risk of mortality; after that, the STS-PROM 
was better calibrated than the EuroSCORE II (Fig. 3A). Discrimination in CABG patients 
was better with the STS-PROM model than with the EuroSCORE II (AUC=0.81 versus 0.77, 
respectively; p < 0.001).
For patients who underwent AVR, the STS-PROM over-predicted mortality in almost a 
linear fashion (Fig. 3B). The EuroSCORE II under-predicted in low risk patients, while 
it also showed over-prediction in higher risk patients. The O:E ratios according to pre-
defi ned risk categories showed a similar picture (Table 3). The STS-PROM over-predicted 
relatively similarly across risk categories(O:E ratios, low 0.76, intermediate 0.79, and 
high 0.71); the EuroSCORE II under-predicted in low risk patients, and over-predicted in 
intermediate and high risk patients (O:E ratios, low 1.51, intermediate 0.74 and high 0.51, 
respectively). Discrimination in patients who underwent AVR was similar between scores 
(AUC=0.74 for STS-PROM versus 0.71 for EuroSCORE II; p = 0.40).
Both the STS-PROM and EuroSCORE II performed equivalent in patients undergoing com-
bined AVR+CABG procedures, although the EuroSCORE II was slightly better calibrated 
in lower risk patients (Fig 3C). Calibration in high risk patient was poor in both scores. 
Discrimination in patients undergoing AVR+CABG was similar for both scores (AUC=0.74 
for STS-PROM versus AUC=0.72 for EuroSCORE II; p = 0.47).
The calibration plots for MV procedures showed a sizeable amount of uncertainty (Fig. 3D 
and Fig. 3E). There were only 116 patients with a EuroSCORE II>4% in the MV repair group, 
Table 3. Calibration in AVR according to Risk Category
Procedure
STS-PROM Score EuroSCORE II
n Mort (%) Score O:E n Mort (%) Score O:E
AVR
 Low risk 2911 1.44 1.92 0.76 (0.62-0.89)  3435 2.15 1.42 1.51 (1.17-1.86) 
 Intermediate risk 923 4.77 6.02 0.79 (0.56-1.03)  459 4.58 6.20 0.74 (0.42-1.05) 
 High risk 273 12.09 16.95 0.71 (0.47-0.96)  213 11.27 21.93 0.51 (0.31-0.72) 
AUC, area under the curve; AVR, aortic valve replacement; CABG, coronary artery bypass grafting; CI, confi -
dence interval; Mort, mortality; MV Mitral Valve; n, number of patients; O:E, observed versus expected ratio 
for in-hospital mortality. Risk categories were classifi ed as 0-4, 4-10 and >10 for low, intermediate and 
high risk respectively.
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Figure 3. Calibration Plots of Risk Models according to Type of Procedure
The diagonal line represents perfect calibration. Vertical bars represent standard errors of the mean.
AVR, aortic valve replacement; CABG, coronary artery bypass grafting; MV, mitral valve
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Figure 4. Calibration Plots of Risk Models for the Overall Cohort and according to Type of Procedure, 
including only Surgeries performed after January 1st 2008
The diagonal line represents perfect calibration. Vertical bars represent standard errors of the mean.
AVR, aortic valve replacement; CABG, coronary artery bypass grafting; log, logistic; MV, mitral valve
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leading to diffi  culties in making inferences on higher risk patients. In low risk patients, 
EuroSCORE II tended to under-predict mortality, whereas the STS-PROM tended to over-
predict. Also discrimination with the STS-PROM and EuroSCORE II was similar (AUC=0.86 
versus 0.82, respectively; p = 0.55). Among patients that underwent MV replacement, 330 
patients had a EuroSCORE>4%, but substantial variances in O:E ratios hinder inferences 
on the calibration of both scores. Discrimination was similar (AUC=0.79 for STS-PROM 
versus AUC=0.78 for EuroSCORE II; p = 0.69).
Sensitivity Analysis of Recent Cases
The sensitivity analysis showed that both the STS-PROM and EuroSCORE II were better 
calibrated) in a more recent patient cohort (Table 4, Fig. 4). Calibration improved for both 
the STS-PROM and EuroSCORE II in the overall cohort (O:E = 0.96 and 0.80, respectively), 
in isolated CABG (O:E = 0.99 and 0.73, respectively). Especially in low risk recent CABG 
patients both scores are well calibrated. The STS-PROM improved for low risk AVR and 
AVR+CABG procedures (Fig. 4C and Fig. 4D). The small samples of patients who underwent 
MV repair or MV replacement resulted in disparate calibration results. Discrimination was 
similar across procedures, scores, and time (Table 2, Table 4).
DISCUSSION
This is the fi rst study that validated the EuroSCORE II in a large multicenter U.S. database 
and compared its performance with the STS-PROM across a range of cardiac surgical pro-
cedures. Overall, the STS-PROM was better calibrated and was superior in discriminating 
patients that were likely to survive cardiac surgery from those who were more likely not 
to survive. Nevertheless, the performance of the EuroSCORE II was satisfactory, especially 
in recent low risk CABG and non-CABG procedures. In patients who underwent AVR, both 
STS-PROM and EuroSCORE II over-predicted mortality. These fi ndings have implications 
for clinical decision-making, outcome comparisons, and research practices.
Several studies have reported reasonable performance of EuroSCORE II.7-13 Two of them 
compared the performance with the STS-PROM.7, 12 Kirmani et al. used data from more 
than 15 000 patients who underwent CABG, valve surgery or a combined procedure.12 
They concluded that both models provide equivalent discrimination, and that calibration 
is good in patients with a predicted risk of mortality <15%. Diff erences with the current 
results are most likely caused by the diff erent underlying patient population. The STS-
PROM and its variables are routinely collected, scrutinized and calculated in the U.S., 
whereas this is not the case in the majority of European centers.
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There are several reasons for the better performance of the STS-PROM compared with 
the EuroSCORE II. First of all, the STS-PROM was created using datasets that were much 
larger than the development datasets of the EuroSCORE II. The CABG model of STS-PROM 
version 2.61 was based on almost 500,000 patients, whereas the development cohort of 
the EuroSCORE II comprised less than 8000 CABG patients.6, 21 In addition, the EuroSCORE 
II dataset contained data from 43 countries ranging from China to Sudan, whereas the 
STS-PROM database only comprises U.S. centers. Moreover, the STS models used more 
elaborate statistical methods to deal with missing data. Taking these methodological 
considerations into account, the performance of the EuroSCORE II is still satisfactory; the 
diff erences with the STS-PROM are relatively small and calibration is even largely similar 
in low risk patients, which is the most common patient group in everyday clinical practice.
The current results support the importance of frequently updating risk scores. The sensi-
tivity analysis of recent cases showed that the calibration of both models improved when 
applied to contemporary practice. Whereas the STS-PROM score is regularly updated, the 
EuroSCORE II was essentially the fi rst update after the additive and logistic versions that 
were based on data from 1995.2, 3, 6 The poor calibration of the original EuroSCORE has 
been reported elaborately and was confi rmed again in this study.5 The update makes the 
EuroSCORE II better applicable to current practice. Operative techniques, patients, and 
general clinical management change over time and have an impact on outcomes. These 
developments cannot be neglected when developing and applying risk models.
The advantage of the EuroSCORE II is that it is easier to calculate. Whereas the STS-PROM 
contains more than 40 variables, the EuroSCORE II requires only 18 variables.22 Some 
studies even suggest that it could be further simplifi ed by removing 8 variables, without 
sacrifi cing performance.8 A parsimonious model is more user-friendly, less resource-
intensive and is more likely to be used in settings where risk scoring and collection of 
documentation of variables is not obligatory.
Implications for TAVI
Risk models are a method of standardizing inclusion into trials across diff erent study 
sites in diff erent countries. Although not designed for TAVI, the STS-PROM and EuroS-
CORE are currently used in several studies that investigate TAVI in patients with severe 
AS. Two major ongoing multinational trials compare TAVI with surgical AVR in patients at 
intermediate operating risk: the PARTNER 2 and SURTAVI trials.23 These trials use a STS-
PROM >4% to select intermediate risk patients. The validity of this method depends on 
the precision of these models to correctly identify the intermediate risk populations. Our 
study shows that the STS-PROM over-predicts mortality in these patients (O:E = 0.79 in 
intermediate and 0.71 in high risk patients). Dewey et al. found similar over-prediction by 
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STS-PROM in high-risk AVR patients (O:E = 0.71),4 and Osswald et al. showed a signifi cant 
over-prediction by the old logistic EuroSCORE (O:E = 0.20).24 Barili et al. compared the 
EuroSCORE II with the STS-PROM in patients that underwent isolated AVR and found that 
it was associated with worse discrimination, but better calibration as compared with the 
STS-PROM.7 Both scores had a tendency of under-prediction in higher risk patients in this 
dataset of 1758 Italian patients, of which a small proportion was at high risk. In the total 
dataset only 25 (1.4%) patients died, which makes inferences regarding discrimination 
and calibration in the small high risk group less reliable. We found that the EuroSCORE II 
over-predicts mortality in intermediate and high risk patients, and that its calibration is 
similar to the STS-PROM (O:E = 0.74 in intermediate and 0.51 in high risk patients).
If solely selected on the basis of these scores, patients are in fact at lower risk than antici-
pated. The mean STS-PROM in cohort A of the PARTNER trial was 12, which corresponds to 
an actual mortality of 8.5% (O:E = 0.71 in high-risk patients).25 TAVI trials aimed at patients 
with an estimated 4-10% risk of mortality are actually enrolling patients with mean esti-
mated risks of 6.0% (STS-PROM) or 6.2% (EuroSCORE II). Relying exclusively on risk scores 
may introduce bias in the interpretation of the study results due to model limitations. 
While underestimation leads to more conservative patient selection, overestimation 
leads to potentially recruiting patients for an investigational therapy, while they might 
be better off  with conventional AVR with well-established effi  cacy and long-term results.
Also in everyday clinical practice, decision-making should not be based solely on risk 
scores. There are several factors that are not included in the risk scores, but might be very 
important for outcomes: frailty, vessel tortuosity, porcelain aorta, chest wall malforma-
tion or chest radiation. Recently, gait speed was added to the updated STS-PROM as a 
proxy for frailty. New risk models that incorporate these variables are being developed, 
but need to be validated.23
A multidisciplinary heart team approach is essential to combine risk scores, clinical 
judgment and these additional aspects. Over the past years, multidisciplinary decision-
making has gained more attention in the cardiovascular community. The team includes 
a cardiac surgeon, interventional cardiologist, clinical cardiologist, nurse practitioner 
and specialists in imaging, heart failure, cardiac rehabilitation. Physicians have become 
accustomed to this approach and it is recommended to select the optimal treatment 
strategy for patients with aortic stenosis, both in everyday practice and in clinical trials.23
Implications for Outcome Comparisons across Centers
There is an increasing interest in comparative clinical outcomes analyses and perfor-
mance in high risk (cardiac) surgery is likely to be an important quality indicator. These 
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analyses require robust models to adjust for case-mix. However, our study shows that 
using the STS-PROM or EuroSCORE II in certain patient groups is inappropriate because 
of inadequate calibration. While the excellent calibration of the STS-PROM in recent 
CABG surgery allows for robust risk-adjustment, the limited performance in other pro-
cedures should be taken into account when comparing outcomes across centers. More 
specifi cally, comparison of outcomes in high risk patients is troublesome due to common 
miscalibration in these patients.13
Limitations
Defi nitions were based on the STS database, and for the EuroSCORE II, some assump-
tions based on clinical judgment and combinations of other variables had to be made. 
Prospective studies, collecting all the variables exactly according to their EuroSCORE II 
defi nitions are needed to overcome this limitation. Also, the STS-PROM was calculated at 
time of data entry, whereas the EuroSCORE II was calculated retrospectively. Therefore, 
we cannot rule out that the performance of the EuroSCORE II is an underestimation. Com-
parability with other validation studies of the EuroSCORE II is not hampered, since they 
also had a retrospective nature and applied similar assumptions. Although we performed 
a sensitivity analyses based on risk and mortality profi les over time, there is the possibil-
ity of dynamic changes in case-mix and risk factors infl uencing the results.17, 18
Another limitation is that risk models and the current manuscript focus on short-term 
mortality. Although the optimal timeframe for the mortality outcome is contentious, a vali-
dation study like ours should use the same outcome measure as the development study.
CONCLUSION
In a large U.S. multicenter database, the STS-PROM performs better than the EuroSCORE II 
for CABG. However, the EuroSCORE II is a reasonable alternative in recent low-risk CABG 
patients and in those undergoing other cardiac surgical procedures. For AVR, both models 
over-predict mortality. Clinical trials and physicians using these scores recruit patients 
that are at a lower risk than anticipated, potentially leading to overtreatment with an 
investigational device. Decision-making should not solely be based on risk scores, but 
should comprise multidisciplinary heart team discussions.
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APPENDIX
Conference Discussion, EACTS 27th Annual Meeting in Vienna, October 2013
Dr W.T. Brinkman (Dallas, TX, USA): The authors are to be complimented on the arduous 
task of trying to go through and reconcile these two disparate risk models. As you point 
out, the STS-predicted risk mortality is based on 500,000 patients, while the EuroSCORE 
II is 23,000 patients. In the STS-predicted risk, the mortality contains one of the 40 
variables, while in the EuroSCORE it is 18. And in fact, the STS database is soon going to 
expand to include more variables to take into account important factors such as cirrhosis, 
calcifi cation of the aorta, things like that.
So proper risk stratifi cation is critical with the advent of new disruptive technologies 
such as TAVR. Currently, the FDA in the United States limits the application of TAVR to 
non-operative and high-risk patients. To broaden the use of TAVR in the US, clear risk 
stratifi cation is mandatory. Trials such as SURTAVI and PARTNER II were designed with 
these questions in mind, as you brought up. So in the light of all that, I have some ques-
tions.
My fi rst question. When calculating your STS risk score, if the New York Heart Associa-
tion classifi cation was absent, you assumed it was Class I. That seemed to me to be an 
important factor in a patient with a valve disease. So what was the absent rate in valve 
patients where you were just assuming Class I? And might that be a problem for calculat-
ing the STS risk, seeing how the New York Heart Association is a strong variable in the 
STS calculation?
Dr Osnabrugge: What we did with the NYHA class is important. When you calculate the 
STS score online and you click on "Congestive Heart Failure," you’ll get a pop-up box 
where you can fi ll in the NYHA class. If you say okay, there is no congestive heart failure, 
then you don’t get that box, and that’s why we felt comfortable to say it was absent in 
those cases.
For the specifi c AVR subgroup, I don’t know the absent rate exactly for this subgroup. 
I would have to go back to the data. But, in line with my fi rst answer, I think we felt 
comfortable to assume Class I when NYHA was missing.
Dr Brinkman: Okay. My next question. Your data does support the STS for being superior 
in performance of all procedures and CABG, and your data was 80% CABG. So, with 
only 7% of AVR in your study group and a non-signifi cant diff erence between the AUC 
comparisons between the STS and the EuroSCORE, do you really think that proves that 
EuroSCORE II is a reasonable alternative to the STS, and is there enough power to really 
make that statement? Dr Osnabrugge: Well, of course, we would like to have more pa-
tients, but I think this is the largest AVR group in which the STS score and the EuroSCORE 
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II have been compared. So I think it’s the best data there is. And, yes, of course, even more 
patients would have been better.
Dr Brinkman: Okay. One fi nal question. In our cardiac surgery clinic in Dallas, on a daily 
basis, we calculate the STS for all our patients. It is required for a lot of reasons, and 
especially for inclusion in trials such as PARTNER II and SURTAVI, and it is not a big deal 
for us to go and use the online tool. It takes us just a few minutes. We don’t use the 
EuroSCORE. Could you tell me why we should be calculating the EuroSCORE?
Dr Osnabrugge: Well, that’s a great question. Less is more, maybe. The EuroSCORE II only 
has 18 variables. And if the performance is similar, I think it would be a good idea to also 
calculate the EuroSCORE II. But more importantly, it is also nice to have the EuroSCORE II 
to compare your patients to patients who are included in studies in Europe. It results in a 
better comparison when you look across the Atlantic.
Dr D. Pagano (Birmingham, U.K.): I have a comment and a question for you. The comment 
is that it is quite clear now that we have a paradox. If you look at the isolated, fi rst-time 
coronary artery bypass grafting, the mortality is so low for in-hospital mortality or short-
term outcome, that you almost don’t need risk stratifi cation consistently for mortality. 
The question is about the high-risk group. There is a common thread here. The groups in 
which it is very important to make a clinical decision, particularly when there are alterna-
tives, are the groups in which the risk algorithms perform badly. Have you got an idea 
why that may be the case, and how would you improve that?
Dr Osnabrugge: The question is, why in the high-risk patients are the scores performing 
badly? There are always fewer patients in this higher-risk category, so the estimates 
become unstable. It is unfortunate, but we have less data on these patients.
Dr Pagano: Can I have the opportunity of asking Fred what he thinks about this issue, 
because it is a fundamental issue?
Dr F.H. Edwards (Chicago, IL, USA): First of all, I think it is a great question, and I agree with 
your answer. Yes, you’ve got smaller numbers once you get up into that higher spectrum. 
For years at STS we’ve talked about just accumulating those high-risk patients and mak-
ing a separate risk model devoted specifi cally to those higher-risk patients. And over the 
years, we would have enough numbers, I think, to be able to obviate the problem that 
you point out. So we’re going to try to do that. In the meantime, I think we’re just left with 
exactly the situation that you describe and, again, I think your answer to it is perfect.
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Dr J. Gummert (Bad Oeynhausen, Germany): One more question. Could you speculate, if 
you were to make the same analysis in European patients comparing EuroSCORE II and 
STS score, could it be possible that the diff erence you’ve seen refl ects maybe diff erences 
in the diff erent healthcare systems, in terms of indication, in terms of treatment policies?
Dr Osnabrugge: It is diffi  cult to really pinpoint that that would be the reason. There has 
been, off  the top of my head, one other study which looked at this. They got similar 
results with slightly fewer patients. That was a European data set, and the overall conclu-
sion was similar.
Dr N. Van Mieghem (Rotterdam, the Netherlands): First of all, I wanted to mention when 
you determined the STS score and you didn’t know the New York Heart Association class, 
if it was I, II, or III, does that not change the score? That is to begin with. And then the 
other thing is, it is very diffi  cult to compare risk models if you do not use the same defi ni-
tions. For instance, peripheral arterial disease is defi ned diff erently in EuroSCORE and 
STS. So did you take that into account?
Dr Osnabrugge: It is diffi  cult, and that is defi nitely a limitation of this comparison. That is 
the only thing I can say about it. And with regard to the fi rst question on NYHA class, this 
is more of a problem if you want to calculate the EuroSCORE II and you have to include 
the NYHA class there, that is where the problem arises. Not in the STS score, because it is 
included there sort of automatically.
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ABSTRACT
Objective
Risk prediction in adult patients undergoing cardiac surgery remains inaccurate and 
should be further improved. Therefore we aimed to identify risk factors that are predic-
tive of mortality, stroke, renal failure, and/or length of stay after adult cardiac surgery in 
contemporary practice.
Methods
We searched the Medline database for English-language original contributions from 
January 2000 through December 2011 to identify pre-operative independent risk fac-
tors of one of the following outcomes after adult cardiac surgery: death, stroke, renal 
failure, and/or length of stay. Two investigators independently screened the studies. 
Inclusion criteria were: (i) the study described an adult cardiac patient population; (ii) the 
study was an original contribution; (iii) multivariable analyses were performed to identify 
independent predictors; (iv) ≥1 of the predefi ned outcomes was analyzed; (v) at least one 
variable was an independent predictor, or a variable was included in a risk model that 
was developed.
Results
The search yielded 5,768 studies. After the initial title screening a second screening of 
the full texts of 1,234 studies was performed. Ultimately, 844 studies were included in 
the systematic review. In these studies, we identifi ed a large number of independent 
predictors of mortality, stroke, renal failure, and length of stay, which could be cat-
egorized in variables related to: disease pathology, planned surgical procedure, patient 
demographics, patient history, patient co-morbidities, patient status, blood values, urine 
values, medication use, and gene mutations. Many of these variables are frequently not 
considered as predictive of outcomes.
Conclusions
Risk estimates of mortality, stroke, renal failure, and length of stay may be improved 
by inclusion of additional (non-traditional) innovative risk factors. Current and future 
databases should consider collecting these variables.
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INTRODUCTION
Predicting procedural mortality in adult cardiac surgery is critical for decision-making 
purposes particularly when there are diff erent treatments options available, as well 
as for benchmarking and outcome evaluation both at institutional and surgeon level. 
Several prediction models have been developed with the main goal of estimating the risk 
of operative mortality for patients undergoing coronary artery bypass grafting (CABG), 
aortic valve replacement (AVR), or cardiac surgery in general.1-4 Despite their useful-
ness, it remains challenging to develop a risk model that performs accurately across the 
spectrum of low-, intermediate-, and high-risk patients evaluated for cardiac surgery. 
Although the recently developed EuroSCORE II may be associated with improvements 
when compared to the original additive and logistic EuroSCOREs,5 risk prediction remains 
a challenge in European patients.6-8 The Society of Thoracic Surgeons (STS) score has 
shown to outperform the EuroSCORE,9-11 but still a number of studies has demonstrated 
poor model performance in certain patient subgroups.12-14 Especially in high-risk patients, 
risk models have been shown to be poorly calibrated and overpredict mortality.
The reasons for suboptimal model performance are multifactorial. While conventional 
cardiovascular risk factors (e.g. renal failure, diabetes) are considered for inclusion in a 
model, less obvious factors may be valuable as well. Many risk models are developed 
through standard statistical approaches not taking into account risk factor interactions 
or procedure-specifi c weightings.15 A mismatch is frequently present between the model 
development patient cohort and the patient cohort that it is used for in practice; some 
patient subgroups are continuously underrepresented.
Considering these arguments, it is important to i) clarify the purpose of a model, ii) 
develop a model that is useful, and iii) defi ne the limits of that usefulness. Any model 
should be based on the available literature and clinical intuition to defi ne the appropri-
ate dataset for model development.
The EACTS is establishing a quality improvement programme for adult cardiac surgery 
with an international database as an important component, aiming to bring forward an 
EACTS risk model. We performed a systematic review of the literature to identify which 
variables may need to be collected to be able to develop a better risk prediction model.
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METHODS
Search Strategy
We systematically searched the Medline database for English-language original contribu-
tions from January 2000 through December 2011 to identify pre-operative independent 
risk factors of one of the following outcomes after adult cardiac surgery: death, stroke, 
renal failure, and/or length of stay. Our search entry consisted of outcome keywords: 
‘mortality’ OR ‘death’ OR ‘stroke’ OR ‘cerebrovascular event’ OR ‘renal failure’ OR ‘length 
of stay’ OR ‘LOS’; subject keywords: ‘cardiac surgery’ OR ‘heart surgery’ OR ‘heart valve 
surgery’ OR ‘valve replacement’ OR ’AVR’ OR ‘MVR’ OR ‘valve repair’ OR ‘MVP’ OR ‘coro-
nary artery bypass grafting’ OR ‘CABG’; and analysis keywords: ‘risk model’ OR ‘risk score’ 
OR ‘risk factor’ OR ‘independent’ OR ‘multivariate’ OR ‘multivariable’ OR ‘c-index’ OR 
‘c-statistic’ OR ‘area under the curve’ OR ‘AUC’.
Study Inclusion
Two investigators (S.J.H. and R.L.J.O) independently screened the studies identifi ed by 
the search. During the fi rst round of screening all titles were judged for their relevance. 
Studies evaluating non-cardiac surgery, percutaneous or transcatheter therapies, or di-
agnostic modalities were excluded. Many risk models have been developed for coronary 
artery bypass surgery and/or valvular surgery, therefore to be homogeneous but also 
comprehensive, we excluded studies that focused on pediatrics, congenital cases, aortic 
arch or root surgery, or heart transplants. Studies that were inconclusive with respect to 
the performed procedures and reported outcomes of a non-defi ned group, for example 
“patients that underwent cardiac surgery”, were included.
After identifying potentially relevant studies, the full-length articles were screened using 
the following criteria: (i) the study indeed described an adult cardiac patient population; 
(ii) the study was an original contribution; (iii) multivariable analyses were performed 
to identify independent predictors; (iv) the outcome of mortality, stroke, renal failure, 
and/or length of stay was assessed; and (v) at least one variable was an independent 
predictor, or a variable was included in a risk model that was developed.
Data Extraction
For each endpoint, independent predictors were extracted from the included studies. 
The terminology of predictors diff ered signifi cantly among studies. For example, “aortic 
calcifi cation” was also reported as “extend of atherosclerotic ascending aorta disease”, 
“thoracic aorta total plaque-burden”, or “severe atheromatous aortic disease”. Risk fac-
tors were measured and reported according to diff erent indexes; for example, renal func-
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tion was indicated with serum creatinine, creatinine clearance, or estimated glomerular 
fi ltration rate. Such variations were merged into a single variable to avoid repetition.
RESULTS
The search yielded 5,768 results (Figure 1). After excluding non-relevant studies from an 
initial title screening a second screening of the full texts of 1,234 studies was performed. 
Another 351 studies were found to be irrelevant because the patient population did not 
meet the criteria, the endpoint used was not death, stroke, renal failure, or length of stay, 
or no independent predictors were identifi ed. The full texts of 78 studies could not be 
retrieved so the abstracts were screened for their relevance. Ultimately, 844 studies were 
included in the systematic review.
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Figure 1. Flow Diagram: Systematic Inclusion of Studies
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The diagnosed disease pathology and planned surgical procedure are essential elements 
in a risk model and always need to be documented (Table 1). The independent predictors 
of death, stroke, renal failure, and length of stay are listed in Tables 2-5. The predic-
tors were categorized as patient demographics, patient history, patient co-morbidities, 
patient status, blood values, urine values, medication use, and gene mutations.
DISCUSSION
In this systematic review we screened 5,768 studies and included 844 studies in which 
we identifi ed relevant independent predictors of death, stroke, renal failure, and length 
of stay after adult cardiac surgical procedures. This study was the fi rst to identify sys-
tematically all predictors of adverse events after coronary artery bypass grafting and/or 
valvular surgery in adults. Many risk factors with a signifi cant impact are frequently not 
considered when evaluating patients for major invasive procedures. Decision-making 
may be improved by taking into account these neglected yet predictive risk factors. 
Beside demographics (e.g. age, gender), disease complexity (e.g. coronary and/or valve 
lesions), and co-morbidities (e.g. renal failure), other factors such as medication intake 
and the patient’s psychiatric, mental, and social-economic status have also been shown 
to have a predictive power.16-17
Over the last decade(s) there has been a growing interest in risk prediction models both 
for monitoring innovations and benchmarking outcomes as well as for clinical use to 
multidisciplinary shared-decision-making. The latter is especially true in an era of ex-
panding multi-modality therapy for coronary artery and aortic valve disease when risk 
Table 1. Patient’s Disease Pathology and Planned Surgical Procedure
Disease pathology Planned surgical procedure
Number of coronary vessel disease Coronary artery bypass grafting
Signifi cant left main stenosis Aortic valve replacement
Coronary artery disease complexity (e.g. SYNTAX score) Aortic valve repair
Aortic valve stenosis Aortic root surgery
Aortic valve regurgitation Mitral valve replacement
Mitral valve stenosis Mitral valve repair
Mitral valve regurgitation Tricuspid valve replacement
Tricuspid valve regurgitation Tricuspid valve repair
Persistent atrial fi brillation Aortic surgery
Ascending aorta aneurysm MAZE
Aortic arch aneurysm
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prediction plays an important role to determine which patients would benefi t most from 
surgery or interventional therapy.18
The inaccuracy of risk models may in part be due to the selection of variables.18 As 
shown by previous studies, risk models are inconsistent in including variables and are 
missing several diff erent yet important risk factors,19-20 although until now it has been 
unclear which factors need to be considered. Furthermore, diff erent defi nitions are used 
for some of the risk factors, resulting in a diff erent weighting of that factor between 
models. Collection of the variables identifi ed in this study may help to improve future 
risk models, and standardize risk factor defi nitions best suitable for inclusion.
A number of studies has identifi ed genetic variations or mutations that carry an increased 
risk of adverse events after cardiac surgery. Indeed, collection of these variables in a large 
database could potentially provide insights into the understanding of the patient’s risk, 
but it might be too optimistic to apply genetic profi ling to a large international database. 
Costs of sequencing technologies are decreasing, but genetic profi ling is still not widely 
used. It will be interesting to see whether genetic phenotyping might be more suitable 
to identify patients at higher risk of adverse events,21 although little evidence is available 
at this time to use this technique for risk stratifi cation in cardiac surgery. Some of the 
laboratory values or echocardiographic measures that have shown to be independent 
predictors may be too costly to collect. Quality of life assessments are time-consuming 
activities that will need to be performed by educated research nurses. Therefore, a model 
will always be lacking some variables that could potentially increase its performance.
The balance between the number of variables and model performance should be carefully 
considered when developing a risk model. Although many variables may be predictive 
(Tables 2-5), they cannot all be included because this will decrease the user-friendliness 
of the model.22 Furthermore, a great number of variables will likely result in missing data 
that will have a negative impact on the accuracy of a newly developed risk model. On 
the other hand, ignoring some of these variables may produce a model with modest 
performance at best. It is recommended to exclude only variables with little impact on the 
predictive value of the model. Factors must be relatively present in the population, and 
enough adverse events must occur in a frequent manner to be able to have enough power 
for each risk factor to weight it in a multivariate model. Factors that are only present in 
a very small minority (<1%) of patients may not be relevant to collect, although their 
relative weight may be high. Ideally, the impact of the identifi ed risk factors would be 
used to select which factors are more important to collect than others. However, to obtain 
an accurate estimate of the impact on the model, a broad range of risk factors need to 
be collected – including (non-)conventional factors – in a large database. Only then can 
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Table 2. Independent Predictors of Death
Demographics Age; Gender; Race; Weight; Height; Body surface area; Geographic region (city, rural); 
Social economic status; Employment status (unemployed); Type of personality; Family 
history; Primary payer; Current smoker; Alcohol abuse
History Pack-years smoking; Previous hospitalization for heart failure; Timing and number of 
previous PCI; Timing of congestive heart failure; Timing and location of previous MI*; 
Timing of dialysis; Timing of previous TIA/CVA; Timing of previous angina; History of 
hematological disorder/coagulopathy; Previous surgery for thrombosis; History of 
thyroid disease; Immune defi ciency; Connective tissue disease; Pathological weight-
loss; Pacemaker implantation; Number and type of reoperations
Co-morbidities Diabetes; Metabolic syndrome; Cerebrovascular disease; Neurologic disorder; 
Depression; Anxiety; Psychoses; Carotid artery disease; Peripheral vascular disease; 
(Severity of) Atherosclerotic aortic disease; Atrial fi brillation; Type of arrhythmia; 
Hypertension; Pulmonary function/disease (e.g. COPD); Pulmonary hypertension; Renal 
function/failure; Liver function/disease; Malignancy
Peptic ulcer disease
Status Frailty; Energy level; Problems with self-care; Non-ambulatory state; Mental 
component score (SF-36); Physical component score (SF-36); Health status (EQ-5D); 
CCS classifi cation; NYHA classifi cation; LVEF; LV end-systolic diameter/volume; LV 
hypertrophy; LV end-diastolic pressure/diameter; Restrictive LV fi lling; LV posterior wall 
thickness; LV mass index; Lack of contractile reserve; Left atrial diameter; Small annulus; 
RV end-diastolic area; Right atrial pressure; Cardiothoracic ratio; Heart rate; Conduction 
defect; Corrected QT interval; Amount of ST-segment depression; Pre-operative 
ICU stay; On intubation/ventilation; Sepsis; Active endocarditis; Vegetation size 
(endocarditis); Prosthetic valve endocarditis; Staphylococcus endocarditis infection; 
Pulmonary edema; Ventilator-associated pneumonia; Multi organ failure; Ventricular 
assist device; Resuscitation; Postinfarct septal rupture; Unstable/Shock; Intra-aortic 
balloon pump; Urgency of surgery; ASA score; Pulse pressure
Blood values Hemoglobin; Hematocrit; Homocysteine; Creatinine; HbA1c; Glucose; CRP; BNP; 
NT-proBNP; Interleukin 6; Endotoxin core antibody; Sodium; Magnesium; Protein; 
Albumin; Bilirubin; ASAT; Uric acid level; CK-MB; High-sensitive Troponin T; Troponin T; 
Troponin I; Lactate dehydrogenase; INR group; PTT; Antithrombin 3; HPF4 antibodies; 
Thrombocytes; Lymphocyte; Neutrophil; Total cholesterol; Non-HDL cholesterol; 
Cholesterol esters; Triglycerides
Urine values Proteinuria
Medications Aspirin; Warfarin or Coumadin; Other anticoagulant; Thrombolysis; Nitroglycerin; 
Statin; Beta-blocker; Catecholamine; Digoxin; Digitalis; Antidepressant (SSRI); Inotropic 
support; Immunosuppressive therapy
Gene mutations C677T mutation in MTHFR gene; VEGF +405 GG; rs10116277 (2 allele) -- Chromosome 
9p21; rs1042579 recessive
*Inferior/anterior myocardial infarction. ACE, angiotensin-converting enzyme; ASA, American Society of 
Anaesthesiologists; BNP, brain natriuretic peptide; CCS, Canadian Cardiovascular Society; CK-MB, creatine 
kinase myocardial band; COPD, chronic obstructive pulmonary disease; CRP, c-reactive protein; CVA, cere-
brovascular accident; HDL, high density lipoprotein; HPF4, heparin-platelet factor 4; INR, international nor-
malized ratio; MI, myocardial infarction; NT-proBNP, N-terminal-pro-brain natriuretic peptide; NYHA, New 
York Heart Association; PTT, partial thromboplastin time; SSRI, selective serotonin reuptake inhibitor; TIA, 
transient ischemic attack.
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unnecessary risk factors be excluded. Collection of these factors will furthermore identify 
specifi c factors with international variation in prevalence or dynamic eff ect weights, which 
might result in diff erent or a changing impact of factors on short- and/or long-term risk.23
It is unrealistic to collect for each patient the hundreds of variables that were identifi ed 
in this study. It might be appropriate to start data collection with a small selection of 
centers as a feasibility project. This helps to determine the relative impact of certain 
variables and whether it is necessary and possible to collect these on a larger scale. Nev-
ertheless, even in a feasibility design there are variables that may need to be prioritized 
over others. This study provides a framework for future model development, from which 
certain variables can be chosen depending on the prevalence of a risk factor, its relative 
Table 3. Independent Predictors of Stroke
Demographics Status
Age Left ventricular ejection fraction
Gender Active infection
Race Active endocarditis
Body surface area Intra-aortic balloon pump
Current smoker Unstable/Shock
History Urgency of surgery
Timing of smoking Pulse pressure
Timing of previous TIA/CVA Blood
Timing of previous MI Hemoglobin
Previous deep vein thrombosis Creatinine
Number of reoperations INR group
Dialysis Medications
Co-morbidities Aspirin
Diabetes Statin
Cerebrovascular disease ACE inhibitor
Neurologic status (e.g. defi cit, dementia) Beta-blocker
Carotid artery disease Inotropic support
Peripheral vascular disease Gene mutations
(Severity of) Atherosclerotic aortic disease Interleukin 6 (−174G/C)
Atrial fi brillation CRP 3'UTR1846C/T
Hypertension
Hypercholesterolemia/lipidemia
Renal function/failure
Pulmonary hypertension
Left ventricular hypertrophy
ACE, angiotensin-converting enzyme; CVA, cerebrovascular accident; INR, international normalized ratio; 
MI, myocardial infarction; TIA, transient ischemic attack.
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impact, the patient population, the type of model (e.g. short-or long-term), the endpoints 
for which the model is developed, and the cost and resources available.
Risk models that have been developed on a cohort of patients undergoing a specifi c 
procedures may have limited value when applied to other population groups, as the 
impact of any one variable can have a very diff erent weighting when applied to a cohort 
of patients undergoing another procedure. This may also be one of the reasons why risk 
models fail to predict accurately outcomes of low- to high-risk patient cohorts. This is 
clearly evident when examining the predictive power of the original EuroSCORE. It was 
developed on relatively low-risk patients undergoing CABG24 but subsequently has been 
widely used with limited value for high-risk AVR, probably because such patients were 
hardly represented in the EuroSCORE database.
The EuroSCORE II was developed with 22381 patients of which 46.7% and 46.3% under-
went isolated CABG and valve procedures, respectively.5 However, recent evidence sug-
gests that this more balanced inclusion of procedures was at the expense of decreased 
model performance in isolated CABG procedures.8 Although generic risk models are 
useful in describing the risk profi le of large patient populations included in randomised 
clinical trials or registries, procedure-specifi c models for CABG, AVR, and mitral valve 
surgery are advocated to increase risk prediction for individual patients. Clearly some 
of the risk factors we identifi ed will more likely be included in a CABG risk model while 
Table 4. Independent Predictors of Renal Failure
Demographics Age; Gender; Race; Height; Weight; Body surface area
History Timing of previous MI; Timing of recent cardiac catheterization; Timing of previous 
PCI; Dialysis; Congestive heart failure; Number or reoperations
Co-morbidities Diabetes; Metabolic syndrome; Cerebrovascular disease; Carotid artery disease; 
Peripheral vascular disease; Atrial fi brillation; Hypertension; Renal function/failure; 
Pulmonary disease (e.g. COPD); Pulmonary hypertension; Charlson comorbidity 
index
Status CCS classifi cation; NYHA classifi cation; Left ventricular ejection fraction; Sepsis; 
Active endocarditis; Intra-aortic balloon pump; Unstable/Shock; Urgency of surgery; 
ASA physical status
Blood values Hemoglobin; Hematocrit; Creatinine; Platelet count; HbA1c; Hyperuricemia; Urea 
nitrogen; Bicarbonate; Sodium; Albumin; Bilirubin
Urine values Albumin to creatinine ratio; Proteinuria
Medications Statin; Calcium channel blocker; ACE inhibitor; Renin-angiotensin system inhibitor; 
Diuretic; Immunosuppressive therapy
Gene mutations Catechol-O-methyltransferase LL
ACE, angiotensin-converting enzyme; ASA, American Society of Anaesthesiologists; CCS, Canadian Cardio-
vascular Society; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction; NYHA, New York 
Heart Association; PCI, percutaneous coronary intervention.
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endocarditis, respectively. The predictive power of some factors remains unclear when 
evaluating a cohort of patients undergoing a specifi c procedure, which is why there is a 
need to collect these factors in a generic database. This will furthermore provide the op-
portunity to examine whether useful generic models with procedure-related interaction 
terms can be constructed or whether only procedure-specifi c models are required for 
accurate risk prediction.
One major limitation of the widely used European risk scores remains that they have 
been developed to predict operative mortality although this is not the only outcome 
of interest to either patients, health care systems or policy makers. Many variables 
predictive of death will also be signifi cant for other outcomes including renal failure, 
stroke, and length of stay. However, the associated odds ratios might be diff erent for 
specifi c outcomes. For example, in the STS model for isolated valve surgery the OR of 
active infectious endocarditis for mortality is 1.95 (95% CI 1.68-2.27) but 2.79 (95% CI 
2.51-3.09) for prolonged length of stay.4 One of the goals of the forthcoming EACTS risk 
model will be to develop a model able to predict accurately multiple outcomes using 
outcome-specifi c ORs, similar to the STS risk model.
Table 5. Independent Predictors of Length of Stay
Demographics Age; Gender; Race; Height; Weight; Body surface area; Geographic region (e.g. rural 
area); Social status
History Previous TIA/CVA; Previous embolism; Timing of MI; Timing of PCI; (Duration 
of preceding) Hypertension; Previous arrhythmia treatment; Dialysis; Previous 
endocarditis; Congestive heart failure; Number of reoperations
Co-morbidities Diabetes; Cerebrovascular disease; Peripheral vascular disease; Atherosclerotic aortic 
disease; Atrial fi brillation; Arrhythmia; Hypertension; Pulmonary function/disease (e.g. 
COPD); Pulmonary hypertension; Renal function/failure; Post-traumatic stress disorder; 
Depression; Liver function/failure; Malignancy; Dyslipidemia/hypercholesterolemia; 
Hyperglycemia
Status SF-36 quality of life; CCS classifi cation; NYHA classifi cation; Left ventricular ejection 
fraction; Diastolic dysfunction; Right ventricular end-systolic diameter; Cardiothoracic 
ratio; Frailty; Immunosuppressive therapy; Rheumatic fever; Active infection; Active 
endocarditis; Large endocarditis vegetation (15mm); Unstable/Shock; Intra-aortic 
balloon pump; Urgency of surgery
Blood values Hemoglobin; NT-pro-BNP; BNP; Creatinine
Medications Beta-blocker; Nonaspirin platelet inhibitor; Inotropic support
Gene mutations Il-8-251AA; Catechol-O-methyltrasferase LL
BNP, brain natriuretic peptide; CCS, Canadian Cardiovascular Society; COPD, chronic obstructive pulmonary 
disease; CVA, cerebrovascular accident; MI, myocardial infarction; NT-proBNP, N-terminal-pro-brain natri-
uretic peptide; NYHA, New York Heart Association; PCI, percutaneous coronary intervention; TIA, transient 
ischemic attack.
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Although risk models can be improved, random events will always occur and a predic-
tion model can therefore never be perfect. Thus, clinical guidelines recommend that 
clinical decision-making related to interventional and surgical interventions should be 
performed by a multidisciplinary Heart Team that consists of at least an interventional 
cardiologist and cardiovascular surgeon to interpret and weight risk models and addi-
tional information to come up with the most appropriate treatment recommendation for 
the individual patient.25
Limitations
The focus of this study was adult patients undergoing coronary artery bypass grafting 
and/or valve surgery, because the available surgical risk models have predominantly 
been developed for these populations. Although there may indeed be signifi cant over-
lap, the identifi ed independent risk factors may not be applicable to other surgeries such 
as on the aortic root or aorta, congenital cases, or heart transplantations.
Conclusions
This systematic review identifi ed a signifi cant number of independent predictors of 
adverse outcomes after adult coronary and valvular procedures, many of which are 
frequently not considered. These variables will be collected in a dedicated European 
database, and used for the development of the forthcoming EACTS risk model. However, 
the clinical value of these risk factors needs to be weight against the cost and eff ort of 
collecting them.
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Risk scores, such as The Society of Thoracic Surgeons (STS) Predicted Risk of Mortality 
(PROM) and the European System of Cardiac Operative Risk Evaluation (EuroSCORE), are 
important tools to better understand which variables play a role in predicting hospital 
outcome in patients undergoing cardiac surgery. However, these scores are inadequate 
to predict long-term outcome and unable to assess the negative consequences of a 
procedure. Risk-benefi t analysis is particularly important when several treatment options 
are available. Myocardial revascularization by either percutaneous coronary intervention 
(PCI) or coronary artery bypass graft surgery (CABG) is appropriate when the expected 
benefi ts, in terms of survival or health outcomes (symptoms, functional status, and 
quality of life), exceed the expected negative aspects of the procedure. For multivessel 
disease, CABG is associated with a lower rate of major adverse cardiac and cerebrovas-
cular events, mainly driven by a lower repeat revascularization rate and in subsets even 
with a lower mortality. Conversely, surgery is associated with post-operative cognitive 
impairment and higher stroke rate, longer hospitalization, and post-operative pain. The 
tradeoff  that physicians and patients face in choosing between the benefi ts of CABG 
versus PCI (or medical treatment) requires complex risk-benefi t modeling.
The decision support tool as presented by Raza and colleagues1 is a valuable instrument 
as it predicts prognosis after PCI and CABG. A model was constructed to predict 5-year 
outcome for CABG versus PCI with drug-eluting stents and 10-year outcome of CABG ver-
sus PCI with bare metal stents. The reliability of these models depends on the variables 
that were collected in the past and that can be used to construct a model that is reliable 
in the current era.2 The extensiveness of coronary artery disease is a major predictor 
for outcome among patients treated with PCI, and the categorization of patients into 
one-, two-, or three-vessel disease is insuffi  cient. There are patients with three-vessel 
disease with discrete lesions and easy to treat with PCI (type A lesions); and there are 
also patients with chronic total occlusions, excessive tortuosity, or a length of more than 
2 cm (type C lesions) whose outcome for PCI is less optimal. The Synergy Between Per-
cutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) score takes 
these factors into account and is a major predictor for outcome with PCI.3 Cardiologists 
are treating increasingly complex lesions, and a description of the coronary anatomy 
is crucial to account for these diff erences in practice. Raza and coworkers1 provide an 
example how their model can be used to predict long-term outcome with PCI or CABG 
in patients with left main stenosis. That should, however, be interpreted with caution. A 
midshaft left main stenosis is diff erent from one with bifurcation or associated three-
vessel disease. The SYNTAX study showed that even patients with diabetes mellitus and 
left main stenosis with a low SYNTAX score did as least as good with PCI as with CABG 
whereas patients with a higher SYNTAX score and left main stenosis were better off  
with surgery.2 If the results of the SYNTAX study are repeated in the EXCEL (Evaluation 
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of XIENCE PRIME Everolimus Eluting Stent System or XIENCE V EECSS Versus Coronary 
Artery Bypass Surgery for Eff ectiveness of Left Main Revascularization) trial (PCI versus 
CABG in left main stenosis and a SYNTAX score less than 33), it is likely that the recom-
mendation for PCI in patients with left main disease will be upgraded.
The recently published SYNTAX score II combines anatomic factors as well as comorbidi-
ties to predict long-term mortality associated complex coronary artery disease.4
These models help physicians to make recommendations, but a heart team approach 
to individualize treatment is needed to ensure that every patient receives the optimal 
therapy. The paper by Raza and colleagues adds to the armamentarium of the heart 
teams so as to not only focus on hospital mortality but also on the long-term results as 
well.1 It is hoped that future models will also be able to predict outcomes other than just 
mortality.
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Chapter 19. Meta-Analysis on CYP2C19 and Clopidogrel Response – Letter
TO THE EDITOR:
The meta-analysis of Mega et al. shows that among patients treated with clopidogrel for 
percutaneous coronary intervention, carriage of 1 reduced function CYP2C19 allele is 
associated with an increased risk of major adverse cardiovascular events (hazard ratio 
(HR), 1.55; 95% confi dence interval (CI), 1.11-2.17).1 Two methodological issues hamper 
the interpretation of the results.
First, the authors used an inappropriate strategy to reduce the substantial heterogeneity 
in their meta-analysis (I2 = 73%). They removed the two studies that caused heterogene-
ity (AFIJI2 and FAST-MI3) and found that the summary HR remained signifi cant (HR, 1.42; 
95% CI, 1.19-1.69; I2 = 0%). Removing the AFIJI study seems justifi ed since the mean 
age, smoking status and sex of the patients were substantially diff erent compared to 
the other studies.2 For example, the mean age of patients in the AFIJI study was 40.1 
years, whereas the overall mean age across all studies was 64.2 years. Yet, excluding 
the FAST-MI study cannot be justifi ed. The study is very comparable and should not be 
removed for the mere fact of introducing heterogeneity.3 We repeated the meta-analysis 
excluding AFIJI only and found a lower and borderline signifi cant summary HR of 1.34 
(95% CI, 1.01-1.78; I2 = 62%).
Second, the authors did not report on the assessment of potential bias that may have 
impacted their results. It is known that meta-analyses are subject to bias including fi rst-
study, selective reporting and publication bias.4, 5 The presence of bias is examined using 
several plots and tests that are available. One indication for the presence of publication 
bias is a diff erence in eff ects between the large and small studies.5 We compared the 
summary HR of the four smallest and four largest studies and found a summary HR of 
2.09 (95% CI, 1.29-3.40; I2 = 0%) in the smallest studies and a HR of 1.15 (95% CI, 0.84-
1.59; I2 = 75%) in the largest studies. The absence of a genetic association in the larger 
studies suggests that the statistically signifi cant HR in the overall meta-analysis may be 
due to publication bias.
Our analyses raise questions about the presence of an association between CYP2C19 
and the risk of adverse cardiovascular events in users of clopidogrel. More studies are 
needed to clarify the persisting heterogeneity in results.
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ABSTRACT
We systematically investigated how 11 overlapping meta-analyses on the association 
between CYP2C19 loss-of-function alleles and clinical effi  cacy of clopidogrel could yield 
contradictory outcomes. The results of the meta-analyses diff ered because more recent 
meta-analyses included more primary studies and some had not included conference 
abstracts. Conclusions diff ered because between-study heterogeneity and publication 
bias were handled diff erently across meta-analyses. All meta-analyses on the clinical 
endpoint observed signifi cant heterogeneity and several reported evidence for publica-
tion bias, but only one out of eight statistically signifi cant meta-analyses concluded that 
therefore the association was unproven and one other refrained from quantifying a pooled 
estimate because of heterogeneity. For the endpoint stent thrombosis, all meta-analyses 
reported statistically signifi cant associations with CYP2C19 loss-of-function alleles with 
no statistically signifi cant evidence for heterogeneity, but only three had investigated 
publication bias and also found evidence for it. One study therefore concluded there was 
no evidence for an association, and one other doubted the association because of a high 
level of heterogeneity. In summary, meta-analyses on the association between CYP2C19 
loss-of-function alleles and clinical effi  cacy of clopidogrel diff ered widely with regard 
to assessment and interpretation of heterogeneity and publication bias. The substantial 
heterogeneity and publication bias implies that personalized antiplatelet management 
based on genotyping is not supported by the currently available evidence.
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INTRODUCTION
Clopidogrel, in combination with aspirin, is a standard treatment for patients with acute 
coronary syndrome (ACS) and is one of the top-selling drugs in the world.1, 2 However, there 
is substantial inter-individual variability in response. Polymorphisms of the Cytochrome 
P450 (CYP) gene have been identifi ed as a potential risk factor for non-response.3 This 
gene plays a central role in drug metabolising processes in the liver and clopidogrel makes 
use of these processes to transform into an active metabolite capable of inhibiting platelet 
aggregation. Identifi cation of CYP2C19 polymorphisms could lead to personalized treat-
ment based on genotype in patients with ACS and therefore the US Food and Drug Admin-
istration recommends CYP2C19 genotyping for individualized antiplatelet management.4
The association between CYP2C19 loss-of-function alleles and clinical effi  cacy of clopi-
dogrel has been studied extensively and several meta-analyses have summarized the 
results of those studies.5-8 Systematic reviews and meta-analyses are often considered 
the highest level of evidence,9-11 and their popularity in the cardiovascular fi eld increased 
almost 13 times as fast as the increase in number of published randomized clinical trials 
(RCT).12 However, the interpretation of meta-analyses is confusing when the conclusions 
of overlapping meta-analyses are discordant. Some meta-analyses on CYP2C19 loss-of-
function and clinical effi  cacy of clopidogrel conclude that the association is proven,7, 8 
whereas others conclude the opposite.5, 6
Our objective was to systematically evaluate the discordant evidence for the association 
between CYP2C19 loss-of-function alleles and clinical effi  cacy of clopidogrel through a 
critical methodological appraisal of published meta-analyses.
MATERIALS AND METHODS
Our review adheres to the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) statement,13 and we consulted the Cochrane Handbook for Systematic 
Reviews of Interventions for methodological aspects of meta-analyses.14
Literature Search and Study Selection
A MEDLINE search was performed in August 2013 using a combination of search terms: 
(clopidogrel OR Plavix OR Iscover OR thienop* OR P2Y12) AND (cytochrome OR cyp OR 
polymorph* OR genetic*) AND (review OR meta-analysis). The Cochrane Database of 
Systematic Reviews, The Web of Knowledge, EMBASE and reference lists of retrieved 
systematic reviews were inspected for additional studies.
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Two reviewers (RO and SH) independently assessed all titles and abstracts for eligibility, 
and examined all full-text articles to fi nd meta-analyses of CYP2C19 polymorphisms and 
clinical outcomes in clopidogrel users. Disagreements were resolved by discussion.
Data Extraction
General, clinical and methodological characteristics of each meta-analysis were 
extracted from for each meta-analysis, independently by two researchers (RO and 
ACJWJ). General characteristics consisted of fi rst author, year of publication, and the 
date (month/year) when the authors had performed their systematic search. Clinical 
characteristics comprised the population and outcome defi nitions, and methodological 
characteristics were the eligibility of abstracts, the number of included studies, the 
method of assessment of primary study quality, details of the statistical analysis (ran-
dom/fi xed eff ects meta-analysis), and the main results with confi dence intervals. The 
literal conclusion of the authors about the presence of an association was documented 
from the abstract and categorized into present or absent. When the literal conclusion 
was unclear or not reported in the abstract, the wording was obtained from the discus-
sion in the main text.
We examined whether and how the meta-analyses had addressed between-study 
heterogeneity and publication bias. These methodological characteristics are important 
for grading the quality of the evidence in the Grades of Recommendation, Assessment, 
Development and Evaluation (GRADE) and Assessment of multiple systematic reviews 
(AMSTAR) tools.15-17 Heterogeneity is an apparent diff erence between the results of the 
primary studies,13, 14 and may be present when study populations, interventions, out-
comes, or methodologies diff er across the studies. Heterogeneity is generally quantifi ed 
by the I2 or Cochran’s Q-statistic. Values of <25% suggest little heterogeneity, 25–50% 
suggests moderate heterogeneity, and >50% means large heterogeneity.18 We extracted 
these metrics, and documented the methods that the authors had used to examine 
diff erences in the results. To evaluate heterogeneity, primary study characteristics were 
extracted, which included study design, follow-up duration, patient characteristics and 
outcome defi nitions. Publication bias is the tendency by investigators, reviewers and edi-
tors to submit or accept manuscripts for publication based on the direction or strength 
of the study fi ndings.19 Tests that assess publication bias include funnel plots, Harbord-
Egger tests, and trim and fi ll analyses.20-22 We extracted the specifi c methods that the 
authors used as well as their conclusions on the presence of publication bias.
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RESULTS
Search Results
The MEDLINE search yielded 347 articles from which 11 meta-analyses on the associa-
tion between CYP2C19 loss-of-function alleles and clinical effi  cacy of clopidogrel were 
identifi ed. The searches in other databases and reference lists yielded no additional 
meta-analyses. The 11 meta-analyses included a total of 30 primary studies, but not all 
studies were included in all meta-analyses.
Meta-Analyses Characteristics
The 11 meta-analyses were published within a timeframe of 24 months, and their lit-
erature searches were performed between October 2009 and October 2011. All articles 
presented separate analyses for composite clinical endpoints and stent thrombosis 
(ST). The defi nitions of the composite clinical endpoint varied across meta-analyses, but 
generally included death, myocardial infarction (MI) and stroke (Table 1). ST was typically 
defi ned according to the academic research consortium defi nitions.23 Five meta-analyses 
used a checklist to assess the quality of the primary studies,5, 7, 8, 24, 25 three meta-analyses 
used their own approach,6, 26, 27 or did not check the quality.28-30 The Newcastle-Ottawa 
scale is a formal quality scoring list,31 whereas the Strengthening the reporting of obser-
vational studies in epidemiology (STROBE),32 and its genetic extension STrengthening the 
REporting of Genetic Association studies (STREGA) also serve as reporting guidelines.33 
However, all three checklists comprise methodological aspects of observational studies 
including patient selection, outcome assessment and adequacy of follow-up.
The total number of included studies ranged from 7 to 27 for the clinical endpoint 
and from 4 to 14 for ST (Table 1, Supplementary Table 1-2, Appendix). As expected, 
more recent meta-analyses generally included more primary studies. The percentage 
of all studies that were included in the meta-analysis, calculated as the percentage of 
all available studies at the date of the study selection, ranged from 25% to 90% for 
the clinical endpoint and from 9 to 82% for ST (Supplementary Table 1-2, Appendix). 
Five meta-analyses did not include conference abstracts,5, 25, 28-30 and all but one of the 
meta-analyses left out data from one or more full articles that were included in other 
meta-analyses (Supplementary Table 1, Appendix).34-41 For example, the post-hoc ge-
netic analysis of the ACTIVE-A trial was included in only two of the seven meta-analyses 
that did their literature searches after the publication of the trial.6, 24 and one meta-
analysis had limited the inclusion to only primary studies with a follow-up time of 6-12 
months.30
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Primary Study Characteristics
The characteristics of the 30 primary studies varied (Supplementary Table 3, Appendix). 
Follow-up duration ranged from 1 to 43 months and there were 23 cohort studies and 
7 post-hoc analyses of randomized trials. The mean age ranged from 60 to 70 in most 
studies, with the exception of one study that involved patients with a mean age of 40 
years old.42 The percentage of patients that had undergone percutaneous coronary inter-
vention (PCI) varied from 0% to 100%, and the proportion of smokers ranged from 8% 
to 56%, with three studies including more than 50% smokers.42-44
All 30 studies addressed clinical endpoints, and 17 also investigated ST. The defi nition of 
the composite clinical outcome and the event rates varied between primary studies. MI 
was most commonly included in the composite clinical endpoint (24 studies), followed 
by cardiovascular death (18 studies), stroke (17 studies), and all-cause death (10 studies).
Outcomes and Conclusions of the Meta-Analyses
Eight out of 11 meta-analyses on clinical endpoints reported a statistically signifi cant 
association (Table 2, Supplementary Table 4, Appendix).6-8, 24, 26-29 Mean eff ect sizes of the 
signifi cant association (random eff ects models) ranged from 1.26 to 1.96. Five of these 
eight concluded that there was an association between CYP2C19 loss-of-function alleles 
and the clinical endpoint,24, 26-29 two inferred that there was a possible association,7, 8 
while one concluded that the association was not proven because of publication bias 
(Table 2, Supplementary Table 4, Appendix).6 The remaining three meta-analyses found 
no statistically signifi cant pooled eff ect,5, 25 or did not pool the data because of between-
study heterogeneity.30 Of the four meta-analyses that concluded absence of association, 
three were among the fi ve most recently published.5, 6, 30
For ST, all 11 meta-analyses reported a statistically signifi cant association with CYP2C19 
loss-of-function alleles.5-8, 24-30 Mean eff ect sizes (fi xed eff ects models) ranged from 1.77 
to 3.82. One meta-analysis concluded that there was a possible association,6 and one 
other meta-analysis observed the presence of heterogeneity and publication bias, and 
downgraded the evidence (Table 2, Supplementary Table 4, Appendix).5
Heterogeneity
Heterogeneity assessment of each meta-analysis is presented in Table 3. All meta-
analyses reported signifi cant heterogeneity between the primary studies for the 
clinical endpoints, but they handled and interpreted the presence of heterogeneity 
in diff erent ways. Six meta-analyses reduced heterogeneity by excluding one or more 
studies,5, 8, 24-26, 29 and four of these found that the resulting pooled eff ect estimate 
remained unchanged.5, 8, 24, 26 Five meta-analyses performed stratifi ed meta-analyses by 
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study and population characteristics,7, 8, 25, 26, 29 two performed meta-regression,5,20 and 
one inspected primary study characteristics.5 Higher sample size and poorer quality of 
the primary studies were associated with lower eff ect sizes,7, 25 but other studies did not 
fi nd an impact of study characteristics.5, 6 For ST, four meta-analyses observed moderate 
heterogeneity, with I2 ranging from 32% to 44%,5, 6, 24, 27 but the degree of between-study 
heterogeneity was not statistically signifi cant in any of the 11 meta-analyses. One meta-
Table 2. Main Outcomes for Clinical Endpoints and Stent Thrombosis
First
authorref
Publication
date
Main result*
(95% CI)
Statistical
signifi cance
Heterogeneity Bias
Conclusion 
about the 
presence of 
association
Clinical endpoint
Hulot7 July 2010 1.45 (1.12-1.89) Yes Yes No Possible
Jin28 Sept 2010 1.46 (1.01-2.13) Yes Yes NR Yes
Mega8 Oct 2010 1.57 (1.13-2.16) Yes Yes NR Possible
Sofi 29 June 2011 1.96 (1.14-3.37) Yes Yes Yes Yes
Zabalza25 June 2011 1.23 (0.97-1.55) No Yes Yes No
Liu24 July 2011 1.26 (1.06-1.50) Yes Yes Yes Yes
Bauer5 Aug 2011 1.11 (0.89-1.39) No Yes Yes No
Holmes6 Dec 2011 1.34 (1.15-1.56) Yes Yes Yes No
Jang26 May 2012 1.42 (1.13-1.78) Yes Yes Yes Yes
Singh27 June 2012 1.28 (1.07-1.55) Yes Yes No Yes
Yamaguchi30 July 2012 Not performed NA Yes NR No
Stent thrombosis
Hulot7 July 2010 3.45 (2.13-5.57) Yes NR Yes Yes
Jin28 Sept 2010 3.81 (2.27-6.40) (F) Yes No NR Yes
Mega8 Oct 2010 2.81 (1.81-4.37) Yes No NR Yes
Sofi 29 June 2011 3.82 (2.23-6.54) (F) Yes No NR Yes
Zabalza25 June 2011 2.24 (1.52-3.30) Yes No NR Yes
Liu24 July 2011 2.58 (1.77-3.77) Yes NR NR Yes
Bauer5 Aug 2011 1.77 (1.31-2.40) Yes Yes Yes No
Holmes6 Dec 2011 1.88 (1.46-2.41) Yes NR NR Possible
Jang26 May 2012 2.41 (1.76-3.30) (F) Yes No NR Yes
Singh27 June 2012 2.41 (1.70-3.41) (F) Yes No Possible Yes
Yamaguchi30 July 2012 2.65 (1.46-4.84) (F) Yes NR NR Yes
Abbreviations: CI, confi dence interval; F, fi xed-eff ects model; ST, stent thrombosis; LOF, loss-of-function; 
MACE, major adverse cardiovascular event; NA, not applicable; NR, not reported.
Authors’ descriptions of their conclusions are shown in Supplementary Table 4.
* main results are based on random eff ects analysis, unless otherwise indicated, and represent odds ratios 
or hazard ratio according to each of the meta-analyses. Fixed eff ects analyses are reported in Supplemen-
tary Table 4.
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analysis discussed that exclusion of studies reduced heterogeneity, but did not justify 
the exclusion on clinical grounds.5
Bias assessment
The assessment of publication bias is presented in Table 4. All but two meta-analyses 
investigated publication bias for clinical endpoints.8, 28 Nine meta-analyses used fun-
Table 4. Analyses and Reporting of Publication Bias in the Meta-Analyses
First authorref
Publication
date
Analyses
Conclusion
Clinical endpoint Stent thrombosis
Hulot7 July 2010   Funnel plot
  Egger test
No publication bias Publication bias present
Jin28 Sept 2010 Not reported Not reported Not reported
Mega8 Oct 2010 Not reported Not reported Not reported
Sofi 29 June 2011   Funnel plot Funnel plot slightly 
asymmetric; publication 
bias could be present
Not reported
Zabalza25 June 2011   Funnel plot
  Stratifi ed analysis by 
study size
Funnel plot slightly 
asymmetric; 
overestimation of eff ect 
size in smaller studies 
could be related to 
publication bias.
Not reported
Liu24 July 2011   Funnel plot Funnel plot showed a 
degree of asymmetry 
that may be consistent 
with small study bias
Not reported
Bauer5 Aug 2011   Funnel plot
  Harbord-Egger test
  Re-analysis without fi rst 
studies
  Trim and fi ll analysis
  Cumulative and 
recursive meta-analyses
Funnel plot showed a 
degree of asymmetry 
that may be consistent 
with small study or 
publication bias. No 
evidence for missing 
studies.
Funnel plot showed a 
degree of asymmetry 
that may be consistent 
with small study or 
publication bias. 
Evidence for fi rst study 
bias and missing studies.
Holmes6 Dec 2011   Funnel plot
  Harbord-Egger test
  Stratifi ed analysis by 
study size
  Trim and fi ll analysis
Publication bias present 
and had signifi cant 
impact on the results
Not reported
Jang26 May 2012   Funnel plot
  Egger test
  Trim and fi ll analysis
All analyses show 
evidence for publication 
bias
Not reported
Singh27 June 2012   Funnel plots
  Egger test
No publication bias Possible publication bias
Yamaguchi30 July 2012   Funnel plot Not discussed Not discussed
Abbreviations: CI, confi dence interval; CVD, cardiovascular disease; LOF, loss-of-function; MACE, major ad-
verse cardiovascular events; OR, odds ratio; RR, relative risk; ST, stent thrombosis.
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nel plots to explore publication bias,5-7, 24-26, 29 of which fi ve applied additional analyses 
such as (Harbord-)Egger tests, stratifi cation analysis, and trim and fi ll analysis.5-7, 26, 27 Six 
of the nine meta-analyses that assessed publication bias concluded that there was at 
least some evidence for bias due to selective missing studies,5, 6, 24-26, 29 two did not fi nd 
evidence for bias,7, 27 and in one meta-analysis the results of the funnel plot were not 
discussed.30 For ST, only 3 out 11 meta-analyses reported the analyses of publication 
bias and concluded that presence of bias could not be ruled out.5, 7, 27 One of these meta-
analyses concluded that the epidemiological credibility for an association of CYP2C19 
loss-of-function alleles with ST with was weak, due to publication bias.5
DISCUSSION
This review of 11 meta-analyses on the association between CYP2C19 loss-of-function 
alleles and clinical effi  cacy of clopidogrel shows that results and conclusions of 11 over-
lapping meta-analyses were discordant. Eff ect sizes diff ered because some meta-analyses 
did not include data from conference abstracts and more recent meta-analyses included 
more primary studies. Yet, conclusions predominantly diff ered because between-study 
heterogeneity and bias were handled diff erently across meta-analyses.
Overall, the meta-analyses consistently showed a larger eff ect of CYP2C19 loss-of-
function alleles on ST as compared to the eff ect on the clinical endpoint. ST is associated 
with higher risk of experiencing MI and death, both components of the composite clinical 
endpoint.45 The absence of consistent association with clinical endpoints might indicate 
that the alleles have no impact on distant outcomes as MI and death, and that the sig-
nifi cant eff ect of ST is diluted when combining the various endpoints. Liu and colleagues 
had performed meta-analyses on the separate clinical endpoints, such as bleeding com-
plications, MI, stroke and death, and found that eff ect sizes ranged from 0.99 to 1.55, with 
the exception of 2.37 for stroke. None of these eff ect sizes were statistically signifi cant 
and most analyses showed substantial between-study heterogeneity.24 This suggests 
that CYP2C19 impacts ST, and maybe stroke, but that its eff ect may not be strong enough 
to also infl uence the more distant outcomes.
All meta-analyses on the clinical endpoints observed substantial between-study het-
erogeneity. The heterogeneity was most likely explained by diff erences between study 
populations and primary outcome measures (Supplementary Table 3, Appendix). For 
example, the mean age of the participants in the study by Collet et al. was 40 years,42 
compared to 60 to 68 years in all other studies. In all studies, the percentage of smokers 
ranged from 8 to 56%, the percentage of men from 55 to 92%, and the percentage of 
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participants who underwent PCI from 0 to 100%. The eff ect of clopidogrel response 
should preferably be in a more homogenous subgroup, since the infl uence of age, 
gender, and smoking status on CYP enzyme activity cannot be neglected.46-48 The study 
by Collet et al. had the highest eff ect size of all studies (5.4, 95% confi dence interval 
2.3-12.5), and its exclusion from meta-analyses would have been justifi ed based on its 
incomparable study characteristics.49 Also from a clinical perspective, exclusion of the 
study by Collet et al. is warranted: a decision about genotyping 60-70 year old individu-
als should not be aff ected by a three-fold higher eff ect size in young adults.
The substantial heterogeneity between the primary studies was handled diff erently 
across the meta-analyses. Several meta-analyses excluded studies with extreme eff ect 
sizes (outliers) one by one to reduce heterogeneity. The removal of studies for the mere 
fact of introducing heterogeneity is however unjustifi able, because, by defi nition, hetero-
geneity is introduced by the studies with the most extreme eff ects and never by studies 
that have eff ect sizes similar to the pooled estimate. Moreover, only very large studies 
with extreme eff ects may lead to a change in the pooled estimate after its exclusion. 
Exclusion of smaller studies easily reduces heterogeneity without changing the pooled 
eff ect. Yet, exclusion of studies should not be based a posteriori on the eff ect sizes, 
but a priori on the basis of patient or study characteristics, preferably by pre-specifi ed 
subgroup-analysis that details and motivates the exclusion of specifi c studies.14, 50, 51 
The presence of substantial unexplained heterogeneity should be a major factor in the 
interpretation of the evidence and a good reason to refrain from drawing conclusions 
based on the quantitative results.14
Another factor that aff ected the interpretation of the relationship between CYP2C19 
variants and clinical effi  cacy of clopidogrel was the presence of bias. Meta-analyses are 
subject to various biases including small-study and publication bias.13, 52 Small-study bias 
is present when the smaller studies show stronger eff ects than the larger studies, and 
publication bias might occur when studies with statistically signifi cant results are more 
likely to be published than those with non-signifi cant results.22 For the clinical end point, 
6 of 11 meta-analyses found evidence for publication bias, and the 3 meta-analyses that 
investigated publication bias for the ST end point found that the results were biased 
due to missing studies.3, 5, 27 These bias checks suggest that the association of CYP2C19 
loss-of-function alleles and clinical effi  cacy of clopidogrel is aff ected by missing studies, 
studies that would have shown smaller eff ects or even eff ects in the opposite direction.
Despite the substantial heterogeneity in the meta-analyses of the clinical endpoint and 
the suggestions of publication bias in both the clinical endpoint and ST, most meta-
analyses did not seem to consider these data problems in their conclusions. Only 1 of the 
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11 meta-analyses on the clinical endpoint explicitly refrained from quantitative analysis 
because of heterogeneity,30 one downgraded the statistically signifi cant association to 
evidence of no association,6 and two others phrased their conclusions of associations 
cautiously.7, 8 Yet, 5 out of 8 meta-analyses that observed statistically signifi cant eff ects 
concluded that the CYP2C19 genotype was associated to the clinical endpoint despite 
the presence of substantial between-study heterogeneity.24, 26-29 For ST, 8 out of 11 meta-
analyses did not reported about the assessment of bias,6, 8, 24-26, 28-30 whereas the 3 who 
did such assessment found evidence for publication bias. Inspections of heterogeneity 
and bias are integral parts of meta-analyses and their results should impact the conclu-
sions of the quantitative analysis.13, 15-17
The latest meta-analysis was the only one who performed a separate eff ect-modifi cation 
analysis using data from four randomized trials.6 There was no evidence for genotype-
treatment interaction in clopidogrel users for the composite cardiovascular outcome. 
These results are in line with our conclusion and further substantiate there is no evidence 
that CYP2C19 loss-of-function alleles are associated with worse outcomes in clopidogrel 
users.
Evaluating Discordant Meta-Analyses
The popularity of meta-analyses in the cardiovascular fi eld has increased by almost 
1800% over the past 20 years, whereas the number of randomized controlled trials 
(RCTs) only increased by 140% over the same time period.12 This practice leads to 
increasing duplication of meta-analyses on the same topic.53 A recent study showed 
that 67% of the reviewed meta-analyses had at least one overlapping and 5% of the 
topics were studied in at least eight overlapping meta-analyses.11 While overlapping 
meta-analyses may seem unnecessary, our review shows that authors make diff erent 
choices in their conduct. Since there is no single best way how to defi ne inclusion and 
exclusion criteria, how to defi ne and select study populations and endpoints, and how 
to interpret heterogeneity and bias in light of the results, the variety in meta-analyses 
might be as wide-ranging as that in primary studies. When the variety in meta-analyses 
results from informed choices about the defi nitions, selection criteria, and analyses, this 
variety refl ects paradigms in the fi eld and should not be seen as duplication. Greater 
awareness and understanding of the subjectivity of meta-analyses and the impact of 
methodological choices on their results will enhance the appreciation of meta-analyses 
as high level of evidence.12
In 2010, the US Food and Drug Administration recommended CYP2C19 genotyping for 
individualized antiplatelet management.4, 6 Based on a re-evaluation of then-current and 
later meta-analyses we conclude that this recommendation is currently not evidence-
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based. The GRAVITAS, ARCTIC and TRILOGY-ACS trials have shown that bedside platelet 
reactivity testing did not result in clinical benefi ts,54-56 but recently a trial randomized 
patients undergoing PCI to either point-of-care genotyping and subsequent personalized 
treatment or standard clopidogrel treatment.57 The point-of-care genotyping strategy 
showed signifi cantly lower on-treatment platelet reactivity in CYP2C19 loss-of-function 
carriers than the standard treatment strategy. However, the genetic substudy of the ARC-
TIC trial showed no benefi ts of genotyping.58 In the absence of evidence that CYP2C19 
loss-of-function alleles truly aff ect outcomes, it will be interesting to see whether larger 
future trials of personalized treatment based on platelet monitoring and genotyping can 
show improvement in clinical endpoints.
Conclusion
The current study systematically evaluated overlapping discordant meta-analyses on 
the same topic. The results and conclusions of 11 overlapping meta-analyses on the 
association between CYP2C19 loss-of-function alleles and clinical effi  cacy of clopidogrel 
are discordant. Eff ect sizes diff ered because some meta-analyses did not include data 
from conference abstracts and more recent meta-analyses included more primary stud-
ies. Yet, conclusions predominantly diff ered because between-study heterogeneity and 
bias were handled diff erently across meta-analyses. Confi dence in the presence of an 
association is limited and personalized antiplatelet management based on genotyping is 
not supported by the currently available evidence.
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Supplementary Table 4. Main Results and Conclusions for Clinical Endpoints and Stent Thrombosis
First authorref
Publication
date
Model
Main result
(95% CI)
Conclusion about the presence of association
Yes/no Description (Abstract/Discussion)
Clinical endpoint
Hulot1 July 2010
Random
Fixed
1.45 (1.12-1.89)
1.29 (1.12-1.49)
Possible
“[…] reduced CYP2C19 function appears 
to expose clopidogrel treated patients to 
excess cardiovascular risk and mortality. 
Confl icting results among studies may be 
explained by diff erences in types and/or 
levels of risk of patients.” (Abstract)
Jin2 Sept 2010 Random 1.46 (1.01-2.13) Yes
“CYP2C19*2 carrier status is signifi cantly 
associated with an increased risk of 
adverse cardiovascular events.” (Abstract)
Mega4 Oct 2010 Random 1.57 (1.13-2.16) Possible
“Carriage of even one reduced-function 
CYP2C19 allele appears to be associated 
with a signifi cantly increased risk of 
MACE.” (Abstract)
Sofi 3 June 2011
Random
Fixed
1.96 (1.14-3.37)
1.33 (1.09-1.61)
Yes
“[…] the CYP2C19*2 polymorphism is 
associated with an increased risk of 
MACE and ST.” (Abstract)
Zabalza5 June 2011 Random 1.23 (0.97-1.55) No
“The results question the relevance 
of the CYP2C19 LOF alleles in the 
prediction of major cardiovascular events 
[…].” (Abstract)
Liu7 July 2011 Random 1.26 (1.06-1.50) Yes
“[…] our analysis included more 
studies and more widely supported 
the conclusion that CYP2C19 loss-of-
function alleles increase the rate of 
MACE and stent thrombosis.” (Letter)
Bauer6 Aug 2011
Random
Fixed
1.11 (0.89-1.39)
1.07 (0.96-1.19)
No
“[…] does not indicate a substantial or 
consistent infl uence of CYP2C19 gene 
polymorphisms on the clinical effi  cacy of 
clopidogrel.” (Abstract)
Holmes11 Dec 2011
Random
Fixed
1.34 (1.15-1.56)
1.18 (1.09-1.28)
No
“[…] overall there was no signifi cant 
association of [the] genotype with 
cardiovascular events.” (Abstract)
Jang9 May 2012 Random 1.42 (1.13-1.78) Yes
“[…] carrier status for LOF CYP2C19 is 
associated with an increased risk of 
adverse clinical events in patients […].” 
(Abstract)
Singh8 June 2012 Random 1.28 (1.07-1.55) Yes
“[…] CYP2C19*2 polymorphism is 
associated with signifi cantly increased 
adverse CV events.” (Abstract)
Yamaguchi10 July 2012 None Not performed No
“An association between the CYP2C19 
polymorphism and clinical outcome was 
not observed […].” (Discussion)
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Supplementary Table 4. Main Results and Conclusions for Clinical Endpoints and Stent Thrombosis 
(continued)
First authorref
Publication
date
Model
Main result
(95% CI)
Conclusion about the presence of association
Yes/no Description (Abstract/Discussion)
Stent thrombosis
Hulot1 July 2010
Random
Fixed
3.45 (2.13-5.57)
3.45 (2.14-5.57)
Yes
“The hazard of reduced-function 
CYP2C19 allele carriage was even more 
striking for ST […].” (Discussion)
Jin2 Sept 2010 Fixed 3.81 (2.27-6.40) Yes
“[…] We also noted a marked higher rate 
of ST in patients carrying at least one 
CYP2C19*2 allele.” (Discussion)
Mega4 Oct 2010 Random 2.81 (1.81-4.37) Yes
“Carriage of even one reduced-function 
CYP2C19 allele appears to be associated 
with a signifi cantly increased risk of 
MACE, particularly ST.” (Abstract)
Sofi 3 June 2011 Fixed 3.82 (2.23-6.54) Yes
“[…] the CYP2C19*2 polymorphism is 
associated with an increased risk of 
MACE and ST.” (Abstract)
Zabalza5 June 2011 Random 2.24 (1.52-3.30) Yes
“The results question the relevance of 
the CYP2C19 LOF alleles in the prediction 
of major cardiovascular events beyond 
ST […].” (Abstract)
Liu7 July 2011 Random 2.58 (1.77-3.77) Yes
“ […] our analysis included more 
studies and more widely supported the 
conclusion that CYP2C19 loss-of-function 
alleles increase the rate of MACE and 
stent thrombosis.” (Letter)
Bauer6 Aug 2011
Random
Fixed
1.77 (1.31-2.40)
1.67 (1.34-2.08)
No
“Specifi cally, the association of ST with 
LOF genotypes was subject to bias from 
small study eff ects and to interaction 
with publication year. Adjustment for 
these quality modifi ers tended to abolish 
the association.” (Discussion)
Holmes11 Dec 2011
Random
Fixed
1.88 (1.46-2.41)
1.75 (1.50-2.03)
Possible
“This […] meta-analysis does not 
demonstrate a clinically important 
association […] with the possible 
exception of ST.” (Discussion)
Jang9 May 2012 Fixed 2.41 (1.76-3.30) Yes
“[…] carriers of ≥1 CYP2C19 LOF allele 
have two times greater mortality and 
ST compared to wild-type homozygote 
carriers.” (Discussion)
Singh8 June 2012 Fixed 2.41 (1.70-3.41) Yes
“Our meta-analyses indicates that 
CYP2C19*2 polymorphism results 
in signifi cantly increased risk of 
cardiovascular events like MI, ST and CV 
deaths.”(Discussion)
Yamaguchi10 July 2012 Fixed 2.65 (1.46-4.84) Yes
“[…] CYP2C19*2 carrier status was 
associated with ST only.” (Discussion)
Abbreviations: CI, confi dence interval; ST, stent thrombosis; LOF, loss-of-function; MACE, major adverse 
cardiovascular event;
Model indicates whether eff ect estimates were obtained using random or fi xed eff ect models. Main results 
are odds ratios or hazard ratio according to each of the meta-analyses.
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ABSTRACT
Meta-analyses aim to summarize the totality of fi ndings on a specifi c research ques-
tion and are considered the highest level of evidence. Over the past two decades, all 
medical disciplines, including the cardiovascular fi eld, have witnessed an explosive 
dissemination of meta-analyses that outpaced increasing number of other study types 
such as randomized controlled trials. This trend entailed the publication of duplicate 
meta-analyses on the same topic. Although some replication of research is generally 
warranted, a large number of overlapping (discordant) meta-analyses refl ects waste of 
resources, adds confusion to the fi eld and threatens the value of the study design. In 
this review, we stress that considerations regarding heterogeneity, publication bias and 
quality of primary studies serve as a basis to appraise the evidence across overlapping 
meta-analyses. A fl owchart is presented to help interpret the evidence. To maintain the 
appreciation of meta-analyses as the highest level of evidence, authors should adhere to 
the appropriate reporting guideline, describe the rationale for performing the (updated) 
meta-analysis, register their project in a dedicated database and evaluate the whole 
body of evidence.
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INTRODUCTION
Systematic reviews and meta-analyses identify, appraise and synthesize all evidence on 
a specifi c research question. They are considered the highest level of evidence, help 
physicians stay up to date and enable them to make informed clinical decisions.1 It is 
therefore not surprising that this study design has become increasingly popular.2, 3
Inevitably the phenomenon of duplicate meta-analyses is also increasingly common. A 
recent study showed that more than half of meta-analyses have at least one overlap-
ping meta-analysis, and some topics had up to 13 overlapping meta-analyses.2 While 
some degree of duplication is warranted in research, large numbers of overlapping 
meta-analyses seem unnecessary and could refl ect wasted eff orts and ineffi  ciency in the 
process of summarizing evidence.2 In addition, the interpretation of evidence becomes 
confusing if the conclusions of duplicate meta-analyses are discordant.
In this paper, we review the current practice of meta-analyses in cardiovascular medicine, 
the implications of overlapping meta-analyses, and provide recommendations on the 
interpretation and prioritization of (duplicate) meta-analyses.
THE INCREASING POPULARITY OF META-ANALYSES
The increasing popularity of meta-analyses is illustrated in Figure 1. A PubMed search 
showed that the number of meta-analyses in the cardiovascular fi eld has increased 
almost 1800% between 1993 and 2012, whereas the number of randomized controlled 
trials (RCTs) increased by only 140% in the same time period. In 1993, on average 28 
RCTs were published for every meta-analysis, whereas this RCT:meta-analysis ratio was 
2.7:1 in 2012. This trend is an indication of the relative growth of meta-analyses as com-
pared with other published research and was seen in both the cardiovascular discipline 
(Figure 1B), as well as in other medical disciplines (Figure 1A). Between 1993 and 2013, 
on average 18% of all meta-analyses concerned a cardiovascular topic. This proportion 
remained stable over time.
The increasing popularity led to duplicate meta-analyses on the same topic.4 A recent 
study investigated overlapping meta-analyses on the same topic by assessing a randomly 
selected 5% of all published meta-analyses in 2010. The authors found that 67% of all 
meta-analyses had at least one overlapping meta-analysis that did not represent an update 
and 5% of the research questions were investigated in at least eight overlapping meta-
analyses.2 Replication of research generally leads to more knowledge and confi dence in the 
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conclusions, but could also represent wasted time and eff ort. Some authors suggest that 
four or more meta-analyses on the same topic with similar eligibility criteria and outcomes 
is too many, but there is no specifi c number regarding the correct amount of duplication.4
EXAMPLES OF OVERLAPPING META-ANALYSES
Two case-examples of overlapping meta-analyses in the cardiovascular fi eld are illustrat-
ed in Table 1 (Supplementary Table 1) and Table 2 (Supplementary Table 2), respectively. 
For each meta-analysis, we extracted information on the year of publication, search date, 
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Figure 1. Number of Annually Published Meta-Analyses and RCTs in (A) the Cardiovascular Field and (B) 
all Disciplines
The red and blue bars represent the annually published RCTs and meta-analyses, respectively. The green 
line represents the number of published meta-analyses compared with the number of published RCTs in 
each year. It is an indication of the relative growth of meta-analyses as compared with the overall growth 
of published research in the cardiovascular fi eld. Data is based on the following PubMed searches: A: (ran-
domi* OR meta-analysis [ptyp]). B: (randomi* OR meta-analysis [ptyp]) ("Cardiovascular Diseases"[Mesh]).
N, number; RCT, randomized controlled trial.
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treatment eff ect for outcomes of interest, number of studies screened and selected, and 
patient population. We also noted fi rst author, journal and year of publication of the 
studies included and combined in each meta-analysis.
Through a PubMed search, seven overlapping meta-analyses of intracoronary versus 
intravenous administration of abciximab in patients with acute coronary syndromes were 
identifi ed.5-11 An additional meta-analysis with patient-level data on the same topic is pub-
lished in this issue of the Journal.12 The meta-analyses were published between 2010 and 
2013 (88% in 2012-2013), and the number of primary studies included ranged between 
four and ten (Table 2). Seven meta-analyses included only RCTs, and one meta-analysis 
comprised both RCTs and observational studies (OSs). The search dates ranged from No-
vember 2009 to May 2012, which was refl ected in the number of screened studies (from 
37 to 6,562). The treatment eff ect for mortality was reported in all meta-analyses but 
was of inconsistent statistical signifi cance; four (50%) meta-analyses found a statistically 
signifi cant benefi t of intracoronary abciximab administration, whereas four studies (50%) 
did not. Similarly, the risk of major adverse cardiac events (MACE) was signifi cantly reduced 
in only two of four (50%) meta-analyses reporting on this outcome, the risk of myocardial 
infarction in two of four (50%) and the risk of repeat revascularization in one of three 
(33%). Of four meta-analyses that sought to assess the risk of bleeding, none (0%) found 
a signifi cant diff erence between intracoronary and intravenous administration.
Another PubMed search identifi ed twelve meta-analyses of PCI vs. CABG in patients 
with left main coronary artery disease. These meta-analyses were published between 
2008 and 2013 (58% in 2012-2013) and the number of primary studies included 
ranged between 3 and 27 (Table 3).13-24 Four meta-analyses included only RCTs, one 
meta-analysis comprised only OSs and seven meta-analyses included both RCTs and OSs. 
The authors’ search date varied from September 2006 to April 2011, and the number of 
screened studies ranged between 12 and 9,120. Mortality was reported in eleven meta-
analyses, which all found no statistically signifi cant benefi ts of either treatment. MACCE 
was reported in eight meta-analyses, of which three (38%), one (13%) and four (50%) 
found a higher, lower or similar risk for this composite endpoint after PCI versus CABG. 
All meta-analyses that reported an eff ect size for myocardial infarction (n = 7) found no 
statistically signifi cant diff erence between treatments. Also, all ten meta-analyses that 
investigated repeat revascularization (N = 10) found signifi cantly higher rates after PCI 
than after CABG. On the other hand, stroke was signifi cantly higher with CABG in all six 
meta-analyses reporting this outcome.
Taken together, these fi ndings indicate that meta-analyses on the optimal administration 
route for abciximab and the optimal treatment strategy for left main revascularization 
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published in the last 5 years diff ered not only in the magnitude of the treatment eff ect 
for some outcomes, but also occasionally in the direction of the eff ect (e.g. MACCE in the 
left main meta-analyses). In the illustrative examples above, these diff erences might be 
attributed to varying eligibility criteria regarding inclusion of OSs, the target population 
analyzed (e.g. acute coronary syndromes or ST-segment elevation myocardial infarction 
in the abciximab route meta-analyses; patients with diabetes mellitus or acute coronary 
syndromes in the left main revascularization meta-analyses) and the non-consideration 
of studies published after the search date of each meta-analysis. In contrast, while more 
recent meta-analyses might have included newly published studies, their incremental 
value remains uncertain (e.g., similar results were noted in all meta-analyses of left main 
revascularization with regards to all the components of MACCE). Interestingly, three meta-
analyses of left main revascularization included exactly the same 4 RCTs but derived 
slightly diff erent summary eff ects, underscoring the potential for diff erences introduced 
at the stage of data synthesis15, 16, 22.
WHAT TO DO WHEN META-ANALYSES OVERLAP
Overlapping meta-analyses can result in uncertainty when they come to discordant 
conclusions. Discordance can occur at the level of results or interpretation, and the 
underlying sources are summarized in Table 3.25, 26 Eff ect sizes can diff er because some 
meta-analyses use slightly diff erent eligibility criteria for study selection, such as the 
eligibility of abstracts or language restrictions. Perhaps more subtle are discordances 
due to handling and interpretation of heterogeneity and publication bias.
Table 3. Potential Sources of Discordance in Overlapping Meta-Analyses
Design Analysis Interpretation
Search (date, key words)
Summary measure
(crude OR, HR, RR)
Interpretation of all results, 
including heterogeneity, publication 
bias and quality assessment
Information sources used 
(databases, abstracts from 
meetings)
Fixed/random eff ects analysis
Combining all results and linking 
this to the overall conclusion of the 
meta-analysis
Eligibility criteria Heterogeneity assessment
Data extraction (solitary/duplicate, 
retrieving unpublished data)
Publication bias assessment
Study- or patient-level data
Quality assessment of primary 
studies
Defi nitions, length of follow-up
Extensiveness of extra analyses 
(sensitivity analyses, meta-
regression)
OR, odds ratio; HR, hazard ratio; RR, relative risk.
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Heterogeneity is an apparent diff erence between the results of the primary studies,27, 28 
and may be present when study populations, interventions, outcomes, or methodologies 
diff er across the studies. Heterogeneity is generally quantifi ed by the I2 or Cochran’s 
Q-statistic.29 To evaluate heterogeneity, authors should not only examine the statistic, 
but also scrutinize potential sources of heterogeneity by comparing primary study char-
acteristics, design, follow-up duration, patient characteristics and outcome defi nitions.30 
Meta-regression is a typical approach to relate sources of variation in heterogeneous 
treatment eff ects to specifi c study characteristics. However, study-level meta-analyses 
have some limitations in explaining heterogeneity, and using individual patient data 
in patient-level meta-analyses may lead to a more unbiased assessment.31 In addition, 
patient-level meta-analyses allow better alignment of defi nitions and follow-up. This 
is illustrated by the above-mentioned meta-analysis by Piccolo et al., which pooled 
individual patient data from trials of intracoronary versus intravenous administration of 
abciximab, enabling investigation of detailed endpoints such as post-procedural Throm-
bolysis in Myocardial Infarction Study (TIMI) 3 fl ow, myocardial blush grade and complete 
ST-segment resolution.12
Publication bias is the tendency by investigators, reviewers and editors to submit or 
accept manuscripts for publication based on the direction or strength of the study fi nd-
ings.32 Tests that assess publication bias include Funnel plots, Harbord-Egger tests, and 
trim and fi ll analyses.33-35 If these tests identify missing studies with a smaller eff ect or 
an eff ect in the opposite direction, investigators should be very careful with their conclu-
sions regarding the presence and/or direction of the association under study.
Discordant meta-analyses form challenges for authors, clinicians and editorial boards. 
Which meta-analysis is most applicable to the clinical question, and which one is 
methodologically most solid? A fl owchart to help with the interpretation of discordant 
meta-analyses is provided in Figure 2.26 When meta-analyses truly study the same ques-
tion, the fl owchart guides the reader to methodological appraisal of the discordant meta-
analyses. Quality scoring lists might be useful as well, such as the Oxman Guyatt list 
and the AMSTAR checklist.36, 37 These checklists can be used to map the methodological 
quality of meta-analyses. AMSTAR includes questions on design (e.g. “was there dupli-
cate study selection and data extraction?”;“was a comprehensive search performed?”), 
analysis (e.g. “was the scientifi c quality of the included studies documented?”; “were the 
methods used to combine the fi ndings of the studies appropriate?”), and interpretation 
(e.g. “was the scientifi c quality of the included studies used appropriately in formulating 
conclusions?”). The use of scoring systems for assessing quality seems easy and attrac-
tive, and AMSTAR is a validated quality measurement tool. On the other hand, calculating 
these summary scores involve assigning weights to diff erent items in the scale and thus 
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prioritizing studies based on arbitrary assumptions. Using full reporting of how meta-
analyses were rated based on each criterion is preferable.
HOW TO PRESERVE THE VALUE OF META-ANALYSES
A list of considerations for maintaining the value of meta-analyses and improve the qual-
ity of research in this fi eld is provided in Table 4. Adherence to accepted guidelines for 
reporting is the essential to preserve the quality and value of meta-analyses. The PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses, formerly QUO-
RUM) statement consists of a 27-item checklist and a four-phase fl ow diagram aimed at 
improving the consistency and completeness of reporting of meta-analyses of RCTs.38 
Figure 2. Flowchart for the Interpretation of Discordant, Overlapping Meta-Analyses
The fl owchart helps the reader interpret overlapping, discordant meta-analyses, by guiding him/her to a 
methodological appraisal. Adapted from Jadad et al.26
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An analogous document has been elaborated by the MOOSE (Meta-Analysis Of Observa-
tional Studies In Epidemiology) group for meta-analyses of OSs.39
Because the evidence on a topic is typically dynamic and evolves over time, incorporation 
of new studies into an existing meta-analysis may lead to diff erent conclusions.40 Addi-
tional incentives for updating a meta-analysis may include the potential availability of new 
tools or markers to characterize subgroups,41 the introduction of new outcome measures,42 
or even advances in the methodology for conducting a systematic review/meta-analysis.24 
However, the merits of publishing a new meta-analysis on the same topic needs to be 
evaluated, since redundant overlapping meta-analyses refl ect waste of resources and 
potentially adds confusion. Authors of possibly overlapping meta-analyses should report 
the rationale for performing the meta-analysis (e.g. outdated and/or low quality previous 
meta-analyses). The PICO (Population, Intervention, Comparator, and Outcome) framework 
could be used to point out what aspect of the research question has changed. Optimal 
timing for a new meta-analysis depends on the speed of scientifi c progress in the specifi c 
fi eld and the importance of the research question. Periodic literature surveillance, expert 
opinions and scanning of abstracts are helpful to identify new relevant evidences that 
may eventually be used for an updated meta-analysis. Once the need for updating a meta-
analysis has been identifi ed, the update should be performed properly and eff ectively. 
Technically, a previous search strategy can be useful and specifi c statistical methods for 
updating a meta-analysis have been described, such as “cumulative meta-analysis” and 
“null meta-analyses ripe for updating” approaches.43, 44 Bayesian methodology for meta-
analysis might provide a way to update and/or consolidate the evidence on a topic. In 
contrast to the frequentist approach, Bayesian statistics incorporates clinical judgment and 
pertinent information that would otherwise be excluded, and establishes inferences based 
on a wide range of fl exible methods based on the theory of conditional probability.24, 45, 46
An important potential strategy to avoid multiplication of unnecessary meta-analyses is 
consultation of dedicated registries. For instance, the PROSPERO registry (http://www.
crd.york.ac.uk/NIHR_PROSPERO) includes over 2,000 prospectively registered protocols 
of systematic reviews and meta-analyses in health and social care.47-49 Registering meta-
Table 4.
Maintaining the Value of Meta-Analyses
 Adhere to the PRISMA/MOOSE checklists
 Perform high quality analyses and interpret appropriately (see fi gure 2, table 3 and PRISMA/MOOSE)
 Refl ect on timing when updating a meta-analysis
 Provide the rationale for performing a meta-analysis, referring to prior work
 Register the protocol in the PROSPERO registry
 Evaluate the whole body of evidence on a topic, not only small fragments
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analyses into a central database, similar to registration of trials into www.clinicaltrials.
gov, helps to avoid unplanned duplication, increases transparency in the review process, 
and enables assessing the results of reported reviews versus what initially planned by 
the authors in the protocol. While authors increase the reputation of their work, journal 
editors are provided a safeguard against fl awed methodologies.
Finally, meta-analyses should be comprehensive and not only evaluate small fragments 
of the evidence on a clinical question of interest.50 To address this issue, umbrella re-
views and network meta-analyses are gaining attention.24, 51 Umbrella reviews consider 
multiple treatment comparisons for the management of the same disease or condition, 
with each comparison considered separately and clustered meta-analyses performed as 
appropriate.52, 53 A treatment network typically uses nodes for each available treatment 
and each link between the nodes refl ects a comparison of treatments in at least one 
or more primary studies. Compared with classic meta-analyses, umbrella reviews and 
network meta-analyses provide the reader with a wider vision on many treatments for 
a given condition, although typical limitations of standard meta-analyses (e.g. inherent 
bias of studies included, heterogeneity and publication bias) continue to apply.
CONCLUSIONS
The explosive dissemination of meta-analyses entailed the publication of duplicate me-
ta-analyses on the same topic. The scope of a meta-analysis is to provide the reader with 
the most up-to-date evidence on the eff ect of an intervention and increase the statistical 
power of treatment comparisons for a given condition beyond that of individual studies, 
with the ultimate goal of informing clinical practice and guiding healthcare decisions. To 
refl ect the evolving knowledge on a topic, meta-analyses are regularly updated as new 
studies become available. However, redundancy of overlapping meta-analyses on the 
same topic is frequently obvious and refl ects waste of time, energies and economic re-
sources. Considerations regarding heterogeneity, publication bias and quality of primary 
studies serve as a basis to appreciate the evidence across overlapping meta-analyses. 
Raising the quality of research is a collective eff ort of authors, peer-reviewers, editors 
and other players in the fi eld. When preparing and submitting a meta-analysis, authors 
should take responsibility for advancing the fi eld by adhering to the appropriate report-
ing guideline, report the rationale for performing the (updated) meta-analysis, register 
their project in a dedicated database and evaluate the whole body of evidence. Similarly, 
peer reviewers and editorial boards should carefully evaluate the additional merits of 
the meta-analysis under review over previous work, thereby fi ltering out inappropriate 
meta-analyses, avoiding confusion and maintaining the value of meta-analyses.
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TO THE EDITOR:
With great interest we read the article by Di Eusanio and associates1 in a recent issue of 
the Journal. We congratulate the authors on their favourable results after aortic valve 
replacement (AVR) and the identifi cation of predictors for post-operative mortality. How-
ever, some methodological issues exist concerning the comparison of survival rates with 
a reference population. The investigators use a static method to compare the three-year 
survival after AVR for octogenarians with the expected survival of an age- and gender-
matched regional population and concluded that the survival was similar (p = 0.157).
Intuitively, survival after AVR is unlikely to be comparable to the general population. Pa-
tients undergoing heart valve replacement are vulnerable to valve and non-valve related 
events and the left ventricle of patients with aortic valve disease is characterized by 
progressive accumulation of interstitial myocardial fi brosis and impairment of myocyte 
ultrastructure leading to decreased survival. Aortic stenosis has been shown to be an 
infl ammatory process associated with histopathological changes in the valve leafl ets 
that are similar to those in other atherosclerotic diseases and the presence of calcifi c 
valve disease is associated with hypertension, diabetes, and the metabolic syndrome.2 A 
survival comparable to the general population can therefore only be achieved by strict 
selection of patients undergoing AVR, which is the case in the study by Di Eusanio.
The major shortcoming in the static comparison method is that a dynamic cohort, the oc-
togenarian study population, is compared with a static reference cohort from the regional 
life tables. Changes in the patient group caused by withdrawal at diff erent times make 
the study cohort dynamic and need a rate-adjustment to make the comparison more 
accurate.3-5 Rate-adjustment can be achieved by matching the reference cohort on age-, 
gender- and calendar time every moment an event occurs in the study population. When 
this mechanism is not taken into account then the benefi t of treatment is overestimated. 
It would be interesting if the authors could compare the survival of the patient group with 
the age, gender- and calendar time-matched regional population using rate-adjustment.
Matching should not only be performed for age and gender, but also for other important 
demographic indicators such as race or socioeconomic class.5 Unfortunately, this data is 
seldom available and consequently comparisons with the general population should be 
interpreted carefully.
Finally, we question some of the numbers and the corresponding fi gures in the article. 
Figure 1 shows a signifi cant lower survival in Class III-IV as compared with class I-II 
(p < 0.001), whereas in the text a non-signifi cant p-value of 0.157 is stated. In addition, 
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fi gure 3 shows a 2-year survival of 87.4% for the AVR >80 y group whereas in the text a 
2-year survival of 89.7% is mentioned.
In our opinion comparison with a reference group should be handled with caution. We 
suggest the development of specifi c guidelines to compare an accurately matched popu-
lation to ensure that all factors are taken into account and the comparison performed is 
methodologically correct.
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TO THE EDITOR:
With great interest we read the article on cost-eff ectiveness of transcatheter aortic 
valve implantation (TAVI) by Doble and colleagues in a recent issue of the Journal.1 We 
congratulate the authors on their well-designed analysis of this timely and important 
topic. The investigators reported a base-case incremental cost-eff ectiveness ratio (ICER) 
of $51,324/quality-adjusted life-year (QALY) for TAVI versus standard management (SM) 
in surgically inoperable patients. In high-risk patients TAVI was economically dominated 
by surgical aortic valve replacement (SAVR). They concluded that TAVI is a cost-eff ective 
treatment option for inoperable patients, but not for high-risk patients. However, some 
methodological issues and questionable assumptions infl uence the outcomes.
The quality-of-life utilities were based on a conversion of New York Heart Association 
function classes, although direct EQ-5D utilities from the PARTNER trial have been 
available since the presentation at TransCatheter Therapeutics, November 7 2011, in 
San Francisco.2 Moreover, TAVI via the transfemoral route is associated with improved 
quality-of-life compared to surgery, whereas this has not been demonstrated for the 
transapical route.3 The authors lumped the quality-of-life improvement with these two 
distinct techniques together and reported 0.102 less QALYs after TAVI as compared with 
SAVR. This decrease is inconsistent with the quality-of-life results of transfemoral TAVI 
in the PARTNER trial and result in a too pessimistic ICER for TAVI versus SAVR in high-risk 
patients.
The authors used Canadian life tables to simulate long-term survival in all treatment 
groups, whereas a survival comparable to the general population is highly unlikely.4 Table 
2 shows that the method for extrapolating survival has a large infl uence on the ICER of 
TAVI versus SAVR.1 A better approach would be to fi t survival curves separately for the 
treatment groups using Weibull, log-normal and other models. In this way comorbidities 
such as diabetes mellitus, coronary artery disease, and prior myocardial infarction can be 
taken into account as covariables.
The inputs for the model came from a variety of sources and some assumptions are 
questionable. While unadjusted costs of balloon valvuloplasty were directly plugged in 
from a 23 year old study, fi gure 2 showed that these costs actually have a major infl uence 
on overall cost-eff ectiveness.1 Also, the investigators used an excessive 36-day hospital 
stay after SAVR, and based the procedural costs of SAVR on septuagenarians instead of 
high-risk octogenarians. Furthermore, the short-term probability of acute kidney injury 
was estimated at 0.112, whereas 0.011 seems appropriate according to the PARTNER 
cohort B data.
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The authors mentioned that the ICER of TAVI versus SAVR would be more favourable 
towards TAVI if the costs of the TAVI procedure had been lower. It would be interesting 
to report what the price of a TAVI valve would need to be in order to be a cost-eff ective 
alternative for SAVR.5 Also, an elaboration on the diff erences with the PARTNER cost-
eff ectiveness analyses would be valuable.
Methodology and assumptions infl uence the estimated outcomes in cost-eff ectiveness 
analyses. It would be interesting to see what the impact of our remarks would be on the 
cost-eff ectiveness estimates of TAVI in the current analysis.
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APPENDIX
Reply by Doble et al.
All properly conducted model-based economic evaluations should be a synthesis of best 
available evidence. It is important to note that economic models need to be updated 
once new evidence is available. The methods and assumptions used in our economic 
evaluation on transcatheter aortic valve implantation (TAVI) were appropriate because 
the evaluation was based on the best evidence available at the time of the analyses. 
Nevertheless, evidence on TAVI has grown rapidly in the past 2 years. We appreciate the 
comments raised by Osnabrugge and Kappetein and agree that a reexamination of the 
model with the new evidence is warranted.
Our analysis of TAVI compared with surgical aortic valve replacement (SAVR) grouped the 
patients undergoing transfemoral (TF) or transapical (TA) approach into 1 treatment arm. 
The reported clinical data from the Placement of Aortic Transcatheter Valve (PARTNER) 
cohort A also grouped these two diff erent TAVI approaches to show the noninferiority 
of TAVI in terms of 1-year mortality. This was based on a sample size calculation of 650 
patients at approximately 85% power.1 The stratifi ed clinical event rates provided in the 
Supplementary Appendix were not appropriate to use because of the lack of statistical 
power. It was estimated that 450 patients would need to undergo TF placement to show 
noninferiority of TAVI compared with SAVR at 85% power; however, only 244 patients 
were assigned to TF placement in the trial. It was therefore necessary to use utility values 
derived from the New York Heart Association functional classes, because this was the 
only relevant source that provided data for a similar patient population (i.e., patients 
undergoing TF and TA grouped together). Now that the full details of the PARTNER cohort 
A quality of life study are available,2 we have imputed these EQ-5D utility values into our 
analysis (Table 1). TAVI was dominated by SAVR when using these EQ-5D utility values 
observed in both the TF and TA arms. TF compared with SAVR had an incremental cost-
eff ectiveness ratio of $67,934/quality-adjusted life year (QALY) when the diff erence in 
utility values at years 2 to 20 of the model was assumed to be 0.09 in favor of TF.
The evidence on the long-term survival of patients undergoing TAVI is not available. 
Therefore, in the model, we directly used the mortality observed in the PARTNER trial for 
the fi rst year and the mortality of the general public for the subsequent years. However, 
this approach does not imply that the survivals predicted by the model are comparable 
to those of the general public as argued by Osnabrugge and Kappetein. There were other 
mortalities caused by stroke, myocardial infarction, and acute kidney injury considered 
throughout the time horizon. We believe this is a reasonable approach to predict the 
survivals for the patient population. Of note, this base-case analysis was also supple-
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Table 1.One-way sensitivity analysis of various model parameters
TAVI vs SAVR TAVI vs SM
PARTNER EQ-5D values
Base case (NYHA converted to EQ-5D utilities) Dominated $51,324/QALY
EQ-5D utilities from the TF arm Dominated* $46,701/QALY†
EQ-5D utilities from the TF arm (assume 0.03 
diff erence at ≥ 2 y)
$13,031,292/QALY NA
EQ-5D utilities from the TF arm (assume 0.06 
diff erence at ≥ 2 y)
$135,163/QALY NA
EQ-5D utilities from the TF arm (assume 0.09 
diff erence at ≥ 2 y)
$67,934/QALY NA
EQ-5D utilities from the TA arm Dominated NA
Cost of balloon valvuloplasty
Base case ($29,600) NA $51,324/QALY
$15,000 NA $75,473/QALY
$20,000 NA $67,203/QALY
$25,000 NA $58,933/QALY
$30,000 NA $50,662/QALY
$35,000 NA $42,392/QALY
$40,000 NA $34,121/QALY
Length of stay after SAVR
Base case (36 d) Dominated NA
10 d Dominated NA
15 d Dominated NA
20 d Dominated NA
25 d Dominated NA
30 d Dominated NA
35 d Dominated NA
40 d Dominated NA
Procedural cost of SAVR
Base case ($32,784) Dominated NA
$25,000 Dominated NA
$30,000 Dominated NA
$35,000 Dominated NA
$40,000 Dominated NA
$45,000 TAVI costs $1063 less at 0.102 less QALYs NA
$50,000 TAVI costs $6063 less at 0.102 less QALYs NA
Cost of TAVR valve
Base case ($39,796) Dominated $51,324/QALY
$15,000 TAVI costs $13,642 less at 0.102 less QALYs $10,310/QALY
$20,000 TAVI costs $8642 less at 0.102 less QALYs $18,580/QALY
$25,000 TAVI costs $3642 less at 0.102 less QALYs $26,851/QALY
$30,000 Dominated $35,121/QALY
$35,000 Dominated $43,391/QALY
$40,000 Dominated $51,662/QALY
$45,000 Dominated $59,932/QALY
NA, Not available; NYHA, New York Heart Association; PARTNER, Placement of Aortic Transcatheter Valve; 
QALY, quality-adjusted life year; SAVR, surgical aortic valve replacement; SM, standard management; TA, 
transapical; TAVI, transcatheter aortic valve implantation; TF, transfemoral.
* Diff erence in EQ-5D utility score at 1 year was equal to 0.01 as reported by Reynolds et al.2
† Utilities values for TF placement in inoperable patients obtained from Neyt and Van Brabandt.3
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mented by the scenario analyses with diff erent mortality assumptions. As suggested 
by Osnabrugge and Kappetein, the use of survival functions to fi t patient-level data is 
another approach. This approach is obviously conditional on the access to patient-level 
data and is also subject to criticism. If there was any mortality benefi t from TAVI observed 
at the end of the trial, the use of fi tted survival functions is likely to enlarge the diff er-
ence in favor of TAVI.3
Osnabrugge and Kappetein also were concerned about some resource use and cost inputs 
in the model. To address these concerns, we updated our 1-way sensitivity analyses (Table 
1). Increasing the cost of balloon valvuloplasty improved the cost-eff ectiveness of TAVI, 
whereas changes in the length of hospital stay after SAVR had no impact. At high SAVR 
procedural costs or lower TAVI valve costs, TAVI gained less QALYs at lower costs compared 
with SAVR. The short-term probability of acute kidney injury was incorrectly listed in Table 
1 of our original article, and the correct value of 0.011 was used in our model.
The trial-based economic evaluation by the PARTNER investigators used patient-level 
data to estimate the cost-eff ectiveness of TAVR compared with standard therapy from a 
US perspective.4 Detailed costing was performed at an individual level using hospital-
billing data. This is in contrast to the estimation of costs in our model, which were mainly 
based on average costs of long-term complication health states and may account for the 
diff erence in lifetime costs observed (incremental cost of $79,837 and $31,029, respec-
tively). Larger values for incremental life-years (LYs) and QALYs (1.6 LYs and 1.3 QALYs 
compared with 0.9 LYs and 0.6 QALYs in our analysis) can be accounted for by the use of 
exponential models for survival extrapolation and a lower discount rate of 3% compared 
with 5% used in our model. Consequently, overall results were more favorable in our 
analysis with a reported incremental cost-eff ectiveness ratio of $51,324/QALY compared 
with $61,889/QALY in the trial-based analysis.
A comparison of the results from our cohort A analysis and that presented by Reynolds5 
at the TransCatheter Therapeutic conference is limited by the fact that the analysis by 
Reynolds was a trial-based approach using only 12 months follow-up and thus may 
not have captured all of the long-term costs and benefi ts of TAVR and SAVR. It will be 
important for Reynolds to model the lifetime eff ects of these two comparators to obtain 
more reliable estimates of cost-eff ectiveness.
Despite extensive review by an expert advisory panel and subsequent approval by the 
Food and Drug Administration, the appropriate use of the SAPIEN (Edwards Lifesciences, 
Irvine, CA) heart valve for high-risk operable patients remains uncertain. Unfortunately, 
uncertainty surrounding the benefi ts and risks of TAVI largely aff ects estimates of the 
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incremental cost-eff ectiveness. Although recently available evidence has shed some 
light, uncertainty still remains signifi cant.
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TO THE EDITOR:
In a recent issue of the Journal, Flather et al.1 reported a subgroup analysis of individual 
patient data from 10 randomized trials comparing percutaneous coronary intervention 
(PCI) and coronary artery bypass grafting (CABG) for multivessel coronary disease. Their 
analysis showed that there was a signifi cant treatment-by-age interaction for 10-year 
mortality (p < 0.001). Strikingly enough, in the youngest age group of patients ≤56.2 years 
old there was no diff erence in mortality (hazard ratio for PCI = 1.23; 95% CI 0.95-1.59), 
while the hazard ratio shifted towards a signifi cant benefi t of CABG over PCI in older 
patients ≥65.2 years old (hazard ratio = 0.79; 95% CI 0.67-0.94).
Although the data from these trials are compelling, they were not performed accord-
ing to the ‘all-comers’ design and it is therefore likely that there was a severe selection 
bias in the inclusion of patients. Young patients were probably those with low lesion 
complexity and it is known that in these patients CABG does not off er a survival benefi t.2 
In contrast, even though the results of this study suggest superiority of CABG over PCI in 
elderly patients, this is counterintuitive and these results may not be generalizable to the 
majority of patients requiring coronary revascularization. Those patients with a higher 
risk profi le were excluded from randomization because of procedural risks associated 
with CABG.3 The advantage of PCI in the elderly patients could therefore not be identifi ed 
in this pooled analysis.
Furthermore, long-term survival of young patients with more complex coronary artery 
disease is best realized through surgical revascularization with a left internal mammary 
artery to the left anterior descending artery. This will optimize long-term survival due to 
excellent graft patency,4 which is critical especially in young patients with a relatively 
long life expectancy. Young patients that undergo PCI will have a high risk of multiple 
repeat revascularizations and are susceptive to the associated procedural risks.
The ancillary benefi t of PCI to be preferred over CABG is its lesser invasiveness and 
shorter initial hospitalization.5 However, the short-term deterrence of CABG in younger, 
fi tter patients is less due to lower complication rates and shorter length of stay and 
time needed to resume normal activities of daily living. The benefi t of PCI over CABG 
in younger patients may therefore be small, while long-term effi  cacy is clearly superior 
in the majority of young patients. The treatment of choice in young patients should 
therefore preferable be CABG.
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PART I. INTRODUCTION
Chapter 1 is a general introduction to this thesis, describing the need for the combined 
evaluation of clinical outcomes, quality of life and costs in cardiovascular medicine. The 
aims and outline of this thesis are presented.
Chapter 2 introduces the reader to aortic stenosis and its considerable burden of dis-
ease. The treatment options surgical aortic valve replacement (SAVR) and transcatheter 
aortic valve implantation (TAVI) are introduced and the existing literature on the cost-
eff ectiveness of TAVI is discussed. Despite underlying diff erences in methodology and 
healthcare systems across these studies, the relatively consistent results lead to the 
conclusion that TAVI is economically attractive when compared with medical manage-
ment in patients who are not candidates for surgery. The cost-eff ectiveness analyses that 
compare TAVI and SAVR studies in patients at high operative risk draw markedly diff erent 
conclusions on the economic attractiveness of TAVI in these patients. These diff erences 
largely depend on the cost input and the healthcare system in which the analysis is 
conducted.
Chapter 3 introduces alternative treatments for complex coronary artery disease. The 
most important clinical trials and large registries comparing coronary artery bypass 
grafting (CABG) and percutaneous coronary intervention (PCI) are discussed. In complex 
multi-vessel disease, CABG results in lower rates of long-term mortality, myocardial 
infarction and repeat revascularization when compared with PCI. These results are more 
pronounced in diabetics and in patients with lesions that are anatomically more complex. 
The application of the results of clinical trials may be limited due to restrictive eligibility 
criteria. Comparative eff ectiveness studies are, therefore, needed to complement the 
results of trials, but also have inherent limitations. Appropriate use criteria provide an 
important tool to measure how evidence from trials, large registries and guidelines is 
integrated in clinical practice. Decision-making is centered around heart team discus-
sions and risk scores. Economic considerations will increasingly be included in decision-
making, since the economic impact of ischemic heart disease is high and the growth of 
healthcare expenditure is unsustainable. In this context, the current studies show that 
CABG is associated with higher upfront costs, but is economically attractive at long-term 
follow-up.
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PART II. AORTIC STENOSIS
In Chapter 4 we study the disease prevalence of severe aortic stenosis and model the 
number of potential candidates for TAVI. A systematic search and meta-analysis show 
that the pooled prevalence of severe aortic stenosis in the elderly (>75 years old) is 
3.4%. Using Monte Carlo simulations and literature searches of decision-making studies, 
we estimate that there are approximately 290,000 TAVI candidates under the current 
indications in North America and Europe. Annually, nearly 27,000 patients become 
eligible for TAVI.
In Chapter 5 the adoption of TAVI in Western Europe is examined and factors that infl u-
ence the heterogeneous utilization of this therapy are investigated. Between 2007 and 
2011, more than 34,000 patients underwent TAVI in 11 European countries. There is 
wide variation in the number of TAVI implants per million individuals and penetration 
rates across countries. National economic indices and reimbursement strategies are 
closely linked with TAVI use and help explain the inequitable adoption.
Chapter 6 characterizes the health status outcomes for patients with severe aortic ste-
nosis and extreme surgical risk who undergo TAVI with a self-expanding bioprosthesis. 
Given the advanced age and multiple comorbidities in these extreme risk patients, 
improvement in quality of life from the patient’s perspective may be of even greater 
importance than prolonged survival. We show that TAVI is associated with substantial 
and meaningful improvement in both disease-specifi c and generic health status mea-
sures. However, there is a minority of patients who die or have very poor quality of life 
after TAVI. Baseline factors that are associated with poor outcome include measures of 
disability and frailty, comorbidities, and valve physiology.
The introduction of TAVI has led to more rigorous evaluation of SAVR as a benchmark 
for TAVI.
In Chapter 7 the clinical outcomes, costs and resource use associated with SAVR in patients 
at diff erent operating risk are evaluated. With increasing risk, the rates of post-operative 
mortality (low 1.2% vs. intermediate 2.7% vs. high 6.2%) and post-operative complica-
tions are higher. Similarly, length of stay and mean total costs increase according to risk 
category (low $35,021 vs. intermediate $46,101 vs. high $51,145). These data provide a 
basis for the evaluation of TAVI cost-eff ectiveness and its impact on the health care budget.
Chapter 8 compares the costs associated with TAVI and SAVR in patients at intermediate 
operating risk. In a propensity-matched analysis, the in-hospital costs are higher in TAVI 
patients than in SAVR patients (€40,902 vs. €33,354, respectively; p = 0.010). At one year 
463
Chapter 25. Summary
25
the diff erence in total costs persists (€46,217 vs. €35,511, respectively; p = 0.009). The 
diff erence is mainly caused by the higher costs of the transcatheter valve and is not 
compensated by the lower costs for blood products and hospital stay in TAVI patients.
Chapter 9 is a letter to the editor that adds to the discussion on the evidence base for the 
use of TAVI. Methodological comments on the most important TAVI trials and insinuations 
towards trial investigators are put into perspective.
Chapter 10 discusses the impact of severe aortic stenosis in patients requiring non-car-
diac surgery. Commenting on a large study, we suggest that the better than anticipated 
outcomes imply that the threshold to proceed with the non-cardiac surgical procedure 
could be lowered. In symptomatic patients with severe aortic stenosis, however, non-
cardiac surgery should be postponed until the aortic stenosis is treated with either TAVI 
or SAVR.
PART III. CORONARY REVASCULARIZATION
In Chapter 11 the long-term clinical benefi ts and cost-eff ectiveness of CABG and PCI 
with drug-eluting stents (DES) are studied from a U.S. health care perspective. The total 
hospitalization costs are higher with CABG, but over the next 5 years, follow-up costs 
are higher with DES-PCI due to more frequent hospitalizations, repeat revascularization 
procedures, and higher medication costs. When extended to a lifetime horizon using a 
modeling approach, CABG is a clinically and economically attractive revascularization 
strategy compared with DES-PCI for patients with 3-vessel or left main coronary artery 
disease. However, among patients with less complex disease, DES-PCI may be preferred 
on both clinical and economic grounds.
In Chapter 12, the European perspective is applied on the lifetime cost-eff ectiveness 
of CABG versus DES-PCI. Moreover, the discriminative power of the SYNTAX Score II is 
assessed. This score is an individualised decision-making tool weighing anatomical 
and clinical factors to establish the optimal revascularisation strategy for patients with 
complex coronary artery disease. Despite diff erences in costs, utilities and lifetime ex-
trapolation methodology, the overall results are comparable to those in Chapter 12. The 
SYNTAX Score II allows for objective decision-making between CABG and PCI, and also 
discriminates economic outcomes adequately.
Chapter 13 studies the impact of patient characteristics, comorbidities and complica-
tions on post-operative length of stay and total costs. Compared with post-operative 
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complications, patient characteristics have little impact on length of stay and costs. Upon 
validation, the models that combine pre- and post-operative variables explain variance 
better and are better calibrated than the pre-operative models. The pre-operative mod-
els are useful for prediction of costs and length of stay for groups of patients, case-mix 
adjustment in hospital benchmarking and pay-for-performance measures. The combined 
models identify incremental costs associated with complications and can be used for 
prioritizing quality improvement eff orts.
In Chapter 14, value in CABG is defi ned and a framework to identify high-value centers is 
provided. Risk-adjusted length of stay and risk-adjusted morbidity/mortality are impor-
tant outcome measures for assessing value in cardiac surgery. The proposed framework 
can be used to determine value in CABG, and identify high-value centers. This provides 
important information for quality improvement and pay-for-performance initiatives.
Chapter 15 discusses appropriate use criteria. These criteria integrate guidelines, clini-
cal trial evidence, and expert opinion in order to determine the most appropriate care 
for a range of distinct clinical scenarios. Approximately 12-14% of all PCI and 1-2% of 
all CABG procedures in patients with stable angina are deemed inappropriate. Several 
reasons for this diff erence are identifi ed. Continuous improvement of the criteria, multi-
disciplinary discussions, and the correct fi nancial incentives will be essential in reducing 
the number of inappropriate procedures, improve patient outcomes, and contain costs.
PART IV. RISK PREDICTION IN CARDIAC SURGERY
Chapter 16 presents a validation study comparing the performance of two risk prediction 
models: the European System for Cardiac Operative Evaluation II (EuroSCORE II) versus 
the U.S. Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM). In a large 
U.S. multicenter database, the STS-PROM performs better than EuroSCORE II for CABG. 
However, the EuroSCORE II is a reasonable alternative in low-risk CABG patients and in 
those undergoing other cardiac surgical procedures. Due to overprediction of mortality, 
TAVI trials that use these scores for patient selection are enrolling patients that are at 
lower risk than anticipated.
Chapter 17 is a systematic review of risk prediction in adult cardiac surgery. Using an 
elaborate systematic literature search, we identify an extensive set of risk factors that 
are predictive of mortality, stroke, renal failure and/or length of stay after adult cardiac 
surgery. Current and future databases should consider collecting these variables in order 
to develop improved risk models.
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Chapter 18 is a commentary on a strategic decision-support tool that predicts individual 
long-term survival (1, 5, and 10 years) after PCI with bare metal stents, after PCI with DES, 
and after CABG. These models help physicians to make recommendations, but a heart 
team approach to further individualize treatment is needed to ensure that every patient 
receives the optimal therapy.
PART V. METHODOLOGICAL APPRAISAL OF CARDIOVASCULAR RESEARCH
Chapter 19 is a letter to the editor about a meta-analysis. The letter highlights two meth-
odological issues that hamper the interpretation of the association between CYP2C19 
loss-of-function alleles and clinical effi  cacy of clopidogrel. First, the authors used an 
inappropriate strategy to reduce substantial heterogeneity in the results. Secondly, there 
was no assessment of potential bias that may have had impact on their results.
Chapter 20 systematically investigates how 11 overlapping meta-analyses on the as-
sociation between CYP2C19 loss-of-function alleles and clinical effi  cacy of clopidogrel 
could yield contradictory outcomes. The results of the meta-analyses diff er because 
more recent meta-analyses included more primary studies and some had not included 
conference abstracts. Conclusions diff er because between-study heterogeneity and 
publication bias were handled diff erently across meta-analyses. The substantial hetero-
geneity and publication bias implies that personalized antiplatelet management based 
on genotyping is not supported by the currently available evidence.
Chapter 21 evaluates the enormous increase in the number of meta-analyses in the 
cardiovascular fi eld. This trend entails the publication of duplicate meta-analyses on the 
same topic. Although some replication of research is generally warranted, a large number 
of overlapping (discordant) meta-analyses refl ects waste of resources, adds confusion 
to the fi eld and threatens the value of the study design. Considerations regarding het-
erogeneity, publication bias and quality of primary studies should serve as a basis to 
appraise the evidence across overlapping meta-analyses. To maintain the appreciation of 
meta-analyses as the highest level of evidence, authors should adhere to the appropriate 
reporting guideline, describe the rationale for performing the (updated) meta-analysis, 
register their project in a dedicated database and evaluate the whole body of evidence.
Chapter 22 is a letter to the editor that stresses the importance of correctly comparing 
the survival of a specifi c patient population (patients undergoing SAVR) with that of the 
general population.
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Chapter 23 is a letter to the editor on the impact of methodology and assumptions 
on the cost-eff ectiveness results for TAVI. The methodology for modeling utilities, 
extrapolating survival and the assumptions for model inputs infl uence the outcome of 
cost-eff ectiveness analyses.
Chapter 24 discusses the generalizability and interpretation of the results of a patient-
level meta-analysis comparing CABG and PCI across diff erent age categories.
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The aim of this thesis was to study the clinical, economic, and quality of life considerations 
for clinical decision-making and policy development in cardiovascular interventions for 
aortic stenosis and coronary artery disease. In this discussion chapter, the results will be 
put in a broader perspective, highlighting the implications for clinical decision-making 
and policy development. In addition, future developments will be discussed.
AORTIC STENOSIS (PART II)
In the fi eld of structural heart disease, aortic stenosis is the most common valvular prob-
lem and its burden is expected to increase as the population is aging.1 Surgical aortic 
valve replacement (SAVR) used to be the only treatment option, but now safe and reliable 
catheter-based techniques have emerged.2-4 In patients with severe aortic stenosis who 
are not suitable candidates for surgery, transcatheter aortic valve implantation (TAVI) has 
been shown to result in substantial reductions in mortality (30.7% in the TAVI group 
versus 50.7% in the standard therapy group at 1 year).3 Moreover, in patients at high 
surgical risk, TAVI was non-inferior to SAVR. Recently, the CoreValve US pivotal trial was 
the fi rst randomized comparison showing that TAVI with a self-expandable valve resulted 
in higher one year survival compared to SAVR in patients at increased surgical risk.5
Disease Prevalence and Number of Candidates for TAVI
Since statistics on potentially treatable patients were only scarcely available, we con-
ducted a systematic review and meta-analysis on the prevalence of aortic stenosis and 
estimated the number of candidates that are potentially treatable with TAVI (Chapter 
4). Before this study, the prevalence of severe aortic stenosis in the elderly population 
was not clear as studies were scarce and reported disparate results. We found that the 
prevalence of severe aortic stenosis in the elderly was 3.4%. Although the studies dif-
fered with regard to the defi nition and severity of aortic stenosis, our fi nding relies on 
consistent estimations across studies. We also found that on average as many as 40.5% 
of patients with symptomatic severe aortic stenosis were not treated surgically. While 
the included studies diff er with regard to the time period and degree of symptoms and 
stenosis, the analysis is the fi rst to systematically assess this across studies, and stresses 
the undertreatment of patients with AS at high-operating risk.6, 7
Using population estimates and the estimates on decision-making in patients with aortic 
stenosis, we projected that currently almost 300,000 patients are candidates for TAVI 
in the US and Europe combined. Moreover, nearly 27,000 patients become eligible for 
TAVI annually. As a result of the heterogeneity of the underlying studies, these estimates 
are not exact and come with large confi dence intervals. Nevertheless, our study was the 
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fi rst to systematically project the number of potential TAVI candidates and provide some 
insights on the market size for these new devices.
TAVI Adoption and Policies for the Introduction of New Medical Technologies
Besides clinical evidence and costs, there are several other factors that determine the 
adoption of novel technologies like TAVI. In Chapter 5 the actual number of TAVI implants 
across Europe is described, and a signifi cant correlation between healthcare spending 
per capita and TAVI use was found. Moreover, countries with TAVI-specifi c reimbursement 
systems had more implants than countries that used restricted systems. While this was 
the fi rst study to correlate TAVI adoption with economic indicators, the relationship was 
also seen for implantable cardiac defi brillators.8 Economic prosperity and reimburse-
ment seem to drive clinical practice.
Also, the review processes of new medical devices diff er widely among countries. In 
the United States (U.S.) the Food and Drug Association (FDA) require clinical studies 
evaluating the safety and eff ectiveness of a high risk device as TAVI.9 In Europe, devices 
require a Conformité Européenne (CE) mark that indicates market approval throughout 
the European Union (E.U.). The specifi c requirements for the CE mark are vague, but are 
usually met when the device is manufactured using a technically correct method. More-
over, it should perform as intended in a way that the benefi ts outweigh the expected 
risks and is followed by postmarketing surveillance.9 The CE marking takes one to three 
months, whereas the average review time for high risk devices is 21 months in the U.S. In 
summary, the requirements in the E.U. are more easily met, since less rigorous proof of 
eff ectiveness is required. As a consequence, patients within the E.U. have faster access to 
new medical devices such as TAVI, but have a greater chance of later-identifi ed adverse 
events. On the contrary, once approval has been given, the U.S. are quicker to arrange 
insurance coverage of the newly approved device.10
Risk Models and Decision-Making in Aortic Stenosis
Patient selection is important both for research purposes and clinical decision-making. 
To facilitate the process, several surgical risk scores are available to estimate the risk of 
perioperative mortality after aortic valve surgery. These scores are also used for patients 
undergoing TAVI. We show in Chapter 16 that both the Society of Thoracic Surgeons Pre-
dicted Risk of Mortality (STS-PROM) and EuroSCORE II signifi cantly overpredict mortality 
in patients who are potentially treatable with TAVI. Consequently, patients selected for 
TAVI may be at lower risk than anticipated based on these scores. Instead, a dedicated 
risk model for TAVI should be developed from a large and uniform multicenter database.11 
Variables that would have to be considered include vessel tortuosity, frailty, access-site 
characteristics and angles of the aortic arch.
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The patients’ risk score should be combined with clinical judgment in a multidisci-
plinary heart team. After its fi rst application in the SYNTAX trial for the discussion on the 
optimal revascularization therapy, the heart team concept has become a cornerstone 
in cardiovascular clinical decision-making.12, 13 A valvular heart team should include a 
cardiac surgeon, an (interventional) cardiologist, an imaging specialist, a heart failure 
specialist, a cardiac rehabilitation specialist and a nurse practitioner. All relevant risk 
scores and additional information should be discussed and, with all the specialties 
aboard, they are more likely to come to a consensus on the optimal treatment for the 
patient at hand.
Quality of Life Considerations
Given the advanced age and multiple comorbidities in patients undergoing TAVI, 
improvement in quality of life from the patient’s perspective may be of even greater 
importance than prolonged survival. We found that TAVI using a self-expanding biopros-
thesis in patients at extreme operating risk is associated with substantial and meaningful 
improvement in both disease-specifi c and generic health status measures (Chapter 6). 
The study thus confi rms that the health status benefi ts of TAVI are not restricted solely 
to balloon-expandable transcatheter valves,14, 15 but also apply to the CoreValve self-
expanding transcatheter valve.
Nevertheless, we found that almost 40% of the patients did not experience meaningful 
improvement in health status or survival at 6 months. Several factors, including comorbid 
conditions, disability/frailty, and valve physiology, were independently associated with 
poor outcomes after TAVI. One other study investigated predictors of poor outcome after 
TAVI, with a large overlap in predictors.16 Further studies are required to determine a 
model that can be used prospectively to distinguish patients who are likely to benefi t 
from TAVI from those for whom TAVI is futile. Being able to select the right patients will 
help obtain the best results, both from a clinical and economic perspective.
Costs and Cost-Eff ectiveness
The estimated large number of potential TAVI candidates has clinical, economic and social 
implications. Given the considerable costs of implanting TAVIs,17 as well as the large and 
growing population of potential candidates, it is clear that not only clinical but also care-
ful economic evaluation is required. The estimation of health care costs is based on the 
resources used by a health intervention and should be valued at its opportunity costs.18 
The measurement of opportunity costs are often expressed as market prices, since prices 
in competitive markets refl ect the opportunity costs of resources. However, health care 
charges do not necessarily refl ect market prices due to market distortions caused by e.g. 
health insurance, hospital accounting systems, and pricing policies. Therefore, adjust-
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ments such as cost-to-charge ratios are applied and/or a micro-costing approach should 
be employed.
Both cost-to-charges on hospital billing data (Chapter 7) and micro-costing (Chapter 8) 
were applied in this thesis in order to estimate the costs associated with TAVI and SAVR. 
In Chapter 7 we found that the cost of high-risk SAVR, based on adjusted hospital bills, 
are lower than the costs of SAVR in a randomized trial that combined resource-based 
accounting and hospital bills to estimate the cost-eff ectiveness of TAVI.17 Our results sug-
gest that in everyday practice TAVI is less likely to be an economically attractive treatment 
compared to SAVR than in the setting of a clinical trial. Another reason for the disparity 
in costs might be that the randomized trial included only 12% of the screened severe 
aortic stenosis patients, thereby limiting the generalizability of its clinical and economic 
results. However, a direct comparison across studies should always be considered explor-
atory. In Chapter 8 we applied micro-costing to compare the direct hospital costs and 
one-year follow-up costs of TAVI versus SAVR in a propensity matched cohort of patients 
at intermediate operating risk. It is the fi rst and currently only study with a detailed focus 
on costs in this patient category. Importantly, the four times higher costs of materials 
in TAVI were not compensated by lower costs of blood products and length of stay. It 
is important to note however that the TAVI patients in this study refl ect relatively early 
experience and that market forces are likely to decrease the price of transcatheter valves 
(currently almost €18,000) as more valves enter the market. Still, with approximately 
€10,000 higher costs after TAVI at one year, it will be interesting to see what the qual-
ity of life results of ongoing randomized studies will show in patients at intermediate 
operating risk. These results are important for the cost-eff ectiveness and accompanying 
economic attractiveness of TAVI in those patients.
Future Developments infl uencing Cost-Eff ectiveness
Several factors and developments are likely to infl uence the cost-eff ectiveness of TAVI 
compared with SAVR in the future. First, there are currently no long-term follow-up 
data regarding TAVI durability. Although the biomaterials comprising current transcath-
eter valves are quite similar to those of current surgical bioprostheses, it is unknown 
whether the process of crimping and valve deployment might have a harmful eff ect 
on the long-term integrity of the valve that could result in higher rates of structural 
valve deterioration and late reoperation, particularly as TAVI is performed in younger 
and lower risk individuals. Although studies have yet to address these issues explicitly, it 
is intuitive that the additional costs, complications, and quality of life reductions associ-
ated with premature valve failure would reduce the cost-eff ectiveness of TAVI compared 
with SAVR.
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The costs of the TAVI procedure and hospitalization are also likely to evolve over the next 
several years. For example, as more manufacturers enter the TAVI market, it is expected 
that the price of transcatheter valves will drop, making TAVI more cost-eff ective com-
pared with current levels. Length-of stay is another important driver infl uencing both the 
cost and cost-eff ectiveness of TAVI. Although TAVI is less invasive than SAVR, the mean 
length of stay after TAVI among truly high risk patients was 10 days in the Placement 
of AoRTic TraNscathetER Valves (PARTNER) A trial (16 days among patients treated via 
the transapical approach) and 11 in our study of intermediate risk patients (Chapter 
8).14, 17 As device profi les continue to decrease and operator experience grows, it can be 
expected that length of stay for TAVI will decrease, which should also favorably impact 
the cost-eff ectiveness of TAVI relative to SAVR. SAVR, on the other hand, is a relatively 
mature procedure that is unlikely to achieve comparable length of stay reductions.
Recently, it was shown that TAVI resulted in better one year survival compared to SAVR in 
patients at increased surgical risk,5 and now the ongoing SURTAVI (Surgical Replacement 
and Transcatheter Aortic Valve Implantation) and PARTNER II trials will compare TAVI 
versus SAVR in even lower risk patients. In Chapter 4 we estimated that a further 145,000 
patients would become TAVI eligible when these trials show favorable results for TAVI. 
If in the future, TAVI will show good safety and eff ectiveness compared to SAVR in even 
low risk patients, another 730,000 patients in the U.S. and Europe would become TAVI 
eligible. Given the size of these numbers and the costs associated with TAVI, demonstrat-
ing both economic and quality of life benefi ts will be an important goal of randomized 
trials in order to justify expansion of TAVI indications into such lower risk patients.
Of note, only the U.S. perspective PARTNER trial has specifi cally captured the cost of 
high-risk SAVR in patients who would otherwise be considered for TAVI. The rapid ac-
ceptance and proliferation of TAVI for high risk patients (and even intermediate risk 
patients) in many European countries has made randomized trials challenging in those 
settings—leaving unanswered questions about the costs and outcomes of SAVR in truly 
high risk individuals.
Finally, it is important to recognize that whether TAVI is truly ‘cost-eff ective’ depends 
on a society’s ability and willingness-to-pay for health benefi ts.19 The World Health 
Organization applies a threshold of three times the gross domestic product (GDP). Thus, 
an incremental cost-eff ectiveness ratio of $50,000/QALY or €30,000/QALY gained may 
be acceptable in the United States or relatively wealthy countries in Western Europe, 
but is likely to far exceed the societal threshold in less developed societies where the 
cost-eff ectiveness threshold may be <$10,000/QALY gained.
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CORONARY REVASCULARIZATION (PART III)
Compared with TAVI, the catheter-based technique for the treatment of coronary artery 
disease is more mature. Since Andreas Grüntzig performed the fi rst percutaneous coro-
nary intervention (PCI) in 1977,20 millions of patients have undergone this procedure, 
and it has been compared extensively versus medical therapy and versus coronary artery 
bypass grafting (CABG) (Chapter 3). The Synergy between PCI with TAXUS and Cardiac 
Surgery (SYNTAX) trial is the most contemporary trial to compare PCI with drug-eluting 
stents (DES-PCI) versus CABG in patients with 3-vessel or left main disease. At 5-year 
follow-up, CABG was associated with a lower rate of the composite endpoint (cardio-
vascular death, myocardial infarction, stroke, or repeat revascularization) compared with 
DES-PCI.21 The diff erence was predominantly driven by reductions in non-fatal myocar-
dial infarction and repeat revascularization. However, DES-PCI was associated with a 
lower rate of stroke in the overall population, and DES-PCI is a reasonable alternative in 
subgroups of patients with anatomically less complex disease (low SYNTAX score), or left 
main coronary artery disease.21
Cost-Eff ectiveness Results
Procedures for coronary revascularization account for nearly $12 billion/year in direct 
costs alone, and virtually all healthcare systems are faced by economic challenges. 
Therefore, it is critical that the alternative revascularization procedures PCI and CABG 
are not only compared clinically but also economically. In this thesis, the long-term cost-
eff ectiveness and clinical benefi ts of DES-PCI versus CABG were described for patients 
with 3-vessel or left main coronary artery disease from a U.S. (Chapter 11) and Dutch 
perspective (Chapter 12). The initial hospitalization costs were higher with CABG, but 
during the 5-year follow-up the costs were higher with DES-PCI due to more frequent 
repeat revascularization procedures, hospitalizations, and higher costs for medication. 
Using a modeling approach to extend the trial results to a lifetime horizon, CABG was a 
clinically and economically attractive revascularization strategy compared with DES-PCI 
in these patients. However, among patients with anatomically less complex disease, DES-
PCI may be preferred, both from a clinical and economic perspective.
Country-Specifi city of Cost-Eff ectiveness Results
Results from cost-eff ectiveness analyses diff er among countries for many reasons, in-
cluding the epidemiological context, health care system characteristics, clinical practice 
patterns, severity of disease and diff erences in prices for labor and resources. Even 
though the SYNTAX trial was conducted in 18 diff erent countries, guidelines for cost-
eff ectiveness studies recommend the application of country-specifi c costs.22-24 In Chap-
ter 11 we applied the U.S. health care perspective, while in Chapter 12, we analyzed the 
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cost-eff ectiveness from a Dutch perspective. At the same time, the recommendations for 
economic analyses alongside multinational trials indicate that all the clinical outcomes 
can be assumed to be similar across countries.25 Although costs, EQ-5D utilities and 
lifetime extrapolation methodology diff ered, the overall conclusions are comparable 
between the two chapters. In order to facilitate further comparison, we applied exchange 
rates and purchasing power parities (PPP). Small diff erences remained, which is likely 
the result of diff erences in utilities, practice patterns and the signifi cantly higher health 
care prices in the U.S.26 More importantly, PPP is a generic conversion factor based 
on generic goods and services. It is not specifi c for health care, let alone for specifi c 
procedures like coronary revascularization.27 In short, the international transferability 
of cost-eff ectiveness evaluations is a fi eld of debate,28 and future studies are required 
to determine the optimal methodology for conducting economic analyses alongside 
multinational clinical trials.
Time Horizon
An important fi nding was that an appropriate time horizon should be used in cost-
eff ectiveness analyses. Meaningful clinical diff erences between treatments might arise 
only after 3 years. A prior SYNTAX cost-eff ectiveness analysis based on the 1-year results 
showed totally diff erent results. In contrast with the fi ndings in Chapters 11 and 12, DES-
PCI was the economically dominant treatment strategy.29 The discrepancy emphasizes 
the importance of basing policy decisions on clinical trials with appropriate follow-up 
times.
Subgroup Analyses
An important fi nding of the SYNTAX trial was that the preferred treatment strategy de-
pends on the anatomical complexity of the coronary lesions, as described by the SYNTAX 
Score.21, 30 Although the overall long-term cost-eff ectiveness results in the SYNTAX trial 
were in favor of CABG, subgroup analyses showed that DES-PCI was favored in patients 
with low SYNTAX Scores, both from an economical and clinical perspective. In contrast, 
for patients with high SYNTAX Scores, CABG was strongly favored on economic grounds.
In Chapter 12 we also analysed the economic implications of the SYNTAX Score II. 
This score was recently introduced to provide an impartial, evidence-based tool in the 
decision-making process for clinicians weighing clinical and anatomical factors to es-
tablish the optimal revascularization strategy for patients with complex coronary artery 
disease.31 Similarly to the original SYNTAX Score, we showed that the new score is not 
only an excellent clinical risk stratifi er, but also adequately discriminates economic 
outcomes. Although subgroup analyses are usually considered ‘hypothesis-generating’ 
in clinical trials, cost-eff ectiveness analysis is driven by absolute measures of cost and 
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benefi ts. Therefore, subgroup results in cost-eff ectiveness analyses are often considered 
to be valid for guideline development and healthcare policy, provided that the results 
are pathophysiologically plausible and supported by appropriate uncertainty analyses.32
New Developments infl uencing the Cost-Eff ectiveness of PCI versus CABG
In the rapidly moving fi eld of PCI, there are several developments that have potential 
impact on the cost-eff ectiveness results of PCI versus CABG. First, second-generation DES 
have demonstrated lower rates of MI, target vessel revascularization, and stent thrombo-
sis as compared with fi rst-generation DES.33 These developments are likely to enhance 
the economic profi le of PCI in cost-eff ectiveness analyses. However, there is no evidence 
(yet) that this newer generation improves survival compared with earlier generations.
Moreover, continuous development and market dynamics are driving down the price of 
stents further. In Chapter 11 and Chapter 12 we showed that the results were only mini-
mally sensitive to stent pricing. Although stent prices are frequently perceived to be a 
principal determinant of cost-eff ectiveness, the gain in life expectancy rather than stent 
price appears to be the major determinant. Finally, fractional fl ow reserve (FFR) guidance 
for PCI has shown to improve clinical outcomes and lower long-term costs compared 
with angiography-guided PCI.34, 35 Future studies will have to determine the clinical and 
economic results of PCI with FFR versus CABG.
Resource Management and Policy Development
This thesis also provides tools that can be used for resource management and policy 
development for centers and surgeons that perform CABG. In Chapter 13, we provided 
models allowing hospital administrators, operating room managers, and cardiac surgeons 
to identify the implications and predictive power of patient characteristics, comorbidi-
ties, and complications on the resource use and costs of CABG. This information is useful 
in planning resource use and for prioritizing quality improvement eff orts. In our models, 
patient characteristics and comorbidities explained only a small portion of length of 
stay and costs. Therefore, policy makers should fi rst focus on reduction of complica-
tions. Frequent, high-cost complications were identifi ed and should be the fi rst focus of 
quality-improvement eff orts.
Current health care policy measures such as pay-for-performance provide fi nancial 
incentives to improve value (i.e. to keep costs low by improving outcomes and quality 
of care).9, 36 In general, these measures provide incentives that inversely relate payment 
with risk-adjusted clinical outcomes and risk-adjusted resource use. The high annual 
volume and associated costs of CABG procedures make this type of surgery a natural 
target for cost containment and process improvement. Chapter 14 is the fi rst study to 
479
Chapter 26. General Discussion
26
apply the concept of value to a specifi c procedure (CABG). We found distinct variability 
in value when both risk-adjusted quality and cost measures were combined, but the 
exact defi nitions of low/high performers still require close collaboration with the physi-
cian community before changes in payments can be implemented. In addition, future 
studies should measure direct resource consumption per patient and apply standardized 
unit costs.37 Nevertheless, our fi ndings suggest that better quality leads to shorter post-
operative length of stay and resource use. Substantial savings and improved outcomes 
can be realized if all centers achieve the same performance of high-value centers.
The reduction of waste, or not value-added care, is another focus in the quest for sus-
tainable health care fi nances. The most conservative estimates show that approximately 
20% of total health care expenditure in the U.S. consists of waste.38 There are roughly six 
categories of waste in health care: failures of care delivery, failures of care coordination, 
overtreatment, administrative complexity, pricing failures, fraud and abuse. In Chapter 
15 we discuss the application of appropriate use criteria for coronary revascularization, 
which is related to three of these categories (failure of delivery, overtreatment, and fraud 
and abuse). If there is stricter application of guidelines and appropriate use criteria, 
patient outcomes will improve while costs are reduced.
RISK PREDICTION IN CARDIAC SURGERY (PART IV)
While Part III focused on the economic aspects in clinical decision-making, the expected 
risks and benefi ts in terms of survival are at least as important. To estimate the expected 
risks and benefi ts, several risk models are available, including the original EuroSCORE, 
EuroSCORE II, and the STS-PROM. In Chapter 16, we found that the STS-PROM was supe-
rior in identifying patients that were likely to survive cardiac surgery and was also better 
calibrated. The performance of the EuroSCORE was inadequate, whereas the EuroSCORE 
II performed satisfactorily, especially in recent low risk CABG and non-CABG procedures. 
In general, the models overpredict mortality, meaning that patients have lower operating 
risks than anticipated based on the scores.
There are several reasons why the STS-PROM performed better than the EuroSCORE II. 
The STS-PROM used a database containing >25 times more patients than the EuroSCORE 
II, and used more uniform defi nitions in the underlying database. On the other hand, 
the EuroSCORE II is easier to use as it only requires 18 variables compared to >40 vari-
ables in the STS-PROM model. Chapter 16 also stresses the importance of frequently 
updating risk scores. Recent scores performed better in more recent validation cohorts. 
When updating and improving risk scores, the underlying database should be large and 
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also consider less common variables and outcomes other than mortality, including renal 
failure, stroke, and length of stay (Chapter 17). However, the added value of collecting 
this extra information needs to be weighed against the cost of collecting them.
Still, despite attempts to improve models by incorporating additional variables, there will 
always be factors that are not included, rendering the score suboptimal and not suitable 
for the individual patient. Therefore, risk scores are supplements to clinical judgment 
and serve as a starting point for multidisciplinary heart team discussions. The heart team 
itself should be reimbursed in order take fi nancial incentives out of the clinical decision-
making process.
METHODOLOGICAL APPRAISAL OF CARDIOVASCULAR RESEARCH (PART V)
The fi nal chapters of this thesis accentuate the importance of methodological aspects in 
cardiovascular research. Increasingly, there is concern that most published research fi nd-
ings are false.39 The concern is larger when studies and eff ect sizes are smaller; when the 
number of tested relationships is larger; when a variety in designs, defi nitions, outcomes 
and analytic methods is available; when there is greater fi nancial or personal interest; 
and when more research teams are involved. Cardiovascular research regularly meets 
many of these criteria.
Methodological fl aws in meta-analyses may infl uence the interpretation and clinical con-
sequences of results. With the exciting promises of whole genome sequencing and its 
translation to health care practice, careful reporting and appraisal of evidence is crucial.40 
In Chapter 19 we express our concerns regarding the methodology and interpretation 
of a meta-analysis on the association between CYP2C19 loss-of-function alleles and the 
clinical effi  cacy of clopidogrel. The authors use an inappropriate strategy to reduce the 
substantial heterogeneity in the results and there was no assessment of potential bias. 
Distressingly, 10 other meta-analyses on the same topic also pay little attention to het-
erogeneity and publication bias (Chapter 20). Nevertheless, the substantial heterogene-
ity and publication bias found in the meta-analyses imply that personalized antiplatelet 
management based on genotyping is not supported by the currently available evidence. 
These methodological diffi  culties combined with the disproportionate increase in the 
number of (discordant) meta-analyses form the rationale behind the recommendations 
for the appraisal of meta-analyses in cardiovascular medicine (Chapter 21).
Methodological aspects also infl uence the validity of other study designs. For instance, 
when survival is incorrectly compared with a reference population, the eff ect of treat-
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ment (SAVR) could be overestimated (Chapter 22). Cost-eff ectiveness analyses are in 
particular prone to assumptions with regard to model inputs and extrapolation tech-
niques (Chapter 23).
The generalizability of results is a very important additional consideration when inter-
preting results of clinical trials. There is a subtle balance between the need for exclusion 
criteria to optimize internal validity and the need for less stringent criteria to determine 
an intervention’s eff ectiveness in everyday clinical practice. Chapter 24 explains that 
a remarkable fi nding may be the result of strict selection of patients in clinical trials. 
Such a selection bias limits the applicability of the results to everyday clinical practice 
and should be considered when interpreting the results. In summary, a continuous and 
sensible debate on the most appropriate methodology and critical appraisal of research 
should be the foundation for progress in the fi eld of cardiovascular medicine.
CONCLUSIONS
The management of aortic stenosis and coronary artery disease are rapidly moving fi elds. 
In this thesis we showed updates of clinical, economic and quality of life aspects as treat-
ment considerations in decision-making. Aortic stenosis will remain prevalent among the 
elderly. TAVI is a new and promising catheter-based technique in a world where treat-
ments are increasingly performed less invasively. Since the majority of patients consists 
of the elderly, quality of life aspects may be even more important than increased survival. 
Also, specifi c models will help identifying patients that are most likely to benefi t from 
the procedure, thereby enhancing the clinical and economic profi le of TAVI. Due to the 
large (potentially) treatable patient population and the high costs associated with TAVI, 
economic comparisons with SAVR are warranted.
The high clinical and economic burden of coronary artery disease and soaring health care 
costs demand health economic analyses of CABG and PCI. CABG is a clinically and eco-
nomically attractive revascularization strategy compared with DES-PCI in patients with 
3-vessel or left main coronary artery disease. However, among patients with anatomically 
less complex disease, DES-PCI may be preferred, both from a clinical and economic per-
spective. The prediction of resource use, pay-for-performance measures and appropriate 
use criteria will lead to improved outcomes while reducing costs.
The performance of risk prediction models is suboptimal and not always suitable for the 
individual patient. Rather, multidisciplinary heart team discussion in which risk scores and 
clinical judgment are combined, should be the cornerstone of clinical decision-making. 
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Moreover, the critical appraisal of research and continuous debate on the best methodol-
ogy should be the foundation for progress in the fi eld of cardiovascular medicine.
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DEEL I. INLEIDING
Hoofdstuk 1 is de algemene introductie waarin de beweegredenen worden beschreven 
voor de gecombineerde evaluatie van klinische uitkomsten, kwaliteit van leven en 
kosten in de cardiovasculaire geneeskunde. De doelen en onderzoeksvragen worden 
uiteengezet.
Hoofdstuk 2 introduceert de ziekte aortaklepstenose en de bijbehorende ziektelast. 
Chirurgische aortaklepvervanging (SAVR) en transkatheter aortaklepvervanging (TAVI) 
worden besproken en de bestaande literatuur over kosteneff ectiviteit van TAVI wordt 
bediscussieerd. Ondanks verschillen in methodologie en zorgstelsels laten de resulta-
ten van bestaande studies zien dat, voor patiënten die geen kandidaat zijn voor SAVR, 
TAVI economisch aantrekkelijk is wanneer het wordt vergeleken met medicamenteuze 
behandeling van aortaklepstenose. De conclusies van kosteneff ectiviteitsanalyses die 
TAVI en SAVR vergeleken in patiënten met een hoog operatief risico, verschillen sterk. De 
verschillen worden met name veroorzaakt door verschillen in toegepaste kosten en het 
zorgstelsel waarin de analyse werd uitgevoerd.
Hoofdstuk 3 introduceert verschillende behandelingen voor complex coronairlijden. De 
belangrijkste clinical trials en registries die coronary artery bypass graft operaties (CABG) 
vergeleken met percutane coronaire interventies (PCI), worden besproken. In complex 
coronairlijden leidt CABG tot een lagere lange termijn mortaliteit, minder hartinfarcten 
en minder hernieuwde revascularisaties in vergelijking tot PCI. Deze verschillen in resul-
taten zijn sterker in diabetici en in patiënten met anatomisch meer complexe laesies. De 
toepasbaarheid van de resultaten van clinical trials op de klinische praktijk kan beperkt 
zijn vanwege restrictieve selectiecriteria van patiënten. Comparative eff ectiveness studies 
refl ecteren de werkelijke klinische praktijk beter, maar kennen hun eigen beperkingen. 
Het hart team en risico voorspelmodellen zijn belangrijke aspecten van de klinische 
besluitvorming. Daarnaast worden economische afwegingen steeds belangrijker, van-
wege de hoge economische impact van coronairlijden en de onhoudbare groei van de 
zorgkosten.
DEEL II. AORTAKLEPSTENOSE
In Hoofdstuk 4 wordt de prevalentie van ernstige aortaklepstenose bestudeerd en wordt 
het aantal potentiële TAVI kandidaten gemodelleerd. Systematisch literatuuronderzoek 
en meta-analyse laat zien dat de prevalentie in bejaarde patiënten (>75 jaar oud) 3.4% 
was. Met behulp van Monte Carlo simulaties en literatuuronderzoek schatten we dat 
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er, onder de huidige indicaties, ongeveer 290.000 patiënten TAVI kunnen ondergaan in 
Noord-Amerika en Europa. Jaarlijks zijn er bijna 27.000 nieuwe TAVI patiënten.
In Hoofdstuk 5 wordt de adoptie van TAVI in verschillende West-Europese landen bestu-
deerd, alsmede de factoren die van invloed zijn op verschil in gebruik van deze therapie. 
Tussen 2007 en 2011 ondergingen meer dan 34.000 patiënten een TAVI procedure in 
11 Europese landen. Er zijn grote verschillen in het aantal TAVI implantaten per miljoen 
inwoners en de penetratie van TAVI tussen de landen. Indicatoren van de economie en 
vergoedingen zijn geassocieerd met TAVI gebruik en verklaren deels de ongelijke adoptie 
tussen landen.
Hoofdstuk 6 beschrijft de kwaliteit van leven van patiënten met ernstige aortaklepste-
nose die TAVI ondergaan met een self-expanding bioklepprothese. De patiënten hadden 
een extreem hoog operatief risico. Gezien de hoge leeftijd en verschillende comorbidi-
teiten in deze extreem hoog risico groep, kan vooruitgang in kwaliteit van leven hoger 
worden gewaardeerd dan verlengde levensduur. We laten zien dat TAVI is geassocieerd 
met substantiële, belangrijke vooruitgang in zowel ziekte-specifi eke als algemene 
kwaliteit van leven. Invaliditeit, algehele zwakte, comorbiditeiten en klepfysiologie zijn 
belangrijke factoren die zijn geassocieerd met een slechte uitkomst na TAVI.
De introductie van TAVI heeft geleid tot een herevaluatie van SAVR als maatstaf waar-
mee TAVI wordt vergeleken.
In Hoofdstuk 7 worden de klinische uitkomsten en kosten van SAVR in verschillende 
risico-categorieën geëvalueerd. Met toenemend risico, neemt de operatiesterfte (laag 
1.2% vs. gemiddeld 2.7% vs. hoog 6.2%) en het aantal post-operatieve complicaties 
toe. Op eenzelfde manier nemen de ligduur en de gemiddelde totale kosten toe met het 
operatierisico (laag $35.021 vs. gemiddeld $46.101 vs. hoog $51.145). Deze data geven 
een maatstaf voor de evaluatie van de kosteneff ectiviteit en economische impact van 
TAVI.
Hoofdstuk 8 vergelijkt de kosten van TAVI en SAVR in een groep patiënten met een gemid-
deld operatie risico. In een propensity-matched analyse zijn de kosten in het ziekenhuis 
hoger in TAVI patiënten dan in SAVR patiënten (€40.902 vs. €33.354, p = 0.010). Ook na 
één jaar blijft dit verschil in kosten bestaan (€46.217 vs. €35.511, p = 0.009). Het verschil 
wordt met name veroorzaakt door de hogere kosten van de transkatheter klep en wordt 
niet gecompenseerd door de lagere kosten voor bloedproducten en ziekenhuisverblijf 
in de TAVI groep.
493
Chapter 27. Nederlandstalige Samenvatting
27
Hoofdstuk 9 is een brief aan de editor die bijdraagt aan de discussie over het bewijs voor 
de (kosten)eff ectiviteit van TAVI. Methodologisch commentaar op de belangrijkste TAVI 
trials en insinuaties richting hoofdonderzoekers van trials worden in perspectief gezet.
Hoofdstuk 10 bediscussieert de impact van ernstige aortaklepstenose in patiënten die 
een niet-hartchirurgische operatie ondergaan. In een commentaar op een grote studie, 
suggereren wij dat de buitengewoon goede resultaten impliceren dat de drempel om de 
niet-hartchirurgische operatie te ondergaan verlaagd kan worden. Echter, in patiënten 
met symptomatische ernstige aortaklepstenose moet de operatie worden uitgesteld 
totdat de aortaklepstenose is behandeld, danwel met TAVI of SAVR.
DEEL III. REVASCULARISATIE VAN DE CORONAIRARTERIËN
In Hoofdstuk 11 worden de lange termijn klinische voordelen en kosteneff ectiviteit 
van CABG en PCI met drug-eluting stents (DES) bestudeerd vanuit het perspectief van 
het Amerikaanse zorgsysteem. De totale kosten van het ziekenhuisverblijf zijn hoger 
met CABG, maar gedurende een 5-jarige follow-up zijn de kosten met DES-PCI hoger 
vanwege meer ziekenhuisopnames, hernieuwde revascularisaties en hogere medicatie-
kosten. Ook bij extrapolatie naar de resterende duur van de levens van de patiënten, 
blijkt CABG een klinisch en economisch aantrekkelijke revascularisatie strategie te zijn 
vergeleken met DES-PCI in patiënten met 3-vats- of hoofdstam coronairlijden. Echter, 
onder patiënten met minder complex coronairlijden is DES-PCI wellicht te prefereren, 
zowel vanuit klinisch als economisch perspectief.
In Hoofdstuk 12 wordt de kosteneff ectiviteit van CABG vs. DES-PCI bestudeerd vanuit een 
Europees perspectief. Bovendien wordt de discrimineerde kracht van de SYNTAX Score 
II geëvalueerd. Deze score is een geïndividualiseerde beslishulp die zowel anatomische 
als klinische factoren combineert om de optimale revascularisatie strategie te kiezen. 
Ondanks de verschillen in kosten, utiliteiten en extrapolatietechnieken, zijn de resulta-
ten vergelijkbaar met die uit Hoofdstuk 12. De SYNTAX Score II is een geobjectiveerde 
beslishulp bij de keuze tussen CABG en PCI en blijkt ook economische uitkomsten goed 
te discrimineren.
Hoofdstuk 13 bestudeert de impact van patiëntkarakteristieken, comorbiditeiten en com-
plicaties op de duur van het post-operatieve ziekenhuisverblijf en de daarbij behorende 
totale kosten. Vergeleken met post-operatieve complicaties hebben patiëntkarakteristie-
ken weinig invloed op de totale verblijfsduur en kosten. Bij validatie blijkt dat modellen 
met zowel pre- als post-operatieve variabelen beter de variantie verklaren en beter zijn 
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gekalibreerd dan de modellen met louter pre-operatieve variabelen. De pre-operatieve 
modellen zijn nuttig om kosten en ligduur te voorspellen voor groepen van patiënten, 
vergelijkingen van ziekenhuisprestaties en uitkomstbekostiging. De gecombineerde 
modellen identifi ceren incrementele kosten geassocieerd met complicaties en kunnen 
worden gebruikt bij het prioriteren van initiatieven tot kwaliteitsverbetering.
In Hoofdstuk 14 wordt gezocht naar een defi nitie van ‘value’ van CABG procedures en 
wordt een raamwerk gepresenteerd waarmee centra met hoge ‘waarde’ kunnen worden 
geïdentifi ceerd. Risico-gewogen ligduur en risico-gewogen morbiditeit/mortaliteit zijn 
belangrijke uitkomstmaten om de ‘value’ van CABG vast te stellen en goed presterende 
centra te identifi ceren. Deze data zijn belangrijk voor kwaliteitsverbetering en uitkomst-
bekostiging.
Hoofdstuk 15 bediscussieert criteria om de gepastheid van het uitvoeren van revascula-
risatie procedures te bepalen. Deze criteria maken gebruik van richtlijnen, clinical trials, 
en het oordeel van deskundigen om de meest gepaste zorg voor verschillende klini-
sche scenario's vast te stellen. Ongeveer 12-14% van alle PCI en 1-2% van alle CABG 
procedures in patiënten met stabiele angina pectoris wordt als ongepast beoordeeld. 
Continue verbetering van de criteria, multidisciplinaire discussies en de juiste fi nanciële 
prikkels zijn essentieel bij het terugdringen van het aantal ongepaste revascularisatie 
procedures, het verbeteren van uitkomsten en het beheersen van kosten.
DEEL IV. VOORSPELLEN VAN RISICO BINNEN DE HARTCHIRURGIE
Hoofdstuk 16 vergelijkt de prestaties van twee risico voorspelmodellen: het European 
System for Cardiac Operative Evaluation II (EuroSCORE II) wordt gevalideerd en vergeleken 
met de Amerikaanse Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM). 
In een grote Amerikaanse multicenter database presteert de STS-PROM beter dan de 
EuroSCORE II voor patiënten die CABG ondergaan. De EuroSCORE II is echter een billijk 
alternatief voor CABG patiënten met een laag operatierisico en voor patiënten die een 
andere hartchirurgische ingreep ondergaan. De mortaliteit wordt door beide modellen 
overschat in patiënten met aortaklepstenose. Daardoor includeren TAVI studies die 
met behulp van deze modellen patiënten selecteren eigenlijk patiënten met een lager 
risicoprofi el dan was voorzien.
Hoofdstuk 17 is een systematische review van risicopredictie binnen de hartchirurgie. 
Met behulp van een uitgebreide systematische literatuurstudie identifi ceren we een 
groot aantal risicofactoren die voorspellende waarde hebben voor mortaliteit, cerebro-
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vasculaire accidenten, nierfalen en/of ligduur na een hartchirurgische ingreep. Huidige 
en toekomstige databases zouden het verzamelen van de geïdentifi ceerde variabelen 
moeten overwegen zodat in de toekomst verbeterde risicomodellen ontwikkeld kunnen 
worden.
Hoofdstuk 18 is een commentaar op een besliskundig model dat individuele lange 
termijn overleving (1, 5, en 10 jaar) voorspelt na PCI met bare metal stents, na DES-
PCI, en na CABG. Deze modellen helpen artsen bij het aanbevelen van de te kiezen 
behandelmethode. Een multidisciplinair hart team blijft echter de hoeksteen van het 
besluitvormingsproces.
DEEL V. METHODOLOGISCHE EVALUATIE VAN CARDIOVASCULAIR 
ONDERZOEK
Hoofdstuk 19 is een brief aan de editor over een meta-analyse. In de brief worden twee 
methodologische kwesties kritisch beschouwd die de associatie tussen CYP2C19 loss-of-
function allelen en klinische eff ectiviteit van clopidogrel verstoren. Ten eerste gebruiken 
de auteurs een ongeschikte methode om de substantiële heterogeniteit te verminderen. 
Ten tweede werd publication bias niet onderzocht, hoewel deze de resultaten weldegelijk 
kan hebben beïnvloed.
Hoofdstuk 20 onderzoekt op een systematische manier hoe 11 overlappende meta-ana-
lyses tegenstrijdige resultaten konden opleveren ten aanzien van de associatie tussen 
CYP2C19 loss-of-function allelen en de klinische eff ectiviteit van clopidogrel. De resul-
taten van de meta-analyses verschillen omdat de auteurs van recentere meta-analyses 
meer primaire studies includeerden en anderen abstracts van conferenties excludeerden. 
De conclusies van de meta-analyses variëren doordat heterogeniteit en publication bias 
verschillend werden geïnterpreteerd. De substantiële heterogeniteit en publication bias 
impliceren dat geïndividualiseerde plaatjesremmende therapie gebaseerd op genotype 
niet wordt ondersteund door de huidige beschikbare literatuur.
Hoofdstuk 21 beschouwt de enorme toename in het aantal meta-analyses binnen de 
cardiovasculaire geneeskunde. Deze trend leidt tot overlappende meta-analyses over 
hetzelfde onderwerp. Hoewel enige replicatie van onderzoek gewenst is, leidt een 
groot aantal overlappende (potentieel tegenstrijdige) meta-analyses tot ineffi  ciëntie, 
verwarring en bedreiging van de wetenschappelijke waarde van de meta-analyse als 
studietype. Overlappende meta-analyses dienen te worden geëvalueerd aan de hand 
van overwegingen als heterogeniteit, publication bias en de kwaliteit van de individuele 
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primaire studies. Bovendien behoren auteurs de beweegredenen voor de (hernieuwde) 
meta-analyse te beschrijven, hun project te registreren in daartoe bestemde databases 
en dienen zij zich te houden aan de betreff ende richtlijnen.
Hoofdstuk 22 is een brief aan de editor die het belang benadrukt van correcte metho-
dologie in de vergelijking van de overleving van een specifi eke patiëntenpopulatie 
(patiënten die SAVR ondergingen) versus de overleving van de algemene bevolking.
Hoofdstuk 23 is een brief aan de editor over de invloed van methodologie en aannames 
op de resultaten van kosteneff ectiviteitsanalyses over TAVI. De methodologie voor het 
modelleren van utiliteiten, extrapoleren van survival en de aannames betreff ende de 
input van het model beïnvloeden de uitkomsten van kosteneff ectiviteitsanalyses.
Hoofdstuk 24 bediscussieert de generaliseerbaarheid en interpretatie van de resultaten 
van een patient-level meta-analyse die CABG en PCI vergelijkt tussen verschillende 
leeftijdscategorieën.
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Name PhD student: Ruben Leendert Jan Osnabrugge
Erasmus MC department: Cardio-Thoracic Surgery
Research School: Cardiovascular Research School (COEUR), Erasmus MC
Promotor: Prof.dr. A.P. Kappetein
ACADEMIC EDUCATION
2009-2012  MSc in Clinical Epidemiology, NIHES, Rotterdam, the Netherlands
2007-2011  Doctorate (MSc) in Medicine, Erasmus MC, Rotterdam, the Netherlands
2006-2007  Propaedeutic Dutch Law, Law College University of Utrecht, the Netherlands
2006-2008  Honoursclass Erasmus School of Economics, Erasmus University Rotterdam, 
the Netherlands
2005-2008  BSc in Economics, minor Health Economics, Erasmus University Rotterdam, 
the Netherlands
PHD TRAINING
Year ECTS
Oral presentations (9.0)
COEUR seminar on percutaneous valves (Rotterdam) 2012 0.6
Dutch Association for Cardio-Thoracic Surgery (Utrecht) 2012 0.6
EuroPCR (Paris, France) 2012 0.6
Transcatheter Cardiovascular Therapeutics (Miami FL, USA) 2012 0.6
European Association of Cardio-Thoracic Surgery (Barcelona, Spain) 2012 1.2
Dutch Association for Cardio-Thoracic Surgery (Utrecht) 2012 0.6
Society of Thoracic Surgeons (Los Angeles CA, USA) 2013 0.6
Dutch Association for Cardio-Thoracic Surgery (Utrecht) 2013 0.6
European Association of Cardio-Thoracic Surgery (Vienna, Austria) 2013 1.2
Virginia Cardiac Surgery Quality Initiative (Charlottesville VA, USA) 2013 1.2
BRS-ARC meeting (Rotterdam) 2014 0.6
Dutch Association for Cardio-Thoracic Surgery (Utrecht) 2014 0.6
Poster presentations (1.2)
EuroPCR (Paris, France) 2013 0.6
Transcatheter Cardiovascular Therapeutics (San Francisco CA, USA) 2013 0.6
Conferences (12.3)
European Association of Cardio-Thoracic Surgery (Lisbon, Portugal) 2011 1.2
EuroPCR (Paris, France) 2012 1.2
Transcatheter Cardiovascular Therapeutics (Miami FL, USA) 2012 1.2
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European Association of Cardio-Thoracic Surgery (Barcelona, Spain) 2012 1.2
Society of Thoracic Surgeons (Los Angeles CA, USA) 2013 1.2
EuroPCR (Paris, France) 2013 1.2
European Association of Cardio-Thoracic Surgery (Vienna, Austria) 2013 1.2
Transcatheter Cardiovascular Therapeutics (San Francisco CA, USA) 2013 1.2
Dutch Association for Cardio-Thoracic Surgery (Utrecht) 2011-2014 1.5
European Association of Cardio-Thoracic Surgery (Milan, Italy) 2014 1.2
In-depth courses (6.1)
Decision analysis in Clinical Research, Harvard School of Public Health (Boston MA, 
USA)
2011 2.1
Health Services Research, Harvard School of Public Health (Boston MA, USA) 2011 2.1
Chronic Diseases (Cardiovascular), University of Cambridge (Cambridge, UK) 2012 1.1
Good Clinical Practice Training (Rotterdam) 2012 0.8
Courses, seminars and meetings (6.2)
Coeur PhD day (Rotterdam) 2012 0.3
American College of Cardiology Gender Data Forum (Washington DC, USA) 2012 0.3
Virginia Cardiac Surgery Quality Initiative meeting (Fairfax VA, USA) 2012 0.3
Mitral Valve Academic Research Consortium meeting (Washington DC, USA) 2012 0.3
Local scientifi c meetings of Dept. of Cardio-Thoracic Surgery (Rotterdam) 2010-2014 3.0
Local scientifi c meetings of Mid America Heart Institute (Kansas City MO, USA) 2013-2014 2.0
Teaching (2.6)
Supervising students and clinical researchers 2012-2014 2.0
Workshops on PhD training at Career day at the Erasmus University Medical School 2014 0.6
Academic positions (4.0)
Editor Journal and News Scan, The Cardio-Thoracic Surgery Network (CTSNet) 2013-present 2.0
Associate editor Eurointervention (Rotterdam) 2013-present 2.0
Peer reviewer international scientifi c journals (3.3)
The Annals of Thoracic Surgery 2012-present 1.0
Circulation 2014-present 0.5
European Heart Journal 2013-present 0.5
Eurointervention 2013-present 0.5
European Journal of Cardio-Thoracic Surgery 2013-present 0.5
Medical Decision-Making 2013-present 0.3
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Gertrude Stein
…and so, fi nally, it’s time to thank those who have been involved and supportive of this 
thesis!
First and foremost, there is one major person whom I cannot thank suffi  ciently enough: 
my promotor Prof.dr. A.P. Kappetein.
Dear Pieter,
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person; you truly know how to bring out the best in people. Thank you for opening up 
your international network which allowed me to make my PhD an even more memorable 
experience.
I admire your passion, energy, work ethic, social skills and ‘levenskunst.’ It is extraor-
dinary how you manage to combine so many diff erent activities successfully, in order 
to push the boundaries in cardiovascular medicine. You seem insensitive to fatigue and 
always fi nd ways to combine business (discussing papers, work meetings) with pleasure 
(dinner, green egg, wine, and good coff ee). I respect the way you are genuinely interested 
in a pupil’s view.
Moreover, I now know how to fi nd the best fl ights within seconds and how to select the 
right line at immigration at Heathrow or LAX. I hope to continue to learn from you and 
pass on your vision to others. Thank you!
Prof.dr. Bogers, dank u voor het vertrouwen om mij als promovendus aan te stellen. U 
schiep de juiste voorwaarden voor deze thesis, was altijd bereid tot meedenken en onder-
steuning bij het opzetten van nieuwe projecten en samenwerkingen. Uw gebalanceerde 
uitstraling van rust, vertrouwen en weloverwogenheid zijn een voorbeeld voor me.
De vooruitgang in cardiovasculaire interventies is ontegenzeggelijk een team prestatie 
van hartchirurgen en (interventie)cardiologen. Het was voor mij een eer om te mogen 
samenwerken met vooraanstaande cardiologen van het wereldberoemde Thoraxcentrum 
in Rotterdam. Prof.dr. De Jaegere: uw betrokkenheid en vriendelijkheid zorgden ervoor 
dat ik mij welkom voelde om met u en uw groep samen te werken.
Prof.dr. Serruys, a driving force behind the world fame of the Thoraxcenter. You are 
an important reason why doors opened whenever I mentioned that I was a PhD fellow 
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from Rotterdam. I appreciated our discussions on the usefulness of cost-eff ectiveness 
analyses. Thank you for the collaboration and the opportunities you gave me within 
Cardialysis and EuroIntervention.
Nicolas Van Mieghem, dank voor de plezante samenwerking en hulp. Jouw combinatie 
van doelgerichtheid, (sociale) intelligentie en humor maken het verschil. Ik zal nog vaak 
naar je sportprestaties vragen.
Prof.dr. Zijlstra, dank voor het leiden van de afdeling cardiologie en uw input voor de 
paper over CYP2C19 en clopidogrel response.
I am very thankful to Prof.dr. Cohen.
Dear David, when we met at EACTS 2012, you recognized my interest in cost-eff ective-
ness analyses. You immediately invited me to visit the Health Economics & Technology 
Assessment (HETA) Research Group at the Mid-America Heart Institute (MAHI) in Kansas 
City. During the nine months that I spent in the Mid-West, you created the perfect condi-
tions for me to immerse in the world of cost-eff ectiveness and quality-of-life studies. 
Thank you so much for this opportunity to learn from the best. Your research group 
is perfectly tuned and you made sure that I was able to learn from the analyses, the 
processes in your research group, as well as the medical writing process. The SYNTAX 
analyses form the core of my thesis and I owe them to you. Also, I admire your work ethic; 
you seem to constantly think of solutions to statistical challenges and I cannot think 
of any time during the day at which I wouldn’t get an email reply within 15 minutes. I 
feel privileged having you as my mentor and I am honored to have you in my doctoral 
committee.
Prof.dr. Elizabeth Magnuson, the statistical mastermind of the HETA group.
Dear Elizabeth, you made me feel welcome from the moment I stepped into your offi  ce. 
Your profound knowledge, combined with your social and managerial skills make the 
HETA group run smoothly. I really valued your eff orts to fully involve me in the whole 
process of analyzing data. Your remarks on my progress were motivating and the oc-
casional funny notes were greatly appreciated. Thank you!
Prof.dr. Hunink, Dear Myriam, thank you for supervising my fi rst steps in science. Your 
courses on medical decision-making and cost-eff ectiveness analyses are world class and 
formed the foundation for this thesis. I admire your analytical skills and appreciated be-
ing part of your research group, in which quality, integrity and respect are key values. It is 
an honor to have you in my doctoral committee.
Prof.dr. Cecile Janssens, Dear Cecile, our interest in a paper on CYP2C19 alleles and 
clopidogrel response took a course of its own. It was instrumental in teaching me how to 
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critically appraise research and write about science. I appreciate your quick-witted and 
open personality. Thank you for staying in touch after moving to Emory, and for crossing 
the Atlantic to be an opponent in my doctoral committee.
Prof.dr. Klautz en Prof.dr. Steyerberg, bedankt voor uw bereidheid om in mijn kleine 
commissie plaats te nemen en de wetenschap in dit proefschrift te beoordelen. Prof.dr. 
Kromhout, het is speciaal om u als opponent in mijn commissie te hebben. Dank voor uw 
spontane toezegging!
I am thankful to the Virginia Cardiac Surgery Quality Initiative (VCSQI) and its leadership 
including Jeff rey Rich, Alan Speir, and Gorav Ailawadi. You had the open-mindedness 
to collaborate with a group from Rotterdam and give me opportunities to do exciting 
research on the costs and quality of various cardiac surgical procedures. By inviting me 
to speak in Charlottesville, I experienced how quality improvement is done in practice. 
You made me part of your extraordinary collaborative group that aims to reduce costs by 
improving quality. Your vision and leadership are an inspiration and I am looking forward 
to continuous collaboration.
Dank aan de Rotterdamse thoraxchirurgen en (oud) arts-assistenten voor de getoonde 
interesse in mijn onderzoek en de goede sfeer op de kamer en afdeling. Ik hoop nog veel 
klinische en operatieve vaardigheden van jullie te mogen leren.
Veel dank aan de onderzoekscoördinatoren, datamanagers, en medewerkers van het 
secretariaat thoraxchirurgie. Annet dank voor je betrokkenheid en Els, dank voor je hulp 
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en voor EACTS. Je nuchtere kijk is verfrissend en de gezelligheid die je meebrengt, mag 
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Maaike ,Richard, Jeanette, Sjaak, Dwight, Jasper Haverkamp en Anne-Marie Maugenest, 
dank voor jullie interesse in mijn onderzoek en hulp bij de kosten-onderzoeken op de 
OK en Cathlab.
A big thank you to the staff  at Cardialysis and Eurointervention: Gerrit-Anne van Es, 
Paul, Sylvie, Wendel and Hanny. Thank you for thinking of me, giving me opportunities 
and making me feel welcome.
The dream team from Windsor: Kathy, Amanda, Sharon, Elvira, Diana, and Elka. Thank 
you for your help before, during, and after the Annual Meetings.
One of the aspects I have greatly enjoyed is the international collaboration with fellow 
researchers around the globe. I have had the privilege to work with established inter-
national leaders including Friedhelm Beyersdorf, Volkmar Falk, Teresa Kieser, Sir Bruce 
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Keogh, Rüdiger Lange, Nicolo Piazza, Duane Pinto, Michael Mack, Douglas Mathisen, Neil 
Moat, Marie Claude Morice, Friedrich Mohr, Thomas Modine, Vuyisile Nkomo, Domenico 
Pagano, John Pepper, Matthew Reynolds, Rafael Sadaba, Miguel Sousa d’Uva, and Douglas 
Wood. Thank you very much for maintaining a fruitful international scientifi c environment 
and for allowing me to get involved. A special thanks to Joel Dunning, who introduced me 
to CTSNet and is an amazing and reliable TV host in the EACTS TV studio sessions.
Moreover, thanks to all my co-authors and young, ambitious international colleagues. 
Darren Mylotte, Chris Meduri, Davide Capodanno, Heng Zhang, and Andreas Rück: it has 
been a pleasure to work with the future of cardiovascular medicine and I wish you the 
best of luck with your projects and careers. I am looking forward to work with you again.
The group at the Mid-America Heart Institute showed me how research is done in the 
Mid-West: a friendly and warm professional way of collaborating. A special thank you 
to the research leaders John Spertus, Carole Decker, Mikhail Kosiborod, Paul Chan, and 
Suzanne Arnold. Collaborating with and learning from you has been a joy. A major thank 
you to the statistical powerhouse (Phil Jones, Kate, Kaijun, Khaja, and Haiyan), thanks to 
my roomies Federico, Kevin, John, Sandy, and thank you Donna for looking after me.
The fellows Natalie, Mouin, Faraz, Tim, Anna, Praneed, and Jason took care of the good 
vibe and made me feel welcome instantly. I know you guys still think Sinterklaas is a 
rip-off  Santa Claus, but actually it’s the other way around. Please do your homework.
Natalie, I really appreciated your eff orts to take care of me and being creative in mak-
ing up reasons why I should stay in Kansas City and become a U.S. citizen. Thanks also to 
your husband JT, who is obsessed with Dutch words. Here’s to you JT: Dank je wel! Little 
Fiona is blessed to have you as her parents. Mouin and Patricia, thanks for the friendship 
and wearing orange on the Dutch Kings Day and during the World Cup! Faraz, thanks for 
introducing me to Mountain Dew and later on for saving my life by making me aware of 
its caff eine content. The Sporting KC game, BBQ-lunches and farewell dinners are special 
memories. Thanks guys!
My stay in the US was fi lled with authentic American hospitality. This thesis wouldn’t 
have been the same without the support of the late Ed Fonner. It was overwhelming 
how Ed wanted to help me with my career as well as with my stay in Kansas City. He 
connected me with the right people and made sure I drove a ’89 Chevy Silverado. He was 
the soul of VCSQI and I wish he could have been witness to the fi nalization of my PhD. 
His son Eddie is doing a terrifi c job as the new driving force behind VCSQI and I know few 
people that have a warmer heart than Maribeth. Thank you Fonner family!
Bill and Uta, thanksgiving dinner with you and your family was memorable. You showed 
me Dallas and how a good team can combine a busy CT-surgeon’s job with the true spirit 
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of family life. Feel welcome when you make a trip to the Netherlands. Heather and Jan, 
thanks for your interest and showing me Chicago.
The ART Group guided me in my fi rst scientifi c project: thank you Tessa, Bart, Bob, Nathalie, 
Farzin, Suman, Raluca, John, and Erica! Colleague PhD researchers at the Thoraxcenter: 
Aart, Bardia, Carina, Catalina, Elrozy, Gerdien, Jonathan, Milan, Nelleke, Robert, Rutger-Jan 
en Sahar, thank you for the good atmosphere and I wish you the best of luck with your 
careers!
Beste Stuart, de meeste tijd van mijn promotie heb ik met jou doorgebracht. De mix 
van business and pleasure was bijzonder. Ik heb veel van je geleerd, veel met je gediscus-
sieerd en heel veel met je gelachen. Dank voor een fantastische tijd. Met je analytische 
denkwijze, doelgerichtheid en doorzettingsvermogen ga je een mooie carrière tegemoet. 
Veel succes!
Mostafa, jouw wijsheid en CV lijken niet overeen te komen met je leeftijd. Ik vind het 
prettig om met je samen te werken en wens je veel succes met het verwezenlijken van 
je dromen.
Dit promotietraject was niet alleen een beroepsmatig, maar ook een persoonlijk avontuur. 
Ik wil al mijn vrienden en familie bedanken. Ik heb het geluk dat ik me altijd gesteund 
heb gevoeld door dierbaren die mij een warm hart toe dragen. Dit dankwoord is niet 
compleet zonder hen.
Clasine, Christine en Martijn: jullie betrokkenheid is groot. Geen Huskbus kan onze 
vriendschap aantasten en het is bijzonder hoe we de hele wereld overvliegen om samen 
avonturen te ondernemen!
Maren: jij wist precies de goede steun te geven toen dat nodig was, veel dank. Je 
nuchtere blik is heerlijk en ik kijk nu al uit naar jouw verdediging!
Marijn: dank voor je wijze raad, Top Gear, goede wijn, fi etsen, en humor. They go a long 
way in writing a PhD thesis.
Inger-Elze, Marnix, Joost, Niels, Jef, Maurits, Stefan en Jan-Willem, Jonghe 8 2009: 
dank voor het begrip teamwork! Jullie kunnen veel meer dan alleen hard roeien. Het 
verwisselen van (veel) samen ergometeren voor (veel) samen eten, bevalt me overigens 
uitstekend.
Irene Fleur en Niek, leuk dat we elkaar zovele jaren na het JvO nog zien. Het stimuleert 
me om jullie verhalen te horen en ik ben benieuwd naar jullie ‘boekjes’. Gerald, dank 
voor onze langdurige vriendschap. Matthieu, jij gaf me het laatste zetje om toch vooral 
voor die promotieplek te gaan. Veel dank daarvoor, net zoals voor je gezelligheid, relati-
veringsvermogen en scherpzinnigheid.
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Beste Stefan, ik prijs me gelukkig met een vriend als jij. Jij hebt aan één oogopslag 
voldoende om me te begrijpen, of het nu gaat om life-events of een mooie grap. Dank 
voor je support, ongekende betrokkenheid, en voor het feit dat jij mijn paranimf wilt zijn.
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Marije, lieve zus, ik ben vast niet altijd het ideale broertje geweest, maar ik denk dat we 
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de volharding die je hebt getoond. De archieven van Napels kennen voor jou nu geen 
geheimen meer en ik kijk uit naar je verdediging. Ik ben supertrots op jou!
Oma, mijn voorbeeld voor wilskracht. Uw betrokkenheid doet me veel en ik ben dankbaar 
dat ik nog zoveel met u kan delen. Veel liefs!
Lieve papa en mama, de onvoorwaardelijke warmte en liefde die jullie me geven zijn 
onbeschrijfelijk. Jullie weten me op een prettige manier te stimuleren en af te remmen 
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“Let us be grateful to people who make us happy;
they are the charming gardeners who make our 
souls blossom.”
Marcel Proust
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Ruben Leendert Jan Osnabrugge was born on October 7, 
1986, in Soest, the Netherlands. He attended the Johan 
van Oldenbarnevelt Gymnasium in Amersfoort, from 
which he graduated in 2005.
In the same year he started his studies in Economics & 
Business at Erasmus University Rotterdam. In addition, 
he obtained a propaedeutic exam in Dutch Law from 
Utrecht Law College in 2007 and simultaneously started 
medical school at Erasmus University in Rotterdam. In 
2008, alongside his medical studies, he completed his 
Bachelor’s program in Health Economics and its accompanying Honours Class. In 2009, 
Ruben was selected to participate in a special program for medical students, off ered 
by the Netherlands Institute of Health Sciences (NIHES). This program enabled him to 
combine a Master of Science in Clinical Epidemiology with his Medical Degree. The 
Master’s program consisted of summer and winter schools during recess periods. Part 
of this program was spent at the Harvard School of Public Health, Harvard University, 
Boston, MA, U.S.A., and the Cambridge Institute of Public Health, Cambridge University, 
U.K. For his research project, Ruben worked at the departments of Epidemiology and 
Cardio-Thoracic Surgery under the supervision of Prof.dr. Myriam Hunink and Prof.dr. A. 
Pieter Kappetein. This resulted in his fi rst publication. Furthermore, Ruben was student 
chairman of the Steering Committee of his medical school (2008-2010) and representing 
member in the University Council (2010-2011).
After obtaining his M.Sc. degrees in Medicine (2011) and Clinical Epidemiology (2012), 
he started his Ph.D. research at the department of Cardio-Thoracic Surgery, under the 
supervision of Prof.dr. A. Pieter Kappetein. His work focuses on the costs, quality and 
value of cardiovascular interventions.
In 2013, Ruben received a Fulbright Scholarship from the Dutch Minister of Education. 
This allowed him to spend part of his Ph.D. research in the United States. Between Feb-
ruary 2013 and January 2014 he worked as research fellow for the Health Economics 
and Technology Assessment group of the Mid-America Heart Institute, Kansas City, MO, 
U.S.A. This group has a longstanding interest in cardiovascular outcomes research and 
in particular in using data from clinical trials and registries to help improve medical 
decision-making and health care policy. Under the direct supervision of Dr. David Cohen 
and Dr. Elizabeth Magnuson, he acquired additional knowledge and experience in the 
fi elds of quality of life studies and cost-eff ectiveness analyses.
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Ruben collaborates with the Virgina Cardiac Surgery Quality Initiative (VCSQI),  a volun-
tary consortium covering 99% of all cardiac surgical centers in the Commonwealth of 
Virginia, U.S.A. Learning from its leadership, including Dr. Alan Speir, Dr. Gorav Ailawadi 
and Dr. Jeff rey Rich, Ruben investigates the opportunities for reducing costs by improv-
ing quality.
In October 2013, Ruben was awarded the European Association of Cardio-Thoracic 
Surgery (EACTS) Young Investigator Award for the best manuscript in the cardiac domain. 
Moreover, he is associate editor of the journal EuroIntervention, member of the research 
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